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Abstract 
 
The research described here considers molecular variations of the acute phase 
response protein, C-reactive protein (CRP), and the presence of CRP and anti-CRP auto-
antibodies in rheumatoid arthritis (RA) patient serum. 
Monomeric CRP (mCRP) was generated in vitro by 2M urea induced dissociation 
of native pentameric CRP (pCRP), over a 10 week period in the absence of calcium. The 
subunit size (23kDa) and identity were confirmed by size exclusion chromatography, and 
western blotting with mCRP specific antibodies. Once dissociated, it was not possible to 
induce re-association.  
Human RA (n=30) and healthy control samples (n=30) were tested for the presence 
of serum mCRP. RA patients had higher mean mCRP levels than non RA (0.092mg/l, 
0.069mg/l), however no samples were elevated above the calculated normal threshold for 
mCRP (≥ mean + 2SD, 30 control samples). There was no correlation between serum 
levels of mCRP and pCRP, suggesting physiological dissociation of pCRP may not be 
solely responsible for the presence of mCRP. 
Auto-antibody detection by competitive ELISA confirmed the presence of anti-
mCRP and pCRP auto-antibodies of the classes IgG, IgA and IgM in both RA and control 
groups. Anti-mCRP and pCRP auto-antibodies in RA samples were significantly higher 
than controls in the female cohort in all but anti-mCRP IgM, with only anti-m/pCRP IgA 
significantly higher for the males (P<0.01). Both mCRP and pCRP were found to interact 
directly with anti-IgG at high concentrations of both. A greater proportion of RA samples 
contained all three auto-antibody classes, anti-pCRP - RA 66.6%, control 50%; anti-
mCRP- RA 50%, control 13%. Auto-antibody profile varied between RA and control 
groups, elevated anti-mCRP IgA antibodies being a key predictor of RA risk P<0.0001, 
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more so when combined with advancing age although no correlation between CRP and 
auto-antibody concentrations was found. This may prove useful diagnostically.     
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Chapter 1 - Introduction 
1.1 Overview 
 
C-reactive protein (CRP) is an evolutionarily conserved member of the pentraxin 
family of proteins and has been identified within a variety of organisms including 
mammals, fish and the horseshoe crab Limulus polyphemus. Pentraxin comes from the 
Greek words penta (five) and ragos (berries), due to its electron micrograph appearance 
(Pepys et al., 1978). CRP forms part of the acute phase response, with levels rising rapidly 
in response to inflammation and infection within the body. Upon detection of infection the 
liver increases transcription of CRP and levels rise in the serum within hours, making this 
protein a valuable and routinely used, nonspecific marker of infection, inflammation or 
damage to tissue (Pepys & Hirschfield, 2003). 
Patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) have 
raised levels of CRP, with the increase in serum used to diagnose and monitor levels of 
inflammation. This pentraxin is involved in several host defensive functions due to its 
ability to recognise foreign pathogens or damaged cells, leading to activation of the 
humoral and cellular arms of the immune system. Although serum levels vary due to 
disease state or genetics variants, there are no records of human deficiency in CRP (Pepys 
& Hirschfield, 2003), suggesting that, in conjunction with its conserved nature across 
species, CRP is a protein of great physiological importance.  
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1.2 The Human Immune System 
 
Immunology may be a relatively new science in terms of the modern day 
understanding of the body’s defence system, however it was first referenced during the 
plague of Athens in 430 BC, where it was recorded that people who had survived a 
previous bout of plague did not appear to contract the disease a second time (Retief & 
Cilliers, 1998). Fast forward nearly 2500 years and perhaps the father of immune system 
study, Edward Jenner, observed that cowpox appeared to confer protection against 
smallpox. In 1796 Jenner demonstrated his vaccination technique to initially skeptical 
peers, who soon recognized the potential of his discovery (Murphy & Weaver, 2017). 
Louis Pasteur in the late 19th century continued research into the vaccination process 
(Murphy & Weaver, 2017), and Robert Koch published his findings showing how isolating 
disease-causing organisms was key to the understanding of infectious disease. We now 
have a thorough understanding of the pathogens Koch was observing and immune system 
research follows in the footsteps of these pioneers. 
The human and mammalian immune system is broadly split into two interacting 
systems, the innate immune system and the acquired immune system. The innate system is 
a fast acting and short lived non-specific line of defence, which recognizes ‘non-self’ 
agents and mounts a defence against them. The acquired system provides a more selective 
response, specific to targeted pathogens. Broadly, the immune system has a series of well-
orchestrated tasks which begin with recognition of the pathogen, undertaken by the 
leucocytes, part of the innate system, and lymphocytes of the adaptive system. The body 
must then overcome the pathogen and contain it, preventing further infection, before 
ultimately removing it from the body. The complement system plays an important role at 
this point which when activated, sets in motion a pathway consisting of more than 30 
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plasma and membrane bound proteins, essential within the body’s defence mechanism in 
the inflammatory response. One aspect of the complement system response is the 
activation of antibodies and recruitment of leucocytes. Once the pathogen has been 
eliminated, the body then instigates immunological memory, allowing a rapid reaction 
should the host need to respond to a subsequent challenge. Lastly the body must be able to 
regulate the immune response, ensuring it does not begin to cause harm to itself. 
Dysfunction of the regulatory and modulatory immune system risks causing harm to the 
host through autoimmune disease and allergies (Medzhitov & Janeway, 1997; Simon et al., 
2015). 
The human body has two systems of defence in the form of either physical or 
chemical barriers with which it prevents infectious disease causing agents such as virus, 
bacteria, fungi, unicellular or multicellular parasites from gaining access to the body. 
Physical barriers include skin, mucosa and cilia lining the respiratory tract and mucus 
secreted by epithelial cells of the gut. Chemical barriers include acidic conditions such as 
the surface of the skin or stomach acid, collectins which attach to sugars on microbial 
surfaces marking them for destruction and lysozymes, a constituent of tears and sweat. 
However, should the pathogen gain access, the body must be able to draw on further 
resources to fight against invasion rapidly (Murphy & Weaver, 2017).  
Not all infectious organisms are harmful to the host, with many essential to 
physiological function. Bacteria living within our gut, known as commensal bacteria, help 
digest food and play important roles in maintaining intestinal homeostasis. The commensal 
microbiome aids maturation of the mucosal immune system and as such ensures the 
protective barrier of the intestinal tract is maintained (Shi et al., 2017). There are however 
many pathogens which constantly threaten our body and without a well-functioning 
immune system we would be vulnerable to infection by these pathogens on a daily basis. 
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1.2.1 The Innate Immune System 
 
The innate immune system is an evolutionarily conserved form of defence found in 
multicellular organisms which allows the body to defend itself rapidly against pathogens 
such as bacteria and other microbes. This system relies upon the recognition of pathogens 
in a non-specific pattern recognition manner. The recognition of these patterns allows the 
host to determine self from non-self quickly and activates the acute phase response which 
involves the rapid release of platelets, leucocytes and the acute phase proteins including C-
reactive protein (Medzhitov & Janeway, 1997; Beutler, 2004; Sjöwall & Wetterö, 2007a; 
Shishido et al., 2012; Simon et al., 2015). Organisms are born with innate immunity, with 
organisms from vertebrates to the fruit fly Drosophila melaogaster and the nematode 
worm Caenorhabditis elegans, (Murphy & Weaver, 2017) sharing genes involved within 
the intercellular signaling pathway of innate defence. This system mounts a defence that 
although not specific to the particular pathogen detected, is in place within hours of 
infection.  
The innate system can be divided into two distinct arms of defence, the humoral 
and the cellular. The humoral response contains a diverse assortment of agents capable of 
instigating an attack on the pathogen by multiple components. Macromolecules including 
naturally occurring antibodies (NAb), serum proteins, and peptides are secreted into 
extracellular spaces following recognition of a non-self-entity. The breakdown and breach 
of external barriers resulting in pathogenic infiltration of tissue, leads to a local increase of 
blood proteins such as collectins (surfactant protein A and D,  mannose binding lectin), 
C1q, pentraxins (C-reactive protein, PTX3, serum amyloid protein) and ficolins (Janeway 
et al., 2001; Iwasaki & Medzhitov, 2015). Complement activation follows recognition and 
binding of a pathogen or damaged/apoptotic tissue by C-reactive protein, which in turn 
activates C1q and the complement cascade (McInnes & Schett, 2007). The accumulation of 
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proteins resulting from instigation of the inflammatory pathway causes pain, redness and 
swelling to the area (Janeway et al., 2001; Murphy et al., 2008; Artis & Spits, 2015). 
Complement system activation will also be instigated allowing further recruitment of other 
immune agents such as antibodies and leucocytes, enhancing the response and level of 
inflammation at the site of infection (Chen et al., 2010; Shishido et al., 2012; Nonaka, 
2014). 
Central to the innate system is a network of phagocytic cells and proteins which 
recognise conserved features of pathogens (Medzhitov & Janeway, 1997; Murphy & 
Weaver, 2017). The discrimination between self and foreign cells through recognition of 
these highly conserved motifs called pathogen associated molecular patterns (PAMPS), is 
crucial to the ability of immune components to function without destruction of self-tissue 
(Berg et al., 2010). PAMPs are present on pathogen molecules and include proteins, 
nucleic acids, lipids and polysaccharides, often in repeating patterns. Conservation of these 
molecular structures is key to the success of the pattern recognition system, for instance 
lipopolysaccharide (LPS) is shared by all gram negative bacteria.  PAMPS are detected via 
pattern recognition receptor proteins (PRRs) which are expressed on the surface of immune 
cells including dendritic and macrophage cells (Medzhitov & Janeway, 1997; Kawai & 
Akira, 2011; J. Shi et al., 2014), allowing the host to recognise a great variety of molecular 
structures that are associated with different pathogens. The PRRs are composed of a 
diverse set of receptors that belong to different protein families. Some like CD14 and 
collectins recognise PAMPs directly and others such as Toll and complement receptors 
recognise the products generated by PAMP recognition. Functionally PRRs fall into 
distinct classes, circulating humoral proteins, endocytic receptors expressed on cell 
surfaces such as macrophages and dendritic cells, and signaling receptors expressed on the 
surface or intracellularly (Medzhitov & Janeway, 1997). The exact nature of response will 
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be dependent upon the cell expressing the PRRs; antigen presenting cells induce activation 
of lymphocytes specific for pathogen antigens and effector cells of the innate immune 
system induce expression of cytokines such as IL-12 and IL-4 leading to activation of the 
adaptive immune system. Transmembrane proteins such as toll-like receptors (TLRs) upon 
recognition of PAMPs trigger an inflammatory immune response via cytokine signaling 
(Medzhitov & Janeway, 1997; Kawai & Akira, 2010; Sims & Smith, 2010). 
The cellular component of the innate immune system relies on recruitment of 
immune cells to the point of infection and amplification of the initial inflammation state 
through local secretion of inflammatory signaling mediators, including cytokines and 
chemokines. The complex cycle of cytokines and chemokines released by the acute phase 
proteins and cells at the point of tissue injury can enhance either a pro or anti-inflammatory 
response (McInnes & Schett, 2007; Artis & Spits, 2015). These cytokine and chemokine 
releasing leucocytes include dendritic cells, neutrophils, natural killer cells, monocytes, 
eosinophils and basophils together with mast cells and macrophages (Lacy & Stow, 2011). 
The coordinated release of soluble mediators including tumour necrosis factor (TNF),  
interferon gamma (IFNγ), transforming growth factor beta (TGFβ), chemokine (C-C motif) 
ligand (RANTES) also known as CCL5 and interleukins (IL) such as IL-1β, IL-4,IL-6, IL-
10, IL-12 and IL-18 carefully orchestrates further immune responses, which lead to the 
initial inflammatory response before subsiding (Lacy & Stow, 2011).  
Phagocytes recruited during an inflammatory response ingest foreign particles such 
as bacteria, parasites, foreign debris and dead self-cells and digest them via internal 
enzymes located within the lysosome. Alternatively phagocytes employ a lysosome 
independent killing mechanism via expression of NADPH oxidase producing superoxide, 
hydrogen peroxide and inducible nitric oxide (iNOS), which generates nitric oxide (NO) 
(Pannen & Robotham, 1995; Robinson, 2008; Baptista et al., 2012; Iwasaki & Medzhitov, 
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2015; Simon et al., 2015). The innate immune system whilst different in terms of response 
time and specificity to the acquired or adaptive immune system, works in synergy with it, 
with many areas of overlap. The signaling components of the innate system and antigen 
presenting cells are intrinsic in the implementation of a full adaptive immune response and 
vertebrates have evolved to initiate both arms of the immune system, working together to 
protect the host from pathogenic agents. 
1.2.2 The Adaptive Immune system 
 
Should the innate immune system be unable to provide a response adequate enough to fully 
contain an infectious agent. In this instance, vertebrates have evolved an enhanced and 
sophisticated countermeasure known as the adaptive immune response. This specialised 
system contains a diverse range of cells capable of responding, albeit in a less rapid 
manner, to cytokine and chemokine signals originating from the innate system and raises 
an enhanced defence against the pathogen in question. What this system loses in  response 
time, it gains in specificity, with a capacity to form long lasting protection or memory 
against previously encountered pathogens. An individual who may have previously 
encountered an  infectious agent, such as measles, and recovered from an associated 
infection, would be protected against further infection due to the specific recognition 
ability of the immune system, however they would not be protected against other viruses 
(Alberts et al., 1994; Dörner and Radbruch, 2007). 
Where the innate system relies upon PAMPs, the adaptive system is highly specific 
to a particular pathogen (Alberts, 1994; Kumar et al., 2011; Rachner et al., 2011). 
Cytokines and chemokines released by cells of the innate system raise the alarm and signal 
the adaptive system, which results in migration of immune cells to the site of infection. Of 
these cells B and T lymphocytes play a crucial role (Murphy et al., 2008; Artis & Spits, 
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2015; Iwasaki & Medzhitov, 2015), with their activation resulting in two classes of 
response, an immunoglobulin (antibody) and a cell-mediated response. The antibody 
response is the domain of the B cell which when activated secretes antibodies. These 
antibodies circulate the bloodstream and perfuse into other body fluids, ultimately binding 
the foreign antigen initially responsible for their production. B cells contain membrane 
bound immunoglobulins (B-cell receptors) which allow detection and presentation of an 
antigen, activation of the B cell follows presentation of an antigen to a helper T cell. Upon 
binding to the antigen via T cell receptors, the T cell releases cytokines which induce 
proliferation of B cells into memory cells and antibody secreting plasma cells (Janeway  Jr. 
& Medzhitov, 2002; Berg et al., 2010; Sela-Culang et al., 2013; Murphy & Weaver, 2017). 
Antigen presenting cells (APC), such as dendritic cells and macrophages engulf 
pathogens, processing and breaking them into peptides which are then presented upon their 
surface allowing them to interact directly with B cells or T cells. This intereaction occurs 
via major histocompatibility complexes (MHC) of either type I or II. The presentation of 
these fragments allows further signals initiating an adaptive immune response and 
activation of B cells, through specific cytokine signals received from an activated T helper 
cell. Both B and T cells recognise the same pathogen although not necessarily via the same 
epitope (Alberts et al., 1994; Murphy and Weaver, 2017).  
T lymphocytes as a group, work together to provide a direct cell mediated response, 
attacking foreign pathogens such as a virus or bacteria. T helper cells (Th) work with 
antigen presenting cells (APC) to activate B cells. CD4+ helper cell/inducer cells (TH)  and 
CD8+ cytotoxic/suppressor T cells (TC), express surface T-cell receptors which bind to 
their respective MHC class II or I ligands, found on antigen presenting cells (Miceli & 
Parnes, 1993; Artis & Spits, 2015; Hoffman et al., 2016; Shi et al., 2017). These cells are 
prevalent in a ratio of between 1.5 to 2.5 CD4+/CD8+ in healthy hosts, whilst a lower or 
 
 
Chapter 1. Introduction  The Human Immune System 
 9 
inverted ratio presents an immune risk, often associated with immune function alterations 
and chronic inflammation (McBride & Striker, 2017). T helper cells are responsible for the 
activation of other immune cells through MHC protein binding. Infected cells present 
fragments of the foreign pathogen on their surface enabling the T cell to distinguish 
between healthy and infected cells (Alberts et al.,1994; Murphy and Weaver, 2017). When 
a TC cell recognises an antigen and becomes activated it initially secretes cytokines, 
primarily TNFα and IFNγ, both of which have anti tumour and anti-microbial effect, it then 
eradicates the virus infected, damaged, dysfunctional or cancer cell, inducing its death via a 
release of perforin, granulysin or granzyme leading to cell lysis or apoptosis. The caspase 
cascade which results in apoptosis of the cell via Fas/FasL interaction is a further tool with 
which the Tc cell eliminates infected or problem cells (Alberts et al., 1994; Murphy and 
Weaver, 2017). Additionally, antigen specific T memory cells provide long lasting 
immunity post infection. 
On occasion the immune response against viruses such as hepatitis B and C, 
Epstein-Barr virus, rabies or even smallpox can cause more damage than the virus itself 
(Dörner & Radbruch, 2007). The balance between the initiated immune response as a 
protective or pathogenic measure is key to our survival. 
1.2.3 The Acute Phase Response 
 
The acute phase response (APR) is instigated upon tissue injury, trauma and inflammation 
and encompasses a range of changes to the concentration of many plasma proteins. These 
proteins are predominantly synthesised within the liver in response to inflammatory signals 
which bind to receptors on hepatocytes inducing transcription of these acute phase proteins 
(APP), (Pannen & Robotham, 1995). Whilst non-specific in nature these proteins are used 
as markers of disease. At the site of injury, pro-inflammatory cytokines are released and 
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the local vascular system and inflammatory cells are activated, resulting in production of 
further cytokines which permeate throughout the circulation of the body. The response is 
characterised by changes to endocrine, metabolic, neurologic and immunologic functions. 
Cytokines activate key receptors which in turn lead to systemic reactions and onward 
activation of the hypothalamic pituitary adrenal axis together with a reduction in growth 
hormone secretion (Gruys et al., 2005). In addition to this, levels of adrenocorticotrophic 
hormone (ACTH) and glucocorticoids increase, complement and the blood coagulation 
systems are activated and serum levels of calcium, iron, zinc and vitamin A fall (Gruys et 
al., 2005; Dinarello, 2009). The liver synthesis of APP increases and within a few hours 
levels of C-reactive protein (CRP) and serum amyloid A (SAA) increase. Platelets 
aggregate, dilation and leakage of blood vessels occurs and granulocytes and monocytes 
accumulate and are activated. Activated fibroblasts and endothelial cells produce yet more 
cytokines resulting in leukocytosis and an increased erythrocyte sedimentation rate due to 
elevated plasma concentrations of fibrinogen and other APP (Castell et al., 1990). 
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1.3 Components of the Immune System 
1.3.1 Monocytes and Macrophages 
 
Peripheral-blood mononuclear cells (PBMCs) and macrophages are key effectors 
and regulators of the innate immune response and inflammation. The monocyte is a class 
of leucocyte which when mature differentiates into macrophage or dendritic antigen 
presenting cells and develops from a common myeloid progenitor cell in the bone marrow. 
In humans, monocytes differentiate from CD34-positive stem cells, leaving the bone 
marrow to circulate the body for approximately five days until they become macrophages 
following transmigration from the lumen of blood vessels into tissue (Burmester et al., 
1997).  This translocation follows recruitment to localised sites of inflammation or 
infection upon detection of monocyte chemotactic protein 1 (MCP-1) (Lundberg & 
Hansson, 2010).  
Macrophages are considerable phagocytic cells which can clear 2 x 1011 
erythrocytes each day (Mosser & Edwards, 2008). Macrophage action is independent of 
immune cell signaling and the clearance of apoptotic cells effects little to no production of 
immune mediators by unstimulated macrophages suggesting most ongoing phagocytosis 
occurs independently of other immune cells (Mosser and Edwards 2008). Interestingly the 
clearance of cellular debris resulting from necrosis leads to changes in the macrophage 
physiology and production of cytokines and pro-inflammatory mediators. Macrophages 
can be activated by IFNγ and TNF produced by natural killer and T helper cells (O’Shea et 
al., 2002), which are then responsible for producing IL-1, IL-6 and IL-23 (Langrish et al., 
2005), thus amplifying the immune response. 
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1.3.2 Neutrophils  
 
Neutrophils are formed within the bone marrow from the same myeloid progenitor 
cells as monocytes. An integral part of the immune system the neutrophil contains 
distinctive cytoplasmic granulocytes and a nucleus divided into three distinct segments. 
These are the most abundant leukocyte within the human immune system and are rapidly 
recruited to the site of infection with P selectin observed to play a part in this recruitment 
(Diacovo et al., 1996). These cells can phagocytose foreign microorganisms directly or can 
produce toxic antimicrobial mediators (Kruger et al., 2015). Neutrophils are not only able 
to phagocytose pathogens but employ neutrophil extracellular traps (NETs) capturing 
microbes extracellularly and then autophagy to digest them intracellularly (Brinkmann et 
al., 2004; Mantovani et al., 2011). Although neutrophils play an intrinsic role within the 
immune system, impaired clearance of apoptotic neutrophils is linked to autoimmune 
disease (Vandivier et al., 2006). Neutrophils also contribute to the inflammatory response 
via production of immune stimulating factors including cytokines, proteases and reactive 
oxygen species (Sampson, 2000). 
1.3.3 Lymphocytes 
 
Lymphocytes are a class of leucocyte and form an intrinsic part of the vertebrate 
immune system (Gasteiger & Rudensky, 2014). They are derived from hematopoietic stem 
cells within the bone marrow and include T cells, B cells and natural killer cells (NK). The 
NK cell contains granules with enzymes such as perforin and proteases which when close 
to a target cell, form a pore in the cell membrane and causing lysis (Berg et al., 2010). NK 
cells target tumour cells or self-cells infected with a virus and are critical to the functioning 
of the innate immune system. These cells do not require antigen presentation via MHC 
proteins to elicit an immune response and lack antigen specific cell surface receptors 
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(Vivier et al., 2011). NK cells can exacerbate or limit immune responses; however they are 
also regulatory cells interacting with dendritic, endothelial, macrophage and T cells 
through the release of cytokines such as IFNγ, TNFα and IL-10. They also release an array 
of chemokines, including monocyte chemoattractant protein 1 (MCP-1/CCL2), 
macrophage inflammatory proteins (MIP) MIP1α/CCL3, MIP1β/CCL4, RANTES/CCL5 
and IL-8, helping recruit other immune cells to localised inflammatory sites (Alberts et al., 
1994; Walzer et al., 2005).  
T lymphocytes are also derived from precursors generated in the bone marrow 
which then migrate to the thymus, where they develop fully into T cells (Di Rosa & Pabst, 
2005). The T cell can be subcategorised into T helper cells, cytotoxic T cells and T 
memory cells and have many roles within the immune system. Each T cell has an antigen 
recognising T cell receptor (TCR) with the potential to recognise a single antigen, but are 
described as Naïve T cells until they contact this antigen (Hall, 2015). Once activated the T 
cell replicates during the process of clonal expansion and following cytokine signal 
differentiate into effector cells. Dependent on the cocktail of cytokines present during 
activation functionally distinct T cells are induced including Th1, Th2 or Th17.  Th17 cells 
mediate many autoimmune responses including rheumatoid arthritis and can kill target 
cells directly by their release of cytokines, or indirectly via promoting IgM production 
(Boniface, Moyet et al., 2013). Effector T cells mediate immunity and destroy cells with a 
recognised antigen and monitor the intracellular contents of the host cell infected with 
pathogen, or malignant cells expressing tumour associated antigens. In autoimmunity they 
also kill normal healthy cells (Hall, 2015). T cells are involved in the activation of B 
lymphocytes when presented with an antigen by the B cell, to their T cell receptors 
(Alberts et al., 1994).  
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Activation of B cells by T cells results in the release of antigen specific antibodies. 
B cells originate and mature within the bone marrow, express B cell receptors and are 
capable of ingesting antigens before presenting fragments on their receptors initiating an 
immune response. B cells like T cells are also divided into subgroups based on their 
functional properties within the adaptive immune system, namely the plasma cells, which 
secrete antibodies and memory cells which provide a more rapid defence against a 
pathogen which has previously invaded the body (Berg et al., 2010). A B1 subgroup 
secrete natural IgM antibodies which play an important role in homeostasis due to their 
ability to bind self-antigens, this group also secretes polyreactive IgA antibodies which aid 
mucosal immunity. Whilst developing within the bone marrow B cells undergo two types 
of selection leading to correct development, that of positive and negative selection. 
Positive selection occurs through antigen-independent signaling involving the B cell 
receptor, where these receptors are unable to bind their ligand the B cell does not receive 
the correct signal and no longer develops. If a B cell receptor binds a self-antigen with high 
affinity, negative selection occurs, leading to one of four fates- clonal deletion, receptor 
editing, anergy or the B cell continues to develop ignoring the signal. The negative 
selection process is essential within the state of central tolerance whereby mature B cells 
do not bind with self-antigens (Tobón et al., 2013)  
1.3.4 Antibodies 
 
Antibodies, also known as immunoglobulins (Ig), are glycoproteins involved within 
immune system identification and elimination of pathogenic and disease antigens from the 
host body. These immune proteins are found on the surface of B cells acting  as surface 
receptors, or secreted into the extracellular space circulating within the blood where they 
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can bind to their target antigen, eliminating it through processes such as agglutination, 
precipitation or neutralisation (Hoffman et al., 2016). 
An antibody molecule consists of four protein chains, two heavy and two light, 
linked together by disulphide bonds in a roughly ‘Y’ shaped hinged conformation. Each 
light chain is composed of a single variable and constant domain. The longer heavy chain 
is made up of one variable but also three constant domains. The antigen binding fragment, 
Fab, is formed from the variable regions of both a heavy and light chain, together with the 
light chain constant region and first constant of the heavy chain, it is located at the N-
terminus and apex of the ‘Y’. This region recognises the specific antigen which stimulated 
their production. The constant regions are composed of the remaining domains of the 
heavy chain and form the Fc, or crystallisable fragment region. This Fc region is important 
in antibody function due to its binding and interactions with Fc receptors on the surface of 
lymphocytes (Alberts et al., 1994; Hoffman, Lakkis and Chalasani, 2016; Murphy and 
Weaver, 2017). Binding of these Fc receptors activates other parts of the immune system 
such as macrophages or C1q leading to complement pathway initiation. 
Heavy and light Ig chains are encoded by a multigene family, with individual V and 
C domains encoded by independent elements. Somatic recombination occurs in the early 
stage of T and B cell maturation resulting in a diverse repertoire of Igs following 
rearrangements of the variable (V), joining (J) and occasionally diversity (D) segments. 
V(D)J gene segments encode the variable (V) domains and individual exons the constant 
(C) domains (Schroeder and Cavacini, 2013). 
Antibodies are categorised into five isotypes, or classes (IgM, IgD, IgG, IgA, and 
IgE), dependent on their overall conformation and heavy chain region C-terminus domain 
(µ, δ, γ, α and ε respectively) as seen in Table 1.1. There are also four subclasses of IgG 
antibodies, IgG1, IgG2, IgG3 and IgG4 and two subclasses of IgA antibodies, IgA1 and 
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IgA2. The heavy chain isotype and Fc binding determines the effector function initiated by 
each class, for instance IgG3 and IgM are strong complement activators, whilst IgG1 
activates macrophages and IgE mast cells proteins (Alberts et al., 1994; Hoffman, Lakkis 
and Chalasani, 2016; Murphy and Weaver, 2017). IgG1 and IgG3 bind FcγR and activate 
complement, with IgG1 being the most abundant isotype making up 60-75% of serum IgG. 
The IgG molecule is approximately 150kDa, circulates in a monomer conformation and 
forms the major Ig in serum (75%). IgA is the second most abundant serum 
immunoglobulin and is the major class found within tears, saliva and mucus, with IgM the 
third most common. IgA is found in dimers within secretion and monomers within serum. 
IgM is the first immunoglobulin to be made by the feotus and also the initial antibody 
produced by a new B cell when stimulated by an antigen. IgM circulates as a pentamer, 
although is sometimes found as a monomer. Lastly IgD and IgE both of which are 
monomers. IgD is found at low levels in serum and IgE, the least common antibody which 
is involved in defence against parasites but also allergic reactions (Murphy et al., 2008; 
Schroeder et al., 2010; Murphy & Weaver, 2017). 
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Table 1.1 Table detailing differences between antibody structure function and binding, + 
respresenting weak interaction and +++ strong interaction. Adapted from Schroeder and Cavacini 
2010. 
Name Serum (%) Structure 
Complement 
Fixation Opsonizing 
Cross 
Placenta 
Other 
Functions FcR 
             
IgG 75% Monomer + +++ Yes 
For all IgG 
subclasses: 
Main 
antibody of 
secondary 
response, 
neutralise 
toxins and 
virus 
FcγR 
  IgG1 
67% IgG Monomer Yes Yes Yes I,II,III 
  IgG2 
22% IgG Monomer Yes Yes Yes II 
  IgG3 
7% IgG Monomer Yes Yes Yes I,II,III 
  IgG4 
4% IgG Monomer No No Yes I,II 
IgM 10 Pentamer +++ + No 
Primary 
response 
secreted 
into blood, 
monomer 
attached to 
B cell 
surface 
  
IgA 15 Monomer, Dimer No No No 
Mucosal 
Response, 
tears,  
saliva, 
colostrum 
FcαR 
(CD89) 
  IgA1   Monomer, Dimer No No No     
  IgA2   Monomer, Dimer No No No     
IgD <0.5 Monomer No No No 
Part of B 
cell 
receptor, 
activated 
by 
basophils 
and mast 
cells 
FcδR 
IgE <0.01 Monomer No No No 
Allergic 
response, 
protects 
against 
parasitic 
worms 
FcεR 
I,II 
 
The Fc region of the antibody can be the site of auto-antibody binding such as 
rheumatoid factors found within the blood of rheumatoid arthritis sufferers. This class of 
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auto-antibody recognises the Fc portion of IgG antibodies. Within clinical or research 
immunological techniques, the Fc section of an antibody bound to an antigen is also the 
site of secondary antibody binding. Many secondary antibodies have dyes or enzymes 
covalently bound enabling visualisation of proteins or antigens recognised by the detection 
antibody (Alberts et al., 1994). 
1.3.5 Eosinophils and Basophils 
 
Basophils and eosinophils account for less than 1% and 5% of leucocytes 
respectively and are key players in allergic inflammation (Nadif et al., 2013). Eosinophils 
are responsible for regulation of allergy reactions and for preventing parasite and pathogen 
infections within the body. They develop in the bone marrow until they mature at which 
point they circulate the body until reaching a site of inflammation or infection (Murphy et 
al., 2008; Murphy & Weaver, 2017). Activated eosinophils fight viral infections via the 
release of granular proteins and the production of proinflammatory cytokines. Basophils 
are the least common white blood cell, they release histamine and following activation 
produce IL-4 in response to parasites together with IL-13, and are found in increased 
number within the lungs of patients who die of asthma (Stone et al., 2010). 
1.3.6 Platelets 
 
Platelets are small (2-3µm diameter), discoid and anucleate cell fragments, which 
circulate within the blood and were first observed by Giulio Bizzozero in 1882 (Ribatti & 
Crivellato, 2007; Ghoshal & Bhattacharyya, 2014). Also known as thrombocytes, they are 
abundant within circulation and originate from megakaryocytes (bone marrow cells), 
which fragment into 1000’s of platelets within the bone marrow in response to 
thrombopoietin, and are then released into circulation. Each megakaryocyte can produce 
5000-10000 platelets, with a healthy adult producing 1011 a day (Ribatti & Crivellato, 
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2007). Their primary role within the body is within wound repair through the initiation of 
coagulation cascades, preventing uncontrolled bleeding following tissue damage. 
Platelets circulate in their inactivated form until they are activated upon damage to 
a blood vessel, which results in the initiation of coagulation, known as hemostasis. 
Membrane lipids phosphatidylserine and phosphatidylinositol present in the inner plasma 
membrane during the inactive state are exposed during activation by ATP-dependent 
floppases and scramblases, leading to the coagulation cascade. 
Pro-aggregation signals known as platelet agonists enhance platelet adhesion to the 
site of injury and the platelet changes shape, releases granule contents and leads to 
aggregation with other platelets (Ribatti & Crivellato, 2007; Murphy et al., 2008). Surface 
receptors trigger the release of granule contents which includes α granules (GPIIbIIIa, 
fibrinogen, P selectin and vWF) and dense granules (catecholamines, serotonin, calcium, 
ADP and ATP), both of which play a role in normal (coagulation, inflammation, wound 
healing) and abnormal processes (atherosclerosis and tumourigenesis), (Blair & 
Flaumenhaft, 2009). The release of platelet granules amplifies the platelet response, 
leading to recruitment of further platelets and blood cells, formation of a platelet plug and 
eventually a thrombus preventing bleeding (Berg et al., 2010; J. L. Li et al., 2017). 
1.3.7 Cytokines and Chemokines 
 
Cytokines are a group of small proteins or glycoproteins which serve as chemical 
messengers involved in cell-to-cell signaling and are involved in a variety of processes 
such as cell growth and differentiation, tissue repair and immune function. Cytokines play 
a key role in regulating the magnitude, duration and nature of an immune or inflammatory 
response and range from 5-50 kDa. During inflammatory or acute phase response they can 
be easily detectable within serum. Three cytokines of particular importance within 
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initiation and regulation and communication between the innate and acquired immune 
systems are IL-1, IL-6 and TNF-α all of which are key to development and propagation of 
the acquired immune response (Tracey & Cerami, 1994; Brennan & McInnes, 2008; 
Dinarello, 2009), these cytokines are included in Table 1.2 illustrating cytokines, their key 
functions, origin and the cells they impact.  
Table 1.2 Key cytokines, their originating cell, function and cells impacted. 
Type of 
cytokine Function / Secreted by 
Cell type 
impacted References 
IL-1 
(IL-
1α,IL-
1β) 
Co-mitogen for T lymphocytes. 
Stimulate liver inducing 
transcription of acute phase proteins 
(APP). Leads to increase expression 
of inflammatory genes. 
Secreted by monocytes, 
macrophages, B cells, dendritic 
cells, endothelial cells. 
Endothelial cells, 
TH cells, B cells, 
hepatocytes, 
macrophages and 
neutrophils 
(Baumann & Gauldie, 
1994; Tracey & Cerami, 
1994; Gabay & Kushner, 
1999; Brennan & 
McInnes, 2008; 
Dinarello, 2009) 
IL-6 Growth factor for B cells. Stimulate 
liver inducing transcription of APP. 
Induces antibody production within 
B cells. Downregulation of TNF-α, 
IL-1. 
Secreted by monocytes, 
macrophages, TH2 cells, bone 
marrow cells. 
Hepatocytes,  
B cells, plasma 
cells, myeloid 
stem cells. 
(Baumann & Gauldie, 
1994; Tracey & Cerami, 
1994; Gabay & Kushner, 
1999; Brennan & 
McInnes, 2008; 
Dinarello, 2009) 
TNF-α Propagates T cell response via T 
helper cell type 1 (Th1). Stimulate 
liver inducing transcription of APP. 
Pro-inflammatory, induces cytokine 
production, cell proliferation and 
apoptosis. 
Secreted by macrophages, NK cells, 
CD4+ lymphocytes, adipocytes, 
basophils, eosinophils, dendritic 
cells. 
Endothelial cells, 
TH1 cells, 
hepatocytes. 
(Baumann & Gauldie, 
1994; Tracey & Cerami, 
1994; Gabay & Kushner, 
1999; Sun et al., 2005; 
Brennan & McInnes, 
2008; Dinarello, 2009; 
Chen et al., 2018) 
IFN-γ Pro-inflammatory, activation of 
macrophages and NK cells, 
inhibition of TH2 differentiation. 
Secreted by TH1, CD8 T cells, NK 
cells. 
Macrophages, NK 
and TH2 cells  
(Chen et al., 2018) 
IL-7 Pro-inflammatory, role within 
synovium reducing B cell apoptosis, 
increasing antibody production. 
Induces differentiation into 
progenitor B and T cells. 
Secreted by bone marrow and 
B Cells, 
hepatocytes, 
resting T cells, 
lymphoid stem 
cells 
(Lubberts et al., 2005) 
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thymic stromal cells. 
IL-10 Anti-inflammatory. Inhibits gene 
expression of T cell and 
macrophage pro-inflammatory 
cytokines, reducing function of 
antigen presenting cells.  
Secreted by TH2 cells, T cells, B 
cells 
Macrophages, 
antigen 
presenting cells, 
T cells. 
(de Waal Malefyt, 1991; 
Petrovic-Rackov & 
Pejnovic, 2006; Chen et 
al., 2018)  
IL-12 Highly inflammatory cytokine and 
stimulator of TNF-α and IFN-γ. 
Secreted by macrophages, 
neutrophils, B cells. 
Activated Tc 
cells, NK and 
activated TH1 
cells. 
(Furst & Emery, 2014; 
Chen et al., 2018)  
IL-15 Stimulates intestinal epithelium 
growth, T cell proliferation, co-
mitogen for B cell activation and 
proliferation. Promotion of CD8 T 
cell survival, osteoclastogenesis and 
bone destruction. 
Secreted by T cells and 
mononuclear phagocytes. 
T cells, intestinal 
epithelium , NK, 
activated B cells, 
osteoclast 
(Saeed & Revell, 2001; 
Cui et al., 2014; Lorenzo, 
2015) 
IL-17 Involved within stimulation of 
iNOS and chemokine synthesis, 
inducer of osteoclasts genesis and 
RANKL expression. 
Secreted by T cells, including Th17 
Osteoclasts, 
fibroblast, 
endothelial cells, 
epithelial cells, 
macrophages. 
(Kotake et al., 1999; 
Ouyang et al., 2008; van 
den Berg & Miossec, 
2009; Pickens et al., 
2010) 
 
IL-18 
Inducer of IFN-γ and gene 
expression in IL-6, iNOS, COX-2 
and increase chemokine production 
in human PBMC. 
Secreted by macrophages, 
monocytes, T and B cells, dendritic 
cells, epithelial cells 
Macrophages, 
monocytic and 
endothelial cells, 
T cells and NK 
cells. 
(Kunikata et al., 1998; 
Petrovic-Rackov & 
Pejnovic, 2006; Arend et 
al., 2008; Smith, 2011) 
IL-23 Acts on memory CD4+ cells, 
promoting proliferation and 
differentiation in to TH1 effectors, 
stimulates dendritic and NK cells. 
Secreted by macrophages, dendritic 
cells. 
Macrophages, 
memory CD4+ 
cells, dendritic 
and NK cells 
(Langrish et al., 2005; 
Gelderblom et al., 2018) 
 
IL-1 is a co-mitogen for T lymphocytes, IL-6 is a growth factor for B lymphocytes and 
TNF-α propagates the T cell response via T helper cell type 1 (Th1). These three cytokines 
stimulate the liver to induce transcription of acute phase reactants including mannose 
binding protein, lipopolysaccharide binding protein, amyloid A, amyloid P and CRP 
(Gabay & Kushner, 1999). IL-1 possesses several biological properties that result in 
increased expression of inflammatory genes, such as intercellular adhesion molecule-1 
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(ICAM-1) on endothelial cell surfaces and inducible nitric oxide synthase (iNOS) leading 
to increased expression of nitric oxide (NO). ICAM-1 in particular supports infiltration of 
inflammatory and immunocompetent cells into the extravascular space. IL-6 induces 
antibody production within B cells and induces hepatic acute phase protein response 
(Baumann & Gauldie, 1994; Brennan & McInnes, 2008), however it is also capable of 
suppressing proinflammatory responses via the downregulation of TNF-α and IL-1, 
however both TNF-α and IL-1 are potent enhancers of IL-6 expression, suggesting a 
carefully orchestrated balance between them. Whilst TNF-α is an important inducer of an 
immune response it is also responsible for inflammation and tissue injury during abnormal 
physiological responses. It plays a role in Th1 immune response regulation and also 
induces synthesis of IL-12 and IL-18 both inducers of IFN-γ, eventually increasing CD4+ T 
cell activation and inflammatory response. Secondary mediators induced by TNF-α include 
IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-18, IL-23 and TGF-β. TNF-α is produced by many 
cell types including B and T cells, macrophages, dendritic cells, basophils, eosinophils and 
NK cells (Bazzoni & Beutler, 1996; Edwards & Hallett, 1997; Brennan & McInnes, 2008). 
Of these cytokines, IL-1, IL-6 and TNF-α are amongst many others involved within 
the inflammatory pathways important within the progression of rheumatoid arthritis. These 
cytokines include pro-inflammatory cytokines such as, IL-7 which plays a role within the 
synovium reducing B cell apoptosis and increasing antibody production (Lubberts et al., 
2005),  IL-12, a highly inflammatory cytokine and stimulator of both TNF-α and IFN-γ 
(Furst & Emery, 2014) and IL-15, produced by monocytes, fibroblasts and endothelial cells 
which induces cytolytic factors, induces IFN-γ and TNF-α, activates neutrophils, and is 
involved in T cell proliferation (Petrovic-Rackov & Pejnovic, 2006). Another two pro-
inflammatory agents are IL-17 and IL-18. IL-17 is a T cell derived cytokine involved 
within the stimulation of iNOS and chemokine synthesis, which induces osteoclast genesis 
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and is found in high concentrations in RA patient synovial fluids (Kotake et al., 1999; 
Brennan & McInnes, 2008). IL-18 is involved in the increase of gene expression in IL-6, 
iNOS and COX-2, and also increases chemokine production within human PBMC. It 
works in synergy with other cytokines to stimulate production of INF-γ in T cells (Ushio et 
al., 1996; Arend et al., 2008). Of the anti-inflammatory cytokines, IL-10 inhibits gene 
expression of T-cell and macrophage proinflammatory cytokines, and reduces the function 
of antigen presenting cells (de Waal Malefyt, 1991; Petrovic-Rackov & Pejnovic, 2006), 
IL-11 down regulates IFN-γ (Kotake et al., 1999), and IL-13, reduces the induction of IL-
1β, TNF-α and iNOS (Arend et al., 2008). 
Working together with cytokines are the group of proteins known as chemokines. 
Chemokine is a shortened version of chemoattractive cytokine(s) and references a group of 
40 plus secreted proteins ranging between 6-14kDa. Chemokines recruit and activate 
lymphocytes, monocyte/macrophages, eosinophils and neutrophils. This family of proteins 
include IL-8, MCP-1, MCP-2, MCP-3, RANTES and IFN-γ-inducible protein 10 (IP-10) 
amongst others (Szekanecz et al., 2010). 
1.3.8 The Pentraxin Family 
 
CRP belongs to the pentraxin family of calcium dependent ligand-binding plasma 
proteins, made up of long pentraxin 3 (PTX3) and short pentraxins serum amyloid protein 
(SAP) and CRP (Osmand et al., 1977). These proteins show high sequence homology, are 
evolutionarily highly conserved and are expressed in response to systemic inflammation, 
tissue damage or infection (Sjöwall & Wetterö, 2007a). The short pentraxins CRP and SAP 
recognise harmful pathogens and eliminate them via macrophage or complement action 
(Agrawal et al., 2009).  SAP is involved in resistance to bacterial infection and is also 
found as a pentamer, although this has the ability to form decamers in the absence of 
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calcium in the conformation of two stacked pentameric rings (Hutchinson et al., 2000).  
PTX3 is produced from vascular and immune cells, SAP and CRP are produced 
predominantly within the liver, all in response to pro-inflammatory signals and stimuli 
(Hutchinson et al., 1994; Koenig et al., 1999). All three pentraxins are implicated in the 
inflammatory disease atherosclerosis, a condition greatly accelerated in RA patients (Bassi 
et al., 2009). 
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1.4 Human C-reactive Protein 
1.4.1 Overview of C-reactive Protein 
 
The human CRP molecule (115 kDa) consists of five 23 kDa, identical, 
nonglycosylated subunits, non-covalently associated and arranged symmetrically around a 
central pore known as pentameric CRP (pCRP) (Shrive et al., 1996). CRP was first 
observed in the laboratory by Oswald T. Avery, who was developing therapies against 
pneumococcal pneumonia (Tillett & Francis, 1930).  Tillet & Francis in the early 1930’s 
discovered a new antigen within the serum of patients with inflammatory and infectious 
diseases, calling it Fraction C (Tillett & Francis, 1930). They noted that this agent 
produced a strong precipitation reaction with C-polysaccharide (CPS) during initial acute 
disease stages, but fell as the patient recovered. The same reaction occurred within patients 
suffering from other diseases such as bacterial endocarditis and acute rheumatic fever with 
the three researchers terming the protein C-reactive (Tillett & Francis, 1930).  
The necessity of calcium ions to enable CRP binding was established in addition to 
its role within a non-specific response to infection or inflammation.  CRP was the first of 
the acute phase proteins to be described due to the sudden and dramatic rise in its serum 
levels in the initial phase of inflammatory disease (de Beer et al., 1982). As part of the 
acute phase inflammatory response, it forms part of the body’s non-specific biochemical 
and physiological reaction to tissue damage through infection, inflammation or malignant 
neoplasia (Hirschfield & Pepys, 2003). 
In healthy adults, baseline levels of CRP range from 1-3mg/l (Pepys & Hirschfield, 
2003). Due to the sensitivity of CRP detection within plasma or serum, it is possible to 
predict inflammation within the body when levels are raised above 3 mg/L, which is 
considered a strong predictor of current or future disease (Pepys & Hirschfield, 2003). 
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However it is reported that associations between genetic polymorphisms in IL-1 and IL-6 
can cause fluctuations within this baseline level, with those affected individuals linked to 
elevated basal levels of CRP. In addition to IL-1 and IL-6 polymorphisms, mutations 
within the promoter region of the CRP gene are also implicated within higher baseline 
CRP levels (Vickers et al., 2002; Pepys & Hirschfield, 2003). Our immune defence system 
has evolved over thousands of years, with many proteins and systems retained and 
conserved across species. Some of these proteins are rarely found mutated, non-functioning 
or absent, and therefore suggest a beneficial role within our now complex immune system. 
CRP falls into this category as the common genetic variants found at the CRP locus are 
only associated with levels of CRP translated, not to its structure or functions which are 
both retained. These mutations accounted for an approximate 3.5-fold change in one study 
(Rhodes et al., 2010). 
During periods of tissue damage, inflammation or infection, cytokines produced at 
the site of pathology instigate the upregulation of CRP and other acute phase proteins, 
commonly within hepatocytes of the liver. The functional role of pCRP within the human 
body appears predominantly to be that of binding dead or damaged cells and of 
opsonisation, allowing removal of particles via phagocytosis together with cytokine 
mediated induction of the immune system, it is therefore thought to act in a protective 
manner, avoiding further inflammation (Meyer, 2010). However CRP is also responsible 
for the induction of pro-inflammatory cytokine synthesis and release from other immune 
system components (Ballou & Lozanski, 1992).  
CRP has a role within modulation of the immune system, via interactions between 
itself and C1q a constituent part of the classical pathway. CRP recruits C1q to the surface 
of damaged cells. C1q is the recognition molecule within the larger complex C1, composed 
of one C1q, two C1r and two C1s molecules (Volanakis & Kaplan, 1971; Volanakis et al., 
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1981; McGrath et al., 2006). The C1q molecule is composed of six copies of three 
polypeptide chains, A (223 residues), B (226 residues) and C (217 residues) which 
combine to form a globular head region (GHR) and a collagen like region (CLR) (Kishore 
et al., 2004). Whereas CRP is composed of 5 protomers forming a pentamer of 115 kDa, 
C1q is four times larger with a molecular mass of 460kDa (Volanakis & Kaplan, 1971; 
Volanakis et al., 1981; McGrath et al., 2006). It is the GHR which is suggested to interact 
with CRP as shown within Figure 1.1.   
 
Figure 1-1 Schematic illustration of the hypothesized interaction between the globular head 
region (GHRs) of C1q with the effector face of pentameric CRP. GHR A shown in blue, B 
shown in green and C shown in red. The model was designed to explore the potential 
interactions between the GHR of C1q and CRP. Key residues suggested to interact 
between the two proteins are highlighted as ball and stick models shown (Asp112 and 
Tyr175 of CRP, and Tyr175B, Lyc200A and Trp147A of C1q). Image adapted from 
(Kishore et al., 2004). 
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With a main site of synthesis found to be within hepatic cells, serum levels rise 
rapidly in response to IL-6, IL-1 and TGFE, the latter involved in upregulation of CRP 
gene transcription within hepatocytes (Ganapathi et al., 1990). Serum levels elevated 
above those within the normal healthy CRP range of 1-3 mg/l, often indicate an underlying 
diseased state, inflammation or autoimmune linked conditions such as RA. Due to the often 
rapid increase of serum levels in response to inflammation, upwards of 100 fold within 24-
72 hours, CRP is used routinely within a clinical setting as a marker of a non-healthy 
inflammatory state (Pepys & Hirschfield, 2003).  
Whilst the structure and suggested role of pentameric CRP has been well 
documented, the role, and indeed existence of, monomeric CRP (mCRP) within the human 
body is less certain and has been cause of discordant theories throughout the last decade. It 
is suggested by some to be a pathogenic form of CRP (Mihlan et al., 2011; Thiele et al., 
2014; Chirco et al., 2016) and has been identified in co-localisation with damaged or 
inflamed tissue (Thiele et al., 2014; Chirco et al., 2016). Others  however suggest it may 
not play a physiologically active role at all, because mCRP does not persist within the body 
as it is normally rapidly catabolised, therefore not considered to occur as a physiologically 
active protein (Pepys & Hirschfield, 2003). 
1.4.2 Structure of Human C-reactive Protein 
 
Each of the five identical subunits, termed protomers or monomers, contains 206 amino 
acids, with X-ray crystallography showing that each consist of two layered, antiparallel β 
sheets with a flattened jelly roll conformation similar to lectins such as concanavalin A 
(Shrive et al., 1996). The antiparallel β sheets are illustrated within Figure 1.2 which also 
shows the arrangement of subunits around the central pore. 
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The crystal structure of CRP was solved in 1996 by Shrive et al and shows an 
internal stabilising disulphide bond. Intersubunit binding involves the interaction with salt 
bridges Glu101 – Lys201, Lys123 – Glue197 and Asp155 – Arg118 between the 115-123 
amino acid loops in one protomer and 197-202 and 40-42 in the next (Shrive et al., 1996). 
Each protomer contains two calcium ions, involved in binding coordination of ligands such 
as phosphocholine (PC) (see Figure 1.3), which is expressed on the surface of dead or 
damaged cells. Each subunit has a recognition face consisting of a PC binding site formed 
by a hydrophobic pocket and two adjacent calcium ions (Shrive et al., 1996), and an 
effector face on the opposite side containing a cleft like region, extending from the central 
pore of the pentamer towards the middle of each protomer  (Shrive et al., 1996; Thompson 
et al., 1999). 
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Figure 1-2 The three dimensional structure of pentameric C-reactive protein. The five 
protomers are arranged around a central pore, with the α-helix in pink and the β-sheets in 
blue. Calcium ions are illustrated in orange. C1q binding is suggested to take place on the 
face shown, with globular head region (GHR) of C1q positioned within the central pore. 
Phosphocholine binding takes place on the opposite face in close proximity to the calcium 
ions visible on five protomers. Image of 1GNH (Shrive et al., 1996) created with CCP4MG 
(McNicholas et al., 2011). 
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Figure 1-3 Chemical structure of phosphocholine. PC is the main ligand of CRP and a 
major constituent of cell membranes. PC is expressed on the surface of dead or dying cells 
allowing CRP to distinguish between damaged and healthy. 
 
Each protomer contains two calcium ions, each crucial to the stability and binding 
ability of CRP, with an absence of calcium inducing structural changes to the pentameric 
conformation. When calcium is lacking the loop formed by residues 140-150 exposes inner 
sites vulnerable to proteolysis and destabilisation of the subunit (Ramadan et al., 2002) as 
shown in Figure 1.4. One calcium is coordinated by Asp60 together with Asn61, Glu138, 
Asp140 and Gln139. The second calcium is bound with residues Glu138, Asp140, Gln150, 
and Glu147 (Shrive et al., 1996, Thompson et al., 1999). 
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(a.) (b.) 
 
 
 
 
 
 
 
 
  
Figure 1-4 Monomeric CRP subunit with the residues 140-150 loop highlighted in red, 
with and without stabilising calcium ions shown in orange. (a) The loop stabilised by an 
interaction with calcium and (b) Relaxation of the loop in the absence of calcium allowing 
access to proteolytic enzymes. Image of PDB ID:1GNH (left) and 1LJ7 (right) created with 
PyMol (DeLano, 2002).     
 
Phosphocholine binding is stabilised by a phosphate calcium interaction within the 
calcium binding site as can be seen in Figure 1.5. Two oxygen atoms of PC interact with 
the two calcium ions, with the third oxygen positioned towards the solvent enabling PC to 
interact with other molecules in the area via ester linkage. Choline is then able to position 
away from the calcium binding site towards the hydrophobic pocket formed by side chains 
from Phe66, Thr76 and Leu64 (Shrive et al., 1996, Thompson et al., 1999). A hydrophobic 
interaction is formed between the tertiary methyl groups of the choline moiety and the 
aromatic face of Phe66.  
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Figure 1-5 Structural model of the interaction between phosphocholine and the calcium 
ions on a CRP protomer. Image of PDB ID:1GNH (Shrive et al., 1996) created with 
CCP4mg (McNicholas et al., 2011). 
 
The opposite side of protein from the ligand binding site lies the effector face. A 
cleft like region is found running from the edge of the central pore of the pentamer, to the 
middle of each protomer (Shrive et al., 1996). It is thought that this is the region of 
interaction between CRP and C1q, allowing activation of complement and classical 
pathway following CRP interaction with PC (Agrawal et al., 2001, Shrive et al., 1996, 
Thompson et al., 1999). Forming one side of the cleft is an α helix (Figure 1.2) formed 
from residues 168 – 176, which lies across one of the two β-sheets, with the carboxyl end 
forming one side of the cleft. This cleft runs from the centre of the each individual 
protomer to its edge at the central pentamer pore, with the opposite cleft side formed by the 
carboxyl termini of the protomer, forming a narrow, deep cleft which becomes shallower 
towards the middle of the pentamer (Shrive et al., 1996, Thompson et al., 1999). Three 
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residues rise form the cleft, His38, His95 and Tyr205 and the outer edge is positively 
charged, but the inner parts and lining of the cleft remain negative (Volanakis, 2001). 
1.4.3 C-reactive Protein Synthesis 
 
Proteins such as CRP which show high genetic uniformity through a wide variety 
of species, from mammals to fish, suggest their importance towards survival within those 
animals. CRP is an evolutionally conserved protein which forms an intrinsic part of the 
immune system of even the most primitive of species. The human CRP gene is located on 
the long arm of Chromosome 1 in the 1q23.2 region and is composed of two exons 
separated by one intron. The initial exon encodes the signal peptide and first two amino 
acids of the final expressed serum protein followed by a 278 nucleotide intron which 
includes a GT repeat sequence. The second exon encodes the remaining 204 amino acids, 
together with the stop codon (Hage & Szalai, 2007).  
CRP is synthesised in response to IL-1 and IL-6 stimulation and activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and transcription 
factor NF-IL-6/CAAT-enhancer binding protein (C/EBP), C/EBPβ and C/EBPδ (Pepys & 
Hirschfield, 2003; Sjöwall & Wetterö, 2007a). The principle inducer of CRP is IL-6 whilst 
IL-1, glucocorticoids and other factors including complement activation products act upon 
IL-6 to enhance its effects (Ganapathi et al., 1990). The proximal region of the promoter 
contains two sites for IL-6-inducible CCAAT/enhancer binding proteins (C/EBP) (Li & 
Goldman, 1996), with two HNF-1 and one STAT3 sites located close to these sites (Zhang 
et al., 1996). Binding of C/EBPβ and δ to binding sites upstream of the promoter, results 
from IL-6 stimulation, in the presence of Rel protein p50. Following transcription the 206 
amino acid protomers are assembled into their pentameric conformation within the 
endoplasmic reticulum and under physiologic conditions are retained there by two 
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carboxylesterases. Following the acute phase response the recorded half time for exit falls 
from 18h to 75mins, due to a decreased affinity for one esterase allowing the pooled CRP 
to be released (Yue et al., 1996). 
CRP levels rise rapidly within 2 hours of acute inflammation/infection peaking at 
48 hours (Gabay & Kushner, 1999), with a short half-life 18-19 hours, therefore providing 
a relatively rapid drop in levels (Pepys & Hirschfield, 2003), suggesting that increased 
serum levels are the result of significantly elevated expression rather than a gradual build 
up over a prolonged period. In human hepatoma Hep3B cells, CRP expression is induced 
by IL-6 via activation of transcription factors STAT3 and C/EBPβ (Agrawal et al., 2001). 
However, IL-1 has no direct action on CRP expression, but is thought to work in synergy 
with IL-6 (Ganapathi et al., 1991). A later study investigated the role of NF-κB within 
CRP expression and found that it regulates CRP expression in partnership with C/EBPβ on 
the CRP proximal promoter. Overlapping NF-κB and OCT-1 binding sites were 
determined to be the regulatory element. OCT-1 is a transcription factor responsible for a 
variety of roles in cellular transcriptional regulation as well as an activator of gene 
transcription. Belonging to the Pit-Oct-Unc family of homeodomain protein transcription 
factors (POU), OCT-1 is also able to repress transcription. Baseline CRP expression was 
found to increase markedly when binding of NF-κB and OCT-1 was prevented (Voleti & 
Agrawal, 2005).  
It is suggested that during the acute phase response CRP expression is not only up-
regulated, but that stocks of CRP may have previously been stored within the endoplasmic 
reticulum (ER), and that these may in part account for the rapid increase of plasma CRP 
levels (Macintyre, 1992; Yue et al., 1996). Although CRP is synthesised by hepatic cells at 
relatively low constituent levels it was suggested by Macintyre (1992) that a ‘pool’ is 
retained within the ER via calcium dependent binding, modulated by the flux of internal 
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calcium levels, allowing it to be released during the transiently reduced calcium 
environment found during the initial acute phase response. Macintyre (1992) suggested 
that there may be further functions for CRP within the ER that may be ‘superseded’ during 
an acute phase response, noting the similarities in sequence and structural homology 
between CRP and nucleoplasm, and the ability of CRP to bind chromatin, histones and 
snRNPs (Macintyre, 1992).  Further research by Yue et al., (1996) clarified these findings 
when it became apparent that CRP interacted with two glycosylated microsomal 
carboxylesterases, gp60a and gp60b, within the ER. The carboxylesterases are localised 
within the ER lumen via COOH-terminal retention signals HIEL and HTEL, suggested to 
be part of the KDEL retrieval pathway (Yue et al., 1996). The KDEL receptor is an 
integral membrane protein which retrieves proteins of the ER labelled with a C-terminal 
KDEL sequence (Cabrera et al., 2003).   
During an acute phase response the CRP rate of synthesis within hepatocytes is 
increased and the binding affinity to gp60a/b is reduced, allowing rapid release of the 
pooled CRP. Of the two carboxylesterases, gp60a has a lower binding affinity for CRP but 
is found in abundance whereas gp60b in contrast has higher affinity but is found in less 
abundance. This group further speculated that the sequences involved within CRP and 
gp60 interaction were Ala-Arg-Asn-Arg-Asn found at the beginning of high affinity gp60b 
and the similar Ala-Arg-Asn-Gly-Asn sequence found in the lower affinity gp60a (Yue et 
al., 1996).  These sequences were proposed due to similarities with CRP binding sequences 
found by Du Clos et al, (1999), who looked at CRP binding to histones, H2A, H1 and the 
small nuclear ribonucleoprotein particle protein Sm-D, finding a common motif consisting 
of positively charged amino acids, lysine or arginine which alternate with neutral alanine 
or glycine  (Mold et al., 1999). 
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In addition to expression within hepatocytes, it is now accepted that CRP is synthesised 
locally within a variety of cells and tissues, including renal tumour cells (Jabs et al., 2005).  
In their 2010 study Haider et al showed expression within peripheral blood mononuclear 
cells (PBMC). They were also able to show that induction was increased by IL-1, IL-6 and 
TNF-α with IL-10 reducing CRP expression in these cells (Haider et al., 2006). Another 
study investigating CRP expression in human lung epithelial cells, using cell line A549, 
showed that CRP was expressed following treatment with either TNF-α, carbon particles 
(CB) or ultra-fine carbon black particles (ufCB). It was also found that expression of CRP 
with CB and ufCB treatments was dependent on NFκB (Ramage & Guy, 2004). CRP 
expression has also been shown in human vascular smooth muscle cells (HVSMC) and 
human umbilical vein endothelial cells (HUVEC) (Kang et al., 2005).  
1.4.4 Serum CRP Levels in Health and Disease  
 
In normal, healthy adults the baseline level of CRP ranges from 1 -3 mg/l (Pepys & 
Hirschfield, 2003). Serum CRP has long been used within diagnosis to determine disease 
or risk of disease. Rheumatoid arthritis is just one such disease in which levels climb and 
are often sustained at a higher than normal concentration. As a marker of inflammation it is 
useful to determine severity and risk factor for a variety of inflammatory and autoimmune 
diseases, including cardiovascular disease, atherosclerosis, hypertension and diabetes 
(Kuller et al., 1996; Koenig et al., 1999; Hayaishi-Okano et al., 2002). In addition to 
physical diseases, depressive symptoms, frequently associated with schizophrenia have 
recently been associated with elevated CRP levels above 3 mg/l, with 40.4 % of 125 
participants in the study found to have high CRP levels (Faugere et al., 2018). In fact, 
levels of CRP above this baseline have been suggested to be as strong indicators of disease 
or predicted diseased state in a wide range of conditions. In their 2010 paper Zhao et al 
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described the strong correlation between a levels of CRP ≥ 2.09 mg/l and incidence of 
obesity, hypertension, diabetes, cholesterol imbalance and cardiovascular disease (Zhao et 
al., 2010). 
CRP levels vary with ethnic status and where the risk factor cutoff for CVD is 3 
mg/l in Western populations, this may not be the case within others. It is reported that the 
distribution of CRP in the Asian population differs from that of the Western with a 
suggested ‘safe’ cut off of CRP ≥ 2.09 mg/l with mean values of 0.55mg/l (0.61 mg/L in 
males, 0.51 mg/L in females) (Zhao et al., 2010). Elevated CRP is closely linked with 
inflammatory diseases, although it is still not completely clear as to whether this is due to 
cause or effect. 
1.4.5 Pentameric C-reactive Protein 
The native conformation of CRP is in its pentameric form, with all five PC binding 
sites found on the same face of the pentamer. The effector face forms the opposite side of 
the pentamer, it is here that complement C1q binds CRP; it is presumed Fcγ receptors also 
interact at this face (Shrive et al., 1996). Structural studies investigating FcγRIIa 
interactions with the effector face of SAP show binding via a receptor which lies 
diagonally across each SAP pentamer, with contact made with ridge helices from two SAP 
protomers  (Lu et al., 2008). The structural homology between SAP and CRP suggests this 
location is also the area of Fc binding with CRP.  It is known that in order for C1q to 
activate complement, it must interact with more than one CRP pentamer, this may be due 
to the differences in scale of the two proteins and steric hinderance, C1q being 
considerably larger (Voleti & Agrawal, 2005). Black et al., (2004) suggest C1q interaction 
with the effector face of CRP and optimal binding take place following slight 
conformational changes within the CRP structure; they also propose that conformational 
changes occurring during C1q binding differ according to which ligand is bound (Black et 
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al., 2004), with Figure 1.6 illustrating the range of ligands CRP is known to bind.  Agrawal 
however disagrees arguing PC ligand binding by CRP does not produce a conformational 
change, or signal within the protein leading to C1q initiation of complement, but that the 
necessity of C1q to bind multiple CRP pentamers is overcome by the aggregation of CRP 
bound to exposed PC (Voleti & Agrawal, 2005). 
 
 
Figure 1-6 Diagram illustrating CRP ligands, including phosphocholine present on bacteria 
and apoptotic cells, C1q and  FcγR1, FcγRI1b and FcγR1Ia. Adapted from Marnell et al., 
2005. 
 
 
Histones, 
Fibronectin, 
snRNP 
Laminin, 
Chromatin 
Via C1q 
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1.4.6 Monomeric C-reactive Protein  
 
Although initially dismissed (Pepys & Hirschfield, 2003), growing evidence now 
exists for the presence of a monomeric form of CRP (mCRP) occurring naturally within 
the body (Rees et al., 1988; Ciubotaru et al., 2005; Sjöwall & Wetterö, 2007a; Agrawal et 
al., 2009; Zhao et al., 2010),with auto-antibodies against mCRP found within the serum of 
SLE patients (Sjowall and Wettero, 2007). It is possible that the two conformations hold 
distinctly different inflammatory, stimulation and inhibition roles. Controversy still 
surrounds the biological existence of mCRP and the role it together with the pentameric 
form may play in the development of cardiovascular diseases such as atherosclerosis 
(Schwedler et al., 2005; Agrawal et al., 2010). The controversy surrounding the 
inflammatory effects of either pCRP or mCRP is compounded by the evidence suggesting 
commercially available anti-CRP antibodies used to identify pCRP in many studies (e.g. 
CRP-8 mAb, Sigma Aldrich), actually cross react with mCRP and in some cases have 
greater affinity to the monomeric form (Ciubotaru et al., 2005; Jabs et al., 2005; Schwedler 
et al., 2009). This knowledge may call into question some of the pro-inflammatory effects 
claimed for native pentameric CRP, and it is indicated that mCRP plays an active role 
within the inflammation associated with atherosclerosis (Ji et al., 2009). 
Pentameric CRP is considered to be a soluble serum protein, in contrast mCRP is 
considered a poorly soluble, tissue based form of the protein (Ciubotaru et al., 2005; 
Agrawal et al., 2009; Ji et al., 2009), with a tendency to self-aggregate (Ciubotaru et al., 
2005). Whilst it is possible that the native pentameric form may behave as a precursor to a 
proinflammatory monomeric form (Ji et al., 2009), little is known about the physiological 
origins of mCRP, although there is much speculation regarding possible local expression 
and dissociation mechanisms.        
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Monomeric subunits have been formed in vitro from the native pentamer via 
various harsh denaturing conditions such as a high urea concentration, altered pH, heat 
above 70ºC or low calcium levels, in the presence of a chelating agent (Kresl et al., 1998; 
Sjöwall & Wetterö, 2007a; Taylor & Van Den Berg, 2007). Whilst it is possible that the 
acidic conditions, pH5.5 – 7 (Zhang et al., 2009) and mild hypocalcemia < 2.12 mM 
calcium (Aderka et al., 1987; Zhang et al., 2009) of an inflammatory microenvironment or 
bacterial infection may allow dissociation of pCRP into the monomeric form, these in vitro 
creation methods have led to debate as to the biological relevance of this form (Pepys and 
Hirschfield, 2003). 
In support of the existence of naturally occurring mCRP, evidence appears to 
confirm dissociation under physiologically relevant conditions, following binding to 
plasma membranes (Sjowall and Wettero, 2007), and possible in vivo dissociation 
following membrane interaction (Ji et al., 2009; Schwedler et al., 2009). Although 
originally believed stable and unlikely to dissociate into subunits, Ca2+ dependent binding 
of circulating pCRP to liposomes or cell membranes, was found to result in subsequent 
dissociation (Eisenhardt, Habersberger & Peter, 2009; Ji et al., 2009; Schwedler et al., 
2009).  Apoptotic monocytic THP-1 and Jurkat T cells can mediate this form of 
dissociation (Eisenhardt, Habersberger & Peter, 2009; Eisenhardt, Thiele, et al., 2009), 
with similar results found using activated platelets (Eisenhardt, Habersberger & Peter, 
2009; Filep, 2009; Ji et al., 2009) seen in Figure 1.7 in which dissociation is facilitated by 
platelet membrane binding. In an early study investigating pCRP dissociation on 
monolayer membranes, (Wang & Sui, 2001) observed the specific binding of pCRP to PC 
containing membranes and subsequent dissociation of the pentamer into an open ring 
structure consisting of 2 subunits. This conformation retained C1q binding site availability 
and also exposed two neoepitopes (Wang & Sui, 2001). 
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Figure 1-7 Diagram showing a suggested mechanism of pCRP dissociation mediated by 
activated platelets at the site of atherosclerotic plaques. Inflamed or damaged endothelium 
leads to the adherence of platelets which become activated exposing lipids such as 
lysophosphatidylcholine on the cell surface. Circulating pCRP binds to PC on adhered 
platelets, dissociating into mCRP. Circulating monocytes are stimulated by mCRP and 
integrin receptors activated (shown in green), reactive oxygen species (ROS) are released. 
Monocytic cells bind to receptors on endothelial cells (shown in orange) and transmigrate 
into the intima, forming foam cells. mCRP is then deposited within the atherosclerotic 
plaque. It is also possible that mCRP becomes dislodged from monocytic cell membranes 
becoming circulatory. Figure has been adapted from Eisenhardt et al., (2009). 
 
The binding of pCRP to lysophosphatidylcholine (LPC) expressed on the surface of 
activated platelets and apoptotic monocytic THP-1 cells, reportedly resulted in structural 
changes of the subunits from predominantly β sheet, to predominantly α helix during 
dissociation to mCRP. This was suggested to expose inter-subunit residues 197-202 
normally hidden as indicated within Figure 1.8, which are further suggested to form 
neoepitopes (Filep, 2009). This theory would be dependent on the breakage of a strong 
internal di-sulphide bond formed between the two β sheets of each protomer stabilising its 
conformation. It is possible that newly exposed internal and inter-subunit residues provide 
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the monomer with additional physiological functions, and that all CRP isoforms may have 
distinct bioactivities under differing pathophysiological conditions (Ji et al., 2007).  
 
Figure 1-8 Structure illustrating the intersubunit contacts between two CRP  protomers. 
The two calcium ions are shown in subunit 1 (pink), with their absence illustrated in 
protomer 2 (turquoise). Residues 199-206 within the interface believed to be exposed upon 
dissociation are illustrated in ball and stick. Image of PDB ID:1GNH (Shrive et al., 1996) 
created with CCP4mg (McNicholas et al., 2011) 
 
During urea gradient electrophoresis, Kresl et al. (1998) reported a transitional 
conformation between pCRP and the formation of mCRP, observed at a 3M urea 
concentration. It was not possible to reverse these findings and re-associate the monomers. 
This may be due to the absence of an 18 amino acid leader sequence which forms part of 
the initially expressed pre-CRP protein and is cleaved during post-translational pentameric 
processing. It may also be possible a molecular chaperone protein is necessary during 
conformational folding and subunit association forming the final pentameric structure 
(Kresl et al., 1998). 
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A dissociated open ring conformation has been explored by Ji et al. (2007), with a 
proposed mechanism of mCRP formation. Using egg phosphatidylcholine (eggPC) / lyso-
phosphatidylcholine (lysoPC) liposomes as membrane models, a reduction in the 
tryptophan content of CRP indicated a change of tertiary structure. Monoclonal antibody 
(3H12) created by the group, was used to probe for neoepitopes aa.199-206, as illustrated 
within Figures 1.8 & 1.9, exposed solely in mCRP, which again indicated membrane 
associated dissociation. The group suggests that multipoint attachment to a fluid membrane 
and a hydrophobic micro-environment are essential for the dissociation to take place. They 
propose that the membrane bound subunit (mCRPm) interacts via hydrophobic insertion 
and although dissociated, retains a loose pentameric conformation, as evidenced by dual 
antigenicity to both mCRP and pCRP mAbs. The change to mCRPm also revealed greater 
complement activation efficiency, possibly due to avoidance of steric hindrance provided 
by Lys (114) and overcoming the greater size of C1q, suggested as a biological reason for 
the dissociation (Ji et al., 2007). This dissociation and membrane binding process is in 
broad agreement with similar studies (Wang and Sui, 2001; Ji et al., 2009; Filep, 2009; 
Sjowall and Wettero, 2007; Kresl et al., 1998). 
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Figure 1-9 Structure of pentameric CRP with the intersubunit residues 199-206 highlighted 
as sticks. Residues 199-206 believed to be exposed when the pentamer dissociates, are 
detected by the monomer specific, monoclonal mouse anti-human mCRP (3H12) antibody. 
Image of PDB ID:1GNH (Shrive et al., 1996) created with CCP4mg (McNicholas et al., 
2011) 
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The modified monomeric form of CRP shows differing binding properties to the 
native pentameric form, as well as unique antigenic and electrophoretic reactivities (Kresl 
et al., 1998), resulting in the change of isoelectric point (pI) from 6.4 to 5.4 (Bíró et al., 
2007). Monomeric CRP may not specifically bind PC, as pCRP is observed to; Wu et al., 
(2002) reported that monomeric CRP protomers bind via nonspecific electrostatic forces to 
negatively charged membranes, with positively charged and neutral surfaces found to 
contain few monomers (Wang et al., 2002). It is suggested in their study that the 
interaction between monomers, although mainly via salt bridges is also stabilised by 
hydrophobic forces. The dissociation may result from the breakdown of the salt bridges 
and exposure of the hidden hydrophobic areas within acid or depolarized environment. 
The monomeric form of CRP has now been identified within several diseases 
including age-related macular degeneration (Chirco et al., 2016), stroke and Alzheimer’s 
disease (Strang et al., 2012; Slevin et al., 2015), atherosclerotic plaques and infarcted 
myocardium (Thiele et al., 2014), acute myocardial infarction (Wang et al., 2015) and 
antibodies against mCRP have been observed in systemic lupus erythematosus (SLE) and 
tubulointerstitial nephritis and uveitis (TINU) syndrome (Tan et al., 2008; Sjowall et al., 
2009; Wetterö et al., 2009). 
1.4.7 Human C-reactive Protein Ligand Interactions  
 
CRP is documented to interact with a range of ligands in a calcium dependent 
manner (Figure 1.6), the pentraxin group are characterised by their interaction with 
phosphate containing ligands in addition to PC; these include small nuclear 
ribonucleoproteins, chromatin, histones, phosphoethanolamine, fibronectin, polycations 
and laminin (Black et al., 2004; Sjöwall & Wetterö, 2007a). 
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CRP has been shown to interact with human apoptotic cells, modified plasma 
lipoproteins and small ribonucleoprotein particles, in addition to pathogens within the body 
including bacteria, parasites and fungi. CRP detects ligands present on the surface of these 
microorganisms and will bind enabling an immune response (Mold et al., 1999; Gershov et 
al., 2000; Pepys & Hirschfield, 2001, 2003). The principle ligand of CRP is PC which is a 
constituent part of the polar head group of phospholipids, teichoic acids, bacterial 
lipopolysaccharides and galactan polysaccharides  (Volanakis et al., 1981; Volanakis, 
1982).  
Cell membranes from both eukaryotic and prokaryotic cells are rich in PC, although 
it is inaccessible within the healthy cells of a human body where it forms part of 
compounds such as phosphatidylcholine. Secretory enzyme phospholipase A2 cleaves 
phospholipids upon damage to a cell membrane, exposing PC and therefore allowing 
detection and binding of CRP to damaged but not healthy cells (Volanakis & Narkates, 
1983). When CRP encounters a bacterial cell it will usually bind a PC component which is 
part of a larger structure such as the C-polysaccharide present on Streptococcus 
pneumoniae. C-polysaccharide is a teichoic acid, a bacterial polymer of glycerol phosphate 
or ribitol phosphate, choline phosphate, N-acetyl galactosamine, N-
acetyldiaminotrideoxyhexose and glucose residues, part of the gram positive bacterial cell 
wall (Gotshclich & Liu 1966, Poxton et al., 1978). 
1.4.8 Human C-reactive Protein Receptor Binding 
 
Receptors for the Fc regions of IgG provide important links between the humoral 
immune system and effector cells. Three important receptors involved within CRP cellular 
interactions are FcγRI, FcγRII and FcγRIII, of these receptors FcγRI (CD64) is a high 
affinity receptor and the remaining two low affinity. CRP shares many functions with IgG, 
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including the ability to activate complement and bind monocyte and neutrophil receptors 
with an affinity comparable to IgG. Native pentameric CRP binds normal, undamaged cells 
via FcγRI and RII (CD32, CD64) in a calcium independent manner via the effector face 
(S.-R. Ji et al., 2006). Further studies with COS-7 cells and pentameric CRP found binding 
to both FcγRI and FcγRII but not FcγRIII (Tron et al., 2008). It is expected that CRP 
associate equally with FcγRI and FcγRII, however this was not the case, binding was 
preferential to the high affinity receptor. Possible explanation suggests that CRP is more 
able to bind if clustered to FcγRII. FcγRI has three extracellular Ig like domains, whereas 
FcγRII and FcγRIII have two, suggesting reduced affinity (Tron et al., 2008). The Fc 
fraction of human IgG binds each receptor, however it was found that mouse IgG1 isotype 
does not. Xing et al., (2008) found similar CRP / FcγRI interactions in vivo. 
As the number of Ig classes and isotypes increased during evolution so did the 
number of isotype specific receptors (Akula et al., 2014). The four IgG isotypes are 
accompanied by the four major types of Fc receptor, FcγRI, FcγRII, FcγRIII, FcγRIV, each 
with variable affinity dependent on IgG isotype, these interactions are shown in Table 1.3. 
The Ig binding subunit is the α chain of the receptor and in humans all IgG and IgE 
receptors have two extracellular Ig like domains with the exception of FcγRI which has 
three (Akula et al., 2014). All IgG and E receptors have a transmembrane region anchoring 
to the membrane except FcγRIIIB, which is a glycosylphospatidylinositol (GPI) anchored 
receptor. Both IgG and each FcγR gene are found on Chromosome 1, with  FcγRII and 
FcγRIII in close proximity to the IgG gene location at 1q21.2 (Akula et al., 2014) and CRP 
gene location of 1q23.2. It is suggested by Srinivas Akula et al., (2014) that the Ig 
receptors may originate from a common ancestor. The gene loci of 1q21-23 are subject to 
frequent chromosomal aberration within hematological malignancy with FcγRIIB thought 
to be affected (Callanan et al., 2000). 
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Ji et al., (2006) found that association of pCRP with human aortic endothelial cells 
(HAECs) expressing these receptors also resulted in the conformational structural change 
of pCRP to mCRPm found in monolayer studies. Unexpectedly the binding was found to be 
calcium dependent rather than the calcium-independent association between FcγRs and 
pCRP. They concluded that the binding of, and conformational changes to, pCRP in 
association with these cell membranes, may occur via FcγR independent binding of the 
recognition face to the PC head group of sphingomyelin, within specialised lipid raft 
domains, rather than the C1q associated effector face (S.-R. Ji et al., 2006). FcγRIII 
(CD16) has been identified as the receptor for neutrophil binding of mCRP (Heuertz et al., 
2005), however in a further study,  mCRP was shown to bind U937 macrophage cells 
which do not express CD16. This binding was also shown to be predominantly 
independent of protein receptors CD32 or CD64, a further indication of FcγR independent 
membrane binding (Zhao et al., 2010). 
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Table 1.3 Summary table showing Fcγ receptor binding affinity, expression/function and 
signalling motifs. 
FC 
Receptor 
Binding 
Affinity Expression / Function 
ITAM / 
ITIM 
Signalling 
Motif 
Source 
FcγRI / 
CD64 
High  
IgG1=3>4 
 
High pCRP 
Expression: Macrophages, 
neutrophils, eosinophils, 
dendritic cells 
Function: Enhances 
effector responses at 
inflammatory sites, 
Immune complex capture 
by dendritic cells. 
γ chain 
ITAM 
Getahun and 
Cambier, 2015; Ji et 
al., 2006; Marnell et 
al., 2005;Tron et al., 
2008. 
FcγRIIA /  
CD32 
 
Low 
IgG3>1>2 
 
Low pCRP 
Expression:  
Macrophages, neutrophils, 
mast cells, eosinophils, 
platelets, dendritic cells 
Function: Activation -  
Effector cell activation by 
immune complex, cytotoxic 
Ab 
α chain 
ITAM 
Getahun and 
Cambier, 2015; Ji et 
al., 2006; Marnell et 
al., 2005;Tron et al., 
2008. 
FcγRIIB / 
CD32 
Low 
IgG3>1>2>4 
 
Low pCRP 
Expression:  
Macrophages, neutrophils, 
mast cells, eosinophils, 
dendritic cells 
Function: Inhibition - Set 
threshold for effector cell 
activation by Fc, B cell 
repression, maintain 
tolerance. 
α chain ITIM Getahun and 
Cambier, 2015; Ji et 
al., 2006; Marnell et 
al., 2005;Tron et al., 
2008. 
FcγRIIIA/ 
CD16 
 
 
Medium 
IgG 
 
High mCRP 
Expression:  
Macrophages, mast cells, 
basophils, NK cells, 
dendritic cells 
Function: 
Activation – Dominant 
pathway for IgG activation 
of effector cell, Arthus 
reaction, immune complex 
capture by dendritic cells. 
γ chain 
ITAM  
Akula, 
Mohammadamin and 
Hellman, 2014; 
Getahun and 
Cambier, 2015; 
Heuertz et al., 2005; 
Marnell et al., 2005. 
 
FcγRIIIB Low 
IgG1=3>2=4 
 
High mCRP 
Expression:  
Neutrophils 
Function: 
Decoy –focus immune 
complex to PMN, synergize 
with FcγRIIA 
α chain 
ITAM, ITIM 
Akula, 
Mohammadamin and 
Hellman, 2014; 
Getahun and 
Cambier, 2015; 
Heuertz et al., 2005; 
Marnell et al., 2005.  
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1.4.9 C-reactive Protein as a Clinical Biomarker 
 
In a clinical setting a fast, easy and often automated system based on the ELISA 
concept is often employed. This provides ease of use and sensitivity based on the 
combination of antigen and antibody complexes to determine CRP concentrations (Algarra 
et al., 2013). However although these systems accurately detect levels of CRP, they do not 
seek to identify whether it is of pentameric or monomeric form. Of the analytical methods 
used some are more sensitive than others and able to detect minor changes from healthy 
levels, others indicate the large changes occurring through inflammation. The most 
sensitive methods for measurement of CRP are nephelometric light scattering assays, 
which measure the increase in scattered light occurring via interaction with antigen-
antibody complexes. This method allows highly sensitive determination of low level of 
CRP which may help assess the risk of future disease development (Bassuk et al., 2004; 
Koivunen & Krogsrud, 2006). Other analytic methods include immunosorbent assays, 
immunoturbidity, surface plasmon resonance, latex agglutination and chemiluminescence  
(Gella et al., 1991; Lechuga, 2007; Laiwattanapaisal et al., 2008; Department of Biology 
Davidson College, 2014). These methods when used appropriately allow accurate 
comparison of CRP levels between research and clinical settings internationally. However 
results will depend upon the specificity of antibodies used within the detection assays and 
therefore levels of CRP determined may potentially be a combination of both monomer 
and pentamer. 
1.4.10 U937 Cellular Expression of CRP 
 
Macrophages are nucleated cells which differentiate from monocytes. It has previously 
been shown that macrophages are capable of local CRP expression (Kawai & Akira, 2010; 
Wang et al., 2011). Immortal monocytic cell line U937 is successfully used as an in vitro 
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CRP macrophage expression model. These cells differentiate upon the addition of phorbol 
12-myristate 13-acetate (PMA), expressing a macrophage like morphology and have been 
shown to express monomeric rather than pentameric CRP (Ciubotaru et al., 2005). In 
Cuibotaru et al’s study, U937 CRP expression following PMA differentiation was initially 
unaffected by the addition of lipopolysaccharide following 24 hours, however expression 
increased significantly in a time dependent manner peaking at 48h and with limited 
increase between 48 and 72 hours. No associated increase in mRNA expression was found 
suggesting LPS modulates CRP synthesis at the translational level rather than at the level 
of transcription. Inhibition studies found that increased expression was mediated via IL-6 
and IL-1β (Ciubotaru et al., 2005). 
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1.5 Interactions Between C-reactive Protein and Immune Components 
1.5.1 Monocytes and Macrophages 
 
CRP plays a key role within the recruitment and modulation of several immune 
components in addition to its activation of the inflammatory response via binding of dead 
or damaged cells. During the inflammatory response a site of infection is flooded with 
monocytic cells which mature into macrophages. CRP is suggested to play a part in the 
recruitment of monocytes, their maturation to macrophages and further regulation of these 
cells via Fcγ receptors. Low affinity CRP binding to phagocytic cells was revealed by 
Ballou & Cleveland in 1990, via flow cytometry studies, which occurred in a calcium 
dependent manner (Ballou & Cleveland, 1990). Using a macrophage like cell line (Mono 
Mac 6) Tron et al in 2008 illustrated CRP binding to Fcγ receptors I and II, but 
preferentially to FcγRI. Further studies with COS-7 cells and pCRP found binding to both 
FcγRI and FcγRII but not FcγRIII (Tron et al., 2008). Further it appears CRP is capable of 
inhibiting the maturation of macrophages via Fc receptor binding to the macrophage 
cellular surface (Zhang et al., 2011). This inhibition was prevented by IgG binding, 
presumably via counter blocking of the Fc receptor sites (Zhao et al., 2010).  
CRP interactions with macrophage cells have several correlations with those 
between the macrophage and IgG, including macrophage cytokine production in response 
to CRP or IgG of TNFα, IL-1β and IL-6, together with complement activation, cytokine 
secretions and opsonisation. CRP also facilitates phagocytosis of C-polysaccharide (CPS) 
coated cells and induction of coagulation via the release of tissue factor (Cermak et al., 
1993; Stein et al., 2000; Torzewski et al., 2000). The role of monocytes and macrophages 
within the immune response involves phagocytosing harmful pathogens together with 
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recruitment of other immune cells to the area and CRP plays a role in their activation, 
regulation and enhancement within a coordinated acute phase response. 
1.5.2 Lymphocytes 
 
An interaction between lymphocytes and CRP was first observed in 1937, with 
lymphocytes observed in a later study to bind CRP within children suffering from 
rheumatic fever (Williams et al., 1978). Another early report indicated that CRP bound 
preferentially to T lymphocytes and inhibited their capacity to form spontaneous rosettes 
with sheep erythrocytes and also inhibited their responses to allogenic cells in a mixed 
lymphocyte culture. Mortensen et al., (1975), also found that CRP did not bind B 
lymphocytes nor did it alter B cell function (Mortensen et al., 1975). Ballou and Lozanski 
(1992) also observed CRP bound to lymphocytes and reported that the CRP originated 
from two distinct locations, the first produced primarily by liver hepatic cells, which then 
bound to lymphocyte cell membranes in a calcium dependent manner and the second 
expressed by the lymphocyte itself and inserted into the cell membrane (Ballou & 
Lozanski, 1992). They further found that in the healthy adult population 2.5% of 
lymphocytes expressed and inserted CRP within their membranes and a further 1.5% of 
lymphocytes were found with CRP of hepatic origin bound in a calcium dependent manner 
to their membranes. The percentage of lymphocytes with CRP of lymphatic origin was 
increased in RA patients, whilst CRP of hepatocyte origin remained at the same level, 
except in cases where serum CRP concentration exceeded 50µg/ml. 
The interaction between lymphocytes and CRP takes place through Fc receptors in 
a similar way to those observed between CRP and monocytic cells (Gewurz et al., 1982). 
Early studies suggested CRP added to leucocyte suspension was mitogenic at low 
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concentrations but actually toxic at higher than 10µg/ml and that in vitro studies suggested 
CRP inhibited growth of human melanoma cells in the presence of lymphocytes. 
1.5.3 Platelets 
 
The primary role of platelets is that of wound repair; through activation of the 
coagulation cascade with hemostasis their best characterised function (Monroe et al., 2002; 
Jenne & Kubes, 2015). Platelets are activated by platelet activating factor (PAF), a 
phospholipid mediator of inflammation, released early in inflammation by a variety of cell 
types including platelets, macrophages, neutrophils and endothelial cells (Chao & Olson, 
1993). PAF has been implicated within the pathogenesis of autoimmune conditions and 
inflammatory diseases (Leong et al., 2007; Sato et al., 2014). The luminal walls of blood 
vessels are coated by glycocalyx layers, which separate the platelets from contact with 
endothelium or basal layers. Should the platelet breach this protective layer, platelets 
would become active and clot formation begins to fill the gap (Sato et al., 2014). Upon 
platelet activation, platelet derived microparticles (PMPs) are released from the plasma 
membrane and are associated to RA disease activity (Knijff-Dutmer et al., 2002). 
Interaction between CRP and PAF may enhance PAF induced inflammatory activity in 
vivo as shown in the study by Sato et al., (2014), although alternative research indicates 
CRP may play a protective role in PAF-induced platelet aggregation, via CRP binding to 
PAF and platelet surface phospholipids (Kohayakawa & Inoue, 1986; Nagpurkar et al., 
1988). 
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1.6 The Complement System and C-reactive Protein  
 
The complement pathway consists of more than 30 plasma and membrane bound 
proteins and is an essential tool in the body’s defense mechanism against infectious 
diseases, playing an important role in the inflammatory response (Volanakis, 1982; Sarma 
& Ward, 2011; Nonaka, 2014). Complement may be activated by either the classical, 
alternate or mannose binding lectin pathways; CRP activates the classical pathway. 
Activation of the classical pathway is dependent upon the presence of either IgM or IgG 
within the immune complex, and involves the C1 complex via the C1q subunit  (Volanakis 
et al., 1981; Mold et al., 1999; Matsushita & Fujita, 2001; Dunkelberger & Song, 2010). 
Both pathways stimulate cellular and humoral interactions such as phagocytosis and 
support B-cell differentiation enabling activation of adaptive immune systems. C1q 
recognises targets such as immune complexes, apoptotic and necrotic cells, amyloids and 
micro-organisms which lead to complement activation (Agrawal & Volanakis, 1994; 
Gaboriaud et al., 2003; McGrath et al., 2006). Antibody binding to C1q induces 
conformational changes allowing activation of C1r and C1s serine proteases, leading to C3 
convertase formation (Chen et al., 2010). C1q itself is formed from six subunits each 
containing a C-terminal globular head and N-terminal collagenous tail, held together in a 
bouquet formation, together with C1s and C1r. It is the globular head group of C1q that 
binds a pathogen and activates the complement cascade via the cleavage of C4 by C1 
forming C4b2a also known as C3 convertase (Wallis et al., 2010); it is also the globular 
head region which interacts with CRP. 
Various changes in levels of complement components have been linked to RA, 
including a deficiency in C1q which has been linked to both RA and SLE (Chen et al., 
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2010; Wallis et al., 2010). Table 1.4 details other changes to complement activity 
identified within RA. 
Table 1.4 Summary table of complement activity found within Rheumatoid Arthritis. 
 
Complement Component 
 
 
Deficiency / Increase in RA 
 
Source 
 
C1q Deficiency linked to RA and 
SLE 
(Chen et al., 2010; Wallis et 
al., 2010), 
Complement activity Significantly lower in RA joint 
fluid than non-inflammatory 
arthritis 
(Chen et al., 2010) 
Soluble complement 
activation fragments 
Significantly increased in RA 
joint fluid 
(Chen et al., 2010) 
Complement production Enhanced local complement 
production within synovial 
tissue 
(Neumann et al., 2002; Chen et 
al., 2010) 
C3 and MAC Presence within synovial tissue (Neumann et al., 2002; Chen et 
al., 2010) 
C3a and C5a Increased levels within 
synovial fluid and serum 
(Neumann et al., 2002; Okroj 
et al., 2007; Chen et al., 2010; 
Bradford et al., 2016)  
 
  Excessive complement activation has therefore been implicated in RA, leading to 
the suggestion that complement control agents able to regulate excess complement activity 
may have beneficial uses (Mizuno et al., 2001). Complement is capable of recognising and 
attacking self-cells, and control mechanisms exist to regulate and restrict activity to target 
pathogens. However it is possible that in the case of excessive complement activation, host 
regulatory mechanisms are exceeded, leading to harmful inflammatory pathways (Chen et 
al., 2010). It has been suggested that excessive complement activation may propagate 
inflammation in RA, but that a suppression or deficiency of C1q may actually be involved 
in RA induction (Chen et al., 2010). 
Complement factor H is a major inhibitor of the alternate complement pathway, 
involved within the regulation of complement activation in host cells, plasma, tissue and 
importantly at sites of inflammation (Molins et al., 2016). Factor H is a serum glycoprotein 
expressed by a variety of cells and is involved within accelerated decay of C3 convertase 
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(C3bBb), essentially regulating the alternative pathway of complement ensuring that 
complement action is directed towards pathogens rather than self-tissue. Over activity may 
result in reduced complement action towards pathogenic cells and underactivity results in 
increased complement activity on healthy cells (Ferreira et al., 2010). Factor H is known to 
interact with CRP, studies show both pentameric and monomeric involvement, with two 
binding sites for pCRP identified (Molins et al., 2016). Further research also shows factor 
H interactions with of mCRP within SLE. Auto-antibodies directed against mCRP amino 
acids 35-47 were found within lupus patients to be associated with more severe renal 
damage. This finding suggests mCRP may be protective in nature via a reduction in factor 
H function, and that auto-antibody binding of mCRP may prevent the ability of mCPR to 
bind to and therefore modulate factor H function (Q. Li et al., 2017). However this group 
found factor H binding of mCRP, reduced its proinflammatory effects (Molins et al., 
2016). It is unclear how the interaction between factor H and mCRP modulates the immune 
response; it may be inconsistent across different disease state. 
1.7 C-reactive Protein and Disease 
1.7.1 C-reactive Protein and Cardiovascular Disease 
 
Cardiovascular disease (CVD) was the most common cause of death in the UK for 
women in 2012 (28% of female deaths), however cancer was the biggest killer for males. 
Prevalence of coronary heart disease is highest in the North of England (4.5% in North 
East) and Scotland (4.3%), with about three times more men than women suffering from 
myocardial infarction. In 2012/13 the NHS in England spent £6.8 billion on CVD, 
therefore presenting a significant burden on public health funding (Bhatnagar et al., 2015). 
Atherosclerosis is a major factor in the development of CVD, distinguishable from 
the lesions in arteries throughout the body, with characteristic inflammation (Hanson & 
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Libby 2006). Over time atherosclerotic plaques form leading to complications through 
rupture, myocardial infarction or stroke, dependent upon the location of the plaque (Libby, 
2006). Deposition of CRP within the arterial wall is a feature of atherosclerotic lesions, 
with CRP implicated within the release of inflammatory markers including ICAM, 
VCAM-1 and pro-inflammatory cytokines (Hirschfield & Pepys, 2003; Sun et al., 2005; 
Zhang et al., 2012). CRP binds to LDL and oxidised or partially degraded LDL aiding the 
formation of foam cells and atherosclerotic plaque creation (Hirschfield & Pepys, 2003; 
Zhang et al., 2012). It is therefore suggested that CRP may play a pro-inflammatory role 
within CVD through expression of cell adhesion molecules, instigation of complement and 
release of inflammatory cytokines (Zhang et al., 2012). 
1.7.2 C-reactive Protein and Systemic Lupus Erythematosus  
 
CRP levels are raised in response to inflammation in both atherosclerosis and RA; 
however another autoimmune inflammatory disease, systemic lupus erythematosus (SLE) 
shows a different CRP profile (Bell et al., 1998).  Pentameric CRP levels remain low in the 
disease, however auto-antibodies to mCRP have been found in up to 78% of SLE patients 
(Bell et al., 1998). It is as yet unclear why CRP levels remain low in this disease. SLE is an 
autoimmune disease in which the body mistakenly attacks healthy tissue. Unlike RA which 
is predominantly confined to joints, SLE is systemic affecting skin, joints, kidneys, other 
organs and even the brain. Like RA the condition is more prevalent in women than men 
however unlike RA it affects more people of Hispanic, African or Asian descent than any 
other ethnic group (Gonzalez et al., 2013). This disparity between ethnic groups is thought 
to be a combination of both genetic and non-genetic factors (Gonzalez et al., 2013). 
Genetic factors play a strong role in SLE with concordance between identical twins and 
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increased risk and frequency of disease among first degree relatives, with multiple genes 
responsible (Mok & Lau, 2003). 
Anti-mCRP serum levels are found to be correlated to SLE patients during flare, 
with Sjowall and Wettero (2007) observing SLE disease flares in seven of ten patients who 
also had high mCRP auto-antibodies, a greater correlation was found between patients with 
active lupus nephritis who were all positive for the auto-antibodies (Sjöwall & Wetterö, 
2007b). This finding was mirrored within a further study by  Jakusko et al., (2017) who 
also found that the correlation between mCRP directed self-antibodies in SLE is higher in 
patients with lupus nephritis as compared to SLE patients without renal involvement 
(Jakuszko et al., 2017). Animal models have demonstrated CRP presence in lupus nephritis 
renal immune deposits (Szalai et al., 2002), with further reports suggesting co-localisation 
of auto-antibodies targeted against mCRP leading to amplification of the classic pathway 
activation of complement (Trouw et al., 2004). 
Anti-mCRP is not only correlated to SLE disease but also to IgG levels. In their 
2001 study, Minatani et al. (2001) found serum levels of IgG auto-antibodies directed 
against mCRP raised in 32% of SLE patients and 29% of RA patients, interestingly, within 
SLE patients these levels were directly correlated with serum IgG levels. This group 
suggested an immunopathogenic role for mCRP within rheumatic diseases (Minatani et al., 
2001). Whilst levels of SLE disease, IgG and mCRP auto-antibodies all correspond, no 
such correlation was found between levels of serum CRP and anti-mCRP IgG; however 
previous studies have not tested for serum mCRP as it has been suggested to be tissue 
bound rather than soluble (Tan et al., 2008) Tan et al also propose that levels of CRP are 
low in SLE due to decreased pentameric expression or accelerated conversion of pCRP to 
mCRP, they further suggest that levels of auto-antibodies against mCRP may be due to 
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partial secretion of mCRP by local immune cells (Iwamoto et al., 1994; Duong et al., 
1997).  
1.7.3 C-reactive Protein and Alzheimer’s Disease  
 
Several studies have linked CRP levels to Alzheimer’s disease (AD), with 
neuropathological studies showing CRP associated to neurofibrillary tangles and senile 
plaques taken from AD brain tissue (Iwamoto et al., 1994; Duong et al., 1997). 
The characteristic changes seen at autopsy show neuritic plaques, neuronal loss, 
amyloid angiopathy and neurofibrillary tangles (Cummings et al., 1998). As in RA and 
SLE, female gender is suggested to increase the risk of development, with an onset of 
between 40 and 90 years old. Symptoms include impaired cognitive function, such as 
language and perceptual recognition (Cummings et al., 1998).  
Elevated CRP levels in early life imply a risk of AD in later life which was 
observed within a 25 year follow up on elevated midlife CRP levels within a longitudinal 
study revealed an increased risk of AD in addition to vascular dementia (Schmidt et al., 
2002). However studies have also shown that CRP levels appear to be lower within AD 
sufferers than age matched controls (O’Bryant et al., 2010). A later follow up study 
showed that although these levels were lower within the AD patients, those amongst the 
study who had elevated CRP also suffered greater levels of poor cogitative function and a 
reduction in survival time (Nilsson et al., 2011). 
1.7.4 C-reactive Protein and Diabetes 
 
Diabetes mellitus is a metabolic disease characterised by hyperglycemia and 
associated damage to different organs including kidneys, eyes, nerves heart and blood 
vessels. The condition can be characterised into three groups, type 1 diabetes resulting 
from autoimmune destruction to the β-cells of the pancreas leading to insulin deficiency, 
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type 2 diabetes manifesting in insulin resistance and impaired insulin secretion and 
gestational diabetes mellitus diagnosed within the second to third trimester of pregnancy 
(American Diabetes Association, 2010). Diabetes is a known independent risk factor of 
atherosclerosis and is associated with elevated levels of coronary heart disease and 
coronary atherosclerosis (Schmidt et al., 1999), with studies showing that patients have 
elevated CRP when compared to controls. CRP has also been identified within the tubule 
tissue of diabetic patients. Kidney biopsies showed that enhanced tubular mCRP staining 
was associated with renal decline. Histologic changes were also significantly correlated to 
mCRP staining (Schwedler et al., 2003). 
Type 2 diabetes is also associated with an elevated prevalence of cardiovascular 
disease. Baseline changes to CRP levels are suggested to be an indicator of cardiovascular 
risk in type 2 diabetics. However the prognostic value of CRP within this condition is 
disputed amongst groups (Jager et al., 1999; Schulze et al., 2004; Bruno et al., 2009; 
Schöttker et al., 2013). A study by Pradhan et al in 2001, considered the involvement of IL-
6 and CRP in the development of type 2 diabetes in a cohort of 27,628 women who were 
not originally diabetics, of those 188 went on to develop diabetes. In the diabetic group, 
levels of both IL-6 and CRP were significantly raised compared to age matched controls, 
suggesting CRP and IL-6 levels were useful in predicting future development of diabetes 
(Pradhan et al., 2001). It is suggested that low grade inflammation indicated by CRP may 
over time lead to the manifestation of type 2 diabetes (Pradhan et al., 2001; Ford, 2003; 
Tabak et al., 2010). An additional study also found that elevated serum CRP levels 
enhanced the risk of diabetes development (Dehghan et al., 2007), suggesting that although 
the mechanism is as yet unknown, the association between inflammation, CRP and 
diabetes may be beneficial in the prediction of later disease. 
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1.8 Rheumatoid Arthritis 
1.8.1 Overview 
 
A well balanced, healthy body possesses many tools at its disposal to enable 
maintenance of a non-diseased state. However, our modern lifestyle has resulted in an 
increasing level of disease, including cancers, diabetes, heart disease and autoimmune 
diseases such as RA and SLE.  It has become difficult to determine whether the incidence 
of disease is greater, or we have become better at detecting and diagnosing it, or if we 
simply live longer and no longer escape diseases associated with old age by untimely 
death.  RA is a disease of the immune system - an autoimmune disease whereby the 
normally healthy body begins to attack and destroy itself. Many theories have been 
proposed towards the misdirection of immune components, but no single one fully explains 
it. RA is a common disease with a prevalence of about 1% of the world’s population and 
an annual incidence of approximately three in 10,000 adults (Spector, 1990). The economic 
burden of RA in the United States was estimated at up to $14 billion annually in 1998 
(Callahan, 1998), with that cost estimated to be almost £8 billion in the UK by 2010 
(NRAS, 2010). The financial burden is not just that of treatment cost but in overall cost to 
the economy including productivity due to incapacity.  
This chronic and disabling inflammatory condition leads to joint destruction if 
intervention does not occur early in disease. Characterised by synovitis, the joint 
destruction is associated with a hyperplastic synovial membrane with infiltration of 
synoviocytes, immune cells and inflammatory cells, including macrophages, lymphocytes, 
dendritic and plasma cells (Firestein, 2003). The consequences of this condition include 
joint damage, commonly to the small joints of the hands and feet, joint stiffness, pain and 
bone destruction (Choy & Panayi, 2001).  
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1.8.2 Clinical Features of Rheumatoid Arthritis 
 
Destruction of synovial cartilage and bone are the hallmarks of RA (Scott et al., 
2010), although the severity of symptoms varies greatly between individuals (Goronzy & 
Weyand, 2009). Long term prognosis is poor with a substantial number of patients, more 
than 40% after 10 years (Goronzy & Weyand, 2009), and 80% after 20 years (Choy & 
Panayi, 2001) eventually suffering some level of disability resulting from joint destruction. 
The joint pain and destruction is a result of synovial hyperplasia, and influx of 
inflammatory cells, of which CD4+ T cells form a large part (Choy and Panayi, 2001). 
Early symptoms can include low grade fever, fatigue, early morning stiffness, together 
with pain and swelling to the joints (Boilard et al., 2012).  
An autoimmune disease, RA begins with what is termed the pre-articular phase, in 
which auto-antibodies are generated against host cells rather than foreign entities. During 
this phase the self-antigen and IgG antibody complex activates the innate immune system 
(Fazal et al., 2018). Dendritic cells bind the complex and trigger differentiation and growth 
of Th1 cells, together with Th17 and regulatory T cells. B cells are activated by the 
differentiated Th1 cells, which then go on to produce auto-antibodies such as rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) (Fazal et al., 2018). 
Pathophysiology of RA results from the involvement of both T and B cells together with 
involvement of pro-inflammatory cytokines TNFα, IL-1 and IL-6, with activated CD4+ T 
cells contributing to the pathogenesis of the condition (Rivellese et al., 2017). The 
activation of the autoimmune response then leads to the characteristic destruction of bone, 
synovium and cartilage.  
IL-1 and TNF-α stimulate both the recruitment of neutrophils to the site of joint 
damage and the expression of adhesion molecules on local endothelial cells. Neutrophil 
release of both proteases and elastase lead to the degradation of the proteoglycan layer and 
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exposure of chondrocytes. IL-1, TNF-α and activated CD4+ T cells stimulate synovial 
fibroblast and chondrocytes to express matrix metalloproteinases, which may in turn be 
responsible for the enzymatic joint damage in RA (Choy and Panayi, 2001). The synovial 
membrane or synovium is a coating to the joint which is protected by lubricating synovial 
fluid.  A normal joint has a synovial membrane, called the intima, consisting of a thin layer 
of one to three synoviocytes depth, in contrast to an affected joint in which synoviocytes 
form a thick synovial membrane leading to the hyperplastic synovial lining (Middleton et 
al., 2004; Strand et al., 2009). The intima has an outer lining of two synovial cell types, 
termed A and B intima cells. Type A are macrophages and type B are fibroblast like 
synoviocytes which are secretory cells releasing components such as hyaluronic acid and 
lubricin (Fazal et al., 2018). The hyperplastic synovium together with a cocktail of immune 
components such as neutrophils, osteoclast, fibroblast, dendritic, macrophage, T 
lymphocytes, B lymphocytes and plasma cells, lead to the destructive pannus formation 
and eventual joint destruction (Lundy et al., 2007), as seen in Figure 1.10, which shows the 
influx of immune components within an RA joint in comparison to a healthy normal joint. 
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Associated cartilage 
loss  
Associated bone 
erosion 
(a.) (b.) 
 
Figure 1-10 Illustration showing the effects of rheumatoid arthritis within a normal and 
healthy joint. (a.) showing normal bone and cartilage formation (b.) showing the influx of 
immune components leading to bone and cartilage destruction. Adapted from (Smolen & 
Steiner, 2003) 
Bone destruction occurs due to a modulation of the normal process of bone 
remodeling which is ongoing in healthy joints. Osteoclast cells resorb bone whilst 
osteoblast form it in a process held in careful balance, however in RA patients this process 
is disturbed. Osteoclasts regulate mineral accumulation in the human body by releasing 
calcium and other minerals from the tubercular and cortical bone into the blood stream, 
with the associated bone damage repaired and replaced by osteoblast cells (Smolen and 
Steiner, 2003). In RA the balance between osteoclast and osteoblast differentiation and 
maturation is affected by proinflammatory cytokines, leading to constant osteoclast 
differentiation. Joint destruction results from matured osteoclast binding to the bone matrix 
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and secretion of hydrochloric acid and proteolytic enzyme cathepsin K (Gravallese et al., 
2000; Boyce & Xing, 2007).  A recent paper by Jia et al., (2018) described the effects of 
mCRP within an RA mouse model, with the monomeric, but not pentameric conformation, 
actively modulating osteoclast differentiation through NF-κB and phospholipase C 
signaling. Interestingly mCRP can bind RANKL, the major driver of osteoclast 
differentiation, and prevent its activities. The binding and inhibition of RANKL are 
mediated by the cholesterol binding sequence of mCRP (Jia et al., 2018).  
A further component of RA pathogenesis is cartilage degradation. Articular 
cartilage is composed of the extracellular matrix containing type II collagen, aggrecans and 
proteoglycans. The proinflammatory cytokines within the inflamed joint stimulate synovial 
fibroblasts to release an enzyme capable of degrading the cartilage called matrix 
metalloproteinase (MMPs) (Fazal et al., 2018). This results in degradation of cartilage and 
the eventual rubbing of bones together leading to bone polishing, osteophyte and bone spur 
formation (Ainola et al., 2005). 
RA patients suffer comorbidity with diseases such as atherosclerosis and coronary 
heart disease, one factor attributed to the excess mortality observed in RA patients 
(Myasoedova et al., 2010). It has been suggested that the chronic inflammatory state found 
in RA contributes to not only an increase in cardiovascular mortality, but to an accelerated 
rate of atherosclerosis (Gabriel, 2008; Wu et al., 2013). An association between RA 
inflammation and atherosclerosis has been documented, with RA considered an important 
independent risk factor for its development. The progression of atherosclerosis is not only 
accelerated in RA sufferers but occurs prematurely, and is accompanied by increased 
cardiovascular mortality within the group (Montecucco & Mach, 2009; Yuri Gasparyan et 
al., 2010). 
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The importance of endothelial cell dysfunction and foam cell formation is identified 
in the progression of both RA and atherosclerosis. Foam cells are known to play a 
significant part in atherosclerotic plaque build-up and are also found within the synovial 
membrane of RA patients (Winyard et al., 1993). The study by Winyard et al. (1993) 
showed foam cell formation surrounding blood vessels within intimal connective tissue and 
in association with fibrin deposits, indicating the presence of oxLDL. These results were 
not found within control synovial membranes (Winyard et al., 1993). 
It is suggested that endothelial cells allow entry of low-density lipoproteins (LDL) 
to the intima, via spaces between them, leading to the oxidization of LDL to oxLDL in RA 
patients. In turn oxLDL activates endothelial cells and leads to the up-regulation of 
adhesion molecules and release of chemokines, in turn recruiting leucocytes to the now 
forming atherosclerotic plaque. Circulating monocytes and macrophages attracted to the 
plaques engulf oxLDL and convert to foam cells (Montecucco and Mach, 2009). An 
increase in oxLDL levels together with a decrease in  levels of high density lipoproteins 
(HDL), often considered to exert anti-inflammatory effects, has also been shown in RA 
patients (Montecucco and Mach, 2009).  
Macrophages are an important group of cells mediating RA disease progression, 
with high numbers being found in both the synovial membrane and at the site of pannus 
formation (Mulherin et al., 1996; Kinne et al., 2000). Within atherosclerotic plaques, 
macrophage activation via Toll like receptors (TLR) results in the release of 
proinflammatory cytokines IL-1, IL-6, TNF and matrix metalloproteinase (MMP). IL-1 
and Il-6 are both inducers of hepatocyte CRP expression (Lundberg and Hansson, 2010). 
Macrophages generated from U937 monocyte cell line not only express CRP but in its 
monomeric rather than pentameric form (Ciubotaru et al., 2005). Synovial fibroblasts 
mediated cartilage degradation when co-cultured with U937 macrophage cells in an IL-1, 6 
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and TNFα dependent manner in a study by Scott et al., (Scott et al., 1997),  linking mCRP, 
IL-1, 6, TNFα and RA. 
1.8.3 Etiological Aspects 
 
The cause of RA is poorly understood, a combination of environmental and genetic 
factors may be involved. Interesting clues as to the etiology of the disease have been 
considered by Entezami et al. in their 2012 paper in which they consider various theories 
of ‘Old World or New World’ disease (Entezami et al., 2011). RA was less prevalent in 
previous centuries suggesting RA may be a relatively new disease within Europe and North 
Africa. Where similar diseases such as osteoarthritis, gout and ankylosing spondylitis have 
been found in archaeological skeletons, no evidence for RA has been found. However, 
Hippocrates described a form of arthritis with remarkably similar symptoms to RA, with 
similar observations found in writings by a range of other ancient scribes, including 
Caesar’s physician Scribonius, Emperor Constantines IX’s adviser and Greek physician 
Soranus, these are all anecdotal rather than confirmed RA cases (Entezami et al.2012). The 
first modern day description was by Frenchman Augustin Jacob Landre-Beavais in 1800, 
who examined clients with severe joint pain, which affected women more than men and 
poor rather than wealthy. Landre-Beavais suggested incorrectly that the disease was a 
relative of gout. In 1859 Alfred Garrod an English physician termed the disease 
‘Rheumatic Gout’, with his son Archibald continuing his work giving the condition its 
name ‘Rheumatoid Arthritis’. Archibald proposed it a disease of ancient origin due to his 
observations of ancient bones examined from graves around the world (Entezami et al. 
2012).  
Signs of RA have been found in ancient Native American skeletons dating over one 
thousand years ago, with some of the oldest paleopathological specimens displaying RA 
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found in the Americas (Halberg, 1991; Entezami et al., 2011). Native American-Indian 
populations have the highest recorded occurrence of RA, with a prevalence of 5.3% noted 
for the Pima Indians (Del Puente et al., 1989).  This has led to further suggestions that RA 
may have crossed that Atlantic after Columbus returned from the Americas in 1492 
(Entezami et al.,2012). 
It has also been suggested that an environmental trigger may be responsible for RA 
development, with microbial pathogens such as bacteria and viruses including parvovirus 
B19, rubella and Epsein-Barr all suggested (Sawada & Takei, 2005; Entezami et al., 2011). 
However RA patients may just be more susceptible to disease and therefore these 
infections are not related to cause and are merely coincidence. Another potential 
environmental trigger proposed is smoking, which is linked to RA incidence in RA patients 
who have the HLA-DR SE alleles, which links to suggestions that RA was introduced to 
Europe upon Columbus’ return, together with tobacco. However only a third of RA 
individuals carry the HLA-DR SE gene and not all smoke (Entezami et al., 2012). Nicotine 
has been implicated in the pathogenesis of RA  (Mattey et al., 2002) and is also a known 
independent risk factor for the development of cardiovascular diseases including 
atherosclerosis (Mao et al., 2012).  An interesting study linking nicotine and CRP 
investigated U937 cells and the effect of nicotine on CRP expression. This study showed a 
significant increase in CRP mRNA and protein expression 6 times that of the control 
following, 24 hours incubation with 10-5M nicotine (Mao et al., 2012). 
An association between RA and oral disease/periodontitis is also apparent, with 
similar prevalence across the population (5%) of each. The inflammatory cascade is 
regulated by TNF-α in both RA and periodontitis. Porphyromonas gingivalis is common 
within periodontitis and has also been identified in synovial fluid. In addition to this, P. 
gingivalis is able to citrullinate host peptides by proteolytic cleavage at Arg-X peptide 
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bonds by arginine gingipains. Therefore it may be able to induce autoimmune responses in 
RA through development of anticyclic citrullinated peptide antibodies (Persson, 2012) 
suggesting that infection may play a role in loss of self-tolerance to self-antigens in RA 
pathogenesis. 
RA generally manifests between age 30 – 65 (Majithia et al., 2007) and the average 
life expectancy was only 30 years in 1800 when it was first described in France, suggesting 
people may well have died before the onset of the disease (Riley, 2005). It is likely that RA 
did exist in ancient times; however few people survived long enough for it to become a 
problem. There is a strong genetic link between RA sufferers and various RA associated 
genes including HLA-DRB1, PAD14, PTPN22, TNFAIP3, STAT4 and CCR6 with 
variable risk associations to RA and differences between disease development and 
progression within identical twins, suggesting an interaction between an environmental 
component and the regulation of these genes (Gerlag et al., 2016; Paul et al., 2017). 
Epigenetic studies have therefore become a key area of research. 
1.8.4 Rheumatoid Arthritis Epidemiology 
 
In socio-economic terms, RA is the most common and most important of the 
inflammatory rheumatic diseases, with a prevalence of 0.5-1% of the population 
worldwide, estimated to increase by ∼22% between 2005 and 2025 due to the ageing 
population. The median age of onset of RA is 58 years, with the relatively high prevalence, 
irreversible joint damage and widespread occurrence of co-morbidities determining the 
huge societal impact of this disease (Gerlag et al., 2016).  There are differences between 
different ethnic groups across the world with a high prevalence of RA reported in native 
American Indian populations, the Pima Indians (5.3%) and Chippewa Indians (6.8%), 
compared to low occurrences reported in populations from China and Japan (0.2-0.3%) 
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(Silman & Pearson, 2002). This data suggests a genetic role within the risk of disease, 
however studies show a reduced familial recurrence risk in RA when compared to other 
autoimmune diseases. The greatest genetic risk factor is presence of the HLA-DR gene 
variant in the major histocompatibility locus (MHC), with  the strongest susceptibility 
factor found to be in HLA DRB1 alleles and HLA DRB1*0404 allele (Silman & Pearson, 
2002).  There is a second association with the tyrosine phosphatase PTPN22 gene, which is 
a gain of function polymorphism reducing T-cell activation response to antigens. The 
impact of this polymorphism is thought to be a reduced capacity of the thymocytes to 
negatively select self-antigens and is present in several autoimmune diseases (Bottini et al., 
2006). 
1.8.5 Rheumatoid Arthritis Classification Criteria 
 
Whilst there is currently no cure for RA, early diagnosis and treatment are key to achieving 
a low disease activity state. A DAS score of less than 2.6 signifies remission or 
significantly reduced symptoms; 2.6-3.2, low disease; 3.2-5.1 shows moderate disease 
activity, and may indicate a change of therapy is required and above 5.1 shows severe 
disease. The level above 5.1 is the threshold for being considered for biologic treatment as 
per NICE guidelines. Seropositive patients, who have either RF or anti-CCP have a greater 
likelihood of developing more serious disease than those who are seronegative (nras.org). 
 (https://www.nras.org.uk/data/files/Publications/DAS%20patient%20guide.pdf).  
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Table 1.5, Summary table of classification criteria for RA, a score of  ≥6/10 confirms diagnosis of 
RA. Table adapted from Humphreys, Verstappen et al., 2012 and Nras.org 
Diagnosis Test 
 
Details 
 
Score 
Disease Activity 
Score (DAS) 
28 joint assessed for number of swollen or tender 
 
1 large joint                                                                             
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large 
joints) 
>10 joints (at least 1 small joint) 
 
 
0 
1 
2 
3 
5 
Serology Negative RF/CPA 
Low positive RF/low positive ACPA 
High positive RF/ high positive ACPA 
0 
2 
3 
Acute Phase 
Reactants 
Normal CRP & erythrocyte sedimentation rate (ESR) 
Abnormal CRP & erythrocyte sedimentation rate (ESR) 
0 
1 
Duration of 
symptoms 
< 6 weeks 
≥ 6 weeks 
0 
1 
   
1.8.6 Clinical use of C-reactive Protein in Association to Rheumatoid Arthritis  
 
Once a patient has been diagnoses as having RA, regular testing is important in 
order to ensure the disease is being managed appropriately, with CRP levels just one of the 
indicators used to assess inflammation and disease activity. Chronic inflammatory 
conditions such as RA are characterised by high plasma levels of CRP, especially during 
periods of active flare. In healthy individuals the median, baseline concentration of CRP is 
0.8mg/l, which following inflammatory stimulus resulting from cellular or tissue injury 
may increase over 1000 fold, from levels below 50µg/l to over 500mg/l (Kresl et al., 1998; 
Koenig et al., 1999; Hirschfield & Pepys, 2003). These increases are rapid, with levels 
reaching excess of 5 mg/l after 6 hours, and peaking at 48hours. CRP is useful as not only 
is it elevated in RA patients (Yue et al., 1996; Rindfleisch & Muller, 2005; Rhodes et al., 
2011), but can also be a predictive factor of future RA diagnosis (van Zeben & Breedveld, 
1996). RA has long been considered an autoimmune disease, with the production of auto-
antibodies such as rheumatoid factor (RF) strongly associated with it (Montecucco and 
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Mach, 2009, Peters et al., 2008). First described in 1964, Kunkel and Williams recorded 
the production of IgG auto-antibody involvement in RA, describing them as rheumatoid 
factors (Kunkel and Williams, 1964).   
Studies show that CRP is involved within the activation of complement in RA, and 
levels were also found to correlate with disease activity in a study by Molenaar et al., 
(2001). In their study considering interactions between CRP and complement components 
in RA, plasma levels of C3d-CRP and C4d-CRP were elevated in the majority of patients 
assessed, with significantly elevated levels of CRP complexes in those patients with active 
RA, as opposed to those with inactive RA. Levels of C3d-CRP and C4d-CRP also 
correlated with DAS28 scores (Molenaar et al., 2001). A further study confirmed this 
finding when investigating the actions of Infliximab a key treatment for RA. Infliximab, 
decreased plasma CRP levels by blocking TNF, and was also found to reduce complement 
activity, with levels of plasma C3 and C4 reduced, as were CRP-complement complexes 
and CRP levels (Familian et al., 2005). 
In addition to high levels of CRP within RA patients, several studies have shown 
that auto-antibodies to CRP occur in RA patient blood, although at lower levels to those 
found in SLE. Antibodies to CRP were detected in 23% of patients with rheumatoid 
arthritis in a study by (Rosenau & Schur, 2006). No correlation was found between CRP 
and anti-CRP levels, although it was suggested that these auto-antibodies could be directed 
against modified rather than pCRP. Although it is possible the antibodies increase 
antigenicity of CRP binding to apoptotic cells during inflammation, it is unknown if anti-
CRP is significant in RA (Rosenau and Schur, 2006). The frequency of RA patients with 
high anti-mCRP auto-antibody levels was again reported in Minatani et al’s study (2001),  
this time with 29% of patients presenting with anti-CRP auto-antibodies. This group also 
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concluded that mCRP rather than pCRP was the main target of these antibodies (Minatani 
et al., 2001). 
1.8.7 Cells of the Synovium in Rheumatoid Arthritis 
 
RA is characterised by systemic and synovial tissue chronic inflammation, with bone and 
cartilage erosion and destruction. Several cells play key roles within this destructive 
pathway, including dendritic cells, synovial fibroblasts, osteoclast, osteoblast, macrophages 
and both T and B lymphocytes as shown in Table 1.6. 
Table 1.6 Summary table of cells of the synovium of rheumatoid arthritis, with function 
and role in RA. 
 
Cell 
 
 
Function 
 
Role in Rheumatoid 
Arthritis 
 
Source 
Dendritic cells Major antigen presenting 
cells, important activators 
and regulators of the 
immune system. Prime 
naïve Tc and Th enhancing 
Tc cell cytotoxicity. 
Stimulate differentiation 
and maturation of T cells 
via Toll like receptor 
ligands. Remove 
autoreactive lymphocytes.  
Dendritic cells can prime 
autoimmune responses in 
lymphoid organs and 
therefore enhance 
development of the 
pathology seen in RA. 
Take part in antigen 
processing and presentation 
within synovial tissue and 
fluid, releasing 
inflammatory mediators. 
(Banchereau & 
Steinman, 1998; 
Lanzavecchia & 
Sallusto, 2000; 
Lutzky et al., 
2007)  
Synovial 
Fibroblasts 
(SF) 
Composed of synovial 
macrophage and type B 
synoviocytes. 1-3 cell thick 
in healthy synovium.  
Within RA synovium >3 
cell thick. Feature of 
hyperplastic synovium, 
involved within infiltration 
and degradation of bone 
and cartilage. Bind and 
invade cartilage expressing 
adhesion molecules and 
matrix degrading pro-
inflammatory mediators. 
Release vascular 
endothelial growth factor 
(VEGF), IL-8, IL-15, 
monocyte chemoattractant 
protein (MCP-2). Bone and 
cartilage degradation 
results from matrix 
metalloproteinases (MMPs) 
and cathepsins released by 
SF. Resistant to apoptosis. 
(Firestein et al., 
1995; Müller-
Ladner et al., 1996; 
Pierer et al., 2004; 
Abad et al., 2006).  
 
 
Chapter 1. Introduction  Rheumatoid Arthritis 
 76 
Endothelial 
Cells 
Cell of vascular system 
lining interior surface of 
blood vessels and 
lymphatic vessels. Form 
interface between blood or 
lymph and the vessel wall, 
controls passage of 
leucocytes to and from 
bloodstream. 
Vasoconstriction / 
vasodilation and control of 
blood pressure 
Phenotypic changes – 
apoptoic, leaky, angiogenic 
or activated in RA. Allow 
migration of leucocytes 
into joint tissue. Increased 
expression of adhesion 
molecules, cytokines, 
proteases. Proliferate as 
part of angiogenesis, 
bringing oxygen and 
nutrients to pannus. 
Leucocyte adhesion and 
migration via ICAMs. 
(Butcher et al., 
1999; Kulka et al., 
1955, Schulze-
Koops et al., 
1995;Walsh et al., 
1999, Webber et 
al., 2000) 
Osteoclasts  Multinucleated cell with 
role in resorbing and 
remodelling bone. Work in 
partnership with osteoblast 
to maintain bone mass in 
adults. Osteoclasts may 
recruit osteoblasts to the 
site of bone remodeling 
through sphingosine 1-
phosphate (S1P) and bone 
morphogenic protein 6 
(BMP6) with bone 
formation stimulated 
through enhanced 
activation of Wnt (secreted 
glycoproteins) /BMP 
pathways 
Pro-inflammatory cytokine 
signals modulate SIP, 
BMP6 and Wnt/BMP 
pathways. 
(Haynes et al., 
2001; Atkins et al., 
2003; McInnes & 
Schett, 2007; 
Pederson et al., 
2008; Rachner et 
al., 2011) 
Osteoblast Bone formation. Direct 
osteoclast differentiation 
through RANK, RANKL 
and osteoprotegrin (OPG). 
Balance with osteoclast 
carefully orchestrated in 
normal joints. 
SIP, BMP6 and Wnt/BMP 
pathways modulated by 
pro-inflammatory 
cytokines affecting bone 
repair. 
(Haynes et al., 
2001; Atkins et al., 
2003; McInnes & 
Schett, 2007; 
Pederson et al., 
2008; Rachner et 
al., 2011) 
Chondrocytes Cell of the adult cartilage 
maintaining cartilaginous 
matrix (secreting mainly 
collagen and proteoglycan). 
.Maintain balance between 
degradation and synthesis 
of matrix components. 
Synthesise 
glycosaminoglycan. . 
Cartilage destruction  
during interaction between 
cartilage and synovial 
pannus where SF attach 
and release proteinases 
capable of digesting 
cartilage matrix 
components. Elevated 
MMPs in synovial fluid 
continues cartilage 
degradation, MMP-1, 
MMP-10 and MMP-3 are 
produced by synovium and 
chondrocytes. 
(Maroudas et al., 
1998; Verzijl et al., 
2000; Shikhman et 
al., 2004; Ainola et 
al., 2005; Li et al., 
2006; Müller-
Ladner et al., 
2007) 
Lymphocytes White blood cell including 
natural killer cells (cell-
mediated, cytotoxic innate 
Aggregated T and B cells 
found close to synovial 
membrane due to cytokine 
(Maroudas et al., 
1998; Verzijl et al., 
2000; Shikhman et 
 
 
Chapter 1. Introduction  Rheumatoid Arthritis 
 77 
immunity), T cells (cell-
mediated, cytotoxic 
adaptive immunity), and B 
cells (humoral, antibody-
driven adaptive immunity). 
and chemokine release. B 
cells produce rheumatoid 
factor (RF) and other 
autoantibodies. ROS and 
hypoxic background in 
synovium supports T cells 
which can resist apoptosis 
and lose expression of 
CD25, CD28, CD27 and 
CD40L, but have enhanced 
expression of inflammatory 
cytokines including IFN-γ 
and TNF-α. Th17 cells 
mediate pannus growth, 
osteoclastgenesis and 
synovial neoangiogenesis 
within RA, producing IL-
17, IL-21 and IL-22 and 
pannus growth. Imbalance 
of ratio between Treg and 
other T cells implicated in 
RA. 
al., 2004; Ainola et 
al., 2005; Li et al., 
2006; Mauri & 
Ehrenstein, 2007; 
Müller-Ladner et 
al., 2007; Pickens 
et al., 2010) 
 
 
 
1.8.7.1 Dendritic Cells 
 
Dendritic cells are major antigen presenting cells and are important activators and 
regulators of the immune system, orchestrating immune response by ingesting and 
presenting antigens to T cells (Banchereau and Steinman, 1998; Bell et al., 2017). These 
cells prime naïve Tc and Th and enhance Tc  cell cytotoxicity, following antigenic uptake 
the dendritic cell migrates to the lymphoid organs and stimulates differentiation and 
maturation of T cells via the uptake of the antigen via Toll-like receptor ligands 
(Lanzavecchia & Sallusto, 2000; Liu, 2015; Schraml & Reis e Sousa, 2015). Dendritic 
cells also remove autoreactive lymphocytes and increase the regulatory T cell population 
(Lutzky et al., 2007), playing an important role in self-tolerance (Bell et al., 2017). Within 
RA, dendritic cells can prime autoimmune responses in lymphoid organs and therefore 
enhance development of the pathology seen in RA (Ludewig et al., 1998; Suwandi et al., 
2015), as illustrated in Figure 1.11. They also take part in antigen processing and 
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presentation within synovial tissue and fluid, allowing them to take up and process 
antigens present within the area of inflammation, and releasing inflammatory mediators, 
therefore contributing to disease perpetuation (Ludewig et al., 1998). Dendritic cells 
mature in response to proinflammatory cytokines including IL-6, IL-1 and TNF-α as well 
as tissue factors such a hyaluronic fragments, heat shock proteins, heparin sulphate, the 
action of migration across endothelial cells within inflamed tissue and T cell derived 
signals (CD154) (Lutzky et al., 2007; Schraml & Reis e Sousa, 2015). 
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Figure 1-11 Diagram illustrating the role of dendritic cells within RA.(1) migration of 
conventional dendritic cells (cDCs) presenting antigens in the lymph nodes (LN), normally 
maintaining tolerance (2), however abnormal activation of cDCs through innate / pattern 
recognition receptors following mechanical damage or infection could lead to proliferation 
of autoreactive T cells (3). Presentation of self-antigens by plasmacytoid dendritic cells 
(pDCs) leads to two possible outcomes, inflammation through the production of type I 
interferon and the regulation of autoreactive T cell function via regulatory T cells / 
secretion of indoleamine 2,3-dioxygenase (IDO). Within the lymph node self-restricted B 
cells activity is supported enabling class switching and plasma cell differentiation, leading 
to high levels of self-antibodies. Self-restricted T effector cells recirculate into inflamed 
joints and tissue, encountering APCs (4). T cells re-activated by these DCs support 
macrophage activation, expression of costimulatory molecules i.e. RANKL leading to 
further joint pathology (5). The cycle is perpetuated with increased antigen released from 
the damaged joint within the lymph node (6), eventually allowing the progression of 
disease within the tissue. Adapted from Benson, (Benson et al., 2010). 
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1.8.7.2 Synovial Fibroblasts 
 
A further class of cells found at the site of inflammation within RA, are synovial 
fibroblasts (SF). This group is composed of two cell types, the synovial macrophage and 
the type B synoviocytes, also termed fibroblast-like synoviocytes, which are derived from 
mesenchyme populations. SF cells are a feature of the hyperplastic synovium which is 
involved in the infiltration and degradation of adjacent bone and cartilage.  The SF actively 
bind and invade cartilage expressing adhesion molecules and matrix degrading and 
proinflammatory mediators (Müller-Ladner et al., 1996). In the pre-inflammatory phase of 
RA it is thought that activation of the innate immune system leads to the upregulation of 
effector molecules in SFs, with infectious and non-infectious agents proposed to be 
potential triggers (Müller-Ladner et al., 2007). SFs are stimulated via TLRs which in turn 
release vascular endothelial growth factor (VEGF), IL-8 and IL-15. Interestingly, cytokines 
IL-1 and  TNF-α enhance expression of TLR2 in SFs, perpetuating the inflammatory cycle 
(Pierer et al., 2004).  
1.8.7.3 Endothelial Cells 
 
Endothelial cells are also active participants within RA and undergo phenotypic 
changes characterised as apoptotic, leaky, angiogenic or activated. During leucocyte 
migration within the inflammatory sites, selectins mediate leukocyte tethering and rolling, 
resulting in leucocyte adhesion via integrins and ligands on endothelial cells, such as 
ICAMs (Butcher et al., 1999). Anti-ICAM-1 treatment in RA patients results in a reduction 
of disease activity and blocks trafficking of T cells, suggesting great functional importance 
of adhesion molecules in human RA (Schulze-Koops et al., 1995). Infliximab is an anti-
TNF treatment which decreases E-selectin and ICAM-1 levels, suggesting their reduction 
may reduce migration of leukocytes into RA joints (Van Schouwenburg et al., 2013). 
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1.8.7.4 Osteoclasts and Osteoblasts  
 
Osteoclasts are multinucleated cells of hematopoietic origin and have a primary 
role in resorbing cells and remodeling bone. These are giant cells which are actually a 
fusion product of up to 20 single cells and enable shaping of bones and remodeling of the 
skeleton from birth to old age (Schett, 2007). Bone mass in adults is maintained through a 
close partnership between osteoclast and osteoblasts, mediated through a variety of 
hormones, cytokines, growth factors and matrix proteins. Bone resorption by osteoclasts 
requires a signal from either osteoblast or from cells lining the bone itself, with osteoblasts 
directing osteoclast differentiation through pathways including RANK, RANKL and 
osteoprotegerin (OPG) (Khosla, 2001). In RA, proinflammatory cytokine signals can 
modulate this pathway and may adjust the process in which osteoblasts repair bone. OPG is 
a soluble decoy receptor for RANKL, which blocks the pro-osteoclastogenic activity of 
RANKL. In RA synovial tissue there is an increase in the ratio of RANKL:OPG suggesting 
that pro-osteoclastogenic condition dominate the inflammatory environment of the RA 
joint (Haynes et al., 2001). As osteoblasts mature their expression of RANKL reduces and 
is replaced with an increase in their expression of OPG, creating an environment that 
supports bone formation (Atkins et al., 2003). It is clear that the balance of osteoblast and 
osteoclast is carefully orchestrated within normal joints and that this balance is corrupted 
within RA through alterations to the complex signalling pathways involved together with 
the proinflammatory microenvironment of the RA joint.  
1.8.7.5 Chondrocytes 
 
Adult cartilage is populated solely with a specialised cell called a chondrocyte, 
from the Greek chondros – cartilage and kytos – cell. These cells maintain the cartilaginous 
matrix which is composed of a combination of collagen and proteoglycans and are derived 
 
 
Chapter 1. Introduction  Rheumatoid Arthritis 
 82 
from mesenchymal stem cells. The collagen network is made up of types II, IX and XI 
collagens, providing tensile strength and aids retention of proteoglycans (Verzijl et al., 
2000) Compressive resistance is provided by the aggregating proteoglycan aggrecan, 
which attaches to hyaluronic acid polymers. Chondrocytes maintain a balance between the 
degradation and synthesis of matrix components, with a half-life in excess of 100 years for 
type II collagen (Verzijl et al., 2000), and three to 24 years for aggrecan (Maroudas et al., 
1998). They are surrounded by a type VI collagen microfibril cellular matrix, which 
maintains chondrocyte membrane attachment via interactions with hyaluronic acid, bi-
glycan and decorin (Verzijl et al., 2000).  
Glycosaminoglycan, a component of aggrecan, together with other cartilage matrix 
components are synthesised by chondrocytes during periods of low turnover. Glucose is 
the main energy supply for chondrocytes and is also a precursor for glycosaminoglycan, 
with glucose transport facilitated by the GLUT family of transport proteins (GLUT3, 8, 1 
and 6) (Shikhman et al., 2004). Cartilage destruction occurs in areas of interaction between 
the cartilage and the synovial pannus where evidence shows attachment of synovial 
fibroblasts, which can release proteinases capable of digesting the cartilage matrix 
components (Edwards, 2000). Degraded cartilage matrix components can be considered 
potential autoantigens within RA synovial inflammation.  
1.8.7.6 Lymphocytes 
 
Within RA inflammatory sites, ectopical germinal centre like structures can be 
seen, formed from aggregates of B and T cells and found in close proximity to the synovial 
membrane. It is likely that this gathering of lymphocytes is due to the variety of immune 
cells present within the synovium, including dendritic cells, and fibroblast like 
synoviocytes. These cells release factors such as B cell activating factor of the TNF family 
(BAFF) and chemokine ligands CXCL12 and CXCL13, leading to the organisation, 
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trafficking and survival of B cells (Tan et al., 2003). B cells support an autoimmune 
response following interaction with T cells, processing and presenting antigens via major 
histocompatibility complex class II and further producing cytokines. Genetic susceptibility 
to RA is associated to DRB1 genes encoding HLA-DR4 and HLA-DR1 (Newton et al., 
2004). 
The predominant population of antigen presenting cells in later immune responses 
are the B cell, although dendritic cells also play an important role in priming naïve T cells. 
Interestingly, B cells producing rheumatoid factor (RF), those that bind the complexes via 
membrane immunoglobulins, are effective in presenting immune complexes to T cells, 
irrespective of the antigen within an antigen-antibody complex (Roosnek et al., 1991) 
suggesting any antigen within a complex could be presented to and activate a T cell. 
Antibody secreting B cells may also produce auto-antibodies which form immune 
complexes therefore creating further activation of the immune system. T cells are assisted 
by mature B cells which also activate differentiation of effector T cells. Both T cells and B 
cells are capable of producing proinflammatory cytokines, with a subset of B cells 
secreting IL-10 a regulatory cytokine, capable of downregulating the immune response 
(Mauri and Ehrenstein, 2007). 
T cells found within the synovium express a variety of cell surface antigens 
indicating prior antigen experience, including markers of effector memory cells such as 
expression of chemokine receptors and integrins and markers confirming differentiation, 
migratory experience and effector function amongst others (Cope, 2008). Pro-
inflammatory Th17 cells produce IL-17, IL-21 and IL-22, with the process of conversion 
from naïve T cell to Th17 requiring the presence of IL-6, TGF-β, IL-21, IL-1 and IL-23 
(Sheu et al., 2010). IL-17 binding to target cells leads to release of proinflammatory 
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mediators including cytokines, chemokines and MMPs, supporting pannus growth, 
synovial neoangiogenesis and osteoclastogenesis (Pickens et al., 2010).  
1.8.8 Cytokine Interactions within Rheumatoid Arthritis 
 
Cytokines are a diverse group of proteins including lymphokines, interleukins, 
monokines, colony stimulating factors, and chemokines and act through heterodimeric or 
heterotrimeric receptors. Imbalances within the cytokine network may lead to 
inflammation. In early RA synovial TH cells express IL-2, IL-4, IL-13, IL-17, and IL-15, 
this changes as RA progresses with established RA synovial TH cells expressing IFNγ, 
TNF and IL-10 with little IL-2, IL-4, IL-5 and IL-13 (Cope, 2008). The synovial tissue 
within inflamed RA joints, is infiltrated with activated macrophages and leukocytes and is 
rich in pro-inflammatory cytokines such as TNFα, IL-6, IL-1 and IL-17 together with 
growth factors such as M-CSF, capable of impacting bone remodeling within the RA 
microenvironment (Lorenzo et al., 2008). IL-1 and TNF-α are perhaps the main pro-
inflammatory cytokines involved in RA, with TNFα mediating the inflammatory response, 
promoting the activation of synovial fibroblast whilst IL-1 is involved with cartilage and 
bone destruction (Vervoordeldonk & Tak, 2002), as seen in Figure 1.12. Neutralisation of  
TNF-α, decreases the production of  IL-1, IL-6 and Granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Vervoordeldonk & Tak, 2002). TNF-α is a target of many 
RA biological drugs as illustrated in Table 1.7.  
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Table 1.7 Summary table of cytokines involved within RA pathogenesis, their function, 
originating cell and drug targeted by. 
 
Cytokine 
 
Function in Disease / Secreted 
by 
Cytokine 
Inhibiting 
Drugs  
Source 
IL-1 (IL-
1α,IL-1β) 
Co-mitogen for T lymphocytes. 
Stimulate liver inducing 
transcription of acute phase 
proteins (APP). Leads to increase 
expression of inflammatory 
genes. 
 
Secreted by monocytes, 
macrophages, B cells, dendritic 
cells, endothelial cells. 
Anakinra 
 
 
Tracey and Cerami, 
1994; Brennan and 
McInnes, 2008; 
Dinarello, 2009; 
Gabby and 
Kushner, 1999; 
Baumann and 
Gauldie, 1994; 
Siebert et al., 2015 
IL-6 Growth factor for B cells. 
Stimulate liver inducing 
transcription of APP. Induces 
antibody production within B 
cells. Downregulation of TNF-α, 
IL-1. 
 
Secreted by monocytes, 
macrophages, TH2 cells, bone 
marrow cells. 
Tocilizumab Tracey and Cerami, 
1994; Brennan and 
McInnes, 2008; 
Dinarello, 2009; 
Gabby and 
Kushner, 1999; 
Baumann and 
Gauldie, 1994;  
Siebert et al., 2015 
TNF-α Propagates T cell response via T 
helper cell type 1 (Th1). 
Stimulate liver inducing 
transcription of APP. Pro-
inflammatory, induces cytokine 
production, cell proliferation and 
apoptosis. 
 
Secreted by macrophages, NK 
cells, CD4+ lymphocytes, 
adipocytes, basophils, 
eosinophils, dendritic cells. 
Infliximab, 
adalimumab, 
golimumab, 
certolizumab 
and etanercept  
Tracey and Cerami, 
1994; Brennan and 
McInnes, 2008; 
Dinarello, 2009; 
Gabby and 
Kushner, 1999; 
Baumann and 
Gauldie, 1994; 
Linlin Chen, 
Huidan Deng, 
Hengmin Cui, Jing 
Fang, 2017;  
Siebert et al., 2015 
IL-7 Pro-inflammatory, role within 
synovium reducing B cell 
apoptosis, increasing antibody 
production. Induces 
differentiation into progenitor B 
and T cells. 
 
Secreted by bone marrow and 
 Lubberts, Koenders 
and van den Berg, 
2005 
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The ratio of Th1, Th17 and Treg lymphocytes is altered in the peripheral blood of 
RA patients (Pawłowska et al., 2014), which can be assumed creates an imbalance of 
cytokines released. Th1 cytokines favour T-cell mediated cellular immunity, cytotoxicity 
and monocyte activation, which leads to amplified production of pro-inflammatory 
cytokines IL-2 and IFNγ (van den Berg & Miossec, 2009). The Th2 cytokines, IL-4, IL-5, 
IL-6, IL-10, and IL-13 are involved within the stimulation of antibody mediated immune 
responses and Th17 cytokines are involved in the elimination of fungal and extracellular 
pathogens (Chizzolini et al., 2009). Macrophages produce proinflammatory TNFα, IL-6, 
IL-1,IL-15, IL-23, IL-18 and IL-12; T cells produce anti-inflammatory IL-4, IL-10, TGFβ, 
and IL-6 which has both pro and anti-inflammatory properties, protective IL-22 and pro 
thymic stromal cells. 
IL-10 Anti-inflammatory. Inhibits gene 
expression of T cell and 
macrophage pro-inflammatory 
cytokines, reducing function of 
antigen presenting cells.  
 
Secreted by TH2 cells, T cells, B 
cells 
 Linlin Chen, 
Huidan Deng, 
Hengmin Cui, Jing 
Fang, 2017; de 
Wall Malefyt, 
1991;  Petrovic-
Rackov and 
Pejnovic, 2006 
IL-15 Stimulates intestinal epithelium 
growth, T cell proliferation, co-
mitogen for B cell activation and 
proliferation. Promotion of CD8 
T cell survival, 
osteoclastogenesis and bone 
destruction. 
 
Secreted by T cells and 
mononuclear phagocytes. 
 Joseph Lorenzo,  
2016; S Saeed and 
PA Revell, 2001; 
Guangwei Cui et al, 
2014 
IL-17 Involved within stimulation of 
iNOS and chemokine synthesis, 
inducer of osteoclasts genesis and 
RANKL expression. 
 
Secreted by T cells, including 
Th17 
Secukinumab 
(Phase III 
trial), several 
other Phase I 
& II trials 
ongoing 
Kotake et al., 1999; 
Brennan McInnes, 
2008; Duvallet et al 
2011; Wei Jin and 
Chen Doud, 2013; 
Siebert et al., 2015  
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inflammatory IL-21, IL-17 and IFNγ; with fibroblast producing proinflammatory IL-18, 
IL-6, IL-8 and IL-15 (Brzustewicz & Bryl, 2015). Cytokines are a key target of RA drugs 
with many (discussed in section 1.9.10), designed to knock out aspects of the 
proinflammatory pathways by blocking these signal molecules. 
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Figure 1-12 Diagram illustrating cytokines pathways involved within RA and interactions with CRP.  Monocytic cells secrete IL-1 and IL-6 upregulating 
CRP expression within hepatocytes; in turn CRP binding activates further macrophage/monocyte expression of IL-1 and IL-6. This inflammatory cascade 
enhances TH17 differentiation/release of IL-17 leading to chronicity. Synoviocyte expression of Il-6 upregulates CRP, again leading to further IL-1 and IL-6 
expression and cyclical pro- inflammation cytokine production (Sproston and Ashworth 2018; Noack and Miossec). Figure adapted from Noack and Miossec, 
2017 
IL-1 
IL-6 
TNF 
IL-1 
IL-6 
Macrophage 
CRP 
CRP 
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1.8.9 Auto-antibodies within Rheumatoid Arthritis 
 
RA has long been considered an autoimmune disease, with the production of auto-
antibodies such as rheumatoid factor (RF) strongly associated with it (Montecucco and 
Mach, 2009, Peters et al., 2008). First observed in 1964, Kunkel and Williams described 
the production of IgG auto-antibody involvement in RA, describing them as rheumatoid 
factors (Kunkel and Williams, 1964).  RF consists of between 70–80% of IgM-class auto-
antibodies against the Fc (fragment crystallisable) region of IgG, which then binds to IgG 
within RA joints, leading to immune complex deposition (Haque et al., 2014). The level of 
RF in serum has been correlated to disease severity, with seropositive RA patients 
suffering more aggressive disease with a worse prognosis, with the presence of RF 
detected several years before arthritis begins (van Zeben & Breedveld, 1996). Auto-
antibodies have also been associated with increased risk of atherosclerosis, Peters et al, 
(2008) showing oxLDL auto-antibody association with cardiovascular disease in RA 
(Peters et al., 2008). It is possible that auto-antibodies produced during disease progression 
in RA patients, could also lead to an increase in atherosclerosis (Montecucco and Mach, 
2009).  
Antibodies to citrullinated protein antigens (ACPAs) or anti-cyclic citrullinated 
peptide (anti-CCPs) are highly specific and naturally occurring antibodies, recognising 
citrullinated proteins and peptides and are found in 98% of RA patients (Weyand & 
Goronzy, 2006). Citrullinated proteins arise from the post translational modification of 
arginine to citrulline by the enzyme peptidyl arginine deaminase (PAD) (Kim, 2013). By 
decreasing the net positive charge, citrullination can alter the structure of proteins, 
potentially enabling adjusted intermolecular interactions (Feist & Burmester, 2006; Egerer 
et al., 2009). Citrullination is a normally occurring process, however overproduction can 
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lead to inflammation induced by formation of immunocomplexes and proteins undergoing 
post translational citrullination such as fibrin, a cleavage product of fibinogen, may be 
recognised as an antigen (Weyand and Goronzy, 2006). Citrullinated proteins bind to the 
HLA-DBR1 molecule, leading Th cell conversion to Th17 cells (H.R. Kim, 2013), with the 
ratio of Th1, Th17 and Treg lymphocytes altered in the peripheral blood of RA patients. 
 In addition to anti-CCP and RF, anti-carbamylated protein (anti-CarP), anti-
collagen type II (anti-CII) (Gerlag et al., 2016) and anti-acetylated protein antibodies 
(Juarez et al., 2015), have been found within RA serum, with the level of anti-CarP 
antibodies significantly increased in RA patients compared with healthy controls. 
Carbamlyation is a non-enzymatic post translational modification binding cyanate to 
molecules containing a primary thiol or amine group, forming carbamyl groups (Shi et al., 
2013). Anti-CII is associated with elevated CRP, erythrocyte sedimentation rate (ESR), 
DAS28 and DAS28CRP at diagnosis and up to six months after and predicts a favorable 
outcome as opposed to patients seropositive for anti-CCPs (Manivel et al., 2017). 
Acetylation is a reversible enzymatic process where acetyl groups are added to free amines 
of lysine residues. Juarez et al., (2015) observed both IgG and IgA auto-antibodies directed 
against acetylated vimentin in RA patient serum, together with both IgG and IgA 
antibodies against citrullinated and carbamylated vimentin (Juarez et al.; 2015). Both RF 
and anti-CCPs are used within clinical settings to determine RA and the presence of both 
predicts the development of RA in patients with early arthritis (Rantapaa-Dahlqvist et al., 
2003). It is clear that auto-antibodies of IgG, IgM and IgA classes are present within RA 
serum directed against a variety of proteins, many of which are the result of post 
translational changes. 
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1.8.10 Therapeutic Treatments for Rheumatoid Arthritis 
 
Whilst there is no cure for RA, several therapies and modern advances in 
treatments are making the disease more manageable. There are a variety of different 
treatment options available to a clinician when attempting to contain the initial effects of 
RA. The first 12 weeks after early symptoms occur is regarded as an optimal treatment 
period and the best outcomes are attained when diagnosis is early and treatment is 
aggressive, preventing the onset of bone loss, joint destruction and pain. Generally RA 
treatments reduce inflammation by either blocking immune mediators or by modulating 
immune cell function or numbers (Pisetsky, 2017). Disease Modifying Anti-Rheumatic 
Drugs (DMARDs), reduce the progression of damage and can either be synthetic, small 
molecules or biologics.  Conventional synthetic DMARDs have been the foundation of RA 
treatment for many years with methotrexate (MTX) being the most commonly prescribed. 
MTX is a form of folate which has an increased binding affinity for dihydrofolate 
reductase (DHFR) compared to its parent molecule (Guo et al., 2018). The actions of MTX 
include folate antagonism, adenosine signaling, and downregulation of adhesion molecule 
expression, eicosanoids and MMPs. Another synthetic DMARD, Sulfasalazine, is an anti-
inflammatory and immunosuppressant drug which is thought to suppress leukotriene 
production and chemotaxis, IL-1, IL-6, TNFα and NF-kB activation. 
Chloroquine/hydroxychloroquine, also a synthetic DMARD, has immunomodulatory 
effects, interacting with Toll-like receptors, monocyte-derived pro-inflammatory cytokines, 
T-cell responses, neutrophils and cartilage metabolism and degradation. All three have side 
effects ranging from pulmonary damage to gastrointestinal tract, skin, central nervous 
system and hematologic adverse effects (Guo et al., 2018). 
Over the last decade several new drugs have been brought to market that work in a 
different way to the traditional DMARDs, among these are the group known as biologics, 
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or biological DMARDs. Biologics include monoclonal antibodies e.g. infliximab or soluble 
receptors such as etanercept (Pisetsky, 2017). The different treatments available within 
each group are shown in Table 1.8. This group can be divided into classes dependent upon 
their actions, with adalimumab, etanercept, infliximab, golimumab and certolizumab all 
inhibiting TNFα, therefore reducing phagocytosis and pro-inflammatory cytokines, 
chemoattractant, adhesion molecules, Treg cell function and the function of osteoclasts, 
leucocytes, endothelial and synovial fibroblasts. 
Table 1.8 Disease Modifying Anti-Rheumatic Drugs (DMARDs) classes, information 
taken from from Pisetsky 2017. 
 
B-cell targeting drugs include rituximab which depletes B cells with potential 
mechanisms including complement mediated cell lysis, antigen presentation, B cell 
apoptosis and Fc receptor gamma-mediated antibody-dependent cytotoxicity and 
phagocytosis. Another group target T cells, such as abatacept which interacts with 
CD28/CTLA4 signaling pathways (Guo et al., 2018). This group also produces side effects 
within patients, which without perhaps unsurprisingly include a greater risk to infection, 
together with increases in serum cholesterol, neutropenia, malignancy, hypertension, and 
abnormal liver function (Guo et al., 2018). The last group are small molecule DMARDs 
Classes of DMARD 
Conventional synthetic Methotrexate, sulfasalazine, hydroxychloroquine, 
leflunomide, azathioprine 
Biologic TNF blockers (adalimumab, etanercept, infliximab, 
golimumab, certolizumab); T cell co-stimulatory blocker 
(abatacept); anti-IL-6 receptor (tocilizumab; anti-CD-20 
(rituximab) 
Targeted synthetic Tofacitinib 
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which exploit the use of Janus Kinase (JAK) and signal transducer and activator of 
transcription (STAT) pathways by cytokines. The small molecules such as Jakinibs are 
able to therapeutically block these pathways, proving effective within disease treatment.  
Tofacitinib is a small molecule DMARD which targets signal transduction pathways 
preferentially inhibiting JAK-3 and JAK-1 over JAK-2 (Venkatesha et al., 2015). 
Early aggressive therapy is designed to reduce inflammation and prevent damage, 
methotrexate is frequently the initial drug used and can when necessary be combined with 
glucocorticoids, however these present many patients with significant toxicity and side 
effects (Durez et al., 2007). An alternative therapy uses TNF blockers in association with 
methotrexate, resulting in a rapid reduction in inflammation and pain, however this 
combination is expensive and therefore reserved for patients who cannot be treated 
alternatively (Jalal et al., 2016).  
While biologic treatments tend to be more effective, they are also expensive. Triple 
therapy, the combination of conventional DMARDs for instance hydroxychloroquine and 
sulfasalazine in addition to methotrexate, with glucocorticoids when needed is also found 
to be effective, and less expensive. However once again the side effects associated with 
glucocorticoids must be a consideration (Jalal et al., 2016). CRP levels are reduced in 
patients who take traditional DMARDs such as sulfasalazine and or methotrexate.(Stenger, 
1998; Aletaha & Smolen, 2002). 
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1.9 Research Aims 
This pilot study was designed to investigate two separate aims.  
(i) The first was to clarify whether monomeric CRP was present within RA 
patient serum and if levels could be quantified.  
a. This will involve the production of in vitro produced mCRP in 
addition to the analysis of patient serum samples to determine 
presence of the in vivo form.  Varying methods of dissociation are to 
be used in order to dissociate the pentameric human CRP molecule 
into its individual protomers. This will be purified from the 
pentamer using size exclusion chromatography in order to prepare 
high levels of concentrated stock solution suitable for 
immunological studies. 
b.  It is also necessary to assess the stability of the monomer and 
likelihood of re-association within the stock solution during storage. 
The presence of monomeric CRP within serum may have important 
implications for both clinical practice and within research. It is 
important to understand whether pro or anti-inflammatory functions 
of CRP have been confused due to the conformation detected, and 
how the presence of two forms of the protein, with possibly 
opposing roles within the immune response may affect the patient 
and their treatment.  
(ii) Further aims of the research were to investigate the existence of antibodies 
directed against both monomeric and pentameric CRP, of classes IgG, IgA 
and IgM. This will greatly enhance our understanding of not only RA but 
inflammatory diseases and the role that CRP isoforms play within it. 
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Our research hypothesis was that mCRP would be found within RA serum and would 
correlate in levels to that of any pCRP quantified as a result, potentially, of pentamer 
dissociation. It was further hypothesized that auto-antibodies to mCRP would be found in 
class IgG but not in IgM or IgA, and that auto-antibodies to pCRP will not be found, the 
hypothesis is based on previous research which has not found either IgM or IgA 
autoantiboides against mCRP or any autoantibodies directed against pCRP.  
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Chapter 2 - Materials and Methods 
 
2.1 Overview  
 
Native, pentameric C-reactive protein (pCRP) is stable within normal physiological 
conditions. However evidence suggests that pCRP can in certain circumstances dissociate 
into separate protomers, termed monomers. This isoform of CRP has been described as 
monomeric CRP and therefore will be referred to as mCRP from here onwards. Whilst 
pCRP is freely soluble, mCRP displays reduced solubility and a change in isoelectric point 
suggesting a change to the protein structure. The biological relevance of mCRP is unclear, 
however it is suggested to play a proinflammatory role within the human body (Ciubotaru 
et al., 2005; S.-R. Ji et al., 2006; Eisenhardt, Habersberger, Murphy, et al., 2009; Thiele et 
al., 2015; Jia et al., 2018). 
RA is an autoimmune condition which resembles SLE in some aspects, but differs 
in levels of CRP and in anti-CRP auto-antibodies present. SLE presents with relatively 
normal levels of CRP, but with levels of anti-mCRP IgGs correlating to disease activity. 
RA is characterised by high levels of circulating pCRP and although auto-antibodies to 
citrullinated proteins and peptides together with RFs are present within seropositive serum, 
few studies have investigated anti-CRP auto-antibodies. Of those that have, none have 
sought to determine either IgA or IgM class antibodies directed against mCRP or pCRP. 
Therefore ELISA protocols were developed in order to determine the presence of mCRP 
and associated CRP auto-antibodies. 
This chapter will describe the methodology and techniques developed in order to 
produce in vitro mCRP and to enable detection of human serum mCRP and associated 
mCRP and pCRP IgG, IgA and IgM auto-antibodies. It will then provide an overview of 
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the materials and methods used within each experiment. Production of mCRP experimental 
design is based upon existing literature which was further optimised within our research 
lab as detailed within chapter 3, with an aim to develop a methodology enabling generation 
of reproducible mCRP in vitro within conditions as close to physiologically practical as 
possible. Enzyme linked immunosorbent assay (ELISA) protocols were developed in order 
to overcome interactions between patient serum and constituent reagents, ensuring stability 
and accurate determination of proteins, the development of which are further detailed 
within chapters 4. 
 
 
Chapter 2. Materials and Methods  Techniques 
 98 
2.2 Techniques 
 
The production of monomeric C-reactive protein was first described by Potempa et 
al., in 1983 wherein they described the methods employed in order to dissociate the 
pentameric protein into separate monomers. The process described included heat treatment 
and the alteration of pH to acidic conditions or dissociation through high concentrations of 
Urea (up to 8M) (Potempa et al., 1983). The following techniques were used following 
dissociation trials within our study to determine the level of dissociation and size of the 
resulting subunits, together with their stability over time and likelihood of re-association. 
Also described are the ELISA and western blot techniques adapted in order to detect CRP 
and antibodies within human serum samples. 
2.2.1 Gel Filtration Size Exclusion Chromatography  
 
Gel filtration size exclusion chromatography (SEC) is a simple method allowing the 
separation and purification of biological macromolecules such as proteins, polysaccharides 
and nucleic acids by size. Size exclusion chromatography is a generic name given to liquid 
chromatography separation and can be used to represent any of the following techniques, 
gel permeation chromatography, gel filtration chromatography, steric exclusion 
chromatography, exclusion chromatography or gel chromatography. Using SEC a sample 
can be processed and successfully purified within a variety of conditions and works on a 
simple basis. A column of cross-linked copolymers often of either styrene or 
divinylbenzene is prepared with a narrow range of pore size (Wilson & Walker, 2010). 
Buffer systems can be adapted to allow buffer exchange and the process can be undertaken 
at a range of accurately controlled temperatures or pH, and can take place in the presence 
of harsh chemicals including urea allowing sample purification. The system relies on the 
ability to pass a sample through a gel filtration medium which is closely packed within a 
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column. The medium consists of chemically inert and physically stable spheres such as 
Sephadex, formed from dextran beads which are packed together forming a cross linked 
porous matrix and can be formed from a variety of components chosen to meet specific 
pore size requirements. The liquid within the matrix is known as the stationary phase and is 
equilibrium with the liquid outside of the matrix known as the mobile phase. The various 
types of filtration medium are dependent on the sample components and separation desired. 
Large analytes are unable to enter the pores and therefore pass through the interstitial space 
between the particles and are eluted first. Smaller analytes are suspended within the buffer 
(mobile phase) and move through the particles and are slowed, eluting at a rate which 
correlates to their size. Elution volumes are determined relative to their molecular mass and 
as such a calibration of any system should be completed prior to use (Wilson & Walker, 
2010). Calibration graphs, constructed from the elution volumes of known standard weight 
molecular proteins can be used to determine the molecular weight of unknown proteins 
within samples, based on their elution volumes (Amersham & Amersham, 2003). 
A sample of between 0.1-2% of the column volume is applied onto the column via 
a syringe and once applied both the sample and buffer begin to migrate through the system 
and column. The flow rate is optimised allowing increased resolution of the resulting 
elution profile whilst conserving post purification protein yields. The buffer continuously 
passes through the system and column with larger molecules being eluted off first into 
fraction collection tubes. Whilst samples are eluted off the ultra-violet absorbance is 
measured allowing an elution profile to be collected. The applied protein will be 
completely eluted over one column volume of buffer passing through the column 
(Amersham & Amersham, 2003). 
The flowrate for applying a sample must be optimised and must not exceed 1.6 
ml/minute for the column used within these experiments, although the flow rate with 
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different columns may be faster or slower than this. Between usage columns are stored in 
20% ethanol to prevent bacterial growth. Prior to use the column is flushed through with 
one column volume of degassed and deionised water at the maximum column flowrate (1.6 
ml/min) in order to remove all ethanol. This is followed by one column volume of 
degassed buffer, used to equilibrate the system prior to use. Successful equilibration of the 
system can be monitored via observation of the UV absorbance reading, ensuring it is at 
baseline before use (Amersham & Amersham, 2003). 
It is advised not to run samples such as blood or serum through the system due to 
their composition which may block the size exclusion column, reducing the accuracy of 
sample determination and necessitating rigorous cleaning between samples (Amersham & 
Amersham, 2003). It is also essential that contaminants such as dust, particulate matter or 
precipitation of salts are not introduced to the system by filtering all samples and buffers in 
a 0.2µm filter as it is easier to avoid contamination than remove it from the system. 
Degassing is another important step as air within the system and mobile phase may affect 
the pumps and detector (Amersham & Amersham, 2003). 
2.2.2 Concentration of C-reactive Protein Samples 
 
Eluted samples were concentrated using a Vivaspin Centrifugal Concentrator, with 
a 10kDa molecular cut off, purchased from Fisher Scientific. The centrifugal concentrator 
was first primed with deionised water and spun at 1,000 x g at 4oC for 10 minutes. 
Following the priming step the protein sample was then spun at 1,000 x g at 4oC for 15 
minutes or until the required concentration had been achieved. 
2.2.3 Polyacrylamide Gel Electrophoresis  
 
Gel electrophoresis is a relatively simple and rapid technique which allows 
identification of sample contents. The technique involves the separation of bio 
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macromolecules according to their electrophoretic mobility through a gel under an electric 
field. Polyacrylamide gels are used within protein separation whereas agarose is used 
within deoxyribonucleic acid (DNA) or ribonucleic acid  (RNA) separation. Acrylamide is 
polymerised to polyacrylamide in the presence of bis-acrylamide (N,N'-
Methylenebisacrylamide) which is used as a cross linking agent (Wilson & Walker, 2010). 
Ammonium persulfate (APS), in combination with tetramethylethylenediamine (TEMED) 
provide free radicals which instigate polymerization between bis-acrylamide and 
acrylamide monomers. Dissolving APS in water allows formation of free radicals and 
TEMED acts as a catalyst accelerating the polymerisation reaction due to its ability to carry 
electrons (Hames and Rickwood, 1998). Bis-acrylamide subunits cross-link with elongated 
acrylamide polymer chains and form a matrix of acrylamide chains.  
The solidity/fluidity of the gel is determined by the ratio of acrylamide to bis-
acrylamide and the matrix pore size governed by the amount of acrylamide used within the 
gel and degree of cross-linkage (Hames and Rickwood, 1998). The polyacrylamide forms a 
cross linking polymer and is described in terms of total percentage of acrylamide or bis-
acrylamide present, with higher percentages used to refine smaller sized proteins and lower 
percentages, larger proteins. The suggested range for acrylamide gels is between 5-20%, 
however in practice a high percentage gel would be unable to resolve a larger molecular 
weight protein due to the small pore size formed (Hames & Rickwood, 1998).  
Proteins possess ionisable groups which exist in solution as either cations (+) or 
anions (-) and therefore under the influence of an electric charge migrate towards either a 
cathode (-) or anode (+) dependent upon the protein’s overall net charge. Electrophoresis 
allows the separation of proteins via the use of a power pack, electrophoresis unit and slab 
gel, usually formed from acrylamide as previously described. The complete acrylamide gel 
is formed within a gel cartridge, from both resolving and stacking gels which are poured in 
 
 
Chapter 2. Materials and Methods  Techniques 
 102 
two layers between two clamped glass plates. The resolving gel is first poured and allowed 
to polymerize before a lower concentration stacking gel is added, with comb allowing the 
formation of sample ‘wells’. It is within the stacking gel wells that samples are loaded and 
proteins are then separated according to their properties within the resolving gel (Hames 
and Rickwood, 1998).  
Upon polymerization the gel is loaded into the electrophoresis tank within 
appropriate buffer and the comb is removed. Samples can then be loaded into the 
individual wells left by removal of the comb and a current applied to the tank. The choice 
of buffer pH determines the mobility of the proteins and therefore separation, as does the 
percentage acrylamide used within the gel. The resolving gel may be formed from between 
3-30% polyacrylamide whereas the stacking gel is varied little and usually between 4-5%. 
The stacking gel allows the protein to concentrate in a sharp band and when the current is 
applied enter the resolving gel at the same speed (Wilson & Walker, 2010). 
To enable samples to run through the gel they are mixed with a sample buffer prior 
to loading. The buffer components depend upon the type of gel electrophoresis system that 
is being performed. Within a native gel system the sample buffer contains bromophenol 
blue, a dye that allows visualisation of the dye front whilst the gel is running, together with 
glycerol, providing density ensuring samples sink to the bottom of the loading wells. Once 
the gel has completed running and the dye front is either at the bottom of the gel cartridge 
or has just run off the bottom, the gel is removed from the unit and released from the 
between the gel plates. At this point the gel may be visualised by staining using a 
Coomassie dye based product, silver staining or be used within western blot detection of 
specific proteins of interest. Coomassie dye binds to the basic and hydrophobic residues of 
proteins and can detect as little as 10ng per band within a minigel, whereas silver staining 
can detect proteins to ≤ 0.5 ng of protein per band (Hames and Rickwood, 1998).  
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2.2.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
 
Usually proteins are separated by PAGE in the presence of a detergent such as 
Sodium dodecyl sulfate (SDS) and under denaturing (heat) and reducing or nonreducing 
conditions. Sodium dodecyl sulfate polyacrylamide gel electrophoresis usually denoted 
SDS PAGE is perhaps the most commonly used electrophoresis method for analysis of 
proteins within a sample. It is capable of determining the molecular weight of proteins due 
to its ability to separate proteins by size, when used in conjunction with a molecular weight 
marker ladder. Proteins are denatured to their constituent polypeptides allowing 
identification of the size and number of polypeptide chains within the sample.  
Within an SDS PAGE system the sample is mixed with a sample buffer prior to 
loading which contains the addition of an anionic detergent, SDS and β-mercaptoethanol. 
The addition of SDS provides the protein with an overall negative charge and denatures the 
protein. Proteins are heated to 95oC for five minutes which allows further denaturing to 
take place. The addition of β-mercaptoethanol present within the sample buffer reduces 
disulphide bridges present within the protein. Heating, the addition of β-mercaptoethanol 
and binding of SDS act together to denature the protein, allowing relaxation of the tertiary 
conformation, resulting in linear polypeptide chains. The linear chain bound with SDS 
molecules takes on an overall negative charge and the proteins are drawn towards the 
anode, with smaller particles travelling faster than larger. A protein formed from multiple 
subunits will be separated into bands correlating to the size of its subunits. This method is 
therefore unsuitable within the determination of which conformation of CRP may be 
present (pentameric or monomeric) within a sample, but will accurately show the size of 
individual protomers (Hames and Rickwood, 1998).  
 
 
 
Chapter 2. Materials and Methods  Techniques 
 104 
2.2.5 Native Polyacrylamide Electrophoresis 
 
Native PAGE are non-reducing and non-denaturing, allowing the detection of 
proteins in their physiological conformation with preserved secondary structure. The 
mobility of the protein through the gel is dependent upon the charge of each protein, 
determined by the primary amino acid sequence (isoelectric point) and the pH used within 
electrophoresis. The molecular mass separation of a reducing and denaturing SDS PAGE 
may only allow determination of one band whereas native PAGE may reveal many; 
however it is less accurate in determination of molecular weight due to the dependence 
upon protein charge and isoelectric point.  SDS PAGE uses discontinuous chloride and 
glycine ion fronts which allow polypeptides to stack and move through the gel by charge to 
mass ratio. Native PAGE uses this same principle but the charge to mass ratio becomes 
subject to variability between different proteins. The protein moves through the gel 
according to both mass via the sieving effect and electrophoretic mobility (Lord, 2003; 
Young et al., 2012). 
In some assays the native PAGE protocol was adapted to ensure monomeric CRP 
was able to run through the gel and to allow visualisation of the band. The conventional 
method was adapted to include 1/20th the normal amount of SDS to both the running and 
the sample buffer in accordance with the method used by (Taylor & Van Den Berg, 2007). 
In their method SDS was omitted from the gel itself. Taylor et al found that in native 
PAGE conditions, mCRP could not be detected and it was suggested this may be due to 
insolubility problems. They found that by omitting the sample heating step with the 
lowered amount of SDS, both pCRP and mCRP were easily distinguishable. Both isoforms 
ran within a tight band, whilst pCRP produced a smear when normal SDS conditions were 
applied. This method was therefore used within mCRP detection assays. 
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2.2.6 Gradient Gel Polyacrylamide Electrophoresis 
 
Gradient gels allow a larger range of protein molecular weight sizes to be run on 
the same gel due to the greater resolving range. Where both SDS and native PAGE use a 
combination of resolving and stacking gels, gradient gels utilise a gradient of acrylamide 
with the lowest concentration at the top and the highest concentration at the bottom. The 
gradient gel is formed via a gradient mixer and poured between glass plates in a similar 
fashion to both native and SDS gels forming a concentration range between 5 and 25%.  
2.2.7 Western Blotting 
 
The process of ‘blotting’ in molecular biology is a method of transferring proteins, 
DNA or RNA onto a membrane. The sample being transferred dictates the type of blotting 
performed, western blotting involves the transfer of protein, northern blotting involves 
RNA and southern blotting, DNA. Western blotting detects protein transferred to a 
membrane following gel electrophoresis using specific antibodies to probe for the desired 
protein. The technique was developed within the Friedrich Miescher Institute by Harry 
Towbin (Towbin et al., 1979) and is now used routinely within research and clinical 
settings.  
An SDS or native PAGE gel is first used to separate the proteins as described 
within sections 2.2.4, 2.2.5 and 2.2.6 and the proteins transferred onto a membrane. 
Typically membranes used within western blotting are either nitrocellulose or 
polyvinylidene difluoride (PVDF). Nitrocellulose is a cellulose based membrane in which 
the cellulose is treated with nitric acid and allowed to spread over a thin film. The 
membrane is negatively charged resulting from the esterification of each glucose unit 
within the cellulose polymer with three nitrate groups. Proteins bind to the membrane by 
electrostatic and hydrophobic interactions. Nitrocellulose has high retention of, and affinity 
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for proteins, this together with its ease of use and cost make it a widely used membrane. 
PVDF is produced by the polymerisation of vinylidene difluoride producing a membrane 
and is also widely used in western blotting due to its greater strength and amino acid 
binding capacity when compared to nitrocellulose. PVDF membranes require hydration in 
methanol prior to use due to its hydrophobic surface, this additional step ensures effective 
transfer and binding of macromolecules (Towbin et al., 1979; Komatsu, 2015 ). 
Proteins separated out by PAGE are transferred to the membrane following the 
application of an electrical current, which pulls the proteins from the gel onto the 
membrane as they migrate towards the cathode (+) (Towbin et al., 1979; Komatsu, 2015 ). 
Membranes used within western blot efficiently and effectively bind all proteins 
and therefore steps must be taken to ensure interactions between the detection antibody 
used and the membrane itself are prevented. Therefore effective blocking must be 
undertaken to ensure avoidance of non-specific binding. The membrane is blocked 
following transfer with either bovine serum albumin or non-fat dried milk powder, which 
bind to areas of the membrane where the target protein has not bound (Towbin et al., 1979; 
Komatsu, 2015 ).  
A specific antibody is then applied to ‘probe’ the membrane for the desired protein, 
termed the primary or detection antibody. A monoclonal antibody is generated following 
exposure of an antigen to a host species, therefore ensuring specificity to the target protein, 
or fragment of protein. The primary antibody is incubated with the membrane for varying 
time periods dependent on protocol before removal and the membrane washed to remove 
residual unbound primary antibody. A secondary antibody is then applied, this antibody 
will recognise the Fc fragment of the primary antibody and is enzyme conjugated for later 
visualisation. The enzyme is often either horseradish peroxidase (HRP) or alkaline 
phosphatase (AP). It is important to ensure antibodies are species specific, therefore if the 
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primary detection antibody has been raised in a mouse, the secondary antibody will be 
chosen to recognise a mouse antibody. Once the secondary antibody has been removed and 
the membrane carefully washed the enzyme substrate is added, with various substrates 
available determined by cost and sensitivity required (Murphy et al., 2008). HRP can be 
used to cleave chemiluminescent agents, the reaction resulting in light that can be detected 
by a charged coupled device (CCD) photodetector, captured digitally by camera (Gruner et 
al., 2002).  More cost effective detection methods can be used including 4-chloronapthol 
stain with hydrogen peroxide, which is simple to use and results in a deep purple stain 
upon contact to the bound enzyme conjugated antibody. This can be photographed easily 
and does not require specialist equipment. However, there is a trade between cost and ease 
of use and sensitivity, where cheaper assays provide reduced detection levels (Murphy et 
al., 2008). 
2.2.8 Enzyme Linked Immunosorbent Assay  
 
2.2.8.1 Sandwich Enzyme Linked Immunosorbent Assay 
 
An ELISA system is based upon the principle of immunoassays whereby specific 
antibody binding of an antigen, such as a protein, peptide, hormone or antibody, is detected 
within a fluid sample immobilised upon a solid phase carrier, in this case a 96 well ELISA 
plate. An enzyme acts as the reporter label, allowing measurement of the analyte within the 
sample. The enzymes now routinely used as conjugates to the detection antibodies are 
often either HRP, AP or urease (Winston et al., 2001).  The ELISA technique was 
developed from a radioimmunoassay (RIA) by the research group of Peter Perlmann and 
Eva Engvall at Stockholm University in Sweden and first published in 1971 (Engvall and 
Perlmann, 1971).  
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The solid phase carrier used within an ELISA can be categorised as either high-
capacity or low-capacity, with advantages and disadvantages to each. High-capacity 
materials include cellulose, nitrocellulose and cyanogen bromide-activated Sepharose, 
which are useful for impure preparations of antigen, but involve greater difficulty within 
wash steps and can produce high background signals. Low capacity materials include 
polystyrene, polyvinyl and polypropylene, all of which are easy to use and wash, with 
lower levels of background signal, however they can provide challenge when binding some 
antigens such as haptens and polysaccharides which do not adsorb to plastic surfaces as 
readily as proteins (Coutinho et al., 1995). 
An antigen may be coated directly to the ELISA 96 well microplate by incubating it 
in a bicarbonate buffer pH 9.6 (Coutinho et al., 1995). Within a sandwich ELISA an initial 
coating antibody is used which allows specific binding of the target antigen, applied within 
a sample, this antibody is also added to the plate in a bicarbonate buffer pH 9.6. Figure 2.1 
illustrates the sequence of binding with each component of the ELISA system. 
 
 
 
 
 
 
 
Figure 2-1 Diagram of a sandwich ELISA for the detection of a.) pCRP and b.) mCRP. The 
diagram shows the capture antibody specific to each form of CRP and bound CRP. This is 
followed by a specific detection and secondary antibodies. 
Once the capture antibody (or antigen) has bound, following a wash step, all vacant 
binding sites are blocked with a protein such as BSA, preventing nonspecific binding of 
further antibodies or antigens to the plastic surface (Kemeny, 1991). The antigen (within 
(a.) 
mCRP 
pCRP 
Secondary mAb 
Primary mAb 
Capture mAb 
Blocking agent 
(b.) 
Serum Serum 
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sample) is added to the plate and incubated, allowing binding to the captured antibody, a 
wash step removes unbound sample. A primary detection antibody is then added to the 
plate at an optimised dilution and incubated, allowing binding to the specific target antigen, 
as seen in Figure 2.1. This antibody is then detected by an enzyme-conjugated secondary 
antibody, allowing amplification of the signal and visualisation once the substrate is 
introduced to the antibody/antigen complex. The substrate is incubated for approximately 
30 minutes and stopped using either sulfuric acid or sodium hydroxide and results in a 
measurable colour change, which is either visible of fluorescent (Gan & Patel, 2013). The 
ELISA plate can then be read on a plate reader and quantification of the antigen calculated 
by the inclusion of a known concentration of protein dilutions acting as a calibration.  
A key step to successful ELISA is the wash step which takes place between the 
additions of each component of the ELISA onto the plate. A phosphate buffered saline 
solution is used with the addition of a detergent such as tween allowing effective removal 
of all residual unbound sample or antibody from the plate (Gan and Patel, 2013).  
Whilst the ELISA is sensitive, able to detect smaller amounts of protein than the 
western blot and quantifiable, it is unable to determine the molecular weight of an antigen 
and there is a possibility of false positives occurring due to the sensitivity of the technique 
(Murphy et al., 2008; Gan & Patel, 2013). There are several variations to the basic ELISA 
method, with sandwich ELISA being just one of them. The choice can be dependent upon 
whether an antibody or antigen is the target of interest. The simplest is a direct ELISA in 
which the antigen is bound directly to the plate and a conjugated antibody is used to 
determine its presence, an indirect ELISA relies upon an antigen bound to the plate but 
both a primary and then secondary antibody used within the detection steps. A sandwich 
ELISA is two to five times more sensitive that a direct or indirect ELISA and more specific 
due to the use of two antibodies within the detection of the antigen (Murphy et al., 2008).  
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2.2.8.2 Competitive Enzyme Linked Immunosorbent Assay 
 
A competitive or inhibition ELISA describes an assay in which the measurement of 
a target antigen or antibody relies upon the ability of a substance to interfere with normal 
antibody binding, therefore reducing the resulting chromogenic or fluorescent signal. The 
system can be based upon all types of ELISA from direct to sandwich and is sometimes 
also described as a blocking ELISA. 
A direct ELISA used to detect an antigen within a competitive system involves an 
antigen bound directly to the solid phase, for instance a 96 well ELISA plate. The sample 
is pre-incubated with blocking solution to prevent non-specific binding and added to a 
labelled antibody specific for the bound (and target) antigen. If the antigen within the 
sample is the same as that bound to the plate, it will be bound by the antibody forming an 
antigen-antibody complex and the antibody will therefore be unable to bind the antigen 
immobilised in the well. Unbound labelled antibody will bind the immobilised antigen and 
all other antibodies will be washed away. The amount of competition is dependent on the 
number of molecules of test and solid phase antigens, where there is no antigen present 
within the test sample, the labelled antibody is fully available to bind the solid phase 
antigen. Where large amounts of antigen are present within the sample a reduction in 
antibody binding will occur and therefore a reduction in detection signal proportional to the 
concentration will result (Walker, 2001). 
When a competitive ELISA is used to detect a specific antibody within solution, a 
similar system to that of antigen detection can be used. The competitive aspect is between 
specific detection antibodies and antibodies within the test sample. Following the addition 
of specific antibodies directed against the same antigen as those sought, to the sample 
containing the test antibody, the solution is added to antigen pre-bound to a 96 well plate. 
Sample antibodies compete to bind the antigen with the specific added antibodies. 
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Antibodies that do not detect the solid phase antigen are not able to bind and therefore 
washed away. Anti-species specific antibodies are then added and will only bind to the 
added antibodies which cannot be the same species as those within the test sample. For 
instance if detecting anti-human CRP antibodies, a serum sample would be premixed with 
mouse anti-human CRP antibodies. Human CRP would be bound to the plate and the 
mixture of mouse anti-CRP antibodies and serum sample added to the solid phase. A 
proportion of the antigen would be bound by antibodies present within the serum and 
therefore prevent binding of a secondary conjugated anti-mouse IgG, reducing the colour 
signal upon addition of substrate. A sandwich ELISA can also be used within the 
competitive ELISA system, however care must be taken to ensure no interaction occurs 
between the capture and detection antibodies (Walker, 2001). 
An alternative antigen detection system employs a competitive binding principle 
facilitated by the addition of the original antigen. The primary antibody is incubated with 
the antigen containing sample, forming antigen-antibody complexes if antigen is present. 
This solution is added to a 96-well plate which is pre-coated with the same antigen. 
Antibody-antigen complexes are unable to bind the immobilised antigen and are washed 
from the plate, with the degree of competition proportional to the amount of antigen in the 
sample. The greater the amount of antigen present, the fewer antibodies will be able to bind 
and the secondary antibody conjugate will elicit reduced signal as compared to a control in 
which antibody only is added to the immobilised antigen. This system is also effective 
when used to identify antibodies within a sample; this type of ELISA is illustrated in 
Figures 2.2 and 2.3 for anti-pCRP and anti-mCRP detection respectively. In this situation 
the antigen is once again bound to the plate, either directly or via a capture antibody. The 
antibody containing sample is pre-incubated with antigen for 2 hours at room temperature 
of overnight at 4oC. The antibodies present will once again form antigen-antibody 
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complexes and be unable to bind to the solid phase bound antigen. Pure sample introduced 
to wells containing bound antigen will be able to bind the antigen, however nonspecific 
binding may also occur against blocking and capture agents. The reduction of resulting 
signal measured from secondary conjugated antibody binding is proportional to the 
antibody-antigen complexes formed. It is therefore important that added antigen is in 
excess of that bound to the wells (Walker, 2001).  
 
Figure 2-2 Diagram showing the competitive ELISA system used to determine auto-
antibody presence directed against pCRP within patient samples a.) A specific pCRP 
capture agent is bound to the plate followed by pCRP. The patient sample is pre-incubated 
with blocking solution prior to incubation upon the plate, followed by specific detection 
and then conjugated secondary antibodies. b.) A specific pCRP capture agent is bound to 
the plate, followed by pCRP. The patient sample is pre-incubated within blocking solution 
and pCRP, forming complexes between autoantibodies and pCRP, preventing binding of 
autoantibodies to pCRP captured on the ELISA plate. The reduction in absorbance found 
between plate a.) and b.) is proportional to patient auto-antibody presence. 
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Figure 2-3 Diagram showing the competitive ELISA used to determine auto-antibody 
presence directed against mCRP within patient samples a.) A specific mCRP capture 
antibody is bound to the plate followed by mCRP. The patient sample pre-incubated with 
blocking solution prior to incubation upon the plate, followed by specific detection and 
then conjugated secondary antibodies. b.) A specific mCRP capture antibody is bound to 
the plate, followed by mCRP. The patient sample is pre incubated within blocking solution 
and mCRP, forming complexes between auto-antibodies and mCRP and preventing 
binding of auto-antibodies to mCRP captured on the ELISA plate. The reduction in 
absorbance found between plate a.) and b.) is proportional to patient auto-antibody 
presence. 
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2.3 Materials and Methods 
 
2.3.1 Ethical Application 
Prior to experimental collection of patient samples and any experimental procedure 
took place both peer review and ethical research committee approval was sought. This 
oversight ensured the soundness of the study aims and assessed risk to both participants 
and researcher. 
The Joint Keele Independent Peer Review Committee reviewed the study under 
their peer review system, involving a local research community who review and scrutinise 
quality of the research together with the experimental context, methodology and aims. The 
review panel also assess the feasibility and scientific validity of the study. The application 
for this research study was approved in August 2012. 
Following Peer Review approval an application to the Integrated Research 
Application System (IRAS) was submitted. This system ensures that the study risks are 
acknowledged and that all participants are provided with clear and detailed information 
about the study, allowing them to make an informed decision whether to take part or not. 
Participant Informed consent would be given after explanation of the study aims, sample 
collection, storage of samples and actions in the event of participant withdrawal. IRAS was 
used within the preparation of applications to both the Research Ethics committee and the 
NHS Research & Development offices. This application was formally approved in 
November 2012. The project was approved by: NRES Committee North West – Lancaster; 
REC reference 12/NW/0818; IRAS reference 100079 and NHS Research Governance 
Facilitator permission for research confirmed April 2013. 
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The full title of the research project was: 
 
‘Investigations into the possible involvement of C-Reactive Protein (CRP) in the 
progression of rheumatoid arthritis 
 
The project was submitted as a student study. The chief investigator (CI) was Dr. D. 
Mattey. Other members of the study included Jennifer Moran (PhD student), Dr. A. K. 
Strive (Co-supervisor) and Professor T. G. Greenhough (Advisor). The principle question 
was: 
 
‘Is monomeric CRP found within the serum of patients with a confirmed diagnosis of 
rheumatoid arthritis?’ 
 
Identification of patients took place at the Haywood Rheumatology Hospital, Burslem, 
Stoke on Trent. A criteria for participant eligibility for the study was adhered to: 
I. Patients with confirmed diagnosis of RA according to internationally recognised 
criteria, attending routine monitoring clinic (Haywood Hospital) and due to 
undergo routine blood testing as part of their clinical care 
II. Male or female over the age of 18 years. 
 
Study exclusion criteria were: 
I. Participants under the age of 18 
II. Any patient with a confirmed diagnosis of HIV, Hepatitis B or C 
III. Participants unable to provide or understand informed consent 
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Participants taking part within this study were all in or out patients of the Haywood 
Rheumatology Hospital. Initially participants were identified by a member of the clinical 
care team or a research nurse and given a verbal explanation of the study. All participants 
interested in taking part in the study were provided with a patient information sheet (PIS) 
by a member of the clinical team (see Appendix 1), which outlined the study aims, risks 
and benefits. Participants were given time to decide if they wished to participate and 
informed that an extra blood sample would be taken at the time they were due to undergo 
their routine blood test. They were not required to undergo any additional clinical 
procedures and could withdraw from the study at any time. Further, it was explained that 
any information generated by the study was anonymised and therefore a particular 
participant would gain no direct benefit. 
Participants happy to take part within the study, should the research team be fully 
satisfied that they had fully understood the information discussed, were provided with a 
patient consent form (PCF, see Appendix 2). Patients were then asked to sign and date the 
consent form, initialing boxes confirming full understanding of the studies ramifications. 
These forms were then stored at the Haywood in accordance with NHS procedures, with a 
copy placed on each patient file. Only members of the clinical care team would be 
provided with access to the PIS and PCF. Participants were informed that should they wish 
to withdraw from the study at any point they would be removed and their samples 
destroyed. 
2.3.2 Acquisition and Preparation of Human Serum Samples 
 
Upon recruitment of a patient to the study and a signed and dated consent form 
provided, a qualified phlebotomist at the Haywood Rheumatology Hospital drew venous 
blood, following their internal clinical care protocols. The samples were collected within a 
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red topped Becton Dickinson (BD) Vacutainer blood handling tube without anticoagulant 
and allowed to clot for up to 30 minutes. The sample was centrifuged at 2,000g at room 
temperature (22oC) for 10 minutes allowing separation of the serum and red blood cell clot.  
The serum (supernatant) was carefully removed by Pasteur pipette and stored in 
0.5ml aliquots within cryo tubes at -20oC until further analysis was performed. Freeze thaw 
cycles were avoided by the use of stored duplicate 0.5ml sample tubes. Control samples 
were collected from a pool of volunteers working within UHNS and the Haywood 
Rheumatology Hospital; all provided consent and confirmed no previous identification of 
inflammatory disease. 
Each sample was given an anonymised sample number (e.g. CRPRA001 or 
CRPC001) and kept separately to identification documents which were stored in a locked 
cabinet at the hospital. Detailed list of samples held together with date of collection, 
storage and disposal were kept throughout the study. All information generated throughout 
the study was stored on a password-protected computer, with only named study researchers 
having access to it. 
2.3.3 Calibration of the Size Exclusion Chromatography Column 
 
Before running any samples through the column it was necessary to calibrate it in 
order to accurately determine protein sizes via the reported elution volumes. The GE 
Healthcare AKTA explorer 100, Fast Protein Liquid Chromatography (FLPC) system with 
a HiLoad 16/60 Superdex 200pg Column was used within this study. The operating 
software UNICORN 5.11. allows estimation of protein amounts via recorded UV 
absorbance at 280nm and measured elution volume, allowing the accurate reporting of an 
elution profile correlated to molecular weight (Amersham Biosciences, 2003). 
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The calibration was performed using a Gel Filtration Calibration Kit (GE 
Healthcare), with the included molecular weight markers detailed within Table 2.1. The 
void volume was determined using Blue Dextran. Samples were reconstituted from 
lyophilisate to 20mg/ml in a stock solution of 150mM NaCl, 50mM Tris, and 0.01% 
sodium azide, adjusted to pH 7.20, The stock protein solutions were further diluted to 
working final concentrations as indicated in Table 2.1.  
Table 2.1 Table of protein standards and their respective molecular weights and final 
concentrations used within the calibration protocol of the AKTA 100, HiLoad 16/60, 
Superdex 200pg FPLC system. 
Protein Standard Molecular Weight (Da) 
Final Concentration 
(mg/ml) 
Ferritin 440,000 0.3 
Aldolase 158,000 4 
Conalbumin 75,000 3 
Ovalbumin 44,000 4 
Ribonuclease A 13,700 3 
 
Buffers and solutions used for storage and preparation of the column are detailed in 
Table 2.2. The column is stored in 20% ethanol and three column volumes (120ml/column 
volume) deionised H2O were used to remove ethanol storage buffer from the system. The 
system of tubing and column were then equilibrated using three column volumes of elution 
buffer (50mM Tris, 150mM NaCl, 0.01% sodium azide). All buffers used within the 
system were first filtered using a 0.2Pm cellulose acetate filter (Sartorius Stedim Biotech) 
and degassed. To avoid the risk of protein precipitation or elution peak contamination two 
separate FPLC runs were performed, the first containing Ferritin, Conalbumin and 
Ribonuclease A, and the second, Aldolase and Ovalbumin. The total volume of the loaded 
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sample is recommended to be between 0.1% to 2% of the total column volume (0.12 – 2.4 
ml) in order to achieve good resolution, therefore a sample volume of 500Pl was added to 
the column (GE Healthcare UK Ltd, 2015). Prepared molecular weight samples were 
loaded onto the column via a 2ml sample injection loop and a flow rate of 1ml/min used. 
Absorbance was measured at 280nm and sample fractions of 5ml collected to a total 
volume of 120ml, equating to one column volume.  
Table 2.2 Table listing buffers and solutions used within the equilibration of the HiLoad 
16/60 Superdex 200pg size exclusion chromatography column. 
Buffer/Solution Components pH 
Wash solution Deionised H2O 7.0 
Elution Buffer 50mM Tris, 150mM NaCl, 
0.01% Sodium Azide 
7.2 
Storage Solution 20% Ethanol 7.0 
 
2.3.4 Purification of Pentameric and Monomeric C-reactive Protein 
 
Determination of the molecular weight of CRP samples was achieved by the use of 
an AKTA explorer 100, Fast Protein Liquid Chromatography (FPLC) system (GE 
Healthcare). The resulting elution volumes were used to assess dissociation of pCRP to 
mCRP by comparing the resulting trace to that of the calibration prepared in section 2.3.3, 
with buffers and solutions detailed within Table 2.3. The column was pre-equilibrated 
using one column volume, 120ml, of filtered deionised water followed by two column 
volumes of calcium free elution buffer (20mM Tris, 280mM NaCl, pH 8.0). Initial trials 
involved 500µl of treated CRP sample ~ 200µg/ml injected onto the 2ml sample loop and 
loaded onto the HiLoad 16/60 Superdex 200 pg column (GE Healthcare, 2011). A flow 
rate of 1ml per minute using calcium free elution buffer was used in all assays. Fractions 
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were collected in separate 5ml elution volumes within 20ml universal tubes. This method 
was used to determine molecular weight and purity for the native pentamer and following 
dissociation trials involving treatment by change of pH to either pH6 or pH4, heat or urea 
treated sample, as described in chapter three.  It was further used to determine possible re-
association of monomeric CRP samples. Optimum dissociation conditions were assessed 
and further experiments continued with 100µl CRP and 400µl buffer to a final 
concentration of 2M urea.  
Table 2.3 Table listing the buffers and solutions used within the elution of CRP 
preparations. 
Buffer/Solution Components pH 
Wash solution Deionised H2O 7.0 
CRP Storage Buffer 20mM Tris, 280mM NaCl, 
0.01% Sodium Azide 
8.0 
Storage Solution 20% Ethanol 7.0 
 
2.3.5 Concentration and Storage of pCRP and mCRP Protein Samples 
 
The chosen protein elution fraction was concentrated using a 
Sartorius™ Vivaspin™ 20 Centrifugal Concentrator, 10kDa molecular weight cut off 
(Fisher Scientific). The sample was centrifuged at 1,000 x g for between 10-20 minutes at 
4oC, until the desired volume/concentration was reached. This allowed the buffer to pass 
through the filter whilst the protein is captured and concentrated. Prior to use the Vivaspin 
concentrator was spun with solely deionised water for 10 minutes at 1,000g (4oC), ensuring 
the membrane was primed for optimum protein recovery. The sample was then stored 
within the CRP storage buffer (Table 2.3) at 4oC until required for further analysis. 
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Native pentameric C-reactive protein (pCRP) was purchased from SCRIPPS 
laboratories (C0129), at a concentration of 2.43mg/ml (confirmed to be >99% pure by SDS 
PAGE analysis). The protein was supplied within a standard storage buffer composed of 
20mM Tris, 280mM NaCl, 5mM CaCl2, 0.01% sodium azide, pH 8.0 and was stored at 4oC 
until needed. 
2.3.6 Native Polyacrylamide Gel Electrophoresis 
 
Native PAGE was used to assess the purity and conformation of CRP eluted from 
the size exclusion column, to determine antibody specificity assays and to confirm mCRP 
and pCRP within patient serum samples as determined by ELISA. The native gels were 
typically prepared with a 12.5% acrylamide resolving gel and a 4% acrylamide stacking 
gel. TEMED and 30% acrylamide/bis-acrylamide were purchased from Sigma Aldrich, 
APS was prepared to a 10% w/v solution immediately prior to use. Stock 
acrylamide/bisacrylamide was stored at -20oC and thawed prior to use. Alternatively a 
precast gel was used with up to 30Pl of combined sample/buffer added to each well, 
dependent on sample concentration,  within a pre-cast BioRad native gel (12%). Each gel 
contained positive lanes containing 1Pg each of pCRP or mCRP.  
The conventional Laemmli method was adapted within mCRP detection assays to 
include an addition of 1/20th the normal SDS amount within both the sample and running 
buffers as per Taylor et al 2007 (detailed within section 2.2.5). Samples were added to a 
two times non-reducing native sample buffer with an addition of 1/20th the amount of SDS 
added within a normal Laemmli system buffer, at a 1:1 ratio (as described within Table 
2.4) and detailed within section 2.2.5. A maximum of 20Pl was loaded into each well 
dependent upon protein concentration. Glycine, glycerol and Tris were all purchased from 
Sigma.  
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All gels were run in a BioRad mini PROTEIN II cell (BioRad), connected to a 
Powerpac 300, (BioRad). Gels were run for 20minutes at 100V followed by a further 30 
minutes at 150V in 500ml of running buffer (see Table 2.4), until the dye front left the 
bottom of the gel. The gel was then removed from the electrophoresis tank and carefully 
released from the gel casing, and resolving/stacking gels separated if required. Gels were 
visualised using Coomassie Brilliant Blue (Biorad), or used within western blot analysis. 
Gels stained with Brilliant Blue were allowed to develop over 20 minutes and then rinsed 
in deionised water before being captured on a Syngene GBOX image detector. Brilliant 
Blue has a detection limit of approximately 1µg protein, therefore sufficient protein must 
be loaded to ensure visualisation. 
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Table 2.4 A table detailing the components required for the preparation and casting of 
either native PAGE or the amended PAGE technique including 1/20th SDS within both 
sample and running buffers.  
Component Reagents Volume/Amount 
12% Resolving Gel 30% Acrylamide/bisacrylamide 3.33ml 
Deionised H2O 2.58ml 
Tris 1.5M pH 8.8 2.0ml 
100% Temed 6Pl 
10% APS 60Pl 
4% Stacking Gel 30% Acrylamide/bisacrylamide 0.67ml 
Deionised H2O 3.0ml 
Tris 0.5M pH 6.8 1.25ml 
100% Temed 6Pl 
10% APS Pl 
Sample Buffer (Native) Tris 0.5M pH 6.8 1.25ml 
Deionised H2O 5.55ml 
Glycerol v/v 2.5ml 
Bromophenol Blue 0.5% w/v 0.2ml 
Sample Buffer 
(1/20th SDS technique) 
As above Tris, Glycerol, Bromphenol 
Blue, 
 
SDS 10% w/v 0.1ml 
Deionised H2O 5.45ml 
Running Buffer pH 8.3 
Native (500ml) 
Tris 1.515g 
Glycine 7.21g 
SDS 10% w/v (1/20th SDS technique 
only) 
0.25ml 
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2.3.7 Western Blotting of C-reactive Protein  
 
Protein samples of interest were analysed by western blot following separation by 
native PAGE as described in section 2.3.6. The acrylamide gel was allowed to equilibrate 
within transfer buffer (as shown in Table 2.5), for up to 30 minutes whilst a 0.2Pm 
nitrocellulose membrane, 0.2 µm pore size, 8.5 cm x 13.5 cm (ThermoFisher Scientific), 
filter paper and fibre pads were soaked in transfer buffer for 10 minutes. Once equilibrated 
a ‘sandwich’ was made of the fibre pads, filter paper, nitrocellulose membrane and gel and 
clamped within the cassette, whilst at all times keeping the components beneath the buffer 
and ensuring no trapped air bubbles remain. It is important that the gel is directed towards 
the anode and the membrane towards the cathode. The cassette plus a pre frozen ice pack 
preventing overheating, were placed within a Mini Trans-Blot Electrophoretic Transfer 
Cell (BioRad) which was filled with 500ml transfer buffer. A magnetic stirrer was added to 
ensure even temperature and ion concentration. The transfer module was placed upon a 
plate stirrer and connected to a PowerPac 300 (BioRad) and run at before running at 30mA 
overnight at 4oC or at 80V for two hours at 4oC.  
Table 2.5 A table showing reagents required for the western blotting transfer buffer. 
Buffer/Solution Reagents Volume/Amount 
 
Transfer Buffer 
Tris 24mM 
Glycine 194mM 
Deionised H2O 500ml 
 
Each cassette was removed from the transfer unit and a pencil used to carefully 
mark the wells and perimeter of the gel onto the membrane. The membrane was separated 
from residual gel before immersion in blocking solution (Table 2.6) overnight at 4oC upon 
a mechanical rocker. The blocking solution was then removed by pouring away and the 
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membrane washed five times for five minutes each in BLOTTO (Table 2.6). Once 
thoroughly washed the primary antibody was added. The majority of antibody dilutions 
took place in BLOTTO, however serum was pre-incubated (diluted) within blocking 
solution overnight within auto-antibody studies, antibodies used within western blotting are 
detailed within Table 2.7.  Membranes were then incubated for either 2 hours or overnight 
upon a rocker at 4oC. Once again a wash step took place with five times five minute 
washes within BLOTTO before the addition of the conjugated secondary antibody, at 
various concentrations dependent of sample used. The membrane was incubated for 1 hour 
at 4oC before once more washing five times five minutes.  
Table 2.6 A table showing reagents required for the preparation of western blotting 
solutions. 
Buffer/Solution Reagents Amount/Volume 
Tris-HCL buffered Saline 
(TBS) pH 7.4 or PB 
Sodium Chloride 150mM 
Tris 50mM 
Blocking Solution 
TBS 40ml 
Marvel Dried Milk 1g 
 
BLOTTO 
TBS 200ml 
Marvel Dried Milk 2g 
Triton-X-100 4ml 
ECL Reagent 
Clarity peroxidase reagent 7ml 
Clarity western 
luminol/enhancer reagent 
7ml 
 
The membrane was then washed six further times for five minutes in BLOTTO 
before visualisation via chemiluminescence was achieved. A high sensitivity reagent was 
applied to the nitrocellulose membrane which was then left to incubate whilst rocking for 
five further minutes. BioRad, Clarity Western Enzyme Chemiluminescence Substrate 
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(ECL), was chosen to visualise any detectable bands resulting from HRP conjugated 
antibody binding. Each membrane required a mix of 7ml each Clarity peroxide and Clarity 
western luminol/enhancer reagent to be pre mixed immediately before and added to the 
membrane whilst gently rocking to ensure movement of the reagents against the 
nitrocellulose membrane. Once incubated for a minimum of five minutes the membrane 
was wrapped in Saran Wrap, protein side up, ensuring it at no point dried out. It was then 
possible to view the membrane on a FlourChem M system image detector at an exposure 
time of up to 40 minutes dependent on the intensity of the band and protein concentration 
detected.  
Table 2.7 A table providing details of antibodies used within western blot analysis, supplier and 
concentration. 
Technique Antibody Supplier Target Concentration / Dilution Species 
Western 
Blotting 
Detection Ab  
3H12 
L. Potempa mCRP 1:50 Mouse 
Detection Ab  
1D6 
L. Potempa pCRP 1:50 Mouse 
Detection Ab  
Clone 8 
Sigma  
C1688 
mCRP / 
pCRP 
4.55μg/ml Mouse 
Secondary Ab Sigma 
A9044 
Mouse 
IgG 
35.3μg/ml Rabbit 
Conjugated anti-
human IgG 
Sigma  
A8667 
Human 
IgG 
0.47μg/ml 
 
Goat 
 
Conjugated anti-
human IgA 
Invitrogen 
AH10104 
Human 
IgA 
4.5ng/ml Goat 
Anti-human IgM Sigma I6385 Human 
IgM 
40μg/ml 
 
Mouse 
 
Secondary Ab Sigma 
A5420 
Goat 
IgG 
186ng/ml Rabbit 
 
Within auto-antibody detection assays the above method was amended. Patient 
serum samples were diluted 1:100 in blocking solution and incubated overnight to avoid 
non-specific binding to the blocking step. The membrane was also blocked overnight and 
carefully sectioned following washing. The diluted patient or control serum was then used 
as a primary detection antibody and incubated overnight upon a rocker at 4oC. A mCRP / 
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pCRP control lane was probed with anti-mCRP primary antibody 3H12 diluted 1:50 in 
BLOTTO or Clone 8 (Sigma) diluted 1:1000 in BLOTTO. The secondary antibody, either 
goat anti-human IgG and IgA or mouse anti-human IgM, diluted in BLOTTO was 
incubated, followed by a wash step as previously described (antibody concentrations 
detailed in Table 2.7). Lastly rabbit anti-mouse IgG was added to the IgM assay at a 
concentration of 1:30,000 for 1 hour at room temperature before once more washing, 
followed by development as previously described with an exposure time of up to 40 
minutes dependent on the intensity of the band and protein concentration detected 
2.3.8 Sandwich ELISA Detection of Serum CRP  
 
A commercially available pentameric CRP detection kit (Duo Set ELISA kit, R&D 
Systems) was used to identify and determine levels of pCRP. Initially the protocol and 
antibodies were tested for recognition of mCRP and found to detect only the pentameric 
form (detailed within section 4.3.6), this allowed confident quantification of pCRP alone. 
A range of patient dilutions were assessed enabling optimisation of the seerum dilution that 
was best captured within the calibration range. Within the pCRP detection assay, patient 
samples were diluted 1:16000 in reagent diluent (R&D Systems) following optimisation of 
patient and control sample dilutions (Table 2.8). All antibodies used within the ELISA 
system are detailed within Table 2.9 with buffers and components used described within 
Table 2.10. The Duo Set protocol was designed to identify CRP within a range of 0.00 – 
1000pg/ml, with a serially diluted calibration carried out on each plate using pentameric 
CRP (Scripps Labs).  
The capture antibody used within the ELISA kit was a mouse anti-human IgG, 
reconstituted as per manufacturer’s protocol in 1ml phosphate buffered saline (PBS) and 
further diluted 33Pl within 12mls PBS (1µg/ml), this was a variation from the 
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recommended 66Pl per 12mls (2µg/ml) protocol, final concentrations of this and all other 
antibodies used within ELISA are detailed within Table 2.9. A volume of 100Pl of the 
diluted capture antibody was applied to a Corning CLS3590, 96 well plate, sealed and 
incubated overnight at room temperature.  
Table 2.8 Table showing optimisation of serum samples within the pCRP detection ELISA. 
Samples were diluted between 1:1000 and 1:128,000 with dilutions found within the 
calibration scale shaded. Patient and control samples were diluted to 1:16,000 and 1:1000 
respectively following optimisation.  
Calibration 
pCRP RA2  RA3  RA4  C03  Blank 
Sample 
Dilutions 
1000pg 1000pg           1:1000 
500pg 500pg           1:2000 
250pg 250pg           1:4000 
125pg 125pg           1:8000 
63pg 63pg           1:16000 
32pg 32pg           1:32000 
16pg 16pg           1:64000 
0pg 0pg           1:128000 
 
The plate was immersed in fresh wash buffer, phosphate buffered saline-tween 
(PBS-tween), prepared from PBS tablets (Sigma Aldrich), and carefully washed three 
times ensuring each well filled and liquid removed completely by inverting the plate and 
blotting against clean paper towels following each wash step. The plate was blocked by 
addition of 300Pl of Reagent Diluent (R&D Systems) to each well and incubation at room 
temperature for 1 hour.  
The wash step was repeated and patient samples (1:16000), or control samples 
(1:1000), diluted in reagent diluent (R&D Systems) and 100Pl added per well, together 
with serially diluted calibration standards. Positive and negative controls were also added 
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to each plate, 0.5Pg/ml each of pentameric CRP (Scripps Labs) and urea dissociated 
mCRP, produced as detailed within Chapter 3. The samples were incubated at room 
temperature in triplicate for two hours as per the sample layout in Table 2.11. Samples 
were flicked out and the wash cycle repeated before the addition of the biotinylated mouse 
anti-human CRP detection antibody (R&D Systems). This antibody was initially 
reconstituted in 1 ml PBS before further dilution of 66Pl within 12mls PBS, and 100Pl per 
well incubated for 30 minutes at room temperature.  
Lastly Streptavidin-HRP (R&D Systems) was diluted 1:200 in Reagent Diluent and 
added at 100Pl per well. Once again the plate was washed thoroughly three times in wash 
buffer before 100Pl substrate solution was added. The substrate solution consisted of equal 
volumes Colour Reagent A (stabilised hydrogen peroxide) and B (stabilised 
tetramethylbenzidine), R&D Solutions. The substrate was left to develop for 30 mins in a 
dark place before 50µl of stop solution was added (R&D Systems). At this point the plate 
was read at both 450nm and 540nm with the latter removed prior to calculations in order to 
remove background plate absorbance. 
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Table 2.9 A summary table containing details of antibodies used within ELISA assays including 
final concentrations and suppliers. 
Technique Antibody/Protein Supplier Target Concentration / Dilution Species 
ELISA 
mCRP 
detection 
Capture Ab Sigma C8284 Human 
CRP 
4.6μg/ml Goat 
Detection, 3H12 L. Potempa Human 
mCRP 
1:50 Mouse 
Secondary Ab Sigma 
A9044 
Mouse 
IgG 
0.35μg/ml Rabbit 
ELISA 
pCRP 
detection 
 
 
Capture Ab R&D 
Systems 
842676 
Human 
pCRP 
2μg/ml Mouse 
Detection Ab 
(Biotinylated) 
R&D 
Systems 
842677 
Human 
pCRP 
90μg/ml Mouse 
Streptavidin 
conjugated to HRP 
R&D 
Systems 
890803 
 1:200  
ELISA 
auto-
antibody 
detection 
 
 
PCh-KLH Santa Cruz 
Biotechnolog
y 
Sc-396490 
pCRP 2μg/ml Keyhole 
Lympet 
Conjugated anti-
human IgG 
Sigma 
A8667 
Human 
IgG 
0.35μg/ml Goat 
Conjugated anti-
human IgA 
Invitrogen 
AH10 
Human 
IgA 
4.5ng/ml Goat 
Anti-human IgM Sigma I6385 Human 
IgM 
40μg/ml Mouse 
 
Secondary Ab Sigma 
A5420 
Goat IgG 186ng/ml Rabbit 
Antibody 
specificity 
Studies 
 
 
 
 
Detection Ab 
Clone 8 
Sigma C1688 pCRP / 
mCRP 
9.1μg/ml Mouse 
Detection Ab 8C10 L. Potempa mCRP 1:50 Mouse 
Detection Ab 1D6 L. Potempa 
 
pCRP 1:50 Mouse 
Keratin Sigma 
 
 0-4μg/ml Human 
Fc Specific anti-
human IgG 
Sigma 
A0170 
Human 
IgG 
1.72μg/ml Goat 
PTX3 Sigma 
SRP6323 
 10μg/ml Human 
SAP Sigma  
565190 
 10μg/ml Human 
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Table 2.10 A summary table of all reagents used within the ELISA protocol, including 
monomeric CRP detection antibodies (shaded grey) and pentameric CRP detection 
antibodies unshaded. 
Buffer Solution Components Concentration 
PBS pH 7.4 1 PBS tablet (Sigma) / 
200ml  deionised water 
One tablet dissolved in 200 
ml of deionised water yields 
0.01 M phosphate buffer, 
0.0027 M potassium 
chloride and 0.137 M 
sodium chloride. 
PBS – Tween (Wash 
Buffer) 
PBS 1.4 litre 
Tween 750 ml 
Blocking Solution 
(R&D Systems) Reagent 
Diluent 
R&D Reagent Diluent 10x 10x dilution in deionised 
H2O provides 1% BSA 
Bicarbonate Coating 
Buffer pH 9.6 
Bicarbonate/carbonate 100mM  
Capture Antibody  
1:10,000 Dilution 
Goat anti-human CRP 
(Sigma, C8284) 
1µl 
Bicarbonate Buffer 9.999ml 
Primary Antibody 
1:50 Dilution 
3H12 mouse anti-human 
mCRP 
200µl 
Reagent Diluent 9.800ml 
Secondary Antibody 
1:30,000 Dilution 
Rabbit anti-mouse IgG 
(Sigma, A9044) 
0.5µl 
Reagent Diluent 14.9995ml 
Capture Antibody 
R&D Systems  
Mouse Anti-Human CRP 
Capture Antibody 
33µl 
Reagent Diluent 12.0ml 
Primary Detection 
Antibody 
R&D Systems Biotinylated 
Mouse Anti-Human CRP 
33µl 
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R&D Systems  Antibody  
Reagent Diluent 12.0ml 
Streptavidin-HRP A  
1:200 
Streptavidin-HRP A 
 (R&D Systems) 
60µl 
Reagent Diluent 11.940ml 
Colour Substrate 
(R&D Systems) 
Colour Substrate A (H2O2)  6.0ml 
Colour Substrate B 
(Tetramethylbenzidine) 
6.0ml 
Stop Solution  
(R&D Systems) 
Stop Solution (2 N H2SO4) 5.0ml 
 
 
Table 2.11 An example ELISA plate layout for pCRP detection assay with rows 1-3 
containing various dilutions (ng/ml) of pentameric CRP (Scripps Lab) acting as calibration 
standards between 0-1000pg/ml. Samples were randomly allocated in triplicate with 
additional +ve and -ve controls of pCRP or mCRP 500 ng/ml also added in triplicate. 
Capture, detection and secondary antibody were used as directed within the DuoSet CRP 
kit (R&D Systems), patient samples diluted 1:16000 in reagent diluent and control samples 
1:1000.  
Pentameric CRP ELISA Plate Layout 
 1 
pg/ml 
2 
pg/ml 
3 
pg/ml 
4 5 6 7 8 9 10 11 12 
A 1000 1000 1000 RA1 RA1 RA1 RA9 RA9 RA9 RA 17 RA 17 RA 
17 
B 500 500 500 RA2 RA2 RA2 RA10 RA10 RA10 RA18 RA18 RA18 
C 250 250 250 RA3 RA3 RA3 RA11 RA11 RA11 RA19 RA19 RA19 
D 1255 1255 1255 RA4 RA4 RA4 RA12 RA12 RA12 RA20 RA20 RA20 
E 62.5 62.5 62.5 RA5 RA5 RA5 RA13 RA13 RA13 RA21 RA21 RA21 
F 31.256 31.256 31.256 RA6 RA6 RA6 RA14 RA14 RA14 RA22 RA22 RA22 
G 15.75 15.75 15.75 RA7 RA7 RA7 RA15 RA15 RA15 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
H Blank Blank Blank RA8 RA8 RA8 RA16 RA16 RA16 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
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To enable detection and quantification of mCRP an individually designed ELISA 
was developed after assessment of antibody combinations for specificity and effectiveness. 
The protocol described previously for pCRP was used with specific amendments to capture 
and detection antibodies together with serum dilutions, and are detailed here. An mCRP 
calibration was included within each ELISA plate, ranging from 0 – 10ng/ml, using mCRP 
produced via dissociation and purification methods detailed within Chapters 2 and 3 
(sections 2.3.4 & 3.2.2). All reagents and solutions used are detailed within Table 2.9 and 
Table 2.10 as described previously. Initially the ELISA plate (Corning) was coated 
overnight at 4oC temperature with capture antibody polyclonal goat anti-human CRP IgG 
(Sigma C8284)  at a dilution of 1:10000 in bicarbonate coating buffer pH 9.6 (100Pl per 
well). Wash and block steps were carried out as previous, prior to the addition of 100Pl of 
a 1:100 diluted serum in diluent solution (R&D Systems), calibration dilutions and positive 
control (0.5Pg/ml pCRP). 
The plate was incubated for one hour at room temperature. The ELISA plate layout 
was repeated as per Table 2.12 with samples arranged randomly in triplicate. The primary 
detection antibody used was antibody 3H12, a specific mouse anti-human mCRP 
monoclonal IgG (kindly donated by Dr L. Potempa, College of Pharmacy, Roosevelt 
University, Illinois), 100Pl per well at a 1:50 dilution within reagent diluent solution. This 
was incubated at room temperature for one hour. The secondary antibody used was 
streptavidin conjugated rabbit anti-mouse IgG (Sigma) antibody, added at a dilution of 
1:30,000 in reagent diluent solution and incubated for 30 minutes at room temperature. The 
plate was developed and read as described previously. 
All ELISAs were carried out using 96 well flat bottom plates (Corning CLS3590), 
and sealed with pre-cut sealing tape (Thermo Scientific). 
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Table 2.12 A representative ELISA plate layout for mCRP detection rows 1-3 containing 
various dilutions (ng/ml) of urea dissociated monomeric CRP, acting as calibration 
standards between 0-10ng/ml. Samples were randomly allocated across the plate in 
triplicate with additional positive and negative controls of mCRP or pCRP 0.5µg/ml also 
added in triplicate.  
Monomeric CRP ELISA Plate Layout 
 1 
ng/ml 
2 
ng/ml 
3 
ng/ml 
4 5 6 7 8 9 10 11 12 
A 10  10  10  RA1 RA1 RA1 RA9 RA9 RA9 RA 17 RA 17 RA 
17 
B  5  5  5 RA2 RA2 RA2 RA10 RA10 RA10 RA18 RA18 RA18 
C 2.5 2.5 2.5 RA3 RA3 RA3 RA11 RA11 RA11 RA19 RA19 RA19 
D 1.25  1.25  1.25  RA4 RA4 RA4 RA12 RA12 RA12 RA20 RA20 RA20 
E 0.625  0.625  0.625  RA5 RA5 RA5 RA13 RA13 RA13 RA21 RA21 RA21 
F 0.3125  0.3125  0.3125  RA6 RA6 RA6 RA14 RA14 RA14 RA22 RA22 RA22 
G 0.161  0.161  0.161  RA7 RA7 RA7 RA15 RA15 RA15 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
H Blank Blank Blank RA8 RA8 RA8 RA16 RA16 RA16 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
 
2.3.9 Competitive ELISA Detection of Serum Auto-antibodies  
 
A competitive ELISA system was developed in order to allow detection of CRP 
auto-antibodies within human serum samples. This system allowed sensitive detection and 
avoided interaction between antibodies, blocking solutions and other components of the 
system. The principle is based upon competition between the auto-antibody and the CRP 
isoform of interest. The method varied between individual antibody/protein combinations 
but was based upon a consistent basic method.  
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2.3.9.1 ELISA Analysis of Serum Anti-p CRP IgG, IgA and IgM Auto-antibodies  
 
A competitive ELISA assay was developed in order to identify auto-antibodies 
directed against pCRP as illustrated in Figure 2.4 which shows steps taken within the 
assay. Initially 100 Pl of phosphocholine bound keyhole limpet haemocyanin (PCh-KLH), 
which allows pCRP binding, stabilisation and retention of conformation, was immobilised 
upon a Corning 96 well plate, diluted to 2Pg/ml in bicarbonate buffer, sealed and incubated 
overnight at 4oC temperature. Serum samples were prepared by diluting 1:200 in diluent 
alone (R&D Systems) and a second set in reagent diluent containing pCRP (Scripps Lab) 
at 5Pg/ml and left to incubate at room temperature for an hour minimum. The plate was 
washed and blocked as described within section 2.3.8. pCRP (Scripps Lab) was diluted to 
2Pg/ml in diluent (R&D Systems) and 100Pl per well applied to each plate. The plates 
were resealed and incubated for one hour at room temperature, before washing as previous. 
Samples were added to the plate in triplicate with half the plate containing diluted samples 
with and half without the addition of pCRP, as per Table 2.13, and left to incubate at room 
temperature for two hours. All buffers and reagents used within the assay are detailed in 
Table 2.14. Once again the plate was washed three times and 100Pl detection antibody 
added, either goat anti-human IgG conjugated antibody (Sigma), diluted  1:30,000 in 
reagent diluent and incubated for 30 minutes or goat anti-human IgA conjugated antibody 
(Sigma), diluted 1:100,000 and incubated 1 ½ hours at room temperature.  
The anti-CRP IgM assay was incubated first with mouse anti-human IgM antibody 
(Sigma), diluted 1:1000 in reagent diluent for 1 hour, washed 3 times and followed by a 
secondary streptavidin conjugated rabbit anti-mouse IgG antibody (Sigma) diluted 
1:30,000 in reagent diluent. This was incubated for 30 minutes at room temperature. 
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PCh-KLH bound to plate No capture agent bound  
Wash and block with BSA 
pCRP bound to PCh-KLH mCRP bound to plate 
Wash ELISA plate, add substrate followed by development 
stage.  
 
Side B absorbance values minus Side A values represent auto-
antibody content 
 
Wash plate 
Anti-pCRP Assay Anti-mCRP Assay 
Serum diluted in 
BSA - pCRP 
Serum pre-
incubated / 
diluted with 
BSA + pCRP  
Serum pre-
incubated 
diluted with 
BSA + mCRP 
Anti-human IgA, IgM or IgA incubated on entire plate 
Serum diluted 
in BSA - mCRP 
Wash 
Side A of plate 
incubated with 
serum + mCRP 
Side A of plate 
incubated with 
Serum + pCRP 
Side B of plate 
incubated with 
Serum - pCRP 
Side B of plate 
incubated with 
Serum - mCRP 
Wash and block with BSA 
Wash and block with BSA 
 
Figure 2-4 A flow diagram illustrating the steps carried out within the auto-antibody 
competitive detection ELISA for identification of anti-human pCRP or mCRP of IgG, IgA 
or IgM class. 
Following a final three times wash step, each assay was developed as previously 
described in section 2.3.8, with the addition of 100Pl substrate reagent (R&D Systems) 
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which was left to develop in a dark place for up to 30 minutes, before 50Pl of stop solution 
was added (R&D Systems). Plates were then read at both 450nm and 540nm with the latter 
removed prior to calculations in order to remove background plate absorbance. A negative 
control was included on each side of the plate which omitted the serum. To avoid 
systematic errors, samples from patients and controls were randomly mixed on the ELISA 
plate. Results were calculated by removing the absorbance of wells with pre incubation of 
CRP from those without. Wells were triplicated with the mean of the closest two values 
taken, each plate was also processed in triplicate. 
Table 2.13 A representative ELISA plate layout for the anti-pCRP auto-antibody detection 
assay. The plate is coated overnight with PCh-KLH 2Pg/ml as a capture agent. Rows 1-6 
contain contained 1:200 dilution of serum in reagent diluent only and rows 7-12 contained 
1:200 dilution of serum preincubated in reagent diluent containing 2Pg/ml pCRP. Samples 
were randomly allocated across the plate in triplicate.  
Anti-Pentameric CRP Auto-antibody ELISA Plate Layout 
 1 2 3 4 5 6 7 8 9 10 11 12 
A RA01 RA01 RA01 RA09 RA09 RA09 RA01 RA01 RA01 RA09 RA09 RA09 
B RA02 RA02 RA02 RA10 RA10 RA10 RA02 RA02 RA02 RA10 RA10 RA10 
C RA03 RA03 RA03 RA11 RA11 RA11 RA03 RA03 RA03 RA11 RA11 RA11 
D RA04 RA04 RA04 RA12 RA12 RA12 RA04 RA04 RA04 RA12 RA12 RA12 
E RA05 RA05 RA05 RA13 RA13 RA13 RA05 RA05 RA05 RA13 RA13 RA13 
F RA06 RA06 RA06 RA14 RA14 RA14 RA06 RA06 RA06 RA14 RA14 RA14 
G RA07 RA07 RA07 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
RA07 RA07 RA07 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
H RA08 RA08 RA08 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
RA08 RA08 RA08 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
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Table 2.14 A list of reagents used within the ELISA protocol, both monomeric and 
pentameric CRP auto-antibody detection antibodies were the same, all buffers within the 
pCRP assay contained an additional 2mM CaCl2 enabling pCRP binding to phosphocholine 
bound Keyhole limpet hemocyanin (PCh- KLH) 
 
Buffer Solution Components Concentration 
PBS pH 7.4 1 PBS tablet (Sigma) / 
200ml  deionised water 
One tablet dissolved in 200 
ml of deionised water yields 
0.01 M phosphate buffer, 
0.0027 M potassium 
chloride and 0.137 M 
sodium chloride. 
PBS – Tween PBS 1.4 litre 
Tween 750 ml 
Blocking Solution R&D Reagent Diluent 10x dilution in deionised 
H2O provides 1% BSA 
Bicarbonate Coating Buffer 
pH 9.6 
Bicarbonate/carbonate 100mM  
Capture antigen 2µg/ml PCh- KLH 
(Santa Cruz Biotechnology, 
sc-396490)  
20µl 
Bicarbonate Buffer 9.980ml 
Primary Antibody IgG 
1:30,000 Dilution 
Conjugated Goat Anti-
Human IgG (Sigma, ) 
0.5µl 
Reagent Diluent 14.9995ml 
Primary Antibody IgA 
1:100,000 Dilution 
Conjugated Goat Anti-
Human IgA (Sigma) 
0.5µl 
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Reagent Diluent 49.9995ml 
Primary Antibody IgM 
1:1000 Dilution 
Mouse Anti-Human IgM 
(Sigma) 
15µl 
Reagent Diluent 14.985 
Secondary Antibody IgM 
Assay 1:30,000 Dilution 
Rabbit Anti-Mouse IgG 
(Sigma) 
0.5µl 
Reagent Diluent 14.9995ml 
Colour Substrate 
(R&D Systems) 
Colour Substrate A (H2O2)  6.0ml 
Colour Substrate B 
(Tetramethylbenzidine) 
6.0ml 
Stop Solution  
(R&D Systems) 
Stop Solution (2 N H2SO4) 5.0ml 
 
2.3.9.2 ELISA Analysis of Serum Anti-mCRP IgG, IgA and IgM Auto-antibodies 
 
Whilst many key aspects of the method highlighted within the anti-pCRP ELISA 
remain the same (section 2.3.9.1), key differences are detailed here with an overview 
illustrated previously within Figures 2.3 and 2.4. In order to identify auto-antibodies 
directed against mCRP, 100 Pl of mCRP (previously created in vitro via 2M urea 
dissociation, detailed within section 3.2.2) was immobilised upon a Corning 96 well plate, 
diluted to 5Pg/ml in bicarbonate buffer, sealed and incubated overnight at 4oC temperature. 
Serum samples were prepared by dilution 1:200 in reagent diluent alone (R&D Systems) 
and a second set in reagent diluent containing mCRP at 2Pg/ml and left to incubate at room 
temperature for an hour minimum. The plate was washed and blocked as previously 
described. Serum samples were added to the plate in triplicate with half the plate 
containing diluted samples pre-incubated with mCRP and the other half without the 
 
 
Chapter 2.0 Materials and Methods Materials and Methods 
 140 
addition of mCRP, as per table 2.15 and left to incubate at room temperature for two hours. 
Once again the plate was washed three times and 100Pl detection and secondary 
conjugated antibodies were added as detailed section 2.3.9.1. The plates were also 
developed with the same previously mentioned method and once more read at both 450nm 
and 540nm with the latter removed prior to calculations in order to remove background 
plate absorbance. To avoid systematic errors, samples from patients and controls were 
randomly mixed on the ELISA plate. Negative controls were added to the plate on each 
side by the omission of sera. Results were calculated by removing the absorbance of serum 
wells pre-incubate with mCRP from those without. 
Table 2.15 A representative ELISA plate layout for the anti-mCRP auto-antibody detection 
assay. The plate is coated with 2Pg/ml urea dissociated mCRP as a capture agent. Rows 1-
6 contain 1:200 dilution of serum preincubated in reagent diluent containing 2Pg/ml mCRP 
and rows 7-12 contain 1:200 dilution of serum in reagent diluent only. Samples were 
randomly allocated across the plate in triplicate.  
Anti-Monomeric CRP Auto-antibody ELISA Plate Layout 
 1 2 3 4 5 6 7 8 9 10 11 12 
A RA01 RA01 RA01 RA09 RA09 RA09 RA01 RA01 RA01 RA09 RA09 RA09 
B RA02 RA02 RA02 RA10 RA10 RA10 RA02 RA02 RA02 RA10 RA10 RA10 
C RA03 RA03 RA03 RA11 RA11 RA11 RA03 RA03 RA03 RA11 RA11 RA11 
D RA04 RA04 RA04 RA12 RA12 RA12 RA04 RA04 RA04 RA12 RA12 RA12 
E RA05 RA05 RA05 RA13 RA13 RA13 RA05 RA05 RA05 RA13 RA13 RA13 
F RA06 RA06 RA06 RA14 RA14 RA14 RA06 RA06 RA06 RA14 RA14 RA14 
G RA07 RA07 RA07 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
RA07 RA07 RA07 +ve 
Cont. 
+ve 
Cont. 
+ve 
Cont. 
H RA08 RA08 RA08 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
RA08 RA08 RA08 -ve 
Cont. 
-ve 
Cont. 
-ve 
Cont. 
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 The ELISA techniques used within each detection assay are summarised within 
Table 2.16, which details which form of ELISA was used in the determination of mCRP, 
pCRP or auto-antibodies directed against each. 
Table 2.16 A summary table of ELISA assays used within the detection of either mCRP , 
pCRP or autoantibodies directed against each of them. 
 
ELISA 
 
Detection 
Target Capture Ab Antigen Detection Ab Further Ab 
 
Indirect 
Sandwich 
ELISA 
 
mCRP Goat anti-human CRP mCRP 3H12 
Anti-mouse 
IgG 
 
Indirect 
Sandwich 
ELISA 
 
pCRP 
R&D mouse 
anti-human 
pCRP 
pCRP 
R&D mouse 
anti-human 
pCRP 
(Biotinylated) 
Streptavidin 
conjugated 
to HRP 
 
Competitive 
ELISA 
 
 
Anti-human 
pCRP 
IgA/IgM/IgG 
PCh-KLH pCRP Human Serum Anti-human Iga/IgM/IgG 
 
Competitive 
ELISA 
 
 
Anti-human 
mCRP 
IgA/IgM/IgG 
 mCRP Human Serum Anti-human Iga/IgM/IgG 
2.3.10 Statistical Analysis 
 
All data analyses and statistical tests were carried out in Minitab® Statistical 
Software (Version 18). Power analysis was used to determine the validity of statistical 
analyses to detect significant differences in the pilot study data. A minimum sample size of 
21 and 13, for mCRP and pCRP respectively, was needed to yield a power of 0.8. Hence 
the study sample size of 30 was valid and exceeded the minimum requirements. 
Quantitative data was graphically displayed to check distribution modality and Anderson-
Darling normality test run to confirm normality (p>0.05) to ensure underlying statistical 
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test assumptions were met. The mCPR or pCRP auto-antibody group data did not have 
universally normal distributions and a Box-Cox transformation did not resolve the situation 
so raw values were used. Central tendencies are reported as mean ±SEM and median + 
interquartile range (IQR). A Mann-Whitney test was used to detect differences in mean 
CRP concentration and normalised auto-antibody data by gender (male, female) and health 
condition (healthy, rheumatoid arthritis). Spearman’s rank was used to test for the 
correlation of mCRP concentration with pCRP concentration, CRP concentrations and 
normalised auto-antibody percentages and between auto-antibody groups.  
During initial statistical analysis it became apparent that the male cohort auto-
antibody data was affecting analysis and in many cases the combination of male and 
female data sets produced bimodal data making detailed analysis based on comparison of 
mean or median group data unreliable, in this case the groups were split by gender prior to 
statistical analysis. A Chi-Square test was used to test for an association in the number of 
samples with elevated levels of auto-antibodies between in the RA and control groups. All 
tests yielding P values of less than 0.05 were considered statistically significant, with 
significance levels of 0.05, 0.01 and 0.001 reported. 
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Chapter 3 - Production of Monomeric C-reactive Protein 
3.1 Introduction  
3.1.1 Overview 
 
The structure of native human pCRP was determined via x-ray crystallographic 
studies in 1996 by Shrive et al who identified five protomers arranged around a central 
pore (Shrive et al., 1996). Interprotomer contacts result predominately from salt bridge 
interactions which stabilise the pentameric structure. Furthermore, the native conformation 
is found to be extremely stable under normal physiological conditions. Studies have 
reported an additional form of CRP is present within the body that of a discrete protomer 
referred to as monomeric CRP (mCRP). Growing evidence now supports the existence of 
this modified form although it is as yet unclear as to whether this isoform of CRP is 
membrane bound or soluble within the serum (Ying et al., 1989; Zhao and Shi, 2010; 
Ciubotaru et al., 2005; Sjowall and Wettero, 2007; Potempa et al., 1988; Zouki et al., 
2002; Wang et al., 2007b; Singh et al., 2009). 
Researchers report the monomeric form displays reduced solubility and a change in 
isoelectric point resulting in a reduction of pI from 6.4 to 5.4, pointing to possible 
disruption of the subunit structure (Potempa et al., 1983; Taylor et al., 2005). Studies 
suggesting the physiological existence of mCRP show the protein co-localised with various 
tissue including Aβ plaques, stroke neovessels, necrotic cells and upon damaged and 
activated cells and platelets (Slevin et al., 2010, 2015; Mihlan et al., 2011)(Ji et al., 2007).  
Emerging research supports the presence of mCRP as a serum protein in vivo (Wang et al., 
2015). Auto-antibodies directed against the monomeric form have also been found within 
the serum of various disease state patients (Minatani   2001; Sjowall et al., 2004; Tan 
2008).  
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This chapter will describe the production of mCRP from pCRP within an in vitro 
system, allowing its use within later work designed to identify mCRP and auto-antibodies 
directed against it within RA patient serum. Experimental procedures have been adapted 
from previously published research and seek to develop a system utilising methods as close 
to physiologically relevant as possible. This chapter will discuss the development of in 
vitro monomeric C-reactive protein, its stability and characterisation. 
3.1.2 Dissociation of Pentameric CRP in vitro 
 
The production of mCRP was first described by Potempa et al., in 1983 and 
detailed the methods employed to dissociate the pentamer into individual subunits. They 
were able to  show in vitro that native pentameric CRP will dissociate following treatment 
with various and often harsh, non-physiological denaturing conditions treatments, 
including heat, pH4.0 and 6M urea (Potempa et al., 1983, Kresl et al., 1998). Other groups 
reported pentamer dissociation following calcium dependent binding to membranes, 
including cell membranes and liposomes, forming an intermediate membrane bound form 
of monomeric CRP (Ji et al., 2007), and also during interaction with activated platelets 
(Eisenhardt et al., 2009). Following on from Potempa et al., (1983), other groups explored 
methods of dissociation, including Kresl et al., (1998) who studied the effects of 8M urea 
and 10mM EDTA which caused a rapid and irreversible dissociation of pentameric CRP 
into monomers within two minutes. They were able to show at 30 minutes only partial 
unfolding using 6M urea which reached 88% dissociation after 60minutes. The earlier 
study by Potempa et al., (1983), reported a change in electrophoretic mobility and new 
antigenic properties following 6M urea or heat to 63oC for five minutes. These changes 
were only apparent when calcium concentrations fell below 0.7mM (Potempa et al., 1983). 
However, these methods of dissociation are extremely harsh and would not be replicated 
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within the body. It is therefore important that in vitro treatments developed reflect 
physiologically relevant conditions where possible, and that these must also be replicable 
and reliable. The first conditions trialed took place within a Tris, sodium chloride, calcium 
(5mM) buffer at pH4, which is outside the range of acidosis found even within some 
infection patients  (Waugh & Grant, 2014) and therefore not physiologically relevant. 
3.1.3 Experimental Aims 
 
The aim of experimentation within this chapter was to develop a technique which 
was both accurate and reproducible, and not too harsh, allowing production of a constant 
supply of mCRP for use within further experimentation. This would be used as a capture 
protein within ELISA studies, and western blot analysis of serum samples. It was also 
required to determine the specificity and affinity of antibodies used throughout the 
research. Patient serum analysis requires a high concentration of pure, stable monomeric 
CRP stock solution, therefore a reliable method of preparation and storage is essential. 
Retention of the structural and functional integrity of the protein was required and as such 
production methods were developed to produce a more physiologically relevant form of 
the protein. It became essential that methods replicating the dissociation found within 
studies at 6M urea be sought, however, using less harsh denaturing effects and therefore 
allowing a more meaningful comparison of future findings with those physiologically 
possible in vivo. 
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3.2 Materials and methods 
3.2.1 C-reactive Protein Storage 
 
Native pentameric C-reactive protein (pCRP) was purchased from SCRIPPS 
laboratories (C0129), at a concentration of 2.43mg/ml (confirmed to be >99% pure by SDS 
PAGE analysis). The protein was supplied within a standard storage buffer composed of 
20mM Tris, 280mM NaCl, 5mM CaCl2, 0.01% sodium azide pH 8.0 and was stored at 4oC 
until needed. These storage conditions were adopted for dissociated samples following 
purification and concentration. 
3.2.2 Dissociation of Pentameric CRP 
 
Dissociation methods were tested to assess the least harsh and non-denaturing 
dissociation treatments, presumed closest to physiological relevant conditions, allowing 
production and collection of pure mCRP. The first trials assessed the ability to dissociate 
pentameric CRP (SCRIPPS) in association with calcium (5mM). Results from dissociation 
treatments were analysed by both native PAGE and FPLC, allowing identification and 
separation/purification of the monomer from part dissociated samples.  
Acidic conditions were assessed at pH 4.0 and pH 6.0, in both calcium free and 
5mM calcium buffer. Calcium free buffer (20mM Tris, 280mM NaCl and 1mM EDTA) 
was adjusted to pH4 or pH6 using 2M HCL. 50µl of CRP (121.5µg) was added to 24.95ml 
of either pH4 or pH6 buffer which was further incubated at room temperature for 5 minutes 
before readjustment to pH8 using 2M NaOH. This dilution was concentrated as described 
within section 2.3.5 to 500µl and a concentration of approximately 200µg/ml CRP 
determined via Nano drop spectrophotometer as described within section 3.2.5. In a further 
experiment testing the combined effects of temperature and acidity the CRP/pH4 calcium 
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free, 1mM EDTA sample was heated to 63oC for 5 minutes before rapidly cooling on ice. 
This condition was repeated in 5mM CaCl2. 
Standard Tris buffer (20mM Tris, 280mM NaCl) with the addition of urea to a final 
concentration of either 2M or 6M including added CRP, was tested for the ability to 
dissociate CRP. Once again in both calcium free (1mM EDTA), and calcium (5mM CaCl2) 
conditions. Initially 50Pl (121.5µg) of CRP was added to 450µl buffer and incubated at 
4oC; this was optimised in later trials and increased to 100µl (243µg) CRP with 400µl 
buffer, providing greater levels of resulting mCRP due to a higher ratio of CRP to buffer. 
These treatments were incubated at 4oC for various periods between two days and 12 
weeks to assess optimum dissociation times. Dissociation was determined by both native 
PAGE and FPLC size exclusion chromatography. 
The possible re-association of successfully dissociated, monomeric CRP was tested 
by native gel and FLPC size exclusion chromatography, following up to 12 weeks storage 
at 4oC in standard pH8, 20mM Tris, 280mM NaCl buffer. 
3.2.3 Calibration of Gel Filtration Size Exclusion Chromatography Column 
 
The Fast Protein Liquid Chromatography (FLPC) system with a HiLoad 16/60 
Superdex 200pg Column was used to identify and purify mCRP and pCRP. Prior to 
dissociation experimentation the FPLC was fully calibrated using a Gel Filtration 
Calibration Kit (GE Healthcare). This process is described within section 2.3.3. 
3.2.4 Purification of Pentameric and Monomeric C-reactive Protein 
 
Determination of the molecular weight of the pentameric form of CRP following 
dissociation or reassociation trials was achieved by the use of an AKTA explorer 100, Fast 
Protein Liquid Chromatography (FPLC) system (GE Healthcare). The system, software 
and column are the same as described within section 2.2.1 and all buffers and components 
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detailed within Table 2.3. The column was pre-equilibrated using one column volume 
~120ml, of filtered deionised water followed by two column volumes of calcium free 
elution buffer (20mM Tris, 280mM NaCl, pH 8.0) as described within section 2.3.4. Initial 
trials involved 500µl of treated CRP sample ~ 200µg/ml, injected onto the 2ml sample 
loop and loaded onto the HiLoad 16/60 Superdex 200 pg column (GE Healthcare). A flow 
rate of 1ml per minute using calcium free elution buffer was used in all assays. Fractions 
were collected in separate 5ml elution volumes within 20ml universal tubes. This method 
was used to determine molecular weight and purity for the native pentamer, pH6, pH4, heat 
treated and urea treated samples. It was further used to determine possible reassociation of 
monomeric CRP samples. Optimum dissociation conditions were assessed and further 
experiments continued with 100µl CRP and 400µl buffer to a final concentration of 2M 
urea.  
3.2.5 Quantification of C-reactive Protein  
 
Following sample concentration, the amount of protein within each sample was measured 
by NanoDrop spectrophotometer, which allowed 2Pl to be tested at A280. The NanoDrop 
was first blanked with deionised water followed by sample buffer which should result in a 
reading no greater than 0.04 absorbance units from the baseline 280nm reading. The buffer 
is then reloaded and system blanked before adding the protein sample. A molar extinction 
coefficient must be used to quantify the protein, which is directly related to the tryptophan, 
tyrosine and cysteine amino acid content of the protein. The coefficient for human CRP 
was calculated using the online programme ProtParam from Expasy 
(http://web.expasy.org/protparam/). This program uses the protein sequence to calculate 
the coefficient which for human CRP is 1.7. The absorbance at 280nm divided by the 
coefficient results in the concentration in mg/ml. 
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3.2.6 Native Polyacrylamide Gel Electrophoresis 
 
After isolation of pentameric and monomeric CRP fractions following FPLC, and 
subsequent concentration, samples were analysed using native PAGE to determine the 
purity and subunit size of CRP within the eluted fractions. Native pentameric and 
dissociated samples of CRP at a minimum of 1µg (typically 10Pl) were combined 1:1 with 
a non-reducing, non-denaturing sample buffer and loaded onto a native PAGE non-
gradient gel (12.5% resolving, 4% stacking) with or without the addition of 1/20th SDS as 
detailed within section 2.3.6, to both sample and running buffers. Standard low or high 
molecular weight markers were used (Amersham) in order to estimate the band molecular 
weight. CRP does not reliably correspond to these markers in native gels due to differences 
in pI, resulting in variations within charge to mass ratios between proteins; therefore the 
position of resulting bands was correlated with the elution peaks determined within the 
FPLC assay. The protein molecular weight could be calculated from the calibration 
previously performed on the FLPC system as described within section 3.2.3, allowing 
enhanced determination of mCRP and native CRP (SCRIPPs) molecular weights.   
All gels were electrophoresed between 55 – 90 minutes, at either 100V or 200V 
utilising a BioRad Mini-PROTEAN II electrophoresis system, within 500ml running 
buffer. Bands present were visualised using Instant Blue (Expedeon), or Bright Blue 
(BioRad) Coomassie staining between 30 minutes and one hour. Gels were gently washed 
in deionised water and scanned on a Syngene GBOX image detector.  Alternatively, 
resulting gels were analysed by western blot rather than Coomassie stain. 
3.2.7 Western Blotting of C-reactive Protein Samples 
 
Protein samples of interest were further analysed following FPLC purification and 
native PAGE by western blotting in order to ensure bands present were in fact recognised 
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by specific antibodies to CRP. Samples were quantified as described within section 2.3.6 
and calculated to ensure 1Pg protein was loaded to each well before separation by native 
PAGE (see section 3.2.7). The polyacrylamide gel was run until the dye front left the gel 
bottom was then carefully removed and resolving/stacking gels separated. 
The resulting resolving gel was then placed within a Tris/Glycine transfer buffer 
(Table 2.4) for up to 30 minutes in order to reach equilibrium together with the 0.2Pm 
nitrocellulose membrane, filter paper and fibre pads. Once equilibrated a ‘sandwich’ was 
made of the fibre pads, filter paper, nitrocellulose membrane and gel, clamped within the 
cassette, and loaded together with a pre frozen ice pack within a Mini Trans-Blot 
Electrophoretic Transfer Cell (BioRad) topped up with 500ml transfer buffer. The transfer 
unit was kept at 4oC and run at either 80V for two hours of 30mA overnight.  
Once transfer was complete the membrane was carefully removed from the cassette 
and rinsed in deionised water before being placed within a tray containing 20ml Blocking 
Solution (see Table 2.6) and incubated overnight whilst agitating on a mechanical plate 
rocker. The membrane was then washed five times with BLOTTO solution (see Table 2.6), 
rocking for five minutes each wash. The primary antibody used was Clone-8 (Sigma 
Aldrich) a monoclonal mouse anti-human CRP antibody supplied in ascites fluid. This 
antibody was diluted 1:1000 with BLOTTO and incubated with the membrane overnight at 
4oC, again whilst rocking. Following a second series of five times five minute washes in 
fresh BLOTTO, the membrane was then incubated at room temperature for one hour with a 
1:40000 dilution (in BLOTTO) of the secondary antibody, a polyclonal rabbit, anti-mouse 
IgG antibody, HRP conjugate (Sigma Aldrich, A9044). The membrane was then washed 
six further times for five minutes in BLOTTO before visualisation via chemiluminescence 
was achieved as described within section 2.3.7.  
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3.3 Results 
3.3.1 Calibration of the Size Exclusion Gel Filtration System 
 
Size exclusion chromatography was used to purify and separate dissociated 
monomeric CRP from remaining pentameric native CRP and therefore assess the 
effectiveness of dissociation methods. Initially a calibration of the FPLC system was 
performed using proteins of known molecular weight, Ferritin 440kDa, Aldolase 158kDa, 
Conalbumin 75kDa, Ovalbumin 44kDa and Ribonuclease A 13.7kDa, using the methods 
previously described within section 2.3.3. Figure 3.1 shows the chromatography trace for 
the molecular weight standards. Blue Dextran a high molecular weight glucose polymer, 
was also used in order to calculate the void volume of the column which was 46.79ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 A size exclusion chromatography trace for the molecular weight standards 
calibration - Ferritin 440kDa (59.67ml), Aldolase 158kDa (70.62ml), Conalbumin 75kDa 
(79.04ml), Ovalbumin 44kDa (84.75ml) and Ribonuclease A 13.7kDa (99.38ml). 
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The resulting elution volumes relative to molecular weight of each protein were 
used to construct a calibration graph after determining the Kav value for each which was 
calculated using the following equation: 
 
Equation 3.1  
Kav = (Elution Volume – Void Volume) / (Total Column Volume – Void Volume) 
 
 The void volume was calculated to be 46.79ml, taken from the Blue Dextran 
chromatography run and the column volume calculated to be 124.5ml. 
 
Table 3.1 A table illustrating protein standards their elution values, calculated Kav and Log 
of molecular weights. 
 
Table 3.1 contains calculated values for each protein standard’s Kav and the Log of 
each molecular weight. The two values were plotted against each other in order to 
construct the calibration graph shown in Figure 3.2. 
Protein 
Standard 
Molecular 
Weight (kDa) 
Elution Volume (Ve) 
(ml) 
Kav 
Log of 
Molecular 
Weight 
Ferritin 440 59.67 0.150 5.64 
Aldolase 158 70.62 0.289 5.20 
Conalbumin 75 79.04 0.397 4.88 
Ovoalbumin 44 84.75 0.470 4.64 
Ribonuclease 
A 
13.7 99.38 0.656 4.14 
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Figure 3-2 A calibration graph showing both Kav and Log of molecular weight values for 
each protein standard. The R2 value is 0.9986 and the line equation: y = -0.3348x + 2.0329. 
 
The calibration graph shows the relationship between molecular weight (MW) and 
elution volume, as Kav (representative of elution volume) rises Log molecular weight 
reduces, producing an R2 value of 0.9986 indicating a strong correlation between the two 
data sets. The line equation: y = -0.3348x + 2.0329 describes an inverse relationship 
between molecular weight and elution volume where the latter rises as the former 
increases. The equation allowed accurate determination of a protein’s molecular weight 
from its size exclusion chromatography elution volume, and enabled monomeric or 
pentameric CRP conformation characterisation to be established within further 
experiments. 
 
 
 
 
Chapter  3.0 – Production of Monomeric C-reactive Protein Results 
 154 
3.3.2 Dissociation of Native Pentameric C-Reactive Protein   
 
Following FPLC calibration, native pentameric CRP (Scripps Labs) was tested to 
ensure correct analysis of the protein size. The resulting ~17 mAU peak at 73ml elution 
volume illustrated in Figure 3.3, was used to calculate native CRP molecular weight as 
115kDa using the equation constructed from calibration graph data illustrated within 
section 3.3.1. This allowed confidence within the determination of CRP conformation by 
FPLC and provided a comparison for pentameric CRP in future samples. 
 
Figure 3-3 A size exclusion chromatography trace for the pCRP control assay. 200µg of 
the protein was run through the column. The main peak on the chromatogram, labelled 1, 
has an elution volume of 73ml, (17mAU).  
 
The native pentameric (SCRIPPS) sample applied to the FPLC column in Figure 
3.3, resulted in an elution volume of 73ml, which calibrated correctly to 115 kDa, known 
to be the native conformation molecular weight.  
3.3.2.1 The Effects of pH4 and Calcium on CRP 
 
Initial dissociation conditions tested explored the effects of pH on the stability of 
pentameric C-reactive protein.  Using the equation determined from calibration data in 
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section 3.3.1 it was calculated that an elution peak resulting from the monomeric form of 
CRP would be found in the region of 91ml, which in turn calibrated to 23,508 Daltons, 
consistent with that of the monomer, allowing confirmation of its position in future studies. 
This treatment provided little or no dissociation as can be seen in Figure 3.4 (a.), in 
which the chromatograph shows one elution peak at 73ml consistent with that of the 
pentamer and an absence of a secondary monomeric peak – expected to be in the region of 
91ml elution. This condition was unable to initiate dissociation, therefore calcium was 
omitted and 1mM EDTA, a calcium chelator, included in the next condition trialed. An 
omission of calcium within the dissociation buffer resulted in a small amount of 
dissociation, as can be seen in Figure 3.4 (b.) which shows both a 73ml pentameric elution 
peak (8 mAu), together with an additional 91ml elution peak (0.3 mAu), indicating the 
presence of the monomer. The third peak at 110-117ml, visible on many chromatographs is 
presumed to be degraded protein of low molecular weight.  
Under the calcium free conditions less than 4% of pentamer was dissociated, 
indicating more extreme dissociation methods were required (calculated by comparison of 
the UV absorbance of treatment peaks against control peaks). Heat was therefore applied to 
the pH4 EDTA sample (63oC), which caused slight precipitation, removed by 
centrifugation before the FPLC assay. Figure 3.4 (c.) shows the chromatograph of the 
heat/acid conditions and it is apparent that a greater amount, approximately half that of 
pentameric CRP, was discovered at 110ml (~2400Da) indicating a breakdown of protein. 
No monomeric fraction was observed at 91ml elution volume and the recovery of 
pentameric protein was greatly reduced from that seen in either 3.4 (a.) or (b.). 
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Figure 3-4 Size exclusion chromatograph trace showing the effects of pH4, with and 
without calcium and heat (a.) Chromatograph of pH4, 5mM CaCl2 unheated CRP 
following 6 days incubation, showing a pentameric peak labelled 1, (b.) Chromatograph of 
pH4, EDTA unheated CRP following 14 days incubation, showing a pentameric peak 
(labelled 1) and small monomeric peak (labelled 2) at 91ml, together with small peptide 
peaks (labelled 3, 110-117ml), (c.) Chromatograph of pH4, EDTA, 63oC heat treated CRP, 
precipitate spun out pre FPLC following 4 days incubation, showing pentameric (labelled 
1) and peptide peaks (labelled 2).  
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The monomer was present in calcium depleted treatments only, indicating 
calcium’s known importance in stabilising the pentameric conformation. Physiologically 
normal conditions are pH 7.4 and 2.2 to 2.6mM calcium (Zhang et al., 2009), slight 
acidosis and hypocalcaemia within inflammation-infection patients can result in local 
pH6.5 and 2 to 2.12mM calcium levels (Zhang et al., 2009, Aderka et al., 1987). These 
transient inflammatory states may not be of low enough pH or calcium level to dissociate 
the native CRP protein and are unlikely to be the sole cause of physiological monomers.  It 
is suggested that the monomer has reduced solubility (Singh et al., 2009, Ji et al., 2009b) 
and this may explain the absence of a monomer, Figure 3.4(c.), following removal of the 
precipitate, it is possible that the dissociated CRP fraction was within this precipitate. The 
resulting chromatograph seen in Figure 3.4 (c.), shows a reduced amount of pentameric 
fraction (3.5 mAu) and increased degraded protein (1.6 mAu), but absent 91ml elution 
volume peak of the monomer.  
3.3.2.2 The Effects of Urea and Calcium on CRP 
 
The amount of mCRP generated within pH4 conditions was not great enough to 
accumulate effective volumes of mCRP; therefore urea dissociation treatments were tested. 
Initial dissociation trials included both 6M and 2M urea treatments both of which showed a 
second peak at ~ 91ml elution volume, confirmed as the monomer position. The levels of 
dissociation in 6M urea conditions (data not shown) were not greatly increased to those of 
2M conditions and it was therefore decided to proceed with gentler 2M conditions for all 
following urea trials. 
Having assessed the effects of calcium inclusion within pH dissociation conditions 
it was necessary to determine how the addition or removal of calcium would affect 
dissociation rates within urea treatments. Pentameric CRP was incubated at 4oC in 2M urea 
buffer for approximately 3 weeks with and without calcium. Figure 3.5 shows the sample 
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without calcium beginning to dissociate into its monomeric subunits (a.), whereas the 
sample with calcium (b.), has remained in a pentameric conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 Size exclusion chromatograph trace showing the effects of 2M urea on CRP 
with and without calcium (a.) 2M urea and 1mM EDTA (no calcium) following 24 days 
incubation showing both pentamer (peak 1) and monomer (peak 2) conformations. (b.) 
CRP with 2M urea and CaCl2 following 21 days incubation showing only the pentameric 
peak (labelled 1).  
 
The dissociation effects of 2M urea are greater than those of pH4, and this 
condition was therefore used for the accumulation of mCRP for future studies.   
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Initially native PAGE was also used to detect monomer formation; however the 
monomeric band was never apparent, even in samples of pure monomer post FPLC 
separation. This problem was also encountered by Taylor et al., (2005), who suggested an 
insolubility of the monomer may prevent it running correctly within the gel. They advised 
the addition of 1/20th SDS to the running buffer and sample buffer, but not the gel itself, 
would allow detection of the monomer (Taylor et al., 2005). This method was tried, found 
to be successful, and used in later native PAGE gels to detect levels of dissociation in 
conjunction with the FPLC chromatograms. The dissociation of CRP using 2M urea and 
EDTA can be seen in a 1/20th SDS native PAGE, Figure 3.6 (a), lanes 5 and 6 illustrating 
two replicated samples analysed before FPLC separation, each with two bands (pentameric 
and monomeric). Lanes 2 and 3 show the separated pentameric and monomeric fragments 
produced following FPLC separation, and comparative native pentameric (lane 1) and 
monomer formed by pH4, EDTA and heat treatment (lane 4). 
The stabilising effects of calcium can once again be seen in Figure 3.6 (b.), again 
using a 1/20th SDS native PAGE system which shows a partially dissociated sample 
treated with 6M urea and CaCl2 in lane 4, clearly showing both monomer and pentamer 
bands, compared to the single monomeric band produced following 2M urea and EDTA 
lane 3.  
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(a.)                                                                                                    
           
Figure 3-6 Native PAGE showing dissociation of native CRP Gels prepared with 1/20th 
SDS (a.) 2M urea, EDTA treated CRP, Lane 1 –  pentameric CRP;  Lane 2 – pCRP, 73ml 
FPLC  elution peak; Lane 3 – mCRP, 92ml FPLC elution peak; Lane 4 - CRP pH4, EDTA, 
heat treated; Lanes 5 & 6 – replicate samples of 2M urea/EDTA dissociated samples pre 
FPLC separation showing both pCRP and mCRP. (b) Lane 1 – CRP pH4, EDTA, 63oC, 
showing monomer; Lane 2 – native CRP, showing pentamer, lane 3 – 2M urea, EDTA 
treated showing one band equivalent to the monomer, lane 4 – 6M urea, 10mM CaCl2 
treated, showing two bands, predominantly pentamer and also monomer. Bands are 
visualised following incubation for 10 minutes in Instant Blue (Expedeon). 
 
Table 3.2 A table summarising the CRP dissociation methods trialled with representative 
yields gained following FPLC analysis. Urea dissociation incubations took place over 
between 21-24 days prior to FPLC, a precipitation was removed by centrifugation prior to 
FPLC, but assessed by native PAGE. Urea dissociation provided the greatest yield when 
calcium omitted, with little yield difference between 6M and 2M, therefore the least harsh 
dissociation condition of 2M urea 1mM EDTA (- CaCl2) was taken forward. 
3.3.2.3 The Effects of Incubation Time on 2M Urea Dissociation of CRP 
 
It was then necessary to optimise the minimum dissociation time for monomer 
preparation, as illustrated by Figure 3.7 (a-e). Following two weeks incubation (2M urea, 
EDTA), a third of the protein has dissociated (a.), this dissociation increases over time until 
Dissociation Method Dissociation Conditions FPLC Yield 
Native PAGE 
mCRP +/- 
pH4 + CaCl2 0% - 
pH4 EDTA (- CaCl2) 9% + 
pH4 + heat EDTA (- CaCl2) 0% a + 
2M urea + CaCl2 0% + 
2M urea EDTA (- CaCl2) 50.88% + 
6M urea EDTA (- CaCl2) 55% + 
(b.) (a.) 
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~ 90% of the sample dissociates at 8 weeks (d.), this level of dissociation does not increase 
substantially even after 12 weeks (e). 
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Figure 3-7 Size exclusion 
chromatographs showing 2M urea 
EDTA treated CRP incubated between 
2 and 12 weeks. (a.) 2 weeks 
incubation, 30% dissociation; (b.) 3 
weeks  incubation ~55% dissociation; 
(c.) 6 weeks incubation ~ 75% 
dissociation; (d.) 8 weeks incubation ~ 
90% dissociation; (e.) 12 weeks 
incubation. ~ 95% dissociation. The 
73ml pCRP peak is labelled 1 and the 
91ml mCRP peak labelled 2. 
(a.) (c.) 
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 3.3.2.4 Re-association of Monomeric CRP 
 
Whilst it was possible to produce dissociated CRP using 2M urea, it was important 
to determine the stability of samples during long term storage. A sample of monomer was 
left at 4oC for 12 weeks within both calcium containing and non-calcium EDTA buffers, 
and then re-assessed by FPLC in the same manner as previously described in section 3.2.4. 
Figure 3.8 shows a peak at the ~91ml elution volume position which correlates to the 
correct monomer molecular weight with an absence of pentameric peak at position 73ml. 
This indicates no re-association of monomer has taken place and the effects of urea during 
dissociation prevent future pentamer formation from the subunits created.  
 
Figure 3-8 Size exclusion chromatograph showing re-association trial following 12 weeks 
storage of monomeric CRP previously dissociated using 2M urea. There is no apparent re-
association visible with the only peak at ~91ml as indicated for the monomeric protein 
(23kDa). 
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3.4 Discussion 
3.4.1 Production and Purification of in vitro Monomeric C-reactive Protein  
 
The purification and isolation of different conformations of CRP were carried out 
by the use of size exclusion chromatography. Based on the results of the calibration of the 
column the elution volumes theoretically calculated for pCRP and mCRP were 73ml and 
91ml respectively. The standard commercially available pCRP when applied to the column 
also ran at an elution volume of ~73ml (Figure 3.3) and therefore corresponded to the 
molecular weight expected of 115kDa. The calibration of the system allowed confident 
analysis of samples subjected to various dissociation techniques. 
The native pentameric form of CRP has been studied and characterised extensively, 
however the physiological conformation of the discreet subunit mCRP, its function and 
creation mechanism are still under consideration. What is less in doubt is the ability to 
create a form of monomeric CRP in vitro which can in turn be studied, enabling 
clarification of its structure and function. It is known that over time natural low levels of 
dissociation are found within stored native CRP, even within physiologically relevant 
buffer concentrations (Slevin et al., 2010). It is also documented that pentameric CRP 
added to polystyrene flasks results in a partial dissociation of the pentamer into subunits 
which express novel antigenic sites as detected by specific antibody tests (Eisenhardt et al., 
2011). It therefore suggests that the pentameric protein whilst generally stable at correct 
calcium and pH levels becomes less stable when in contact with and able to bind a surface, 
indicating a physical method of separation may be more relevant in vivo than 
environmental. Recombinant CRP monomers have been produced using modifications to 
selected amino acids allowing the protein to remain soluble at higher concentrations, 
preventing aggregation (Potempa et al., 2015). Whilst useful within functional studies, they 
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lack complete homology with the sequence of naturally occurring mCRP and as such may 
give rise to functions in vitro not naturally occurring in vivo. 
Initial investigations using a combination of acidic conditions, heat and the removal 
of calcium were ascertained for effectiveness in an effort to balance the requirement to 
dissociate CRP with that of minimising the use of harsh dissociation techniques. Using 
acidic conditions of pH 4.0 within a calcium buffer resulted in no discernible dissociation, 
once calcium was removed however, dissociation can be seen, although at very low levels, 
as shown in figures 3.4, it is clear that additional calcium provided a protective effect even 
within these relatively mild conditions. Upon heating at pH 4.0, in the absence of calcium, 
the protein was denatured and appeared as a precipitate, no longer soluble at the 
concentration of 200ug/ml, with reduced recovery of pentameric CRP and no apparent 
peak indicating monomeric CRP within the sample (Figure 3.4). Whilst these conditions 
were not continued due to a lack of effective dissociation, they were also not conditions 
occurring naturally within the body. Although some diseased states result in localised 
drops to pH, they are not found to fall as low as pH4.0.  It is reported that lactic acidosis 
associated with septic shock is defined upon detection of pH ≤ to 7.35, metabolic acidosis 
≤ pH 7.2 (occurring with approximately 50% mortality rate) and severe lactic acidosis 
during clinical shock found at levels below pH 7.0, with no survival reported at this pH 
level or below in a study by Kimmoun et al., (2015). Within cancer tumours, localised 
reductions in pH have also been reported, however again these are contained within a 
narrow range of between pH 6.9-7.1 (Helmlinger et al., 1953). It is therefore unlikely pH 
levels within the body would be within a range that would support the minimal amount of 
dissociation found within this in vitro testing system. 
It was not appropriate to reduce the pH further and therefore another method of 
dissociation was sought. The ability of urea to interrupt subunit bonding is not unique to 
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CRP as many proteins are sensitive to urea and dissociate fully at high concentrations 
(Caballero-Herrera et al., 2005, Wang et al., 2014). The effects of urea within this study 
can be seen in figures 3.5, 3.6, and 3.7, which reflect up to 95% dissociation to monomeric 
units within the protein solution. The lower concentration levels of 2M have taken many 
weeks of incubation with an optimum period of 8 weeks compared to 6M urea which also 
produced monomer within the 8 week period (data not shown). Although dissociation 
levels were slightly higher using 6M urea at the same time point it, was judged to be too 
harsh, and therefore the lower urea concentration of 2M was taken forward. 
 The exact way in which urea causes dissociation is not fully understood and it 
remains unclear as to what if any structural or functional modifications may have occurred 
to the protein. Future X-ray crystallography studies may enable full determination of the 
monomeric subunit following different dissociation techniques. Urea is able to interact 
with polar and non-polar components making it a powerful denaturant, able to disrupt non-
covalent bonds within proteins, it is one the commonly used denaturants within proteomic 
studies (Zou et al., 1998; Rossky, 2008). Hydrophilic group interactions are suggested to 
occur by formation of hydrogen bonds or other polar interactions whereas hydrophobic 
interactions are weakened (Rossky, 2008; Zaingi et al., 2009). The effects of urea on 
protein denaturation and unfolding are suggested to be either of two possibilities, the first 
of which is a proposed indirect mechanism in which urea alters the solvent structure 
weakening the hydrophobic effect between subunits. This occurs via a change in the 
structure of the hydrogen bond network of water surrounding hydrophobic regions of the 
protein, which in turn increases solubility of the protein and weakens the hydrophobic 
effect, leading to protein unfolding (Caballero-Herrera et al., 2005; Hua et al., 2008). The 
second is a direct mechanism; this suggests the protein is solvated by water and urea, with 
urea directly interacting with the proteins backbone via hydrogen bonds or electrostatic 
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interactions compared to water. The greater favourability in hydrogen bond formation 
between the peptide amide units and urea over those with water, allow urea to intrude 
within the protein structure, leading to alterations within protein structure and stability. 
These changes are postulated to be the driving force in protein unfolding and denaturation 
(Caballero-Herrera et al., 2005; Hua et al., 2008; Stumpe & Grubmuller, 2007). Although 
CRP protomers are held together by salt bridges, hydrophobic interactions are also 
involved, and these may be targeted by urea causing dissociation (Caballero-Herrera et al., 
2005).  
It is also likely that the salt bridges are involved within the subunit dissociation by 
urea. Urea when within an aqueous solution can spontaneously dissociate forming cyanate 
and ammonia which then form isocyanic acid. When in contact isocyanic acid can result in 
carbamlylation of N terminal proteins, peptides or lysine and arginine residue side chains 
groups (Sun et al., 2014). The rate of urea dissociation is dependent on temperature, pH 
and concentration together with the time in contact with the protein, therefore these factors 
impact on the degree of carbamylation. Residues 40-42 and 197-202 on one protomer 
interact with the loop of the next protomer, with salt bridges formed between Glu101-
Lys201, Lys123-Glu197 and Arg118 to the carbonyl region of Pro202 (Shrive et al., 1996). 
The urea induced carbamlyation of salt bridges may explain the dissociation effect of urea 
on CRP. 
Once again the protective effects of calcium were shown within the 2M urea trials. 
Figure 3.5 shows calcium prevention of dissociation even within the 2M urea conditions, 
which alone is not able to overcome the inclusion of calcium. The possible protective 
effects of calcium may lie in its ability to prevent the proteolytic cleavage of subunits and 
possible instability resulting from this. Calcium when bound to the protomer enables a loop 
formed by residues 140-150 to fold in protecting proteolytic sites (Ramadan et al., 2002). 
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When calcium is depleted, the loop moves away from the molecule exposing these hidden 
sites (Shrive et al., 1996) allowing cleavage. Nagase protease and pronase cleavage of 
calcium depleted CRP between Phe 146, Asn 145 and  146, 147 respectively was found to 
be inhibited by the addition of 1mM CaCl2 ((Kinoshita et al., 1989; Ramadan et al., 2002). 
Although these residues are not part of the intersubunit associations found between 
protomers, it is possible that slight conformational change and proteolytic susceptibility in 
calcium depleted CRP is responsible for the overall instability of the pentamer in its 
absence. The absence of calcium ions may weaken the interprotein contacts making them 
more susceptible to urea treatment.  
It could be expected that the removal of urea and EDTA and replacement of 
calcium may create conditions enabling a monomeric CRP solution to undergo 
spontaneous re-association to pentameric CRP. As seen in figure 3.8 this was not the case, 
it is not possible to instigate a return to pentameric CRP after urea dissociation as described 
in a study by Kresl et al. (1998) It is possible that during the final stages of protein 
assembly a chaperone protein is involved in bringing the subunits together or that the 19 
residue N-terminal signal peptide is instrumental in association of subunits pre cleavage. 
Alternatively, the salt bridges between CRP protomers may become carbamylated by urea, 
preventing reassociation of subunits. Although it is not fully understood why the protomers 
are not able to re-associate, it is confirmed that once dissociated the solution is stable and 
results seen are not affected by pentameric contamination  
The creation of monomeric CRP via urea or acidic treatments and that observed in 
studies following membrane or polystyrene binding; enable several theories to form 
explaining how it may arise in vivo and what mechanisms may be involved. It is unknown 
whether all physiological monomeric CRP arises locally via mechanical dissociation 
initiated following membrane binding, in response to changes within the extracellular 
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environment such as inflammatory driven changes in calcium concentrations or reduced 
blood pH, or is actually expressed as a monomer rather than a pentamer. It may even be a 
combination of these actions dependent on disease or inflammatory states within the body. 
The use of urea as a method of dissociation within this research allowed for a continual 
source of manufactured monomer, but does not in itself add understanding to the 
mechanism of monomer creation within an intra or extracellular environment.  
3.4.2 Conclusion and Future Work 
 
The techniques used within this study provided a reliable method of producing 
stable monomeric CRP for further investigation within patient serum and antibody studies. 
The results confirmed those previously reported; however these methods have been 
adapted to reduce the harsh techniques used within much existing research and attempt to 
reflect functions and affects found physiologically, with a protein structurally resembling 
that encountered within the body. The monomer created has been confirmed as 23KDa via 
a calibrated FPLC and travels on native PAGE to a position estimated to be that of a 
monomeric subunit, in a distinctly different way to the pentamer. Western blotting 
discussed within chapters two and five further confirms the identity of the created subunit 
through the use of specific antibodies designed to recognise the intersubunit epitopes. It 
has not been possible to re-associate the subunits due to suggested in vivo mechanisms 
present within the cell prior to secretion and absent in vitro. It is also possible to see small 
peaks between 110-115ml; these calibrated to between ~ 2400-4400 Da, and may represent 
the breakup of tertiary protein structure and gradual degradation of the protein. 
Whilst the methodology of monomer generation within our study does not mirror 
physiological conditions, it is less harsh than several methods used within previous studies, 
including those of 8M urea and both heat and extremes of pH. Despite this it is unknown 
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what effect the conditions have had on the protein and future work involving either mass 
spectrometry or X-ray crystallography would aid in the determination of urea dissociation 
changes to structure.  
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Chapter 4 - Antibody Specificity Studies 
4.1 Introduction 
4.1.1 Overview 
 
Consistency and regulation of all results within the study are essential, with the 
interaction between CRP, its structural conformations and detection antibodies key to a full 
understanding. Antibodies directed towards both pCRP and mCRP may recognise other 
proteins within the serum and as such must be tested for specificity. ELISA relies upon the 
binding affinity of proteins to solid surfaces such as micro plates, with indirect ELISA 
determining serum auto-antibody content subject to the inherent binding properties of 
serum immunoglobulins to the solid surface, creating possible false positives. There are 
several possible interactions likely to impact upon results of the ELSIA assays and as such 
it was important within this study to investigate and eradicate any unwanted interactions. It 
is known that CRP is capable of spontaneous dissociation when bound to solid phase such 
as polystyrene ELISA plate wells (Potempa et al., 1983; Sjowall et al., 2004; Singh et al., 
2009), which could cause conformational changes to pentameric CRP and exposure of non-
native sites when bound directly as a capture protein. This spontaneous dissociation would 
confuse results as conformation of the target protein would be changeable, preventing 
correct identification of the auto-antibodies present within a sample tested.  Stability of the 
protein is therefore essential within the design of experiments seeking to identify and 
quantify either CRP conformation. 
Human serum may also contain anti-BSA antibodies, or interact with other 
blocking agents or capture antibodies (Hilger et al., 2001; Waritani et al., 2017). There is 
also potential for interactions between detection antibodies and other pentraxins such as 
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long pentraxin 3 (PTX3) and serum amyloid P (SAP), both of which share sequence 
homology with CRP (Agrawal et al., 2009). 
The correct interpretation of results is therefore dependent upon an experimental 
design which eliminates or mitigates fully for any unrequired interactions caused by these 
or any other factors. With this in mind a range of experiments were performed to 
characterise CRP and antibody interactions within the chosen immune assays to ensure 
consistency between results and eliminate variables likely to be encountered.   
4.1.2 Serum Anti-BSA Antibodies 
 
Human serum antibodies may interact with the blocking agents or capture 
antibodies used within ELISA and western blotting procedures (Hilger et al., 2001; 
Waritani et al., 2017). Bovine serum albumin is a common blocker used within ELISA to 
ensure prevention of non-specific binding. In some studies however it has been reported 
that serum within both healthy and diseased individuals contains antibodies directed 
against BSA, for instance the serum of up to 55% of healthy individuals and diseased 
patients were found to contain anti-BSA IgG in a study by Mogues et al. (2005) in an 
investigation looking at patients with lung cancer (Mogues et al., 2005). An earlier study in 
1982 found anti-BSA antibodies in the serum of patients with upper but not lower gastro-
intestinal diseases such as oesophageal cancer, gastric ulcer and duodenal ulcer, rather than 
Crohn’s disease or colon cancer, with a greater prevalence in women than men (Tamura et 
al.,1982).  
In 2011 Sjowall et al published an article detailing the effect of BSA on their own 
findings due to its use as a stabiliser of some cytokine preparations used within their group. 
They then went on to test a cohort of RA patients of whom 63% were RF-positive, with 
50% of RA and 62% of controls anti-BSA positive. No significant difference was found 
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between the groups, nor between male and females (Sjöwall et al., 2011). It is unknown 
whether the interaction between BSA and autoantibodies is due to natural (innate) 
antibodies or due to MHC antigen presentation, however it is suggested the latter as BSA is 
a dietary antigen (Sjowall et al., 2011). Anti-BSA antibodies are also increased in insulin 
dependent diabetes mellitus (IDDM) patients, where a cross reactivity found between a 
BSA peptide sequence and a pancreatic β-cell surface protein has been suggested as an 
important area of study (Karjalainen et al., 1994). Cow’s milk has also been discussed as a 
possible trigger of IDDM (Saukkonen et al., 1998). In addition to anti-BSA IgG, IgA 
antibodies have also been reported. In a study comparing IDDM patients and a healthy 
group, highest titeres were found in 0-10 year olds, with levels declining as age progressed. 
IDDM patents had significantly higher levels of both IgA and IgG anti-BSA in their serum 
compared to non-IDDM controls (Hilger et al., 2001). 
Therefore the specificity of blocking components must be considered within the 
ELISA system ensuring that suitable steps are taken to insure false positive results do not 
occur via binding of patient auto-antibodies within serum.  
4.1.3 C-reactive Protein Conformational Changes upon Binding of Microwells 
 
Studies have provided evidence showing that not only may CRP dissociate on the 
surface of cell membranes, but that contact with the polylysine of an ELISA plate or other 
solid surface  may provide an environment allowing relaxation of the pentameric form and 
exposure of neo-epitopes (Ji et al., 2009; Potempa et al., 1987; Thiele et al., 2015). This 
provides challenge when using ELISA as an assay in order to determine the conformation 
of CRP within serum, as the CRP present within the serum can dissociate upon binding the 
ELISA plate and therefore create difficulties in accurate determination of monomeric or 
pentameric CRP content. Within auto-antibody studies this also becomes a challenge due 
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to the nature of the protein bound to the plate, without knowledge of the conformation 
bound, it is not possible to determine which auto-antibodies are present within a sample. 
4.1.4 Capture and Detection Antibodies  
For many years, research studies have used a commercially available mouse anti-
human CRP antibody - Clone 8 (Sigma), (Torzewski et al., 2000; Burke et al., 2002; 
Eisenhardt, Habersberger, Murphy, et al., 2009; Eisenhardt, Thiele, et al., 2009) as a 
detection antibody, which was at one time assumed to detect pentameric CRP alone. It is 
now known that the antibody interacts with both forms of CRP, and appears to have higher 
affinity for the monomeric rather than pentameric form of the protein (Ciubotaru et al., 
2003; Jabs et al., 2003; Khreiss et al., 2005; Schwedler et al., 2003) and therefore is useful 
to identify the presence of CRP but not the conformation. It is suggested that early studies 
using this antibody to determine CRP may have recognised mCRP instead of or in addition 
to pCRP adding to the opposing results regarding both pro and anti-inflammatory actions 
of CRP conformations. 
To enable identification of not only the size of the CRP protein within serum 
enabled by western blotting, but also the concentration within an ELISA, a range of 
antibodies which were capable of determining monomer from pentamer were required. 
Several research groups have used antibodies produced and supplied by Dr Lawrence. 
Potempa (Thiele, 2015; Trial et al., 2016; Slevin, 2015; Kreiss 2004; Wang, 2001), and he 
is gratefully acknowledged for his generosity in providing 3 antibodies for this research – 
Mouse anti-human mCRP monoclonal antibodies specific against the mCRP - 3H12 and 
1D6 together with 8C10 specific for the pCRP. These were initially examined for their 
suitability before use within this research. 
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4.1.5 Exploration of Potential Antibody Interactions with other Immune Proteins 
Human serum in diseased and non-diseased states will contain a range of proteins 
and immune complexes, potentially also other pentraxins. There is therefore potential for 
the selected detection antibodies to interact with other serum immune proteins such as the 
acute phase proteins PTX3 and SAP. The pentraxins are a family of evolutionarily highly 
conserved pattern recognition proteins characterised by their multimeric cyclic structures 
and fall into two categories – the long and short pentraxins. Both CRP and SAP fall into 
the short pentraxin category, whilst pentraxin 3 (PTX3) is characterised as a long pentraxin 
(Mantovani et al., 2006). The shared structural components are an indication of their 
common properties, including the activation of complement, and opsonisation of apoptotic 
cells and microorganisms.  
Pentraxins share an approximate ~200 amino acid long domain with a distinctive 
primary motif, the so called “pentraxin signature”. This signature is composed of the 
sequence His-x-Cys-x-Ser/Thr-Trp-x-Ser, where x is any amino acid (Manovani et al., 
2008). SAP and CRP share 51% identical protein sequence (Agrawal et al., 2009), 
additionally PTX3 shares a C-terminal pentraxin like domain with CRP and SAP (Woof & 
Mestecky, 2015). Therefore there is some structural homology between these proteins and 
CRP and therefore it is important that cross reactivity be eliminated. 
Where CRP and SAP are mainly expressed via hepatocytes in response to IL-6, 
PTX3 is expressed in cells across the body such as endothelial, fibroblast and hepatic cells  
via IL-1β and TNF-α, but unlike CRP not IL-6 signalling. The PTX3 transcript consists of 
1861 base pair and is predicted to 381 amino acids. In the COOH-terminal half, PTX3 
contains a “typical 8 amino-acid pentraxin sequence” and is composed of 3 exons, the third 
of which bears sequence homology to CRP (Breviario et al., 1992). In contrast to human 
CRP pentameric conformation, PTX3 structure is composed of covalently linked octamers. 
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It is also involved within host defense against infections caused by pathogens and helps 
regulate scavenging activities of macrophages and dendritic cells. PTX3 also modulated 
complement activity by binding C1q (Inforzato et al., 2006) 
4.1.7 Experimental aims 
 
The aim of this chapter was to determine the affinity and specificity of the chosen 
capture and detection antibodies towards different isoforms of CRP. Once determined the 
most appropriate antibody combination would be taken forward for use within all future 
experiments. It was also necessary to determine the effects of CRP interactions with the 
ELISA plate and assay components to ensure eradication of non-specific binding.  
 
 
Chapter 4.0 - Antibody Specificity Studies  Materials and Methods 
 176 
4.2 Materials and methods 
4.2.1 Analysis of Detection and Capture Antibody Specificity  
4.2.1.1 Western Blotting  
 
Monomeric CRP was produced in vitro using the 2M urea dissociation method as 
described in section 3.2.2. Both mCRP and pCRP were separated by native PAGE as 
described within section 2.3.6, each lane was loaded with 1µg of both monomeric and 
pentameric CRP and run at 100V for 1 ½ hours. The selected antibody was then used to 
probe mCRP or pCRP within a western blot to gauge antibody specificity (methods 
described within section 2.3.7). The primary detection antibodies used were antibody 
3H12, a specific mouse anti-human mCRP monoclonal IgG; 1D6, a specific mouse anti-
human pCRP monoclonal IgG and 8C10, a specific mouse anti-human mCRP monoclonal 
IgG (Dr Lawrence. Potempa, College of Pharmacy, Roosevelt University, Illinois), at a 
1:50 dilution within Blocking solution. In addition to these Clone 8 (Sigma) was also tested 
at a dilution of 1:2000. The primary antibody was incubated for two hours at 4oC. The 
secondary antibody used was streptavidin conjugated rabbit anti-mouse IgG (Sigma) 
antibody, added at a dilution of 1:30,000 in Blotto and incubated for 30 minutes at 4oC. 
4.2.1.2 Enzyme Linked Immunosorbent Assay 
 
Initial determination of antibody specificity utilised a direct ELISA method as 
described in section 2.2.8, in which the protein in question was bound directly to the plate 
within a coating buffer at concentrations between 0.25µg/ml to 4µg/ml (all reagents 
detailed within table 2.7). The method was as described in section 2.3.8, with additional 
primary and detection antibodies used whilst developing the final assay. The primary 
detection antibodies used were antibody 3H12, 1D6, and 8C10, at a 1:50 dilution within 
reagent diluent and Clone 8 (Sigma) mouse anti-human CRP was also tested at a dilution 
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of 1:30000 with the secondary rabbit anti-mouse IgG conjugated antibody (Sigma) also at a 
dilution of 1:30000. 
Within investigations considering the interaction between CRP and goat anti-
human IgG, the detection antibody was omitted and the direct interaction between protein 
and conjugated secondary antibody detected. In addition a rabbit anti-mouse IgG (Sigma) 
was also tested directly against human CRP in varying dilutions and lastly a conjugated 
rabbit Fc specific anti-human IgG (Thermo Scientific) was also used at varying dilutions. 
This assay was extended to further test human proteins PTX3 (Sigma), SAP (Sigma) and 
keratin (Sigma).  
4.2.2 Analysis of Sodium Azide and Peroxidase Interactions 
 
The indirect ELISA method was once again used (section 2.3.8) to investigate 
possible sodium azide inhibition of peroxidase within CRP/anti-IgG studies. The ELISA 
preceded as previously described (section 2.3.8) however mCRP was pre-incubated with 
sodium azide at 0.1% to match the storage conditions of pCRP, the secondary conjugated 
goat anti-human IgG antibody was used at a dilution of 1:30000. 
4.2.3 Human C-Reactive Protein DuoSet ELISA Specificity 
 
A commercially available CRP detection ELISA assay (R&D systems Human CRP 
DuoSet ELISA) was used to detect pCRP. It was first tested for specificity against both 
mCRP and pCRP in order to determine its specificity for the pentameric form only. The 
protocol was followed as described in section 2.3.8, with all samples diluted in reagent 
diluent, however the manufacturer’s suggested protocol was initially applied with no 
reduction in capture antibody dilutions. To optimise the protocol for patient pCRP 
detection a range of patient, control and antibody dilutions were tested. 
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4.2.4 Optimisation of Auto-antibody Detection ELISA 
 
The competitive ELISA method detailed within sections 2.3.9.1 and 2.3.9.2 was 
first optimised to ensure avoidance of interactions between assay components. Initially an 
ELISA was developed directly coating each well with patient samples diluted 1:200 in 
bicarbonate coating buffer (Table 2.13). Half of the plate (side A) was coated with either 
mCRP or pCRP at 2µg/ml in bicarbonate and the other half (side B) in bicarbonate buffer 
alone and incubated overnight at 4oC. The plate was then washed as described in section 
2.3.9.1 and patient samples diluted 1:200 in reagent diluent (R&D Systems), added to both 
sides of the plate and incubated at room temperature for two hours. The plate was once 
again washed and the anti-human IgG, IgM or IgA antibody added as per Table 2.9.  The 
remaining protocol was as described in section 2.3.9. The resulting absorbance for side B 
were removed from side A. Following optimisation the protocol described within section 
2.3.9 was adopted. 
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mCRP 
23kDA 
pCRP 
115kDa 
4.3 Results 
4.3.1 Analysis of Antibody Specificity 
 
The interaction between a commercially available anti-human CRP antibody, Clone 
8 (Sigma) was investigated to confirm specificity for pentameric, monomeric or both forms 
of CRP.  Analysis by western blotting using native human pentameric CRP (Scripps) and 
dissociated CRP (mCRP) were first performed using Clone 8 as a detection antibody, the 
results of which are shown in figure 4.1.  
 
 
 
 
 
It is apparent that not only does Clone 8 recognise pCRP, but it is also very 
effective in determining the presence of mCRP. Whilst both forms of CRP have been 
loaded in equal concentration an mCRP band of greater intensity is visible in the position 
expected for a band of 23kDa. Whilst western blotting allows confirmation of the size 
(monomer or pentamer) of CRP, it is also essential that this can be determined within an 
ELISA to enable confident determination and concentration of CRP conformation within 
human serum samples. For this reason it became necessary to have an antibody specific to 
one form of CRP and not the other as opposed to Clone 8 which recognised both. 
Antibodies supplied by L. Potempa (3H12 and 8CID - specific to monomeric CRP, and 
1D6 specific to pentameric CRP), were tested for specificity via western blotting. Figure 
4.2 shows a representative western blot (n=3) which reveals the specificity of each, 1Pg of 
Figure 4-1 Western blot image of a native PAGE of 
mCRP and pCRP including 1/20th SDS within both 
sample and running buffer. Containing 1µg of both 
mCRP and pCRP. The primary detection antibody used 
was Clone 8 1:1000 dilution. Although both proteins 
were loaded in equal amount the intensity of the 
monomeric band is greater 
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both monomer and pentamer per well were run on 1/20th SDS native PAGE and blotted 
with each antibody. Lane 2 used Clone 8 as a detection antibody resulting in a monomeric 
band only, lanes 3-5 show detection of monomer not pentamer by 3H12 and lanes 6-8 have 
a very faint detection of monomer by 8C10 and strong detection of the pentamer in lanes 9-
10 by 1D6. 
It was also apparent following retention of the stacking gel before transfer that the 
pentameric CRP sample was unable to move fully into the resolving gel, with the majority 
remaining within the stacking layer. The western blot analysis during antibody specificity 
testing at various exposure times allowed detection of several bands present when probed 
with the anti-monomeric antibody 3H12. In addition to the expected monomeric band 
position two others are visible – indicating possible dimer or trimer conformations. The 
monomer tested was prepared as described and isolated by FPLC (Section 2.3.4), however 
there may have been some aggregation or stacking within the gel or within storage 
following FPLC separation.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 4.0 - Antibody Specificity Studies  Results 
 181 
  1        2        3       4       5       6      7       8       9      10 
Pentameric CRP 
Monomeric CRP 
Stacking gel 
 Clone 8 3H12 8C10 1D6 
Stacking  
 
 
 
 
 
 
 
Figure 4-2 Western blot image of antibody specificity, Clone 8 (1:1000), 3H12, 8C10 and 
1D6 (1:50). Native PAGE gel with 1/20th SDS within both the sample and running buffers, 
the stacking gel was not removed prior to blotting. 1ug of both mCRP and pCRP were 
loaded into each lane. Lane 1 is a negative control without primary detection antibody; 
Lane 2 – the positive control (Clone 8); Lanes 3-5 (3H12) showing an intense band at the 
monomer position; Lanes 6-8 (8C10) with a single less intense band at the expected 
monomer position and lastly Lanes 9-10 (1D6), which show a band below the stacking gel 
where expected for pentameric CRP, however the majority of the pentamer has remained 
within the stacking gel and not entered into the resolving section, n=3.  
 
4.3.2 Antibody Interactions with Immune Proteins PTX3 and SAP 
 
Further ELISA and western blots were performed to test for interactions between 
PTX3, SAP and antibodies. It is known that PTX3 may be found on the surface of cells and 
within serum as is SAP, therefore this test ensured that any positive interaction within 
serum were detection of CRP and not either of these proteins. Figure 4.3 shows the 
comparison between detection of 1µg of mCRP and PTX3 within an ELISA with Clone 8, 
3H12, 8C10 and 1DC used as primary detection antibodies. PTX3 was not detected in any 
of the assays by anti-CRP antibodies. Human SAP was separately tested for anti-human 
IgG binding, and with anti-CRP antibodies 3H12 and Clone 8, and was also not found to 
have any interaction (Figure 4.3).  
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Figure 4-3 Bar graph showing the interaction between detection antibodies mCRP, PTX3 
and serum amyloid protein (SAP), (SAP tested with Clone 8 and 3H12 alone), showing a 
strong interaction between mCRP, 3H12 and Clone 8 and weaker with 8C10 n = 3. No 
interaction is shown between mCRP and pentamer specific 1D6, or between PTX3 and any 
of the four antibodies. SAP was also not detected by either Clone 8 or 3H12), n = 2. 
 
4.3.3 Interactions between Anti-Human IgG and CRP 
 
During ELISA optimization an interaction was seen within control wells between 
CRP and goat anti-human IgG. The effect was further investigated and found to be greater 
within lower antibody dilution and at higher CRP concentrations; more interesting was the 
difference between anti-human IgG and mCRP or pCRP. The interaction between mCRP 
and anti-human IgG was more than five times higher than pCRP and anti-human IgG 
samples at 1:1000 antibody dilution, as illustrated in Figure 4.4, absorbances 1.35 and 
0.253 respectively at 4 µg/ml. A less pronounced interaction can be seen between 4µg/ml 
pCRP and higher antibody dilutions, and also with lower CRP concentrations, with 
virtually no interaction at 0.5 µg/ml pCRP.   
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Figure 4-4 Bar graph showing the interaction between CRP and goat anti-human IgG at 
different amounts of bound CRP protein and antibody concentrations. (a.) mCRP dilutions 
ranging from 0.5µg/ml to 4µg/ml (b.) pCRP dilutions ranging from 0.5µg/ml to 4µg/ml.  
 
The nature of the interaction between CRP and anti-human IgG was further 
investigated by pre-incubating anti-human IgG with either mCRP or pCRP to see if this 
abrogated the effect. As can be seen in Figure 4.5, not only does anti-human IgG interact 
more strongly with monomeric CRP but the IgG binding is reduced by half during pre-
incubation with the mCRP when compared to pre incubation with pCRP. 
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Figure 4-5 Bar graph showing binding inhibition of anti-human IgG pre incubated with 
either mCRP or pCRP. Anti-human IgG (1:5000) dilution, pre-incubated with either mCRP 
or pCRP (1µg/ml) overnight. The capture protein is either mCRP or pCRP at 2ug/ml 
coated overnight. Monomeric CRP abrogates the binding of anti-human IgG to both the 
bound monomer and pentamer to a greater degree than pre-incubation with pCRP. 
 
The interaction between CRP and anti-IgG was further investigated with the 
secondary antibody used within many of the assays, rabbit anti-mouse IgG. There was once 
again an interaction found, however there was less difference between pCRP and mCRP. 
Figure 4.6 shows the binding of 2µg/ml mCRP and pCRP by rabbit anti-mouse IgG across 
and antibody dilution range between 1:250 and 1:16000. 
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Figure 4-6 Bar graph showing interactions between human CRP and anti-mouse IgG. An 
ELISA plate was coated overnight with 2µg/ml mCRP or pCRP and probed with a rabbit 
anti-mouse IgG at various dilutions. The absorbance value for an antibody dilution of 
1:8000 is 0.164 and 1:16000 dilution is 0.06 when captured by the monomer and is a little 
lower when captured by the pentamer. 
 
Although an interaction can be seen between anti-mouse IgG and CRP in Figure 
4.6, there is no significant difference between that captured by mCRP or pCRP. Figure 4.6 
also shows an absorbance of 0.164 units for mCRP at an antibody dilution of 1:8000; the 
comparison figure of 0.544 absorbance units at an antibody dilution of 1:7500, over three 
times larger can be seen in Figure 4.4, showing greater interaction/binding of anti-human 
IgG to mCRP as opposed to anti-mouse IgG. 
4.3.4 Interactions between CRP and Fc specific anti-human IgG 
The interaction between the secondary antibody (anti-human IgG) and CRP was 
further investigated using an Fc specific anti-IgG, this was performed in order to determine 
whether the antibody recognition sites resembled Fc regions. Figure 4.7 shows that whilst 
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anti-human IgG recognises monomeric CRP and to a lesser extent pentameric CRP, an Fc 
specific anti-human IgG shows no recognition of either conformation. 
 
 
Figure 4-7 Line graph showing the interaction between mCRP, pCRP and both anti-human 
IgG and Fc region specific anti-human IgG. There is little interaction between the Fc 
specific antibody, although a large interaction between anti IgG and mCRP. 
 
The specificity of the anti-human IgG was further tested using additional human 
proteins. Keratin was easily available and initially used; this also resulted in an interaction 
as can be seen in Figure 4.8. The interaction is comparable to mCRP but lower, with the 
absorbance at an antibody dilution of 1:5000 for 4µg and 2µg keratin 1.106 and 0.49 
respectively. The equivalent values for mCRP were 4µg - 1.35 and 2µg - 0.884 and pCRP 
4µg - 0.243 and 2µg - 0.109. Once again the interaction was assessed for Fc site specificity 
and as with both mCRP and pCRP no binding was present when anti-human IgG Fc 
specific antibodies were used, as seen in Figure 4.9. 
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Figure 4-8 Figure 4.8 Bar graph showing the interaction between anti-human IgG and 
keratin with antibody dilutions ranging between 1:30000 and 1:1000 and capture keratin at 
between 4µg/ml and 0µg/ml. 
 
 
Figure 4-9 Bar graph showing the interaction between keratin, mCRP, pCRP and either 
anti-human IgG or Fc specific anti-human IgG. Plates were coated with 1µg protein and 
challenged with a 1:5000 dilution of antibody. 
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4.3.5 Effects of Sodium Azide on Clone 8 
 
It is possible that differences between the observed binding of various antibodies to 
mCRP and pCRP may be caused by sodium azide present within the pentameric CRP 
solution supplied by Scripps. Sodium azide is known to interact with peroxidase 
conjugated antibodies and is not present within the monomeric sample; this may have been 
responsible for reduced interactions when using pCRP within assays. However as can be 
seen in figure 4.10 the resulting difference is not significant, although once again the 
binding of anti-human IgG to mCRP is higher than that to pCRP. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10 Bar graph showing the effect of sodium azide on CRP/IgG interactions. Wells 
were incubated with 1µg CRP in a bicarbonate buffer overnight followed by 1:30000 
dilution of goat anti-human IgG.  Pentameric CRP is supplied in buffer containing sodium 
azide at 0 .1% protein concentrations. To assess the effects of this on the peroxidase 
conjugated antibody an equivalent amount of sodium azide was added to mCRP.  No 
significant effect was found between anti-IgG binding signal to mCRP with or without the 
addition of sodium azide. There is a significant difference between anti-human IgG 
interactions with mCRP as opposed to pCRP. 
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4.3.6 CRP DuoSet ELISA specificity 
 
In order to test for serum pCRP, a commercial ELISA kit was tested for specificity 
against both mCRP and pCRP. Figure 4.11 shows the absorbances against concentration 
for both monomeric and pentameric CRP. Whilst pCRP shows a clear correlation between 
concentration and absorbance, mCRP is not detected by the kit. 
 
Figure 4-11 Line graph showing the specificity of the R&D Systems CRP DuoSet ELISA 
kit for pCRP and mCRP. Whilst a correlation is present between the detection of pCRP 
with rising absorbance with concentration, there has been no detection of mCRP. 
 
Patient samples were tested within the R&D Systems kit to optimise sample 
dilutions. Dilutions of patient samples between 1:1000 and 1:128,000 were trialed together 
with varied capture and detection antibody dilutions. The optimum conditions taken 
forward were a patient sample dilution of 1:16000 and a control sample dilution of 1:1000 
in reagent diluent (Table 2.8).  
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4.4 Discussion 
4.4.1 Antibody Specificity 
 
In order to design a robust protocol capable of detecting and differentiating 
between both mCRP and pCRP, together with their associated auto-antibodies, it was 
important to ensure antibodies were specific for the desired protein and any additional 
interactions were avoided. With this in mind initial investigations considered the primary 
detection antibodies selected for both the ELISA and western blotting analysis. The first 
antibody considered was the commercially available Clone 8 (Sigma) which not only 
detected monomeric CRP, it appeared to have a higher affinity to this form than that of the 
pentamer, this can be seen in the western blot shown in Figure 4.1. The monomeric band 
has a deeper intensity than the pentamer although both contained the same amount of 
loaded protein, indicating a higher affinity for the monomeric form of CRP than the 
pentameric.  
Whilst the monomer appears in the location expected there is also a third and fourth 
band visible between the monomer and pentamer, it is suggested that this may be dimer or 
trimer formation, although which surface interactions are playing a part are unknown. The 
presence of such conformations have also been noted within a study by Li et al., (2016), 
although they were able to show several conformations of CRP within western blotting 
however not the monomeric form. The knowledge that Clone 8 recognised both forms of 
CRP eliminated it from ELISA serum detection studies as it was important to differentiate 
between the two isoforms of CRP.  Specific anti-CRP antibodies were sourced that would 
allow recognition of individual isoforms of CRP within both ELISA and western blotting. 
These antibodies (3H12, 1D6 and 8C10) were tested against both mCRP and pCRP within 
a western blot (Figure 4.2) and confirmed to be specific for the CRP conformation 
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required. Both 3H12 and 1D6 provided a strong signal against mCRP and pCRP 
respectively; however 8C10 was not found to be as effective and was therefore not used 
further. 
4.4.2 Interactions between Anti-IgG and CRP 
 
Whilst optimising ELISA protocols an unexpected interaction between anti-human 
IgG and both mCRP and pCRP became apparent. Research has shown that the risk of cross 
reactivity is elevated in proteins with a high level of homology amongst species, which 
may also include CRP; for instance, Delgado et al. (2003) reported that anti-human CD36, 
anti-human CD41a and anti-human CD62P antibodies all cross reacted with porcine 
platelets (Delgado et al., 2003). It has also been reported that mCRP binds 
immunoglobulins non-specifically. In their 2012 paper Boncler et al. tested binding of 
antibodies directed against human serum albumin (HSA) and IgG to mCRP and 
additionally to IgG, fibronectin and C1q. They found that anti-HSA and anti-IgG  bound to 
mCRP, however there was a stronger interactions between mCRP and human IgG, murine 
anti-human CD16 and murine anti-human CD32 (Boncler et al., 2003).   
Additionally anti-HSA antibodies bound not only to HSA but also to fibrinogen, 
IgG, fibronectin, C1q and mCRP, this binding was only observed in higher concentrations 
of antibody (10µg/ml). These results reflected the findings in our study which also showed 
greater binding at higher antibody concentrations, although Figures 4.4 shows considerable 
binding at both 2.5 and 5µg/ml.  Interactions between mCRP and both anti-human and 
anti-mouse IgG were also reported (Boncler et al., 2003), although again only at mCRP 
concentrations of 10µg/ml. The interaction of mCRP and immobilised murine antibodies 
directed towards human Fc receptors CD16 and CD32 and immobilised human IgG was 
also assessed with considerable binding of mCRP to all three. Whilst our results show 
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limited interactions between pCRP and anti-human and anti-mouse IgG, Boguslawski et al. 
(2007) reported interactions with only mCRP, once again only at higher concentrations of 
CRP and antibody. It is clear that mCRP and to a lesser extent pCRP interact with anti-
IgG, however it is difficult to determine whether it results from cross-reactivity of the 
antibody, or binding of the antibody by CRP. In order to ensure the particular IgG tested 
was not less specific than required, it was tested against keratin. Keratin was initially 
chosen as it was available within the laboratory group and is also subject of auto-antibody 
activity within inflammatory diseases (Boguslawski et al., 2007). 
Anti-keratin antibodies have been found in normal human sera and that of patients 
with RA, Sjogren’s syndrome, cutaneous lesions, liver disease and lymphoproliferative 
disorders (Borg et al., 1993; Mattey et al., 1993). It was initially surprising to see an 
interaction between keratin and goat anti-human IgG antibody. As with mCRP the 
interaction was only apparent at high antibody and protein concentrations as seen in Figure 
4.8 and as with both pCRP and mCRP, no interaction was found with the Fc specific anti-
human IgG (Figure 4.9). It is known that anti-IgG binds keratin within autoimmune disease 
and that such interactions between anti-IgG and keratin were not in fact as unusual as first 
considered (Endo et al., 2004; Young et al., 1979; Mallya et al., 1983; Lin et al., 2014), 
therefore it was considered that the antibodies were not less specific than required.  
Whilst the interaction between anti-IgG and CRP was accepted as having minimal 
impact within the ELISA assay designed for detection of CRP or associated auto-
antibodies, it was considered interesting and was therefore further investigated. Both IgG 
and CRP bind through Fc gamma receptors, pCRP binds to FcγRI, FcγRIIa and FcγRIIb  
(CD64, CD32A & CD32B), mCRP is thought to bind FcγRIIb and FcγRIII (CD32B & 
CD16) (Li et al 2004; Shih et al 2009). IgG also binds Fc gamma Rs (Ravetch & Bolland, 
2001) and therefore it was considered possible that the recognition of mCRP by anti-IgG 
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may have been due to a shared homology within the Fc binding sites. However, Figures 4.7 
and 4.9 indicate that this is not the case as there was no interactions found between anti-Fc 
specific IgG and either mCRP or pCRP. Although our result has not been able to clarify 
how or where the interactions take place, they may be useful within the body to reduce 
circulating levels of mCRP or to aid removal of damaged or denatured proteins. 
The difference between the interaction between the secondary antibodies and either 
mCRP or pCRP could not be explained and is an interesting area of future research. 
However, within our own experiment it was decided to ensure the potential effect of 
sodium azide upon peroxide was not influencing our results. Horseradish Peroxidase 
(HRP) is commonly used as a conjugate within detection antibodies and sodium azide (SA) 
used as a chemical preservative within some biological compounds and solutions. It is also 
known that SA can inhibit the actions of HRP via its inhibition of the HRP-H2O2-hydrogen 
donor system (Weinryb, 1968; Ortiz de Montellano et al., 1988). The pCRP solution 
supplied by Scripps Labs is within a buffer containing 0.01% SA, whereas the mCRP 
solution did not. The effect of SA on mCRP was therefore tested to ensure the lower results 
gained within the IgG interaction studies were not as a result of SA inhibition. As can be 
seen within Figure 4.10 this was not the case as no significant difference between mCRP 
with or without 0.01% SA was found. 
Although it was important to eliminate any unwanted interactions within the ELISA 
assay, it was considered that the CRP and antibody dilutions intended for use within the 
experiments would not be unduly affected. For instance, the secondary anti-mouse IgG 
used was at a 1:30000 dilution and mCRP or pCRP used to coat the plates was 2µg/ml. 
Interaction studies showed limited interactions at these levels (Figure 4.4), with mCRP 
absorbance reaching only 0.09 and pCRP 0.018. All assays were run with matched control 
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wells which were also subject to the same interactions between CRP and anti-IgG, 
removing the risk of the interaction influencing the results. 
4.4.3 Interactions between Antibodies, SAP and PTX3 
 
It was also important to ensure that the chosen antibodies did not recognise closely 
related pentraxins which may also be present within serum. SAP and PTX3 were therefore 
both tested against the antibodies and none of the capture or detection antibodies were 
found to interact with them (Figure 4.3). The antibodies chosen were therefore all (with the 
exception of 8D10, which did not produce a strong enough signal), considered appropriate 
for use within further optimisation of protocols and in all future experimentation. 
4.4.4 Optimisation of Sandwich ELISA 
 
The R&D ELISA Duoset used within the pCRP detection assays was tested to 
ensure that all CRP detected was in fact pCRP and not mCRP. As can be seen in figure 
4.11, no recognition of mCRP was found at any concentration and therefore the kit was 
optimised for use within the pCRP detection assays. Patient samples and antibodies were 
optimised to allow accurate and reproducible results within the assay system and as such 
patient samples were diluted between 1:1000 and 1:1280000. The range that 
accommodated high to low serum concentrations of pCRP was 1:16000 for patient and 
1:1000 for control samples (Table 2.8). In addition to this the capture antibody 
concentration was halved. 
4.4.5 Optimisation of Competitive ELISA 
 
During study design of auto-antibody detection assays, within both patient and 
control samples, it was necessary to ensure the assay reduced interactions and confounding 
variables with other agents. Human serum antibodies may interact with the blocking agents 
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or capture antibodies used within ELISA and western blotting procedures (Waritani et al., 
2017, Hilger et al., 2001). Patient and healthy control serum may contain levels of 
antibodies directed against dietary antigens such as BSA, with studies reporting between 
50-55% of patient samples and up to 62% of controls anti-BSA positive (Mogues et al., 
2005; Noriaki Tamura, 1982; Sjowall et al., 2011). Rheumatoid factors can also interfere 
with immunoassay results, due possibly to reactions against secondary detection antibodies 
within the assay, or by interaction with immune complexes immobilised on the plate 
(Tarkowski et al., 1983). In addition to these factors, the serum could not be bound directly 
to the plate as the pCRP contained within it could dissociate into mCRP before the assay 
began, thus affecting results. This conformational change was avoided by the use of a 
capture antibody or agent for both pCRP and mCRP assays.  
Several studies have stabilised pCRP by pre-coating the ELISA plate with 
phosphocholine bound keyhole limpet haemocyanin (PCh-KLH), which allows pentamer 
binding when in the presence of 2mM CaCl2 (Potempa et al., 2015; Wang, 2012;). This 
method was adopted within the assays seeking to profile anti-pCRP IgG, IgA and IgM, 
with a goat anti-CRP antibody used to capture mCRP. However the danger of potential  
interactions between the BSA blocking step and capture antibodies remained and therefore 
a competitive ELISA system was developed  
4.5 Conclusion 
 
Following optimisation steps, capture and detection antibodies were assessed for 
their specificity and found to be suitable to correctly identify either mCRP or pCRP, 
additionally no interaction was found between these antibodies and either PTX3 or SAP. 
Considerable steps were taken in order to minimise or remove all other possible 
interactions between the assay components and either antibodies or auto-antibodies.  
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Chapter 5 - Detection of CRP within human serum  
5.1 Introduction 
5.1.1 Detection and Measurement of CRP within Human Serum 
 
The detection and quantification of CRP concentrations within serum or plasma has 
long been a feature of routine blood tests, as a measure of non-specific inflammation or 
infection within a patient. Higher than an accepted normal levels, (>3 mg/L), often 
indicates an underlying diseased state, inflammation or autoimmune linked condition 
(Pepys & Hirschfield, 2003; Ucer et al., 2008; Araújo et al., 2009; Salazar et al., 2014). 
Whilst detection of higher than normal levels of CRP indicates a non-healthy state, 
the actual cause requires further diagnosis through more specific testing. Diagnosis of RA 
can be determined through blood tests for high levels of CRP in association with other 
recognised diagnostic factors such as elevated erythrocyte sedimentation rate (ESR) or the 
presence of rheumatoid factor or anti-citrullinated peptide (anti-CCP) antibodies. MRI and 
ultrasound tests may be undertaken to track the progression of joint damage over time 
(Davis et al., 2012) and symmetrical joint pain and damage is often assessed by Disease 
Activity Score (DAS) of either  a 28 or 66 joint count (Houssien et al., 1999; Scott et al., 
2000; van Riel & Renskers, 2016) of which DAS28 is routinely used for diagnostic 
purposes. Within clinical settings the detection of CRP has been performed by ELISA 
systems which rely on the specificity of antibodies and their detection of the native 
pentameric form of the protein. Increased sensitivity has been accomplished using high 
sensitivity ELISA assays, again reliant on antibody specificity. Upon acceptance that there 
could in fact be additional forms of CRP found within the serum or tissue, the question of 
accuracy and implied meaning of previous testing could be called into question, both 
within clinical and research settings. Findings generated over the last 20 plus years may 
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have assumed detection of native pentameric CRP, however, could possibly have identified 
monomeric or a combination of the two forms instead. A system that cannot consistently 
detect and differentiate between multiple forms may add to conflicting evidence for the 
either pro or anti-inflammatory nature of the protein. RA disease activity is consistently 
found higher in cases of high confirmed CRP levels (Otterness, 1994). Interestingly it is 
not just upon flare that CRP levels are found to be raised, a study in 2004 by Nielen et al,  
via analysis of CRP levels within blood donor populations, found that CRP levels were 
increased up to five years before the onset of RA symptoms, with two years pre onset 
being the most commonly found period of detected increased (Nielen et al., 2004) It is 
clear that the accurate detection of CRP is an important diagnostic tool. Determination of 
both monomeric and pentameric forms has begun within some disease models such as 
atherosclerosis and kidney disease, but is not used clinically within diagnosis or prognosis. 
Patient CRP serum levels are routinely analysed within both clinical and research 
settings, often via immuno-detection methods reliant upon antibody recognition of CRP. 
Within a clinical setting these techniques need to be rapid and efficient and are now often 
automated, for example the National Health Service (NHS), who are now less reliant on 
more costly and time consuming manual techniques such as traditional ELISA now 
commonly use automated systems which allow higher throughput, such as latex-enhanced 
immunoturbidimetry (Koivunen and Krogsrud, 2006; Siemens, 2014). This is not always 
the case within a research setting where many individuals and groups are still reliant on 
standard ELISA protocols carried out manually, often in kit form, but also developed 
specifically using a combination of self-raised antibodies. Even minor deviations from a 
baseline serum level can indicate inflammation or infection connected to disease, therefore 
the development of high-sensitivity CRP tests has aided detection of these subtle variations 
substantially. Within clinical settings it is not always possible to determine which form of 
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CRP is being detected, Table 5.1 summarises some common hs-CRP tests used within 
clinical laboratories and illustrates the range of detection limits in addition to the lack of 
determination of which form of CRP has been detected. 
Table 5.1 A table summarising the range of clinical CRP tests performed, including 
advantages and disadvantage. Table adapted from (Roberts et al., 2001). Additional 
information from  (Deegan et al., 2003; Luo et al., 2012). 
Clinical 
Test 
Description 
Methodology 
Limit of 
detection, 
μg/L 
Advantages / 
Disadvantages 
mCRP or 
pCRP 
detection 
Manufacturer 
N High 
Sensitivity 
CRP 
Immunonephelometric 20.0 
Fast, accurate, 
affordable 
Require trained 
personnel 
 
Not 
specified 
Dade Behring 
(Dade) 
Pure Auto S 
CRP Immunoturbidimetric 40.0 
Fast, cost 
effective, 
sensitive  
Not 
specified Daiichi 
CRP-Latex 
(II) High 
Sensitive 
Application 
Immunoturbidimetric 30.0 
Fast, cost 
effective, 
sensitive 
Not 
specified 
Denka Seiken 
(Denka) 
CRP Immunoluminometric 20.0 
Fast, cost 
effective, 
sensitive 
Not 
specified 
Diagnostic 
Products 
Corporation 
(DPC) 
HS-CRP Immunoturbidimetric 5.00 
Fast, cost 
effective, 
sensitive 
Not 
specified Iatron 
K-Assay 
CRP (I) Immunoturbidimetric 320 
Fast, cost 
effective, 
sensitive 
Not 
specified Kamiya 
CRP (Latex) 
Sensitive 
Application 
Immunoturbidimetric 80.0 
Fast, cost 
effective, 
sensitive 
Not 
specified Olympus 
Tina-quant 
CRP (Latex) 
US 
Immunoturbidimetric 210 
Fast, cost 
effective, 
sensitive 
Not 
specified Roche 
CRP-UL Immunoturbidimetric 60.0 
Fast, cost 
effective, 
sensitive 
Not 
specified Wako 
Hs-CRP Quantum dot-labelled immunosorbent 0.06 
Rapid, sensitive, 
low cost and 
high-throughput 
Not 
specified 
Luo et al., 
2003 
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High-sensitivity CRP testing is based upon a system of light scattering 
immunoassays in which an antigen: antibody complex can be detected within a solution. A 
study of 491 healthy blood donors by (Price et al., 1999), reported median CRP values of 
2.40 mg/l males and 2.20 mg/l females with a 95th percentage range of 1.20 -5.20 Pg/mL 
male and 0.40-5.40 Pg/mL female using light scattering immunoassays. In a more recent 
study, a quantum dot-labelled immunosorbent assay was developed allowing sensitive and 
rapid detection of CRP, this assay allowed detection of CRP within a range of 1.56–400 
ng/ml at a limit of detection at 0.46 ng/ml and quantification limit at 1.53 ng/ml (Lv et al., 
2017). This novel detection method is whilst fast, still reliant on predictable interactions 
with antibodies specific to CRP; in their case mouse anti-CRP purchased from Abcam, but 
allows a detection method of far greater sensitivity than many traditional ELISA systems. 
It is clear that procedures are being developed rapidly enabling faster and more 
accurate/sensitive detection of CRP, but there is little or no distinction within a clinical 
setting defining the isoform of CRP, with detection currently being assigned to native 
pentamer. At research level, groups studying monomeric CRP have developed individual 
protocols based upon sourced antibodies directed towards epitopes exposed on the 
monomer but not the pentamer as ways to differentiate isoforms (Kresl, Potempa and 
Anderson, 1998; Khreiss et al., 2004; S.-R. Ji et al., 2006, 2009). It is very possible 
historical research studies have used antibodies now known to detect both forms of CRP, 
including Clone 8 (Sigma), and drawn conclusions of the effects or presence of CRP 
without distinction of which isoform(s) are present. 
5.1.2 Serum Monomeric CRP in Health and Disease  
 
The ability to produce and detect monomeric CRP dissociated from the native 
pentameric form, within in vitro systems, via various different production protocols has 
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been illustrated in Chapter 3. Documentary evidence indicates a growing number of studies 
which also identify the dissociated form of CRP in vivo within human tissue and less 
frequently serum, occurring most commonly within inflammatory linked diseases (S.-R. Ji 
et al., 2006; Ji et al., 2009; Zhang et al., 2009). The biological and physiological relevance 
of mCRP is yet to be fully understood, however it is frequently suggested to be pro-
inflammatory in nature due to its association within inflammatory and autoimmune 
disease.  
Whilst the biological relevance and exact method of production of mCRP is yet to 
be fully understood, there is a pool of research indicating association with phosphocholine 
(PC) and cell membranes allows rapid dissociation of the pentamer towards a monomeric 
form (S.-R. Ji et al., 2006; Eisenhardt, Thiele, et al., 2009; Ji et al., 2009; Slevin & 
Krupinski, 2009; Habersberger et al., 2012; Molins et al., 2016). In their 2006 paper, Ji et 
al showed that calcium-dependent binding of pCRP to membranes, including cell 
membranes and low density liposomes, allowed a rapid although partial dissociation of the 
pentamer and structural changes towards an isoform allowing exposure of novel inter-
subunit antigenic sites. This partial dissociation retained pentameric conformation in a 
relaxed form and was termed mCRP(m). The properties of this isoform allowed 
significantly enhanced complement fixation and when detached from the membrane was 
observed to form mCRP. Within their study they further documented the ability of mCRP 
to be solubilised (which they termed mCRP(s)), and to apply strong stimulatory effects to 
endothelial cells (Ji et al., 2006). Effects upon endothelial cells linked to mCRP include an 
upregulation of IL-8, monocyte chemoattractant protein, E-selectin together with ICAM-1 
and VCAM-1 the cell to cell adhesion molecules (Ji et al., 2006).  
Few studies have shown a soluble form of mCRP, which is neither associated nor 
bound with tissue, cells or fragments of cells such as the microparticles (MP) derived from 
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endothelial cells as described in Crawford et al’s 2016 study, or the membrane bound form 
mCRP(m) described by Ji et al. previously. In 2013 Habersberger et al. (2012) suggested 
that their research on activated platelets indicated a role for MP within the transportation of 
membrane bound mCRP throughout the body. They suggest a model whereby pCRP 
dissociated upon contact and binding to MP shed by activated platelets which then 
transport the monomeric form throughout the body in response to cardiovascular events 
such as myocardial infarction. In many of these studies the role of mCRP has been 
suggested to be pro-inflammatory in nature, such as Crawford et al’s 2016 finding that 
mCPR instigated pro-inflammatory endothelial shedding, whereas pCRP induced anti-
inflammatory effects via regulation and reduction of inflammatory immune cells.  
One study that has detected solubilised mCRP within circulation is that of Wang et 
al. (2015) who suggested this form of the protein was present within the serum of patients 
who recently had suffered acute myocardial infarction (AMI). The study showed levels of 
plasma mCRP elevated within AMI patients in contrast to those suffering from 
unstable/stable angina pectoris or control groups (0.021mg/l ± 0.0016). Interestingly, not 
only did they detect plasma  mCRP,  but nine of the AMI group who died prior to a 30 day 
follow up had significantly elevated plasma mCRP (0.0367 mg/l ± 0.01  vs 0.0194mg/l ± 
0.00143, P = 0.02) when compared to those who survived, indicating a possible future 
AMI diagnostic value to mCRP testing. Increased mCRP levels were also observed in 6 
patients with high identified levels of pCRP, their plasma mCRP levels ranged from 0.0077 
to 0.1227mg/l. This study ensured the mCRP measured was present within serum tested 
rather than an artefact of the ELISA protocol, by coating a specific capture antibody to the 
ELISA plate, rather than coating serum directly to the plate. This method prevents 
spontaneous dissociation of CRP upon immobile surface binding seen within other studies.  
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As shown, within the field of mCRP research, diseases linked to the cardiovascular 
system are perhaps the most frequently studied. Supporting the findings of Wang et al., 
(2015) researchers within another group have initiated patent proceedings suggesting 
serum mCRP identification may provide a useful diagnostic tool detecting early preclinical 
stages of atherosclerosis (Kiefer et al., 2005 Patent number US2006057642-A1). 
Aside from the cardiovascular system, several other diseases have been identified 
as having mCRP co-localised to diseased tissue or within circulation. The ocular system 
has emerged as one such disease frequently associating mCRP to pathology. Age-related 
macular degeneration has been associated with detectable levels of mCRP elevated within 
tissue taken from genotyped human donor eyes (Chirco et al.,, 2016). Those homozygous 
for the CFH (Y402H) high risk allele showed choriocapillaris and Bruch’s membrane 
associated with elevated mCRP, in contrast to genotypes of low risk. RNA analysis of 
expressed inflammatory genes within cultured choroidal endothelial cells showed increased 
migration rate and monolayer permeability when treated with mCRP in comparison to 
those challenged with pCRP or medium alone. Altered expression of ICAM-1 and CA4 
were reported within organ cultures upon treatment of mCRP (Chirco et al., 2016). Further 
to this, Molins et al suggested that mCRP and not pCRP present within retinal tissue 
disrupted the outer blood-retinal barrier, via functional impairment to the retinal pigment 
epithelium (RPE), from which it is formed. They suggested that mCRP increased 
paracellular permeability and caused disruption to ZO-1, a tight junction protein in addition 
to occludin a protein found within RPE cells. These effects were prevented by the presence 
of corticosteroids or anti-VEGF drugs (Molins et al., 2017). Table 5.2 details the levels of 
mCRP and pCRP found within a variety of disease states where reported. 
 
 
 
 
Chapter 5.0 Detection of CRP within Human Serum Introduction 
 203 
Table 5.2 A summary table of mCRP and pCRP levels detected within key diseases where 
known. AMD (age related maculardegeneration, AMI (acute myocardial infaction), NR 
(not reported). 
 
 
Brain tissue from patients, post-acute ischemic stroke, has been shown to have high 
levels of deposited monomeric CRP within functional neuron and glial cells tissue. This 
deposit, suggested to be expressed within the brain extracellular matrix, was determined to 
be an agent in part responsible for neurodegeneration and abnormal vascular development 
associated post stroke by (Slevin et al., 2010).  The same group further detected 
monomeric CRP at higher levels adjacent to infarcted areas, within Alzheimer’s disease 
(AD) affected brain tissue, possibly linking mCRP to vascular damage within the brain 
Disease mCRP mg/l pCRPmg/l Source 
Healthy - Median 1.3mg/l (range 0.75-2.22mg/l) 
(Pearson et al., 2003) 
(Meyer, 2010) 
AMI 
0.021mg/l 
(range 0.019-
0.036mg/l) 
NR (Wang et al., 2015) 
 
Not defined 0.88mg/l  (range 0.04 -3.52mg/l) 
23.3mg/l 
(range 2.9-66.8mg/l) (Williams 2017) 
Alzheimer’s Tissue bound NR (Strang et al., 2012; Slevin et al., 2003) 
Ischemic Stroke Tissue bound NR (Strang et al., 2012; Slevin et al., 2003) 
cholecystitis, lung 
squamous cell 
carcinoma, 
mucinous gastric 
adenocarcinoma, 
renal cell carcinoma 
Tissue bound NR (Shi et al., 2014) 
RA 
 
- Median 5.3 mg/L 
 
(Graf et al., 2009) 
Inactive Lupus 
 
 
 
SLE non serositis 
NR 
 
 
 
NR 
mean 0.96 mg/l, (range 
0 – 12mg/l) 
 
Median 1.37 mg/l 
(Kakai et al., 2003) 
 
 
(Enocsson et al., 2014) 
Active Lupus 
 
 
SLE serositis 
NR 
 
 
NR 
Mean 7.1 mg/l, (range 
0 – 36) 
 
Median 2.98 mg/l 
(Kakai et al., 2003) 
 
(Enocsson et al., 2014) 
Coronary Heart 
Disease NR 
1.75 ±5.3mg/l 
 (Danesh et al., 2004) 
Myocardial 
infacation 
Tissue bound NR (Habersberger et al., 2012) 
AMD Tissue bound NR (Chirco et al.,, 2016). 
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(Slevin et al., 2017). Elevated mCRP levels were found within tissue of the frontal cortex 
regions of AD affected brains when contrasted against non-diseased brain tissue by Strang 
et al., (2012). In this study they were also able to illustrate the ability of amyloid plaques to 
dissociate pentameric to monomeric CRP (Strang et al., 2012). 
As shown, few studies have detected soluble mCRP within serum, it is as yet 
unclear whether mCRP circulates freely within the blood or if as indicated by some studies 
it is bound MP, or both, with most attributing it to co-localisation with diseased tissue or 
circulating microparticles. In addition to Wang et al’s 2015 paper, Williams (2017) 
research detailed the detection, isolation and quantification of soluble mCRP within serum 
samples from a cohort of patients identified as having high baseline pCRP levels. Serum 
CRP was isolated by PC affinity column and mCRP separated via FPLC, enabling 
quantification by ELISA. In this study the solubilised mCRP detection levels were between 
0.04 mg/l and 3.52 mg/l, however this followed concentration of the FLPC fractions 
(Williams, 2017). 
In their 2016 study, Crawford et al investigated plasma levels of endothelial cell 
microparticles found located in association with mCRP with results indicating a correlation 
to increased peripheral artery disease. This study also observed soluble free mCRP and 
suggested differing biological effects dependent on the manner in which it circulated the 
blood stream (Crawford et al., 2016).  
There is greater focus and wealth of research associated with auto-antibodies 
directed towards mCRP present within SLE patient serum than that of mCRP itself. Whilst 
pentameric CRP has long been associated with RA pathogenicity, and a monomeric CRP 
isoform, or auto-antibodies directed towards it, associated with SLE pathogenicity - there 
is little research investigating the presence of monomeric CRP within RA patients. A study 
by Shi et al., (2014) looked at the association of mCRP with lesions in differing disease 
 
 
Chapter 5.0 Detection of CRP within Human Serum Introduction 
 205 
models. The tissue sites chose included skin tissue of a discoid lupus erythematosus patient 
in the active phase showing mCRP but not pCRP presence and knee joint synovium tissues 
of a rheumatoid arthritis patient which also showed the presence of mCRP and not pCRP 
within the cytoplasm of synovial cells. It was suggested the implication of this finding 
were cellular uptake of mCRP. In addition to these results tissue taken and stained from 
patients with ulcerative colitis, Hashimoto’s thyroiditis, and lupus nephritis also showed 
negligible pCRP but the presence of mCRP, with suggested features of cell and arteriole 
associated expression. It is interesting that these tissues are taken from various locations 
across the body regardless of tissue type indicate co-localisation of mCRP and not pCRP 
within inflammatory sites, suggesting mCRP is perhaps the predominant isoform found 
within local inflammatory processes (P. Shi et al., 2014)(Shi et al., 2014). 
5.1.3 Experimental Aims 
 
To enable meaningful quantification and analysis of mCRP and pCRP within RA 
patient serum it was essential to develop an effective protocol for the identification of CRP 
isoforms. The overall aim was to design an ELISA assay capable of accurately identifying 
and quantifying isoforms of CRP where present within RA patient serum. The 
identification of such would allow greater understanding of RA and the role of both 
pentameric and monomeric CRP play within this inflammatory disease. Rheumatoid 
arthritis is characterised by high levels of serum CRP, which are elevated during flare and 
reduced in response to corticosteroid treatment. Little research has occurred investigating 
the conformational nature of elevated CRP and if, as in several other diseases, it is actually 
found to be at least in part monomeric. An ELISA assay capable of overcoming the 
suggested spontaneous dissociation of pentameric CRP must be developed, allowing 
accurate differentiation between serum mCRP and pCRP.  The successful development of 
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this assay will allow full and rigorous investigation as to whether monomeric CRP was 
present within serum and if it was found to be higher or lower within the RA patient or 
control group serum. This comparison to non-inflammatory disease control serum may aid 
further study as to whether monomeric CRP is pro or anti-inflammatory in nature.  
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5.2 Materials and Methods 
5.2.1 Ethical Application 
 
Prior to collection of patient samples and experimental procedure took place, both 
peer review and ethical research committee approval was sought. This oversight ensured 
the soundness of the study aims and assessed risk to both participants and researcher. The 
review process and ethical application are detailed within section 2.3.1.  
5.2.2 Acquisition of Human Serum Samples 
 
Upon recruitment of a patient to the study and a signed and dated consent form 
provided, a qualified phlebotomist at the Haywood Rheumatology Hospital drew venous 
blood, following their internal clinical care protocols. Samples were collected and 
processed as detailed within section 2.3.2.  
5.2.3 ELISA Quantification of Human Serum Samples 
 
Detection of pentameric CRP within patient serum samples was determined by 
ELISA using a commercially available sandwich ELISA assay kit (R&D systems Human 
CRP DuoSet ELISA) as described within section 2.3.8. Monomeric CRP was detected by 
an optimised sandwich ELISA using a specific anti-human mCRP detection antibody also 
described within section 2.3.8.  
5.2.5 Western Blot Analysis of Human CRP 
 
Native PAGE gels were run as described in Chapter 2, section 2.3.7, with buffers 
and components described within Tables 2.4, 2.5, 2.6 and 2.7. A representative set of 
samples were chosen from both the RA and control sample sets in order to confirm ELISA 
positive and negative results in both monomeric and pentameric assays. In order to allow 
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mCRP to run cleanly within the gel, the method described in section 2.3.7 using 1/20th SDS 
within both the sample and running buffer was used. Serum samples were diluted 1:100 
pCRP and 1:100 mCRP in deionised water and added to an equal volume of 2x sample 
buffer (containing 1/20th SDS). The western blot protocol and reagents used were as 
described in section 2.3.7, with the following amendments. Following the blocking step 
and once thoroughly washed, the primary antibodies diluted in BLOTTO were added. For 
mCRP detection, primary antibody 3H12- mouse anti-human mCRP at a concentration of 
1:50 and for pCRP detection, Clone 8 mouse anti-human CRP (Sigma) at a concentration 
of 1:2000, were added. Both antibodies were diluted in BLOTTO and the membrane was 
then incubated overnight upon a rocker at 4oC.  
Following wash steps the conjugated secondary antibody, rabbit anti-mouse IgG at 
a concentration of 1:30,000 was incubated for 1 hour at room temperature before once 
more washing prior to development with ECL reagent.  
5.2.4 Statistical Analysis 
 
Statistical analysis was carried out as described in section 2.3.10. During initial 
statistical analysis it became apparent that the male cohort data was affecting analysis and 
in many cases the combination of male and female data sets produced bimodal data making 
further analysis based on comparison of mean or median data unreliable. It was therefore 
necessary to subcategorise the data by gender into male and female groups before further 
detailed statistical analysis 
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5.3 Results 
5.3.1 Experimental Design 
All patients were recruited from a routine monitoring clinic at Haywood 
Rheumatology Hospital. Patients with an existing and confirmed seropositive RA diagnosis 
were identified from the monitoring clinic list and only those with a medically required 
routine blood test were approached with an explanation of the study remit and purpose. RA 
diagnosis had been previously documented via DAS28 score which consists of an 
assessment of the number of swollen joints out of 28 tested, the number of tender joints (of 
the 28), blood tests for both CRP levels and erythrocyte sedimentation rate (ESR) and 
lastly a ‘global assessment of health’ indicated by the patient. In addition to DAS28 scores, 
seropositive patients were positive for the presence of RFs and anti-CCP antibodies. Due to 
the nature of the clinic it was not possible to predict the number of suitable patients 
available within the time available for sample collection.  
The primary outcome for this study was to determine whether mCRP could be 
distinguished from pCRP and identified within human RA patient serum. It was possible to 
recruit 30 patient samples and 30 control samples within the time available.  
5.3.2 Enzyme Linked Immunosorbent Assay Analysis of Human CRP  
In order to quantify both monomeric and pentameric CRP levels, if present, within 
serum samples an ELISA system was developed. Analysis by ELISA allows a sensitive 
detection of low levels of protein in a specific manner. Each plate was processed in 
triplicate with samples also triplicated upon the plate, including calibration proteins added 
in order to produce individual calibrations for each assay. A representative example of both 
monomeric and pentameric calibration graphs are illustrated in figure 5.1.  
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Figure 5-1  The calibration graph for CRP ELISA assays. (a.) pCRP with a range between 
0 to 1000pg/ml. The line equation is y = 0.001x + 0.0177 and the R2 = 0.9968. b) The 
calibration graph for mCRP with a range of concentrations between 0 to 10ng/ml. The line 
equation is y = 0.0272x + 0.0075 and the R2 = 0.9892.  
 
Figure 5.1a and 5.1b illustrate representative calibration graphs for both mCRP and 
pCRP assays. The protein standards used were human pCRP purchased from Scripps Labs 
and mCRP produced in vitro using 2M urea dissociated pCRP as described in sections 
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3.2.2 and 3.3.2. The R2 indicates a positive correlation between absorbance and 
concentration indicating reliability within the calibration equation and therefore calculated 
protein values. The line equations generated from each calibration were used to determine 
concentrations of mCRP and pCRP respectively. The range of concentrations chosen for 
the mCRP calibration (0.00 to 10.00ng/ml) allowed detection of patient samples with a 
detection limit of 0.26ng/ml equating to a patient concentration of 0.027mg/l. The range of 
concentrations chosen for the pCRP calibration (0.00 to 1000pg/ml) allowed detection of 
patient samples with a detection limit of 17.68 pg/ml, equating to patient concentrations of 
0.028 mg/l and control concentrations of 0.035mg/l. Each plate contained a positive control 
which tested positive for either monomeric or pentameric CRP and a negative control 
which tested negative (results not illustrated). 
Results of the ELISA quantification of CRP, show that neither the RA nor control 
groups were found to contain samples categorised as elevated within the mCRP assay, 
when compared to the calculated threshold (≥ 0.143; mean + 2SD in 30 normal controls), 
although a greater frequency of samples with mCRP detected were found within the RA as 
opposed to control groups (Figures 5.2 and 5.3). As seen in Figure 5.2 all samples bar one, 
were found to contain detectible levels of mCRP with the highest recorded value at 
0.133mg/l (sample RA23) and the lowest positive value  0.053 mg/l (sample RA20). 
Results of the pCPR ELISA once again showed a significant difference in terms of pCRP 
concentration found between the entire mixed gender RA and control group samples as 
determined by Mann Whitney (P < 0.001, Figures 5.4 and 5.5). Further analysis of results 
is shown within Table 5.3 which details the median (IQR), range and calculated threshold 
for each group. 
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Table 5.3 A summary table illustrating calculated median (IQR), threshold and range 
(mg/l) for CRP detection assays as determined by ELISA. 
 
The higher than normal levels of pCRP in one of the control group (C14) was 
unexpected as this group was determined not to have an underlying inflammatory 
condition upon consent.  
However during initial statistical analysis it became apparent that the male cohort 
data was affecting analysis and in many cases the combination of male and female data sets 
produced bimodal data making further analysis based on whole group comparison of mean 
or median data unreliable. It was therefore necessary to subcategorise the data by gender 
into male and female groups before further detailed statistical analysis. The control group 
comprised of 7 males and 23 females and the patient group of 8 males and 22 females 
(female median 0.086, IQR 0.07499-0.093, male median 0.00, IQR 0.00). Once adjusted 
for gender there was no longer a significant difference found between mCRP levels within 
the separated male and female, RA and control groups (female P > 0.067, male P > 0.09).   
Due to the small sample size it is difficult to predict whether this  finding would be 
observed within the wider population, although power analysis suggests the sample size for 
 
Group 
 
Median (IQR) 
Threshold 
mg/l (Mean 
+ 2SD) 
% 
Samples 
with 
Detectible 
CRP 
Proportion of 
Samples above 
Threshold (mean 
control ± 2SD) 
Range 
mg/l 
 
RA mCRP 
0.098  
(0.080-0.105) 
0.143 
96.6% 
(29/30) 
0 of 30 0.053-0.133 
Control 
mCRP 
0.085  
 
(0.06-0.09) 
0.143 
80% 
(24/30 
0 of 30 0.058-0.131 
RA pCRP 
22.02  
(7.35-29.44) 
2.924 
100% 
(30/30) 
27 of 30 1.08-83.68 
Control 
pCRP 
0.285  
(0.118-0.947) 
2.924 
96.6% 
(29/30) 
1 of 30 0.06-5.41 
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females is adequate (female group sample size suggested minimum 9, power 0.852). 
However the male population is suggested to require a sample size of 50 to achieve a 
power level of 0.8.   These results when taken in conjunction with the fact that no samples 
in either RA or control groups exceed the higher mCRP threshold level, suggest a lack of 
significant difference between the RA and control group despite combined data findings. It 
is however necessary to determine the concentration levels across a much larger 
population, in order to assess whether the female value of P > 0.067 and male value of P > 
0.09 become significant. 
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Figure 5-2 Bar graph displaying monomeric human CRP concentrations within 30 RA group serum samples as determined by ELISA assay. The 
concentration for each sample is expressed in terms of mg/l. Samples were initially diluted 1:100 and measured in triplicate over 3 separate ELISA assays, 
data represents the calculated mean ± SEM. Capture antibody dilutions were 1:10,000, Primary antibody dilutions (mAb 3H12)  1:50 and secondary 
conjugated antibody 1:30,000. Error column represent the SEM for each sample RA group n=30. Samples RA23 – RA 30, highlighted green column = male, 
blue column = female. The dashed line represents upper normal mCRP level (≥0.143; mean + 2SD normal samples) n=3. 
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Figure 5-3 A bar graph displaying monomeric human CRP concentrations within 30 control group serum samples as determined by ELISA assay The 
concentration for each sample is expressed in terms of mg/l. Samples were initially diluted 1:100 and measured in triplicate over 3 separate ELISA assays, 
data represents the calculated mean ± SEM. Capture antibody dilutions were 1:10,000, Primary antibody dilutions (mAb 3H12)1:50 and secondary 
conjugated antibody 1:30,000. Error bars represent the SEM for each sample. Control group n=30. Samples C23 - C30 highlighted green column = male, 
blue column = female. The dashed line represents upper normal mCRP level (≥0.143; mean + 2SD normal samples), n=3. 
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Figure 5-4 A bar graph displaying pentameric human CRP concentrations within 30 RA group serum samples as determined by ELISA assay. 
The concentration for each sample is expressed in terms of mg/l. Samples were initially diluted 1:16000 and measured in triplicate wells, 
replicated in 3 individual ELISA assays, data represents the calculated mean and error bars represent ± SEM for each sample. RA group n= 
30.  Samples RA23 – RA 30, highlighted green column = male, blue = female. The dashed line represents the above normal pCRP threshold 
(≥2.924; mean + 2SD normal samples), n=3. 
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Figure 5-5 A bar graph displaying pentameric human CRP concentrations within 30 control group serum samples as determined by ELISA assay. The 
concentration for each sample is expressed in terms of mg/l. Samples were initially diluted 1:1000 and measured in triplicate wells, replicated across 3 
individual ELISA assays, data represents the calculated mean. Error bars represent ± SEM for each sample. Control group n=30. Samples C23 - C30 
highlighted green column = male, blue = female. The dashed line represents the above normal threshold (≥2.924; mean + 2SD normal samples), n=3.
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5.3.3 Western Blot Analysis of Human CRP 
 
In order to further confirm the presence of CRP within the samples, western blot 
analysis was carried out. All RA samples within the pCRP assay and those above an 
absorbance value of 0.1mgl/l within the mCRP assay were tested. Samples were first diluted 
1:100 pCRP and 1:100 mCRP assay, in deionised H20. A mouse monoclonal anti-human 
mCRP antibody (3H12), specific to the monomeric form of CRP, (Dr L. Potempa, College of 
Pharmacy, Roosevelt University, Illinois), was used in order to test samples for mCRP. A 
commercially available human CRP specific monoclonal antibody (Clone 8, Sigma), was 
used to determine the presence of pCRP. The Clone 8 antibody was pre-tested for detection of 
both forms of CRP with in vitro produced mCRP and human pCRP (Scripps Lab) and found 
to recognise both, see section 4.3.1. Thus indicating the recognised epitope for this antibody is 
conserved upon both isoforms of CRP, with mCRP retaining key structural integrity when 
compared with pCRP, this antibody detects both forms of CRP. Whilst monomeric CRP 
produced in vitro may not be structurally identical to potential forms found within human 
serum, it can be assumed that the epitope antibody 3H12 recognises, the terminal fragment 
(residues 147-206) of proteinase-cleaved CRP, will be apparent on in vivo samples too.  
 
 
 
 
 
 
 
 
 
 
Chapter 5.0 Detection of CRP within Human Serum Results 
 219 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6 A pCRP and mCRP detection western blot image showing a representative group 
of RA samples run on a precast gradient gel developed over 45 minutes. Patient samples from 
left to right (lanes 1-8), lane 9 is mCRP control (0.5µg), and lane 10 pCRP (0.5µg). Primary 
antibodies 3H12 (1:50 dilution) and Clone 8 (1:2000 dilution) were followed by secondary 
rabbit anti-mouse IgG (1:30000 dilution), n=2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
 
Figure 5-7 A pCRP and mCRP western blot image showing a representative group of samples 
run on a pre-cast gradient gel, developed over 2 minutes. Patient samples from left to right 
(lanes 1-8), lane 9 is mCRP control (0.5µg), and lane 10 pCRP(0.5µg). Primary antibodies 
3H12 (1:50 dilution) and Clone 8 (1:2000 dilution) were followed by secondary rabbit anti-
mouse IgG (1:30000 dilution), n=2. 
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All samples within the pCRP assay and those above an ELISA concentration of 
0.1mgl/l within the mCRP assay were subjected to native gel western blot analysis in order to 
confirm the presence of mCRP. Figures 5.6 and 5.7 show duplicated representative western 
blots of RA samples, developed over different times to allow the mCRP band to develop (as 
can be seen in Figure 5.6 and not 5.7). The blot tested for the presence of both mCRP and 
pCRP. Samples RA22, RA2, RA7, RA25, RA30, RA3, RA19 and RA16 were chosen. The 
levels of mCRP identified within the ELISA assay were very low and therefore not all 
previously identified as positive for mCRP were detected within the Western Blot analysis. 
Lane 9 of Figures 5.6 and 5.7, contains an in vitro produced monomeric control produced 
within the 2M urea dissociation trial described previously in Chapter 3. The monomeric band 
is consistent with that of mCRP when run in a gel system containing 1/20th normal SDS 
amounts within both the sample and running buffer, as described within 2.3.6.  Lane 10 of 
both Figures 5.6 and 5.7 contain 0.5µg pCRP (Scripps), which shows a double band within 
the gradient gel. It was found that within non gradient gels an amount of pCRP remains 
within the stacking gel and this is presumed due to mobility problems, and to be responsible 
for the dual bands seen within these gels. Size exclusion chromatography had previously 
confirmed the size of the pCRP supplied by Scripps to be 115kDa. It is evident that mCRP is 
apparent in lanes 7 and 8 (samples RA19 and RA16), however they were very faint. 
5.3.4 The Correlation between Human Monomeric and Pentameric CRP  
 
It would perhaps make sense that samples which contain higher levels of pentameric 
CRP may also contain higher levels of monomeric CRP and the same for samples with lower 
pCRP and therefore lower mCRP. In order to investigate a possible correlation between levels 
of pCRP and mCRP within both the RA and control groups, the ratio of each protein was 
analysed as a group and individually per sample.  There was no significant correlation found 
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between mCRP and pCRP within either the RA or control groups (P > 0.709, P > 0.646 
respectively). Figures 5.8a) and b) illustrate the lack of correlation between mCRP and pCRP 
in both sample groups. It is clear that whilst the control group contains one participant with 
higher than normal levels of pCRP, this was not matched by higher mCRP concentrations. 
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Figure 5-8 Scatter plot illustrating the correlation between human pentameric and monomeric 
CRP within serum samples as determined by ELISA (a) RA patient group. The line equation 
is y = 5E-05x + 0.0904, with R2 = 0.0015 showing no correlation between levels of 
monomeric and pentameric CRP P > 0.709. (b) Control group. The line equation is y =.0031x 
+ 0.0667 with R2 = 0.0081 showing a weak positive correlation between levels of monomeric 
and pentameric CRP P > 0.646. The concentration for each sample is expressed in terms of 
mg/l. Samples were initially diluted 1:100 for mCRP assays and 1:1000 control / 1:16,000 RA 
within pCRP assays, measured in triplicate wells, and replicated across 3 individual ELISA 
assays.  
  
Individual sample ratios can be seen in figures 5.9 and 5.10 which also illustrate the 
lack of correlation between pCRP and mCRP within each of the RA and control group 
 (a.)  
(b.)  
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samples. It does not appear within the RA group, apart perhaps from samples RA16 and RA7, 
that higher amounts of mCRP are found within samples containing higher concentrations of 
pCRP, nor are there lower levels of mCRP in samples containing lower pCRP (Figure 5.9). 
Within the control group slightly greater parity is seen in samples with lower levels of CRP, 
for instance samples C17, C21, C25 and C27 all of which have minimal amounts of both 
pCRP and mCRP. It is less clear within samples of higher CRP concentration whereby C15 
and C14 are closest to possessing high levels of both CRP conformations (Fig 5.10). 
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Figure 5-9 A Bar graph showing the ratio of pCRP/mCRP per patient sample within the RA patient group serum samples as determined by 
ELISA assay. The concentration for each sample is expressed in terms of mg/l. Samples were initially diluted 1:100 for mCRP assays and 
1:16000 for pCRP assays and measured in triplicate wells, replicated across 3 individual ELISA assays. Data represents the calculated mean n=3.  
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Figure 5-10  A bar graph showing the ratio of pCRP/mCRP per sample within Control group serum samples as determined by ELISA assay. The 
concentration for each sample is expressed in terms of mg/l.. Samples were initially diluted 1:100 for mCRP assays and 1:1000 for pCRP 
assays and measured in triplicate wells, replicated across 3 individual ELISA assays. Data represents the calculated mean, n=3. 
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Whilst there are few apparent individual sample correlations between monomeric and 
pentameric CRP, it is evident that mCRP forms a higher ratio of pCRP within the control 
group (5.91%), than within the RA group (0.27%) (Figure 5.11 a. and b.). This is despite 73% 
lower mean concentrations of mCRP within the control group than that found within the RA 
group. However the mean concentrations of pCRP within the control group is only 3.23% of 
that found within the RA group due to the much higher levels of pCRP within those samples. 
It is therefore likely this disparity is affected more by the significant reduction in pCRP than 
increase in mCRP. Whilst the levels of mCRP found within RA and control groups are low, 
they are significantly different to each other P < 0.01 (Figure 5.11c), with levels appearing 
independent of the level of pCRP found within each group. It is however apparent that the 
number of samples within the control group found to have no detectable mCRP (n=6) when 
compared to the RA group (n=1) may be responsible for the significant difference in levels 
determined, affecting the mean concentration across the group. However the remaining 
positive samples are generally of a lower concentration than those in the RA group, for 
example there are less samples within the control group which exceed 0.1mg/l (n=4), when 
compare to the RA group (n=12).  
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Figure 5-11 A bar graph illustrating the difference in mean concentrations between mCRP 
and pCRP, in RA and control groups. (a) Illustrates the difference between mean levels of 
pCPR and mCRP within the RA group of which mCRP formed only 0.27% of pCRP levels. 
(b) Illustrates the difference between the mean levels of pCRP and mCRP within the control 
group of which mCRP formed 5.91% of pCRP levels ± SEM. c) Illustrated the difference 
between mean levels of mCRP within the RA and control groups P < 0.01, n=3. 
5.3.5 The Effect of Gender on Serum CRP Levels 
 
In order to ensure no bias was present towards the effects of gender between the 
samples, groups were subcategorised to carry out analysis by sex. It was evident that a 
significant difference was found between RA and control mCRP levels within the entire 
(a.) (b.) 
(c.) 
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cohort, but Figures 5.2 and 5.3 shows the effect of splitting the group (blue bars represent 
female and green bars male samples). A lower proportion of male subjects in the control 
group were found to have mCRP within their serum (42.85%, n=7) than females (91.3%, 
n=23), indicating control males are less likely to have circulating mCRP than females. Within 
the RA group this deference is less pronounced (males with mCRP 87.5%, n=8, females 
100%, n=22). 
The calculated upper normal range threshold for male subjects was 0.0725 mg/l (mean 
+ 2SD normal samples); two of the control samples together with six of the RA samples are 
above this level suggesting higher levels of mCRP present. When the frequency of elevated 
mCRP male samples was compared by Х2 analysis this was found not to be significantly 
different (P > 0.072). Although the small sample size (male RA n=8, control n=7) makes it 
difficult to assign any influence to sex, and the inference drawn from these results can not be 
projected upon the wider population. However there is a visual difference between the 
profiles illustrated, suggesting possible sex related differences within mCRP concentrations. 
Analysis between female RA and control group mCRP concentrations found no significant 
difference (P > 0.068), there was also no significant difference between male RA and control 
groups (P > 0.093). 
5.3.6 The Effect of Age on Serum CRP Levels 
 
Whilst it is apparent that no significant correlation exists between the individual 
sample concentrations of monomeric and pentameric CRP, further analysis sought to reveal 
whether age bore influence over the CRP levels within samples. A Spearman’s rank 
correlation was carried out enabling assessment of age as a variable in both RA and control 
groups. The RA group ages ranged between 24 and 79 years (mean 62.7 years), with 90 % or 
participants aged 50 years or above. The control group ages fell between 26 and 79 years 
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(mean 46 years), with 44% aged 50 or above. As can be seen in  figures 5.12 a)  and b)  there 
is no significant correlation between age and mCRP in either the RA or control groups, 
although a slight trend towards lower mCRP levels with age is visible. There is a difference 
between the RA and control groups when pCRP serum concentrations are considered. Figures 
5.12 c) and d) show the effect between age and pCPR levels, which are slightly reduced as 
age progresses in the RA group and slightly raised within the control group, however neither 
of these correlations are significant P > 0.05. 
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Figure 5.12 A scatter plot illustrating the correlation between CRP mg/l and age as determined by ELISA. a) mCRP vs Age RA group. b) mCRP 
vs Age control group. c) pCRP vs Age RA group d) pCRP vs Age control group. A Spearman’s rank correlation showed no significant 
correlation P > 0.05 between age and concentration of CRP in all groups. n = 30, mean age RA group 62.73 years, mean age control group 46 
years. 
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Whilst Figure 5.12 considered the correlation of CRP and age across the entire RA 
and control group, in order to determine if sex influenced the data, these groups were further 
split into male and female cohorts. Although the male group size is too small to draw 
significant inference (RA group n = 8, mean age 65.88, range 56 -77 years; control group n = 
7, mean age 46.14, range 30 -73 years), it is interesting to note that where results for mCRP in 
the RA group split by sex, Figure 5.13a and c, are broadly similar in profile to the combined 
male/female RA results seen in figure 5.12a and c. When results for pCRP are considered, 
levels for males appear to drop steeply with age, although not significantly P > 0.08 in 
contrast to female results which show a slight and non-significant decline, (Figure 5.12b and 
5.12d). The trend shown in Figure 5.13d is heavily influenced by just 2 males aged >75 years, 
with lower pCRP than others in that group, however their equivalent concentrations of mCRP 
are not reduced in a similar manner. The profile for male RA group serum mCRP 
concentrations (Figure 5.13c) remains similar in nature to that of the combined gender RA 
group (figure 5.12c). Therefore whilst age appears to have influenced the level of pCRP in 
RA group males, it has not had the same effect on the equivalent concentration of mCRP. The 
profile of age and serum level of female mCRP and pCRP are little changed (Figure 5.13a and 
b) from those in the combined gender group (Figure 5.12a and b); although as the 
predominant group within the original combined gender group it is unsurprising that these 
remained similar. A slight but insignificant rise in mCRP is apparent in older males and also 
in females, with both sexes sharing a trend of declining pCRP in older participants. 
Within the control group a different observation can be considered as the 
concentration of mCRP rather than pCRP is more directly impacted. A sharp, but insignificant 
drop in concentration levels of mCRP within the male sub group (P > 0.26) and to a lesser 
extent pCRP (figure 5.13c and d) was observed as age advances, however this was not found 
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to be the case within the female sub group (figure 5.14a and b), wherein both mCRP and 
pCRP concentrations were found to rise with age (P > 0.328).  
It appears that age may influence the concentration and profile of CRP differently 
between males and females and again this changes between the RA and Control groups. Male 
and female subsets both see a slight rise in mCRP and reduction in pCRP levels with age 
within the RA group. Within control samples the correlation of mCRP vs age results diverge, 
with female levels of mCRP rising with age and males falling, this is mirrored within the 
pCRP results.  
It appears that as non RA women age their levels of both mCRP and pCRP increase 
slightly whereas the level in males may decrease. When combined, the control population 
shows a gradual increase in pCRP with age and little change to mCRP levels; however the RA 
population appears to show a slight reduction in both. 
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Figure 5.13 Scatter plots illustrating the correlation between serum CRP mg/l and sex in the RA group as determined by ELISA.  a)  The 
correlation between mCRP and age in females. b) The correlation between pCRP and age in females. c) The correlation between mCRP and age 
in males and d) The correlation between pCRP and age in males.   n=8 male samples, mean age 65.88 years, n=22 females, mean age 62.26 
years. 
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Figure 5.14 Scatter plot illustrating the correlation between serum CRP mg/l and sex in the control group as determined by ELISA.  a) The 
correlation between mCRP and age in females. b) The correlation between pCRP and age in females. c) The correlation between mCPR and age 
in males. d) The correlation between pCRP and age in males. n=8 male samples, mean age 65.88 years, n=22 females, mean age 62.26 years. 
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5.4 Discussion 
5.4.1 Serum mCRP and pCRP Detection in RA and Control Samples 
ELISA analysis was carried out upon all samples within both RA patient and 
control sample groups and confirmed positive levels of pCRP in all 30 of the RA and all 30 
of the control samples. Statistical analysis prior to splitting the cohorts into gender subsets, 
found a significant difference (P < 0.001) in concentration levels of pCRP detected 
between the RA and control groups, (RA group pCRP mean 22.85mg/l, control group 
pCRP mean 0.742mg/l). Detectable levels of mCRP were found in 29 of the 30 RA 
samples and 24 of the 30 control samples, (RA group mCRP mean 0.092mg/l, control 
group mean 0.069mg/l) once again a significant difference was found P < 0.01. 
Comparison between the groups highlighted some unexpected results, although the levels 
of pentameric CRP were significantly lower within the control group than RA and broadly 
in line with reported normal range of 0.1-3mg/l (Pearson et al., 2003), there was less 
difference detected between the monomeric levels quantified within the two groups. This 
suggests that although the concentration levels of pCRP are universally higher than mCRP 
across all samples, a clear increase is observed within the RA group. There is less 
difference within mCRP concentration between an RA state and non RA control state, 
although significant.  The difference found may have been driven by the higher number of 
negative control samples (n=6) when compared to RA (n=1), however there are fewer 
samples abover 0.1mg/l within the control group (n=4) than the Ra (n= 12), suggesting the 
level of mCRP within positive control samples is generally lower than that found within 
the RA group. The level of mCRP determined within our study only considers that detected 
within the serum and is not representative of that which may be found within the synovial 
tissue itself. There is evidence of mCRP co-localised within inflammed tissue of many 
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disease states including the myocardium of acute coronary syndrome patients (Wang et al., 
2015), the relevant brain regions of patients suffering post stroke inflammation (Slevin et 
al., 2015)  and the choroids of donors with a high risk of age-related macular degeneration 
(Chirco et al., 2016). It is therefore possible that mCRP may occure in the locality of 
inflammed tissue within RA patients and that a greater difference between these subjects 
and a matched control polupation could be found. 
5.4.2 Western Blot Analysis  
 
Western blot analysis confirmed the presence of pCRP within all 30 patient 
samples, which corresponded to ELISA results, aligning to the band profile of pCRP as 
shown in Figures 5.6 and 5.7, lanes 10 and 9 respectively. The stock pCRP purchased from 
Scripps had previously been determined as 115kDa following size exclusion 
chromatography and this together with antibody recognition within the western blot and 
ELISA led to confidence that these bands were pCRP. Corresponding bands in the position 
expected of mCRP (23kDa) were not confirmed within all patient samples. ELISA 
determined the presence of mCRP within 29 of the 30 RA samples, however at very low 
amounts ≤ 0.132mg/l. The western blot was able to confirm a band at 23kDa for both 
RA16 and RA19 (Figure 5.6), however the blot had to be exposed for 45 minutes in order 
for the bands to become visible, a second image showing a reduced time (Figure 5.7) could 
not positively identify either samples for mCRP content. An ELISA is able to detect much 
lower concentrations of protein than a western blot and this is evident within the results 
presented, highlighting the difference in sensitivity between these two techniques. The 
amount of loaded protein per technique for sample RA23, identified as containing the 
highest concentration of mCRP, was 13ng/well within the ELISA and 13pg per lane within 
the western blot.  
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5.4.3 Correlation between pCRP and mCRP  
 
ELISA results show that not only were mCRP levels significantly lower than those 
of pCRP but that the distribution does not correlate uniformly to pCRP across the samples. 
However, mCRP has been detected within the serum, and the levels determined appear to 
support previous findings by Wang et al., (2015) who detected levels of mCRP within 
serum between 0.019 mg/l and 0.037 mg/l. These concentrations were considerably lower 
than the higher range reported by Williams (2017), who demonstrated between 0.04mg/l 
and 3.52mg/l mCRP within samples taken from patients identified with high sera pCRP. 
The mCRP within Williams’ study was first purified from serum by affinity 
chromatography and further concentrated and this concentration step may explain the 
difference in detected concentration between this and our study result (Williams, 2017). 
A correlation between concentrations of mCRP and pCRP within individual 
samples, had one been found, forming reduced but corresponding concentrations of mCRP 
to those of pCRP, may have implied the soluble mCRP detected within our serum samples 
were of pentameric origin resulting from degradation or dissociation. However this was not 
the case as no correlation was detected between RA (P > 0.708), or control (P > 0.646) 
sample mCRP and pCRP levels. It is possible that elements of the mCRP identified within 
both patient and control samples may have originated from circulating pentameric CRP 
through local dissociation, which has been well described within recent literature (Ji et al ., 
2009, Thiele et al., 2014, Eisenhardt et al., 2009).  CRP is produced within hepatic cells 
following inflammatory cytokine signalling, but CRP has also been shown to be produced 
systemically, following local production within a variety of cells, including epithelial cells 
of the respiratory tract, renal epithelium (Gould et al., 2001, Jabs et al., 2003), human 
coronary artery smooth muscle cells, human adipocytes (Calabro et al., 2005), inflamed 
human striated muscle, atherosclerotic plaque and infarcted myocardium (Thiele et al., 
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2014). CRP mRNA has been identified within both normal and plaque tissue of 
atherosclerosis patients (Yasojima et al., 2001).  
Previous literature has suggested circulating pCRP dissociation can occur via 
membrane binding and insertion, with Pneumococcal C-polysaccharide a phosphocholine 
containing molecule, polylysine and the lysophosphatidylcholine exposed on activated cell 
membranes and activated platelets each described as capable of inducing pCRP 
dissociation upon binding  (Ji et al., 2009, Wang and Sui 2001, Thiele et al., 2014, 
Eisenhardt et al., 2009). Additionally Strang et al., (2012) reported dissociation via 
amyloid plaques within cortical inflammation in Alzheimer's disease. Whilst pCRP 
primarily binds cells via FcJRIIA (CD32), mCRP has been associated with binding of  FcJ-
RIII (CD16) (Bharadwaj et al., 1999, Devaraj et al., 2005), however it is also suggested 
that membrane insertion via cholesterol rich lipid rafts may be a key area for anchorage 
(Eisenhardt et al., 2009, Li et al., 2014,). This theory is supported by Ji et al., (2009) who 
further suggested pCRP dissociation occurs during CRP interaction with cholesterol during 
membrane insertion.  
During periods of acute or chronic inflammation associated with RA prognosis, it is 
likely that high levels of circulating CRP are in constant contact with activated cell 
membranes or platelets, with dissociation possible within the local inflammatory 
environment. A hydrophobic microenvironment has also been suggested as a key factor in 
CRP dissociation; mCRP produced via dissociation in vitro is less soluble in nature than 
the pentamer but retains its ability to bind phosphocholine (Williams, 2017), therefore the 
slightly hydrophobic environment of cell membranes may enhance possible mechanical 
means leading to the rapid subunit dissociation described previously in literature. 
Whilst dissociation of circulating or locally expressed pentameric CRP within the 
inflammatory environment of RA goes some way to explain the presence of mCRP within 
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the serum of RA suffers, it does not provide a complete picture. Levels of monomer do not 
correlate with pentamer in either RA or control subjects, with an uneven distribution across 
each group.  There is not therefore a universally plausible method or mechanism capable of 
supporting the wide variety of monomer concentrations observed across the sample groups. 
Additional factors may influence structural changes to pCRP or possibly expression of 
monomeric rather than pentameric CRP may be responsible. However, the feature uniting 
many studies into the presence of mCRP within diseased tissue or serum is that of 
inflammation, be it within amyloid plaques of Alzheimer’s, atherosclerosis or RA itself. 
Rheumatoid arthritis as an inflammatory disease is associated with high levels of 
comorbidity. In their 2013 cross-sectional study of 4586 patients, Dougados et al., (2014) 
described the most frequently associated diseases as depression, 15%; asthma, 6.6%; 
cardiovascular events (myocardial infarction, stroke), 6%; solid malignancies (excluding 
basal cell carcinoma), 4.5%; chronic obstructive pulmonary disease, 3.5% (Dougados et 
al., 2014). 
The pathophysiological conditions often associated with many of these diseases 
may well provide the conditions required for either increased pCRP expression or possible 
dissociation, with inflammatory conditions including atherosclerosis and heart disease 
correlated to high levels of CRP. Activated platelets and endothelial cells together with 
circulating microparticles are a common pathological occurrence within these diseases and 
are known to dissociate CRP (Eisenhardt, Habersberger, Murphy, et al., 2009). Identified 
inflammatory conditions may be responsible for mCRP occurring within a patient sample, 
but not samples of the control group. It is possible that participants of both the control and 
RA groups have additional underlying or undiagnosed disease, which may account for an 
independent increase of either CRP form, or count towards synergistic effects from 
combined factors. 
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The presence of mCRP within the control group, even at statistically lower levels 
than those of the RA participants cannot therefore be fully explained by inflammatory 
environments or high levels of circulating pentameric CRP, in fact 93% of control 
participants fell within the normal pCRP range. However, studies have suggested that RA 
can be predicted within non-symptomatic / undiagnosed people several years before 
symptoms present. It is possible that some participants within this control group were 
exhibiting early signs of future inflammatory or autoimmune disease yet to be diagnosed. 
RA itself can be predicted several years in advance by the presence of certain proteins 
within the blood, although CRP is not one of them. A study in 2006, analysing blood donor 
samples donated before symptoms of RA became apparent, identified 93 people from a 
cohort of 138 who more than two years later went on to develop rheumatoid arthritis and 
whose blood contained anti-CCP antibodies, indicating a risk of future disease (Berglin et 
al., 2006). In another study 83 patients with confirmed RA, identified as previously 
donating blood between one and five years before symptoms of RA presented, were found 
to have anti-CCP antibodies and RFs within the samples, predating the onset of RA by 
several years (Rantapaa-Dahlgvist et al., 2003). 
These studies illustrate that a number of auto-antibodies appear in the preclinical 
phase of RA. Almost half of the RA patients identified had serologic abnormalities several 
years before the onset of symptoms. It is possible that some features of autoimmune 
diseases are a factor within dissociation of CRP, even within a presumed control 
population. It is however likely that just as pCRP has a recognised ‘normal’ baseline level 
below 3mg/l (Pearson et al., 2003) that mCRP may exhibit an equivalent ‘normal’ level, 
and that the levels identified within the majority of the control group of less than 0.143mg/l 
fall within this range. 
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Although no experimental evidence is available to suggest oxidation plays a role in 
pentameric CRP dissociation, it is theoretically possible within the inflammatory confines 
of an RA joint, that these conditions may in isolation or in synergy with as yet unknown 
action lead to CRP dissociation.  A key feature of the inflammatory environment within an 
RA joint is an increase in reactive oxygen species and oxidative stress involved within the 
pathogenesis of the disease (Biemond et al., 1984, Ozturk et al., 1999). The environment 
created by the highly reactive chemical species involved within oxidation has the potential 
to damage lipids, proteins and DNA within joint tissue. Lipid peroxidation, protein 
oxidation, DNA damage and impairment of the body’s enzymatic and non-enzymatic 
antioxidant defence system within RA patients were all recently reported (Mateen et al., 
2016). 
Key protein oxidation markers (significantly increased protein carbonyl and 
decreased sulfhydryl group levels) were found by Mateen et al., (2016) within the RA 
cohort plasma, alongside significantly low levels of non-enzymatic antioxidants (reduced 
glutathione and vitamin C). It is possible the oxidative environment found within RA joints 
may destabilise the pentameric structure of CRP, making it more vulnerable to previously 
mentioned dissociation factors.  Each CRP subunit contains an intra-subunit disulphide 
bond formed between Cys36 and Cys97 during oxidative folding. The subunit first folds 
spontaneously following protein expression and the correctly folded protein drives 
formation of the internal disulphide bond which is dependent upon binding of a stabilising 
calcium atom. The correctly folded subunits are then assembled around a central pore and 
held together with individually weak, but collectively strong, salt bridges and hydrophobic 
forces. It is possible that oxidative stress derived from high levels of reactive oxygen 
species is responsible for damage to the subunit and therefore the stability of pentameric 
CRP. The effects of a highly oxidative environment upon protein stability can be seen 
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within superoxide dismutase (SOD) which is itself vulnerable to oxidative attack within 
RA pathology. SOD forms a stable homodimer and binds with either zinc or copper ions, 
important for its function and also tertiary and quaternary structure (Drazen et al., 2016). In 
their 2016 study they were able to illustrate that oxidative stress could lead to impaired 
dimerization through oxidative modifications of interfacial residues (Drazen et al., 2016). 
Alterations to the body’s normal physiological state within disease progression may 
ensure the essential conditions required for mCRP creation. One factor within CRP 
dissociation is pH, with the normal physiological range tightly regulated to fall within pH 
7.35-7.45. Whilst pH4 trials within our own experimentation were able to elicit 
dissociation of CRP in combination with calcium chelation, it is not physiologically 
possible that this extreme environment exists extracellularly, although sites of 
inflammation are known to become more acidic in nature extracellular due to acidification 
considered due to lactate secretion from anaerobic glycolysis (Riemann et al., 2015, 
Rajamaki et al., 2013, Yasumasa Kato et al., 2013). CRP is able to bind a wider range of 
ligands within acidic than neutral or alkaline conditions and this in itself may facilitate the 
binding required for dissociation (Hammond, 2010; Salazar et al., 2014). Although pH 
alone may not be responsible for monomeric CRP, it could become important in addition to 
a combination of other described factors including mechanical action of lipid raft binding 
or oxidation. 
5.4.4 Age and Gender Effects on CRP Prevalence and Concentration 
 
Our data suggests that whilst it could be expected that as a population ages their 
level of serum CRP may increase, due in part to underlying health issues or inflammation, 
this was not found to be the case consistently across all the sample groups within this study 
as seen in Figure 5.12. RA can occur at any age but is more frequently diagnosed in people 
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aged 40-50 years (Haris, 1989;, Krane and Simon, 1986). There is a weak negative 
correlation between age and mCRP within the control figure 5.12b, and between both 
mCRP and pCRP within the RA group (Figures 5.12a and c respectively), however pCRP 
levels do rise with age within the control group (Figure 5.12d), albeit insignificantly, 
partially supporting this theory.  
It is possible that the difference in pCRP and age correlations between the RA and 
control groups arises due to the use of anti-inflammatory drugs within the RA group, with 
these responsible for a reduction in CRP level due to differences within the category of 
drug and usage period. It was proposed in a study by Innala et al., (2014), that dependent 
upon the age at diagnosis, either young onset RA (YORA) or late onset RA (LORA), 
different drug intervention pathways may be implemented. For instance LORA was found 
to be treated more frequently with corticosteroids and less frequently with methotrexate or 
biologics. YORA was more frequently associated with DMARD treatment.  Methotrexate 
(a DMARD) can have less effect on CRP, although only pCRP levels were monitored in 
historical research, (Aletaha and Smolen, 2002), than moderate to high levels of steroid 
treatments such as prednisolone, which have been found to significantly reduce patient 
CRP levels, again however, unknown effects within mCRP concentrations (den Uyl et al., 
2011; McConkey et al., 1973; Mysler et al., 2004). Evidence within these studies suggest 
that during treatment, CRP levels should reduce, due to the combination of RA drugs used, 
unless serum samples are taken during periods of RA flare. However, this appears not to 
consistently be the case. A study by Siemons et al. (2014) reported a significant association 
between ESR and CRP levels in RA, both of which increased with age (p < 0.001). This is 
supported by Zhoa et al., (2010) who also reported within their study based on a Chinese 
population that a correlation between CRP and age existed. Their study was representative 
of the generally lower levels of CRP found within Asian populations, which tend to be one 
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third to half that of Caucasian populations (Zhoa et al., 2010). The median level of CRP 
within Zhoa et al’s study was 0.55 mg/l (0.51 mg/l female and 0.61 mg/l male), levels 
found within the serum increased with age, from 0.42gm/l in the 18-29 age group, 0.64 
mg/l in the 50-59 age group, 0.82mg/l in the 60-69 age group and reached 0.98 mg/l within 
the 70-80 age group. The rise in CRP during aging was supported by Meyer in both males 
and females (Meyer, 2010), but was in contrast to another study which reported no 
correlation between CRP levels with age or sex (Feldman & Sbong 2014).  
Within our study, no correlation between age and CRP concentration was detected 
within the RA group in concordance with Felman & Sbong’s research (figure 5.14c), 
however figure 5.12d illustrates a slight increase in the control group pCRP concentrations 
as age increases.  This is however a small sample size in comparison Zhao et al’s study 
which drew data from 3133 participants. Their study used an unknown combination of 
antibodies with plasma analysed by immunonephelometry, it is therefore possible that only 
either pCRP alone, or a combination of both mCRP and pCRP were detected dependant on 
the antibody specificity used. 
Physiological changes occurring during the aging process may be partly responsible 
for this finding. Proinflammatory cytokine IL-6, known to instigate CRP expression and 
generally expressed at low levels, rises in response to inflammation or trauma and is down 
regulated by either oestrogen or testosterone. As the general population ages, menopause 
or andropause occur and levels of the downregulating hormones drop, thus allowing higher 
levels of IL-6 to be expressed. It is possible that the increased levels of CRP found within 
the control population during aging occurs partly in response to the effective reduction of 
both oestrogen and testosterone, resulting in higher levels of IL-6 known to instigate CRP 
expression (Daynes et al., 1993).  
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Whilst our study was in general concordance with the age related changes to CRP 
levels reported within literature, differences between CRP concentrations in male and 
female sub groups were not in universal alignment. Higher control group levels of pCRP 
were recorded in the female group (mean 0.80mg/l), in comparison to the male group 
(mean 0.54mg/l). Many studies, especially those based on Asian populations report higher 
CRP levels within males (Zhoa et al., 2010), however in Western populations studies have 
found the reverse with higher levels of CRP in females (Meyer 2010). Within our study the 
RA male group pCRP mean levels were higher than females, (male 24.70mg/l, female 
21.79mg/l), which is supported by Siemons et al., (2014) who reported that in early RA 
men had 1.2 times higher CRP levels than women. There is a significant difference (P < 
0.035), between the frequency of samples with detectable mCRP in the male and female 
control group, of seven male samples three were negative for mCRP (42.9%), with only 
two of 23 females negative (8.7%). There was no significant difference between male or 
female occurrence of mCRP within the RA group, one of the seven control males was 
negative for pCRP (14.3%), as opposed to none of the 23 females. 
When considered further and samples assessed by both sex and age, it is apparent 
that some differences exists between the way male and female serum levels of CRP 
respond to ageing. Whilst both male and female mCRP levels within the RA group show a 
limited increase as they grow older (figure 5.13a and c) and both show declining pCRP 
values with age (figure5.13b and d), pCRP concentrations within the male group show a 
more pronounced decline (figure 5.13d). The two eldest subjects within this male group 
skew the pCRP results as they have much lower concentrations than other members of that 
group. Conversely their mCRP levels are amongst the highest within that group (figure 
5.13c), suggesting mCRP and pCRP could be affected differently and therefore 
independently of each other, age and possibly also RA drugs or pro-inflammatory 
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cytokines such as IL-6. Within the control group mCRP and pCRP rise slightly in the 
female subset with age, however both isoforms of CRP reduce with age in the male group, 
mCRP falling to a greater extent.  
Whilst the RA group male and female subsets follow similar profiles, with little 
difference between the sexes in either the mCRP or pCRP response to age (figure 5.13a-d), 
this differs within the control group. The responses of control male and female subsets to 
CRP against age diverge, with female levels of both CRP isoforms rising and male levels 
falling. These differences between the male and female groups are interesting when the 
incidence of RA diagnosis in women, reported to be four to five times higher than males in 
the under age 50 group and two times higher in the 60-70 group (Kvien et al., 2006), is 
considered. However, the sample number of males and females within this study does not 
fully reflect these ratios and any significance within these results are further undermined by 
the small number of subjects within each group. It is an area which invites further work 
with a larger sample group to discover whether this observation holds true for the wider 
population.  
Whilst many studies are in agreement that mCRP exists in vivo, it is often difficult 
to compare their findings due to irregularities within research methods. Studies have 
indicated that pCRP can spontaneously dissociate upon binding to a fixed surface such as 
an ELISA plate (Eisenhardt, 2011; Sjowall et al., 2012, 2013). This variable was avoided 
within our study by using capture antibodies within the ELISA protocol, thus retaining 
conformation of CRP isoforms within a sample. However, some previous studies have 
used a methodology whereby CRP is bound directly to the plate, suggesting the 
identification of CRP isoforms within these studies may be unreliable. It is also possible 
that some antibodies used within previous studies may have been capable of recognising 
both CRP conformations for instance Clone 8 (Sigma), or pCRP alone, therefore 
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preventing the identification and quantification of possible mCRP within a sample. It is not 
unreasonable to consider that in some cases existing research may have misidentified 
which form of CRP they reported on. 
It is possible that some of the confusion between the pro or anti-inflammatory 
effects of CRP reported within literature is resultant from the lack of specific detection 
properties within methods used to determine study results. The manner in which mCRP 
circulates the system, either freely soluble or bound to microparticles for instance, and the 
sensitivity of different detection methods can obviously affect results determined. As 
described previously, not only is it possible that some studies fail to address the 
nonspecific nature of commercially available antibodies used within their assay, but also 
the method itself may not identify both forms of CRP reliably and selectively when 
measuring. Crawford et al., (2016) considered this point when contrasting results gained 
from a high-sensitivity CRP assay which did not detect any form of CRP bound to 
microparticles, and flow cytometry which did. This group also contrasted the effectiveness 
of the same commercially available CRP ELISA kit (R&D systems) used within our 
research, and also found it unable to detect monomeric CRP, detecting the pentameric form 
only. A Sekisui automated hsCRP assay again failed to measure mCRP within an assay 
indicating how a variety of techniques available do not detected the presence of mCRP 
(Crawford et al., 2016). It is likely that many clinical or research settings are unable to 
detect mCRP effectively and if this form of CRP is shown within future RA studies to be 
important within disease progression or diagnosis, a reliable and accurate system of 
quantification should be developed and used. 
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5.4.2 Conclusion 
Whilst the existence of monomeric CRP has previously been reported within 
scientific literature generally associated with diseased tissue or membrane bound, research 
results described within this chapter indicate its presence within the serum of both RA 
patient and control samples. This soluble form of mCRP has successfully been identified in 
29 of the 30 patient samples as well as 24 of 30 control samples and quantified by ELISA 
analysis. It has been shown that pCRP sample concentration does not influence mCRP 
concentration and no significant correlation between these two values was apparent. Age 
alone does not influence the presence of either isoform of CRP within serum samples of 
the RA or control group. However, there appears to be a weak but not significant 
interaction when age and sex combined are taken into account, with older control group 
males displaying lower levels of both monomeric and pentameric CRP, and older RA 
group males showing reduced pentameric CRP  
Little research has taken place within rheumatoid arthritis considering the effects or 
presence of a monomeric form of CRP. To our knowledge there are no studies which 
consider the effect of age upon the level of mCRP within this disease nor have quantified 
its presence. The levels of monomeric CRP identified are low and indicate a baseline level 
present within the general population in addition to a small but significant increase in level 
within this inflammatory autoimmune disease. It is clear that a consistent approach and 
careful consideration of ELISA protocol and antibody choice are important within both a 
research and diagnostic setting in order to correctly identify CRP isoforms present in 
serum.  
Although these results have not been correlated to disease severity and progression 
there are clear differences in RA patients when compared to controls, in the concentration 
of pCRP and mCRP when both age and sex are taken into account, although due to sample 
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size these results are not significant in nature. Our research indicated that mCRP is present 
in RA patients and suggests the importance of developing an accurate system of mCRP 
determination, allowing fast and reproducible measurement within a clinical setting. 
5.4.5 Future Work 
 
Future work should focus on the link between mCRP concentrations and disease 
severity and progression within RA to elucidate whether its effect are pro or anti-
inflammatory in nature and also if the suggested baseline level is maintained.  These 
findings should also be correlated with the profile, class and dose of RA prescriptive drugs 
to further assess these factors. Whilst it is clear that mCRP is present within RA patient 
serum it is unclear as to the origin of the protein, be it due to pCRP dissociation within the 
local inflammatory conditions, systemic circulation or through local expression of the 
monomer rather than pentamer. Studies investigating the origin of monomeric CRP may 
help further our understanding of both the protein and RA disease progression. Our study 
has investigated mCRP within serum, but synovial fluid may prove an interesting focus 
area for future examination due to the milieu of inflammatory and immune proteins found 
within it. 
The sample size within this study has not allowed all findings to be suggestive of 
those within a larger population and therefore a continuation of this pilot research within a 
larger population is important. Males represented just over 25% of the population within 
this study, they are therefore underrepresented against the wider population, future research 
should ensure a relevant proportion of male subjects are included in order to examine 
further the differences between male and female CRP levels. If this picture is repeated in a 
larger sample size the influence of sex may aid in future understanding of the causes and 
risk factors for this autoimmune disease.  
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Chapter 6 - Detection of Anti-CRP Auto-antibodies within RA 
Serum 
6.1 Introduction  
6.1.1 Overview 
 
As a well characterised autoimmune disease, serum auto-antibodies play a key 
diagnostic role within the identification and development of RA. Some of these auto-
antibodies are well characterised and understood, however the presence of mCRP and auto-
antibodies against it have not been well studied within this disease. Within this study the 
presence of serum IgA, IgM and IgG auto-antibodies directed against either monomeric or 
pentameric CRP were studied within the 30 RA and 30 control subjects in order to explore 
the relationships between these proteins and either CRP isoform and investigate their 
potential association with RA. Auto-antibodies are antibodies that react with self-antigens, 
which may comprise of proteins, carbohydrates, nucleic acids or lipids. The body, during 
normal antibody production has a failsafe system that determines whether the antibodies 
produced by B cells following the presentation of an antigen, have self-recognition 
properties or not. If they are determined to be auto-antibodies they are destroyed. Put 
simply a lymphocyte undergoes a process whereby the lymphocyte-antigen interaction 
instigates a process ending in either the physiological elimination (negative selection) of 
that T or B cell or in clonal anergy, in which the lymphocyte is functionally inactivated. 
(Nossal,1994). This process when working effectively prevents autoimmunity, however in 
some cases an antigen-lymphocyte interaction may not illicit full immunological tolerance. 
Although a weak recognition of a self-antigen may not in all cases initially cause a 
response within the body, this may change should the physiological concentration of that 
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antigen rise. In this case a B or T cell that would previously have ignored the self-antigen 
may now begin to respond to it (Nossal, 1994). 
Within autoimmune disease the system ensuring deletion or silencing of B cells 
generating self-recognition antibodies breaks down and antibodies with the ability to 
recognise the body’s own proteins are allowed to travel through the body. Organ specific 
autoimmune diseases, including myasthenia gravis, thyroiditis, type 1 diabetes mellitus, 
primary biliary cirrhosis or pemphigus (Elkon and Casali 2008, Lesage and Goodnow 
2001), are typified by antibody binding of an injury to a target organ. It is suggested that 
these auto-antibodies may be initially stimulated by inflammation within the target organ, 
or due to molecular mimicry (Cusick et al., 2013). Within systemic autoimmune diseases 
such as RA and SLE, the auto-antibody reacts with non-cell-type specific molecules such 
as phospholipids, nucleoprotein and cell surface antigens (Elkon and Casali, 2008), 
therefore capable of affecting multiple organs. Some auto-antibodies instigate complement 
together leading to inflammation, as seen in the complement mediated damaged to kidneys 
of patients with systemic lupus and lupus nephritis and foetal loss associated with 
antiphospholipid syndrome (Cervera et al., 2002; Cochrane and Koffler, 1973; Wendell et 
al., 1999). However the presence of auto-antibodies in the healthy population has also 
attracted attention and it is now suggested that these may play a protective role, perhaps as 
a mechanism for debris clearance (Nagele et al., 2012). Auto-antibodies are however, a key 
feature of disease pathogenesis and diagnosis within RA, this chapter seeks to investigate 
whether mCRP is a target of self-directed antibodies. 
6.1.2 Antibody Generation  
 
Antibodies that react with self-antigens also occur in normal healthy individuals 
and are termed natural antibodies. This class is composed predominantly of IgM 
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antibodies, which are produced during a primary antibody response in the absence of 
activation by a specific antigen and are polyreactive, they bind to several antigens. These 
antibodies possess broad specificity but a low to moderate affinity to self and foreign 
antigens and are an important bridge between the innate and acquired immune system 
components  (Boes, 2000, Elkon and Casali 2008). Natural antibodies have been studied 
for over two decades and much of this research has focused on natural IgM antibodies, 
originally studied in experimental animals deprived of any potential antigens and 
exhibiting similar reactivity profiles (Haury et al., 1997; Hooijkaas et al., 1984,). Natural 
antibodies may play a useful and conserved role within the removal of cell debris during 
inflammation and those directed against pro-inflammatory cytokines may protect against 
uncontrolled inflammatory cascades and are shown to be universally present in human 
serum (Madi et al., 2009). 
Antigen specific antibodies are secreted by plasma cells in response to antigen 
presentation by cells such as macrophages and dendritic cells, both of which recognise a 
pathogen through a range of pattern recognition receptors. Stimulated B cells then undergo 
somatic hypermutation (Berek et al., 1991; Kelsoe et al., 1991), followed by clonal 
selection, becoming a long lived and antigen specific antibody secreting cells (Tarlington 
and Smith, 2000). Where natural or antigen specific antibodies are the product of a 
functioning immune system and unmutated gene expression, high-affinity and somatically 
mutated IgG auto-antibodies can lead to pathological events within the body including 
disruption of the homeostatic pathways relating to cell clearance, signalling or cell effector 
functions (Elkon and Casali 2008). 
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6.1.3 IgM, IgG and IgA Antibodies 
 
The immunoglobulins IgM, IgG, and IgA are involved in a range of immunological 
processed and functions with roles as diverse as protection against microbial infection, 
immune homeostasis, humoral immunity and detection of cancer formation. IgM is the 
largest antibody due to formation of the pentameric structure taking it to 990 kDa in size, it 
is involved in early immune response and when in serum can indicate a recent infection, it 
is also commonly found within healthy individuals (Madi et al., 2009). This class of 
antibody is produced by the long lived and self-renewing B-1 subset of B cells, which are 
positively selected for when presented with a self-antigen (Boes, 2000; Madi et al., 2009). 
IgM antibodies tend to be more polyreactive than other antibody classes, this allows IgM 
secreting B cells to respond very quickly to a large variety of antigens. These antibodies 
are relatively low affinity and are also commonly known as natural antibodies, playing a 
role in both the first line of defence and immunoregulation (Boes, 2000). Although low 
affinity, they have high avidity, due to their pentameric nature and therefore multimeric 
interaction with an antigen. Functionally IgM opsonises an antigen for destruction and 
complement fixation (Boes, 2000). 
IgG is the most abundant antibody within the human immune system representing 
approximately 75% of serum antibodies and the most common found within circulation 
and extracellular fluid. There are four subclasses of IgG (IgG1, IgG2, IgG3 and IgG4) 
which are labelled in highest to lowest rank order of their levels within serum of healthy 
individuals. Binding a variety of pathogens including bacteria and viruses IgG protects the 
body via a range of mechanisms leading to pathogen elimination, including agglutination 
and opsonization initiating phagocytosis and activation of the classical complement 
pathway (Schroeder and Cavacini, 2010). A key feature of IgG is its ability to leave the 
serum and enter infected tissue due to its small size (150 kDa). IgG predominantly engages 
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within the secondary immune response following class switching and is secreted as a 
monomer playing a part in antibody dependent cell mediated cytotoxicity (ADCC) and 
intracellular antibody-mediated proteolysis and is involved in type II and III 
hypersensitivity reactions.  
IgA is the second most common human immunoglobulin, with between 3-5g 
secreted by the intestinal lumen daily forming 13% of total immunoglobulins it is secreted 
in milk, tears, saliva and mucous (Placzek et al., 2018). In addition to secretory IgA, 
circulatory IgG is also present within the serum, however, the circulatory serum  isoform 
of IgA is of very low levels. This antibody is resistant to digestion and can, when 
aggregated, activate the complement pathway. IgA is able to bind Fc receptors.. 
Structurally the antibody is found as either a monomer within serum or as a polymeric 
(dimer) form in secretions (Pillemer et al., 1987, Singh et al., 2014). It is termed either 
IgA2 which is found in higher concentrations within secretions or IgA1 which comprises 
85% of serum IgA, with serum concentrations of IgA found between 1-4mg/ml (Singh et 
al., 2014).  
This antibody is known as a poor activator of immune complement (Singh et al., 
2014). Auto-antibodies to IgA are relatively common within autoimmune disease as are 
deficiencies in IgA which also lead to selective IgA deficiency. IgA deficient patients can 
have problems within blood transfusion reactions due to their interactions with IgA in the 
blood. Evidence suggests that normal levels of IgA are age-dependent and that these levels 
vary according to ethnicity and gender (Buckley and Dees, 1967; Steihm and Fudenberg, 
1966). IgA is important within immune function of the mucous membranes and is 
especially evident in mucosal tissues including the respiratory and gastrointestinal tract.  
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6.1.4 Auto-antibodies within RA 
 
Rheumatoid arthritis has been associated with several auto-antibodies including, 
rheumatoid factors (RF), anti-keratin auto-antibodies (AKA), anti-filaggrin antibodies 
(AFA) and anti-perinuclear factor (APF) (Goldbach-Mansky et al., 2000). RFs are 
identified as the prevalence of auto-antibodies directed against the Fc region of IgG 
antibodies and other auto-antibodies. These are often IgM in origin but IgG and IgA are 
also identified, with the presence and quantity of RF factors used diagnostically to indicate 
serologically positive RA (Meyer, 2010; Pollard, 2006). Within RA, anti-citrullinated 
protein antibodies (ACPA) and RF are predominantly IgM or IgG isotype with little 
evidence to suggest IgA plays a diagnostic role. However a study in 2006 illustrated that 
44.7% of RA patients were IgA-RF positive. IgA antibodies were found in approximately 
50% of the tested patients and this study suggested both IgA-RF and IgA-ACPA appeared 
to have diagnostic value (Sieghart et al., 2016).  Citrullinated proteins are formed during an 
inflammatory state when arginine residues are enzymatically converted to citrulline. Cyclic 
citrullinated peptide (CCP) is formed when two serine residues of filaggrin are 
enzymatically converted to cysteines, which then undergo disulphide bonding resulting in a 
circular form (Pollard, 2010). Anti-cyclic citrullinated peptide (anti-CCP) antibodies are 
also a feature of RA diagnosis. Clinically these auto-antibodies are significant within RA 
diagnosis, the specificity of anti-CCP within RA is between 89 - 98% (Bas, 2002; 
Goldbach-Mansky, 2000; Klareskog et al., 2006; Schellekens, 2000; Simon, 1993; Suzuki, 
2003), AKA (94%) and IgM RF (74%), (Bas 2002). Interestingly the study by Bas et al. 
(2002) found that although anti-CCP antibodies had the highest level of specificity within 
RA diagnosis, IgM RF was a better predictor of disease severity. These RFs are found in 
60-80% of RA patients, but can also be detected in a range of other diseases (Pollard, 
2006).  
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Where detection of RFs is the only clinical diagnostic in seropositive RA, SLE can 
be characterised by the prevalence of auto-antibodies within patient serum to a variety of 
self-proteins, in addition to nucleic acids and phospholipids, with over 100 different 
identified targets (Meyer, 2010). The identification and quantification of some highly 
specific self-directed antibodies such as anti-CCP auto-antibodies are therefore valuable 
tools used within the confirmation of autoimmune diseases. IgA rheumatoid factor (IgA-
RF) and IgA containing circulating immune complexes (IgA-RF complexed to IgG) have 
also been identified as significantly raised in RA compared to control groups (Pillemer et 
al., 1987). IgA antibodies directed against both cytokeratin-18  and epidermal keratin have 
been identified as significantly raised in patients with RA compared to controls or patients 
with OA (Borg et al., 1993).  
6.1.5 Auto-antibodies Directed against C-reactive Protein 
 
In addition to the collection of recognised auto-antibodies found present within RA, 
studies have emerged with identified autoantigenicity towards mCRP and suggest this may 
also play a role within disease prognosis and severity (Minatani et al., 2001; Rosenau and 
Schur, 2013). Whilst previously not strongly associated with RA disease determination, the 
anti-mCRP auto-antibodies are an important factor within the diagnosis of SLE, with both 
monomeric and pentameric CRP autoantigenicity recorded (Bell et al., 1998; Figueredo et 
al., 2006; Minatani et al., 2001; Rosenau and Schur, 2013; Sjowall and Wettero, 2007). In 
their 1998 paper, Bell et al performed inhibition studies which revealed anti-mCRP IgG 
auto-antibodies in the serum of four SLE patients tested ranging from 42% - 70% 
inhibition following preincubation of serum with 30µg/ml mCRP, whilst anti-pCRP auto-
antibodies were present in only two of the four and at lower levels of inhibition (17% - 
31% inhibition) (Bell et al., 1998). Whilst RA and SLE are both autoimmune inflammatory 
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diseases they present very differently with respect to CRP and its isoforms. Where RA is 
known for its high levels of pentameric CRP  and low frequency of circulating auto-
antibodies directed against it, for example between 23-29% of RA patients within Rosenau 
& Schur’s  study (2013), were found to be positive for anti-mCRP IgG (Minatani et al., 
2001; Rosenau and Schur, 2013); SLE presents an opposite profile, with low serum CRP 
levels but anti mCRP auto-antibodies detected in between 40% to 78% of SLE patients 
(Figueredo et al., 2006; Meyer, 2010; Sjowall et al., 2004, ,), and all patients with active 
lupus nephritis during periods of flare (Sjowall et al., 2004). 
The development of antigenicity is suggested to originate through impairment to 
the clearance of cellular debris and defects within the apoptotic pathway (Herrmann et al., 
1998, Prechl, 2015; Shao et al., 2011,). CRP has a clearly defined role within recognition 
and clearance of apoptotic cells and therefore detection of auto-antibodies directed towards 
it may provide clues towards greater understanding of this disease.   
6.1.6 CRP Auto-antibodies within SLE Patient Serum  
 
Whilst an inflammatory state within many diseases including RA is associated with 
increased CRP serum concentrations, many SLE patients remain within a relatively normal 
range, albeit towards the higher end of that scale (Meyer,. 2010). Generally CRP levels 
only increase moderately during lupus flares, but the same patients are still able to exhibit 
an increase in CRP during bacterial infection for instance (Meyer, 2010). Whilst not 
characterised by high CRP levels, SLE patients are often found to have anti-CRP auto-
antibodies within their serum. These auto-antibodies have been found within an average of  
35 to 40% of SLE patients (Meyer, 2010; Sjowell et al., 2002) and were first reported in 
one of eight patients within a 1985 study (Robey et al., 1985). Bell et al. in 1998 reportedly 
found anti-CRP auto-antibodies in 78% of patient samples, but later studies dating from 
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2002 onwards have reported a frequency of between 10-51% of SLE patients affected (Bell 
et al., 1998, Figueredo et al., 2006; Kessel et al., 2009; Rosenau et al., 2006; Shoenfeld et 
al., 2007; Sjowell et al., 2002, 2004). The levels of CRP directed auto-antibodies was 
found to associate with SLE disease activity (Sjowell et al., 2004), suggesting biological 
and pathogenic functions within SLE  and also significantly correlate to associated kidney 
disease (Figueredo et al., 2006; Sjowell et al., 2009; Tan et al., 2008). Using ELISA to 
determine levels, pCRP was coated overnight and patient sera used as primary antibody 
source followed by anti-human IgG antibodies. The form of CRP detected has been 
suggested to be monomeric rather than pentameric due to conformational changes exposing 
non-native intersubunit regions of pCRP upon binding to polystyrene surfaces (Potempa et 
al., 1987). These studies have not sought to identify pCRP targeted antibodies, nor have 
they sought to determine any other auto-antibody class in addition to IgG. 
6.1.7 CRP Auto-antibodies within RA Patient Serum 
 
Whilst levels of CRP are generally raised within RA in contrast to SLE, auto-
antibodies to either pentameric or the modified monomeric form of CRP are reported with 
less frequency in RA than within SLE patients, it is a little researched area with greater 
focus directed towards SLE as a disease model. However a study by Rosenau and Schur in 
2006 found evidence for anti-mCRP auto-antibodies within 22% of samples tested with an 
earlier paper reporting 29% (Minatani et al., 2001; Rosenau and Schur, 2006). In both 
cases the neo epitopes exposed during dissociation were found to be the targets of the CRP 
directed auto-antibodies. Studies considering auto-antibodies in SLE have found both IgG 
and IgM auto-antibodies directed against mCRP (Pradhan et al., 2013). Both Rosenau et 
al., (2006) and Minatani et al., (2001) considered the presence of IgG auto-antibodies and 
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to our knowledge there are no studies detailing the presence of either IgA or IgM auto-
antibodies directed against CRP in either monomeric or pentameric form within RA.  
6.1.8 CRP Dissociation upon Surface Binding 
 
CRP is known to change in conformation when bound to the polystyrene surface of 
an ELISA plate, exposing neoepitopes and non-native structure. This method has been 
employed within studies to facilitate the examination of bound monomeric CRP (Sjowall et 
al., 2003, 2003). The native pentameric form is bound overnight onto the plate and loss of 
conformation occurs unless the plate has been pre-coated with phosphocholine bound 
keyhole limpet haemocyanin (PCh-KLH), which allows pentamer binding and 
stabilisation. Therefore an important consideration within ELISA experimental design is 
the behaviour of CRP upon binding to ELISA plates. If pCRP is used as a capture agent 
within antibody or auto-antibody detection tests, the stability of pentameric CRP must be 
fully understood in order to fully interpret experimental results. 
6.1.9 ELISA Interactions 
 
The ELISA test is incredibly useful in determining which proteins and antibodies 
are present within serum; however interactions between the serum and assay constituents 
are also possible. A research study in 2013 by Sjowall et al detailed an interaction found 
within RA patients to dietary proteins, with a common antigen found to be being bovine 
serum albumin (BSA). Many ELISA assay kits use BSA within a blocking or diluent step, 
or as an inert carrier to preserve biological function within storage. Results determined 
when BSA is used may prove unreliable should patient samples show sensitivity to this 
protein. In their study Sjowall et al found that 50% of RA patients and 62% of controls 
were anti-BSA positive (using a cut off of 0.1 net OD), although no significant difference 
was found within the groups (P=0.11) or between women and men (Sjowell et al., 2013). 
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It is not known whether anti-BSA antibodies are innate in nature or occur via 
immune system antigen presentation. The possibility that high anti-BSA antibody levels 
are implicated in diseases such as insulin dependent diabetes mellitus (IDDM) is reported, 
with cross reactivity between a BSA peptide sequence and pancreatic B-cell surface protein 
found (Karjalainen et al., 1992; Saukkonen et al., 1998). There is a possibility that past 
studies investigating autoimmune disease serum protein and auto-antibody levels may have 
determined increased anti BSA rather than the proteins of interest. Sjowall et al., (2013) 
justified a lack of blocking step within their assay as a method to avoid serum BSA 
interactions, although it is questionable as to whether non-specific binding occurred 
resulting from this decision. Rosenau and Schur chose to include BSA blocking criticising 
Sjowall’s study robustness, although possibly introducing study bias due to binding of 
BSA (Rosenau,and Schur, 2006; Sjowall et al., 2013). These differences in study design 
may explain differences within results, as this could introduce inconsistency due to anti-
BSA antibodies commonly occurring even within healthy individuals, therefore may be 
detected providing possible false positive results. A different study overcame these 
possible interactions by pre-incubating the serum on a BSA coated plate before adding it to 
a second plate coated in mCRP, thus removing anti-BSA antibodies present (Jakuszko et 
al., 2017). Figure 6.1 illustrates problems encountered within the competitive ELISA 
developed to identify auto-antibodies to both mCRP and pCRP assays including 
interactions with BSA and the steps taken to overcome them. 
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Figure 6-1 A flow diagram illustrating the obsticles encountered during measurement of 
anti-pCRP and mCRP auto-antibodies and the steps taken in order to eliminate them. 
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6.1.10 Experimental Aims 
 
To enable meaningful quantification and analysis of auto-antibodies to mCRP and 
pCRP within RA patient serum, it was essential to develop an effective protocol for their 
identification. The aim of this chapter was to design an ELISA assay system which allowed 
accurate and reproducible determination of IgG, IgA and IgM auto-antibodies directed 
against both CRP conformations. The identification of such would allow greater 
understanding of RA and the role CRP auto-antibodies, in addition to those currently 
determined for diagnostic purposes, play within this inflammatory disease. Little research 
has occurred investigating auto-antibodies directed against CRP within RA, and those 
which have, sought to identify only those recognising mCRP not pCRP. The ELISA 
development must overcome the interactions between human serum and constituent parts 
of the assay including blocking solutions, in addition to ensuring the chosen CRP 
conformation is stable. The successful development of this assay will allow full and 
rigorous investigation as to whether CRP auto-antibodies are present within the serum and 
if levels are higher or lower within RA patient or control group serum. The comparison to 
non-inflammatory control group serum may aid further study as to whether monomeric 
CRP is pro or anti-inflammatory in nature. 
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6.2 Materials and Methods 
6.2.1 Ethical Application 
 
Prior to experimental collection of patient samples and any experimental procedure 
took place, both peer review and ethical research committee approval was sought. The 
details of this review are set out within section 2.3.1. 
6.2.2 Preparation of Human Serum 
Patient samples were collected and processed as described within section 2.3.2 and 
stored at -20oC until required. 
6.2.3 ELISA Analysis of Serum Anti-p CRP IgG, IgA and IgM Auto-antibodies  
 
ELISA assays were carried out following the method in section 2.3.9 with reagents 
listed within Tables 2.9 and 2.10. Patient and control samples were arranged as detailed in 
Table 2.13.  
6.2.4 ELISA Analysis of Serum Anti-mCRP IgG, IgA and IgM Auto-antibodies 
 
ELISA assays were carried out following the method in section 2.3.9 with reagents 
listed within Tables 2.9 and 2.10. Patient and control samples were arranged as detailed in 
Table 2.12. 
6.2.5 Western blot analysis of IgG/IgM/IgA Anti-Human mCRP and mCRP auto-
antibodies 
 
The method previously described in sections 2.2.6 and 2.3.7 was used to run the 
native gel. Each well was loaded with either 1Pg of monomeric or pentameric CRP within 
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sample loading buffer to a maximum volume of 30Pl within a pre-cast BioRad native gel 
(12%). Table 2.4, provides details of buffers and reagents used.  
6.2.6 Statistical analysis 
 
Samples were triplicated upon each plate and the mean of the closest two values 
taken. Each plate was processed in triplicate. Results were calculated by removing the 
absorbance of samples which had been pre-incubated with CRP from those that had not. 
The addition of either mCRP or pCRP allowed binding of any auto-antibodies present 
within the serum and prevented binding to the protein captured on the plate. The net 
difference represented binding of auto-antibodies present within the serum. The upper limit 
of the normal values for serum auto-antibody levels was defined as the mean ± 2SD of 
levels in the sera from the 30 healthy controls; samples elevated above this value were 
determined as high or elevated.  
During initial statistical analysis it became apparent that the male cohort auto-
antibody data was affecting analysis and in many cases the combination of male and 
female data sets produced bimodal data making analysis based on comparison of mean or 
median group data unreliable, in this case the groups were split by gender prior to detailed 
statistical analysis. Data also considers the number of patient or control samples found to 
contain auto-antibody levels above zero Absorbance with comparison of the number of 
elevated or above zero samples between groups analysed by Chi-squared analysis. 
All statistical analysis undertaken within our research was generated by Minitab 18 
and is detailed within section 2.3.10. 
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6.3 Results 
6.3.1 Experimental Design 
Overall experimental design details are as described within section 5.3.1, however 
the primary outcome for this area of study was to determine whether auto-antibodies 
directed against mCRP or pCRP were present within human RA patient serum.  
6.3.2 ELISA Analysis of Human Anti-CRP Auto-antibodies  
The analysis by ELISA allows detection of low levels of antibody present within 
serum in a specific manner. Studies have indicated an interaction between RA patient 
serum and dietary proteins, with a common antigen found to be bovine serum albumin 
(BSA) (Karjalainen et al., 1992; Saukkonen et al., 1998; Sjowall et al., 2013). This was 
also determined to be a problem early within our optimisation of ELISA protocols, as 
initial ELISA tests were complicated by interactions between the patient sample and both 
the BSA blocking agent and capture antibodies. It was therefore necessary to develop and 
use a competitive ELISA system, antibody dilutions were first optimised and the optimum 
assay taken forward for patient sample testing. Serum samples were also diluted and pre-
incubated within BSA before adding to the plate, therefore eliminating as much BSA non-
specific binding as possible. As previously described, pentameric CRP is unstable when in 
contact with a surface or membrane, with previous results showing a dissociation of pCRP 
during initial binding to an ELISA plate overnight and at reduced time periods. Due to this 
it was necessary to use an antibody capable of capturing the pCRP and maintaining it 
within its pentameric form. The capture antibody used to stabilise the pCRP conformation 
when bound to the ELISA plate was first assessed for effect. However, this led to the 
observation that anti-IgG present within serum samples was interacting with the chosen 
capture antibody, providing false positive results (results not shown). Initially a goat anti-
 
 
Chapter 6 - Detection of Anti-CRP Auto-antibodies Results 
266 
 
CRP antibody was used as a capture agent, however when interactions became apparent 
this was changed to phosphocholine bound keyhole limpet haemocyanin (PCh-KLH), 
pCRP is known to bind phosphocholine and has when conjugated to the larger KLH been 
used previously in studies to capture and stabilise CRP upon an ELISA plate (Potempa et 
al., 2015; Wang, 2012;). Within the anti-monomeric CRP auto-antibody detection assay, a 
capture antibody or agent was not necessary as mCRP could be bound directly to the plate 
without structural compromise. 
When considered as a complete, mixed gender group the number of patients with 
elevated antibody levels (≥ mean + 2SD of normal control subjects) was, 10 of 30 (33%) 
for anti-mCRP IgG, 22 of 30 (73%) of anti-mCRP IgA, 8 of 30 (27%) of anti-mCRP IgM, 
9 of 30 (30%) for anti-pCRP IgG, 3 of 30 (10%) of anti-pCRP IgA and 8 of 30 (27%) of 
anti-pCRP IgM. Table 6.1 summarises the mean ± SEM and percentage of samples with 
detectable auto-antibody presence for each of the sample groups and assays investigating 
IgG, IgM and IgA auto-antibodies directed towards mCRP and PCRP. This table also 
provides a comparative overview of the proportion of samples above threshold (control 
mean + 2SD) and calculated threshold. The spread of results varied greatly between control 
and RA groups and between those of the auto-antibodies themselves.  
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Table 6.1 A table summarising the mean ± SEM, % of samples containing auto-antibodies 
and proportion of samples elevated above the calculated upper threshold (≥ mean ± 2SD 
normal cohort), for each of the auto-antibody groups, split by RA (n = 30) and control (n = 
30). 
 
 
 
Auto-
antibody 
 
Mean ± SEM 
(Absorbance 
OD) 
Threshold 
mg/l (Mean 
+ 2SD) 
% Samples with 
Detectible 
Autoantibodies 
Proportion of 
Samples above 
Threshold (mean 
control ± 2SD) 
Anti-mCRP 
IgG RA 
 
0.077 ± 0.0139 
 
0.100 66 (20 of 30) 10 of 30 
Anti-mCRP 
IgG Control 
 
0.024 ± 0.007 
 
 
0.100 
 43 (13 of 30) 2 of 30 
Anti-mCRP 
IgA RA 0.103 ± 0.015 0.039 93 (28 of 30) 22 of 30 
Anti-mCRP 
IgA Control 0.006 ±  0.003 0.039 27 (8 of 30) 1 of 30 
Anti-mCRP 
IgM RA 0.083 ± 0.016 0.149 87 (26 of 30) 8 of 30 
Anti-mCRP 
IgM Control 0.053 ± 0.009 0.149 73 (22 of 30) 0 of 30 
Anti-pCRP 
IgG RA 0.129 ± 0.017 0.205 93 (28 of 30) 9 of 30 
Anti-pCRP 
IgG Control 0.072 ± 0.012 0.205 77 (23of 30) 1 of 30 
Anti-pCRP 
IgA RA 0.039 ± 0.005 0.076 93 (28 of 30) 3 of 30 
Anti-pCRP 
IgA Control 0.019 ± 0.005 0.076 53 (16 of 30) 3 of 30 
Anti-pCRP 
IgM RA 0.101 ± 0.021 0.137 80 (24 of 30) 8 of 30 
Anti-pCRP 
IgM Control 0.033 ± 0.01 0.137 47 (14 of 30) 3 of 30 
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Table 6.2 Laboratory parameters for RA and control samples. presented as median (IQR 
 
As seen within Table 6.2 and Figure 6.2, median levels within four of the six 
controls, anti-mCRP IgG, anti mCRP IgA, anti-pCRP IgA and anti-pCRP IgM and are 
close to or zero (0.00, 0.00, 0.001 and 0.003 respectively), with many zero level samples 
found in each group. There was considerable truncation of data due to the number of zero 
 
Auto-antibody 
 
Median (IQR) 
Anti-mCRP IgG RA 0.054 (0.000-0.129) 
Anti-mCRP IgG Control 0.000 (0.000-0.052) 
Anti-mCRP IgA RA 0.096 (0.039-0.139) 
Anti-mCRP IgA Control 0.000 (0.000-0.003) 
Anti-mCRP IgM RA 0.031 (0.018-0.155) 
Anti-mCRP IgM Control 0.046 (0.005-0.106) 
Anti-pCRP IgG RA 0.095 (0.058-0.214) 
Anti-pCRP IgG Control 0.065 (0.006-0.118) 
Anti-pCRP IgA RA 0.037 (0.015-0.058) 
Anti-pCRP IgA Control 0.001 (0.000-0.034) 
Anti-pCRP IgM RA 0.046 (0.019-0.163) 
Anti-pCRP IgM Control 0.003 (0.000-0.051) 
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samples. Data apart from that of RA group IgA, was not normally distributed, therefore 
several analysis were performed using non-parametric tests as detailed within section 
2.3.10. The nature of the data when subjected to analysis revealed differences between the 
male and female groups. These differences prevented direct statistical comparison of mean 
antibody values as a mixed gender group; therefore participants were split by gender before 
further analysis took place. Initial group data is illustrated within figures 6.2 to 6.8 and 
6.13 to 6.18 showing the overall profile of auto-antibodies within both the RA and control 
sample groups. Analysis of data following the division of groups into male and female is 
presented in Figures 6.19 and Table 6.3. 
 
Figure 6-2 Serum levels of anti-mCRP and anti-pCRP antibody in control (0) and patient 
(1) samples, Absorbance at 450nm (less 550nm) per assay group. Horizontal bars indicate 
the median values. The dashed red lines indicate the upper limit of the normal range (mean 
± 2SD value of normal). 
 
Figures 6.3a and 6.3b display the level of IgG auto-antibodies directed towards 
mCRP within each of the 30 patient and 30 control samples as assessed by ELISA. Within 
the RA group (Figure 6.3a), 20 of the 30 samples (66%) were found to be have detectable 
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levels of anti-mCRP IgG auto-antibodies, with a mean absorbance value across the samples 
of 0.077 ± 0.0139. The absorbance of positive samples ranged between 0.244 (RA15) and 
the lowest of 0.029 (RA7). Within this group 10 samples were elevated above the upper 
limit cut off for normal levels of IgG auto-antibodies, an absorbance of 0.100 (≥ mean + 
2SD of control subjects). Figure 6.3b displays absorbance within the control group 
samples, within this group 13 of the 30 (43%), were found to have detectable levels with a 
mean absorbance value across the group of 0.024 ± 0.007. The recorded absorbance of the 
group ranged between 0.147 (C05) and the lowest 0.0015 (C25), of these samples only 1 
was elevated. The number of RA group samples with elevated levels of anti-mCRP IgG 
was found to be significantly higher than the control P < 0.01. 
The difference seen between the patient and control groups was more pronounced 
within the anti-mCRP IgA group as can be seen in Figures 6.4a and 6.4b. Within the 
patient group (Figure 6.4a), 28 of the 30 samples (93%) were found to have detectable 
levels of anti-mCRP IgA auto-antibodies, with a mean absorbance value across the samples 
of  0.103 ± 0.015. The absorbance of positive samples ranged between 0.3154 (RA11) and 
the lowest of 0.008 (RA30), of the samples 22 were elevated above 0.039 (≥mean +2SD 
normal samples), in contrast to just one of the control samples. Within the control group 8 
of the 30 (26.7%), were found to have detectable levels with a mean absorbance value 
across the group of  0.006 ± 0.03. The recorded absorbance of the group ranged between 
0.0841 (C17) and the lowest 0.001 (C30). The number of RA subjects with elevated IgA 
auto-antibody levels was found to be significantly higher than that of the control P < 0.001. 
This difference is more pronounced than that between the anti-mCRP IgG groups. 
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Figure 6-3 Bar graphs showing serum anti-mCRP IgG in both RA and control samples. (a.) 
RA group and (b.) control group samples. Auto-antibodies presented as Absorbance of 
sample. Data as determined by competitive ELISA (n = 3), following sample dilution of 
1:100 in triplicate. The dashed line represents the upper normal limit, those above are 
considered elevated serum, (≥ mean ± 2SD (0.100 OD)). The number of elevated RA 
group samples (n = 10) is significantly different from the control group (n = 2), P < 0.01. 
Green columns (RA23- 30 C24-30) = male, blue = female.. 
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Figure 6-4 Bar graphs showing serum anti-mCRP IgA in both RA and control groups. (a.) 
RA group and (b.) control group samples. Data as determined by competitive ELISA, (n = 
3), following sample dilution of 1:100 in triplicate. The dashed line represents the upper 
normal limit, those above are considered high, (≥ mean ± 2SD (0.039 OD)). The number of 
elevated RA group samples (n = 22) is significantly different from the control group  (n = 
1), P < 0.001 (Х2 analysis). Green columns (RA23- 30; C24-30), = male, blue = female.   
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Figures 6.5a and 6.4b display the levels of anti-mCRP IgM within the patient and 
control groups. Fig. 6.5a displays the level of anti-mCRP IgM auto-antibodies within the 
RA group and shows that 26 of the samples were found to have detectable levels of auto-
antibodies (87%). The mean absorbance value across the group is 0.083 ± 0.016 SEM. The 
absorances ranged between 0.311 (RA01) and the lowest positive 0.008 (RA04). The 
number of high serum samples found above 48.39% (control group mean + 2SD), was less 
within this group than either the IgG or IgA mCRP directed antibody groups with 8 of 30 
samples elevated. The mean absorbance of the patient group was slightly lower than that of 
the IgG assay result (0.083 vs 0.103), however the control group data differed greatly. 
Whilst a greater proportion of the control population were found to have the presence of 
anti-mCRP IgG when compared to anti-mCRP IgAs, this proportion was raised further to 
73% of control samples with detectible IgM auto-antibody values, (22 of 30), as can be 
seen in Table 6.1.The mean absorbance of this group is much higher than either of the IgG 
or IgA assays at 0.053 ± 0.009 SEM. However, despite a higher proportion of normal 
samples found to contain IgM auto-antibodies, no control samples exceeded the 
determined upper normal level and there were therefore no elevated control samples. The 
number of elevated RA group samples was found to be significantly higher to those of the 
control (P < 0.01). 
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Figure 6-5 Bar graphs showing serum anti-mCRP IgM in both RA and control groups. (a.) 
RA group and (b.) control samples, auto-antibodies presented as Absorbance of sample. 
Data as determined by competitive ELISA (n=3), following sample dilution of 1:100 in 
triplicate. The dashed line represents the upper normal limit, those above are considered 
high serum, (≥ mean ± 2SD (0.149 OD)). The number of elevated RA group samples (n = 
8) is significantly different from the control group  (n = 0), P < 0.01 (Х2 analysis). Green 
columns = male, (C24-30; RA23- 30), blue = female.   
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Analysis of the pentameric form illustrate that auto-antibodies against the pCRP are 
also relevant within this area of study. Figure 6.6a and 6.6b display the level of IgG auto-
antibodies directed towards pCRP within each of the 30 patient and control samples. 
Within the RA group (Figure 6.56), a high proportion, 28 of the 30 samples (93%), were 
found to have detectable levels of anti-pCRP IgG auto-antibodies, with a mean value 
across the samples of 0.129 ± 0.017 SEM. The absorbance of positive samples ranged 
between 0.297 (RA12) and the lowest positive of 0.006 (RA26), of the samples nine were 
elevated above 0.205 (control group mean + 2SD), indicating almost a third of patient 
samples had high levels of this auto-antibody within their serum. Figure 6.6b displays the 
control group auto-antibody levels represented as percentage OD of RA12, the highest 
sample within the RA group. Within this group 23 of the 30 (77%), were found to contain 
auto-antibodies with a mean value across the group of 0.072 ± 0.012 SEM. The recorded 
ODs of the group ranged between 0.257 (C08) and the lowest 0.0062 (C20). Of the 
samples, one was elevated. The number of elevated RA group samples was found to be 
significantly different to that of the control P < 0.01. The number of samples positive for 
IgG auto-antibodies directed against pCRP are similar to those of the mCRP group (Figure 
6.3), with nine as opposed to ten in the RA group and one for both within the control 
groups. A significantly greater proportion of samples with pCRP directed antibodies 
present were observed within both the RA and control samples compared to those directed 
against mCRP, P < 0.01. 
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Figure 6-6 Bar graphs showing serum anti-pCRP IgG in both RA and control groups. (a.) 
RA group and (b.) control samples, auto-antibodies presented as Absorbance of sample. 
Data as determined by competitive ELISA (n=3), following sample dilution of 1:100 in 
triplicate. The dashed line represents the upper normal limit, those above are considered 
elevated, (≥ mean ± 2SD (0.205 OD)). The number of elevated RA group samples (n = 9) 
is significantly different from the control group (n = 1), P < 0.01 (Х2 analysis). Green 
columns = male, (C24-30; RA23- 30), blue = female.  
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Levels of IgA auto-antibodies directed towards pCRP (Figure 6.7) show the same 
number of patients with auto-antibodies detected within their serum, 28 of 30 (93%), as 
those seen in Figure 6.4a directed against mCRP. The mean absorbance value across the 
RA samples was 0.039 ±0.005 SEM. The recorded ODs of the RA group ranged between 
0.113 (RA03) and the lowest positive 0.005 (RA09), and those of the control group 
between 0.08 (C13) and 0.001 (C26) with a mean of 0.019 ± SEM. There is no significant 
difference between the control and RA groups in respect of the number of high level 
samples (both having three), there is however a significant difference between the number 
of samples found  to contain anti-pCRP IgA within the control group, 16 (53%), when 
compared to RA samples, P < 0.01 (Х2 analysis). There is also a significant difference 
between the numbers of positive control samples when compared to the number found 
within the anti-mCRP group, P < 0.005 (Х2 analysis), however there is no difference 
between the mCRP and pCRP RA groups which both have 28 of 30 samples containing 
anti-pCRP IgA.  
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Figure 6-7 Bar graphs showing serum anti-pCRP IgA in both RA and control groups. (a.) 
RA group and (b.) control samples, auto-antibodies presented as absorbance of sample. 
Data as determined by competitive ELISA (n=3), following sample dilution of 1:100 in 
triplicate. The dashed line represents the upper normal limit, those above are considered 
elevated, (≥ mean ± 2SD (0.076 OD)). The number of RA group elevated auto-antibodies 
(n = 3) are not significantly different from the control group (n = 3), P > 0.05 (Х2 analysis). 
Green columns = male (C24-30; RA23- 30), blue = female. 
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Figures 6.8a and 6.8b illustrate the profile of IgM auto-antibodies directed against 
pentameric CRP. As can be seen in Figure 6.8a eight samples had elevated serum levels 
within the RA group above 0.137 (control mean +2SD), as opposed to three elevated 
within the control group (Figure 6.8b). Within the RA group a high proportion, 24 of the 
30 samples (80%), were found to contain anti-pCRP IgM auto-antibodies, with a mean 
value across the samples of 0.101 ± 0.021 SEM. The absorbance values of positive samples 
ranged between the highest 0.425 (RA03) and the lowest positive of 0.016 (RA22). Figure 
6.8b displays absorbance of control samples, within this group 16 of the 30 (53%), were 
found to contain detectable levels of auto-antibodies with a mean value across the group of 
0.033 ± 0.01 SEM. The recorded absorbances of the group ranged between 0.1826 (C08) 
and the lowest 0.003 (C30), of the samples three were elevated with elevated levels 
exceeding the upper normal limit. There is no significant difference between the groups in 
respect of elevated samples (P > 0.05), however there is between the number of samples 
found to contain auto-antibodies within the control group when compared to RA samples, 
with 15 (50%) of control samples positive, P < 0.01 (Х2 analysis). There is no significant 
difference between the numbers of positive RA or control samples within the anti-pCRP 
IgM group when compared to those of the anti-mCRP group, P > 0.05 (Х2 analysis). 
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Figure 6-8 Bar graphs showing serum anti-pCRP IgM in both RA and control groups. (a.) 
RA group and (b.) control samples, auto-antibodies presented as % of known positive 
sample. Data as determined by competitive ELISA (n = 3), following sample dilution of 
1:100 in triplicate. The dashed line represents the upper normal limit, those above are 
considered high, (≥ mean ± 2SD (0.137 OD)). The number of positive RA group samples 
(n = 9) is not significantly different from the control group (n = 3), P > 0.05 (Х2 analysis). 
Green columns = male, (C24-30; RA23- 30), blue = female. 
 
(a.) 
00.05
0.10.15
0.20.25
0.30.35
0.40.45
0.5
RA01 RA02 RA03 RA04 RA05 RA06 RA07 RA08 RA09 RA10 RA11 RA12 RA13 RA14 RA15 RA16 RA17 RA18 RA19 RA20 RA21 RA22 RA23 RA24 RA25 RA26 RA27 RA28 RA29 RA30
Absorb
ance 
Sample 
(b.) 
00.05
0.10.15
0.20.25
0.30.35
0.40.45
0.5
C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26 C27 C28 C29 C30
Absorb
ance 
Sample  
 
 
Chapter 6 - Detection of Anti-CRP Auto-antibodies Results 
281 
 
6.3.3 Western Blot Analysis of Serum Samples 
In order to determine the presence of auto-antibodies in RA patient samples that 
had previously been found positive by ELISA analysis, western blots were carried out. 
Native gels were run containing mCRP generated from 2M urea dissociation and also 
pCRP (Scripps). Patient samples were used as a primary antibody source in order to 
determine their capacity to recognise CRP isoforms. Anti-human IgA, IgM or IgG were 
applied as secondary antibodies. Control bands of mCRP and pCRP were also included on 
each gel for comparison and were blotted with both 3H12 anti-mCRP antibody and Clone 
8. A representative set of samples chosen from the RA patient group are shown.  
Figure 6.9 shows a typical western blot analysis of patient samples within the anti-
pCRP IgG assays. Clear strong bands can be seen in each of the patient sample lanes. 
Lanes one and two contain duplicated control samples (mCRP and pCRP) with which the 
patients were compared against. The control image is separated from the patient samples as 
it was exposed for a shorter period of time (typically less than five minutes). The 
pentameric bands matched the 115kDa band position of the control samples. Figure 6.10 
shows western blot analysis for patient anti-mCRP IgG analysis of serum auto-antibody 
content. Bands can be seen in lane one for the control samples at both 115kDa and 23kDa. 
Less well determined bands are apparent within the 23kDa monomer position, in lanes 
four, five and six, (RA22, RA15 and RA18). 
Figure 6.11 shows a representative western blot of the anti-mCRP and anti-pCRP 
analysis combined on one gel, with nine samples and one control lane. Once again 23kDa 
and 115kDa bands can be seen in the control lane, with clear bands seen in the position of 
mCRP in lanes seven and nine (RA11 and RA17) with a further possible band in lane 4 
(RA08). There is no visible band for anti-pCRP in any of the samples. 
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Figure 6-9 A representative western blot of anti-pCRP IgG auto-antibodies within patient 
samples, n=3. Lane 1 & 2: 1µg mCRP and pCRP, probed with mAb Clone 8 and 3H12; 
lanes 3-6 probed with patient sample serum RA12, RA15 and RA18, lane 10: negative 
control (no pCRP). Anti-pCRP detection is shown in all patient samples. 1μg pCRP was 
initially run within lanes 3-9 prior to probing with patient samples (diluted to 1:100).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-10 A representative western blot of anti-mCRP IgG auto-antibodies within patient 
samples, n=3. Lane 1: 1µg mCRP and pCRP, probed with mAb Clone 8 and 3H12, lane 2-
7 probed with patient serum. Anti-mCRP detection is shown as a faint band in lanes 4, 5 & 
6, samples RA22, RA15 and RA18. 1μg mCRP was initially run within lanes 2-7 prior to 
probing with patient samples (1:100 dilution). 
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Figure 6-11 A representative western blot of anti-mCRP and anti-pCRP, IgA auto-
antibodies within patient samples. Lane 1: 1µg mCRP and pCRP probed with mAb Clone 
8 and 3H12, lane 2-10 probed with patient serum samples (1:100). Anti-mCRP detection is 
shown as a faint band in lanes 4, 7 & 9, samples RA08, RA11 and RA17, anti-pCRP is not 
visible in any lane. 1μg of mCRP and pCRP were initially run prior to probing with patient 
samples. n=3. 
 
Lastly, Figure 6.12 which shows anti-mCRP and anti-pCRP IgM patient sample 
analysis.  Lanes one to four contain patient samples with the control samples in lane 5 as 
describe previously. Bands can be seen located in the 23kDa mCRP position for each of 
the four patients, with band also visible in lanes two, three and four relative to pCRP. As is 
apparent with Figure 6.10, the bands within these two gels are not as clear as those within 
Figures 6.11 and 6.9; banding is not tightly confined or well resolved. It was not possible 
to develop them for longer as background interaction overcome the detection signal. 
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Figure 6-12 A representative western blot of anti-mCRP and anti-pCRP IgM auto-
antibodies within patient samples. Lane 5: 1µg mCRP and pCRP, lane 1-4 patient samples 
RA30, RA03, RA01 and RA07 (1:100). mCRP detection is shown as a faint band in each 
lane, pCRP detection is shown by a faint band in RA3, RA01 and RA07. 1μg of mCRP and 
pCRP were intially run on the gel pre probing with patient samples, n=3. 
 
6.3.4 Comparisons Between Anti-mCRP and Anti-pCRP Auto-antibody Levels 
 
The difference between RA and control mean absorbance value for anti-IgA auto-
antibodies directed towards mCRP is shown in Figure 6.13e and is more pronounced 
(0.103 ± 0.015 SEM vs 0.006 ± 0.003 SEM), than that found within all other groups. It is 
also apparent that the least difference between RA and control group mean absorbance can 
be observed within IgM auto-antibodies directed against mCRP (0.083 ± 0.016 SEM vs 
0.053 ± 0.009 SEM) as seen in Figure 6.13f.  Whilst Figures 6.3-6.8 illustrate individual 
auto-antibodies found within the sample of each subject, Figures 6.14  and 6.15 present the 
profile of all auto-antibodies detected per RA sample, directed against mCRP and pCRP 
respectively. These graphs illustrate the detectable level of antibody in each sample rather 
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than just those judged as elevated. No RA patients were identified as presenting negative 
for all three auto-antibodies, with at least half of samples found to have each of the three 
isotypes present (anti-pCRP 23 of 30, anti-mCRP 15 of 30).  
When the profile of auto-antibodies is examined per subject within the control 
group samples, a different picture emerges. There were four samples that contained no 
detectable level of anti-mCRP auto-antibodies within their samples, C03, C07, C09 and 
C28 (Figure 6.16), and two samples within the anti-pCRP group samples C02 & C14 
(Figure 6.17). A Venn diagram illustrating the distribution of auto-antibodies directed 
against either mCRP or pCRP in both control and RA groups is shown in Figure 6.18. 
Whilst the anti-mCRP detection assay showed eight RA samples contained the 
combination of IgM and IgA auto-antibodies (Figure 6.18b), the anti-pCRP detection assay 
revealed that no RA samples contained the same combination (Figure 6.18a), however the 
anti-pCRP assay included the most patient samples with all three isotypes present, 23 vs 15 
within the anti-mCRP assay.  The distribution of auto-antibodies across the control sample 
auto-antibody groups indicates there were more auto-antibodies present in the anti-pCRP 
group than that of the anti-mCRP group (Figures 6.18c and d), with a clear reduction in  
IgA auto-antibodies compared to the RA group. The anti-pCRP results showed a more 
balanced distribution across the classes. In each control assay group a greater number of 
samples contained a single antibody class (anti-pCRP = 8, anti-mCRP = 11) as seen in 
Figures 6.18c & d in comparison to RA sample group data (anti-pCRP = 4, anti-mCRP = 
2) as seen in Figures 6.18a and b. 
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Figure 6-13 Bar graphs showing serum levels of anti-mCRP or pCRP in RA patient and control sample groups (± SEM) as determined by 
ELISA (n=3).  6.9 a-f, anti-pCRP IgG, anti-pCRP IgA, anti-pCRP IgM, anti-mCRP IgG, anti-mCRP IgA and anti-mCRP IgM respectively. A 
range of differences between the control and patient groups is evident with the greatest observed difference seen between the anti-IgA auto-
antibodies directed against mCRP.  Statistical analysis was not performed on the combined gender group mean data.  
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Figure 6-14 A bar graph illustrating levels of auto-antibody isotypes directed against mCRP present in individual RA patient samples, 
determined by competitive ELISA and expressed as absorbance ± SEM, (n=3). Dashed lines represent the upper threshold (mean ± 2SD normal 
control group), with samples above the line designated as elevated.  
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Figure 6-15 Bar graph illustrating normalised levels of auto-antibody isotypes directed against pCRP present in individual RA patient samples, 
determined by competitive ELISA and expressed as absorbance ± SEM, (n=3). Dashed lines represent the upper threshold (mean ± 2SD normal 
control group), with samples above the line designated as elevated. 
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Figure 6-16 A bar graph illustrating normalised levels of auto-antibody isotypes directed against mCRP present in individual control patient 
samples, determined by competitive ELISA and expressed as absorbance ± SEM, (n=3). Dashed lines represent the upper threshold (mean ± 
2SD normal control group), with samples above the line designated as elevated. There was no detectible level of any auto-antibody in four 
samples, C03, C07, C09 and C28. 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
C0
1
C0
2
C0
3
C0
4
C0
5
C0
6
C0
7
C0
8
C0
9
C1
0
C1
1
C1
2
C1
3
C1
4
C1
5
C1
6
C1
7
C1
8
C1
9
C2
0
C2
1
C2
2
C2
3
C2
4
C2
5
C2
6
C2
7
C2
8
C2
9
C3
0
Ab
so
rb
an
ce
 
Sample 
IgG
IgA
IgM
 
 
Chapter 6 - Detection of Anti-CRP Auto-antibodies Results 
290 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
C0
1
C0
2
C0
3
C0
4
C0
5
C0
6
C0
7
C0
8
C0
9
C1
0
C1
1
C1
2
C1
3
C1
4
C1
5
C1
6
C1
7
C1
8
C1
9
C2
0
C2
1
C2
2
C2
3
C2
4
C2
5
C2
6
C2
7
C2
8
C2
9
C3
0
Ab
so
rb
an
ce
 
Sample 
IgG
IgA
IgM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-17 A bar graph illustrating normalised levels of auto-antibody isotypes directed against pCRP present in individual control patient 
samples determined by competitive ELISA and expressed as absorbance ± SEM, (n=3). Dashed lines represent the upper threshold (mean ± 2SD 
normal control group), with samples above the line designated as elevated.  There was no detectible level of auto-antibodies in two samples, C02 
and C14. 
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Figure 6-18 Venn diagram illustrating the isotype distribution of auto-antibodies within RA 
and control group samples as determined by competitive ELISA. Showing the frequency of 
samples with detectible auto-antibodies within the RA group a) anti-pCRP and b) anti-mCRP 
assays and the control group c) anti-pCRP, which included two samples with no detected 
auto-antibodies and d) anti-mCRP assays which included four samples with no detected auto-
antibodies. 
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During initial statistical analysis it became apparent that the male cohort auto-antibody 
data was affecting analysis and in many cases the combination of male and female data sets 
produced bimodal data making detailed analysis based on comparison of mean or median 
group data unreliable, the serum level profiles can be seen in Figure 6.19 and Table 6.3. It 
was therefore necessary to subcategorise the data by gender into male and female groups 
before further detailed statistical analysis. The control group comprised of 7 males and 23 
females and the patient group of 8 males and 22 females. Male groups were less likely to 
show statistically different patient values from those of their controls than the female groups 
due both to the low number of male samples and lower RA sample levels than those within 
the female cohort.  
There was a significant difference between RA and control groups within the female 
subcategory in all but the anti-mCRP IgM assay, anti-pCRP IgG (P < 0.01), anti-pCRP IgA (P 
< 0.01), anti-pCRP IgM  (P < 0.001), anti-mCRP IgG (P < 0.01) and anti-pCRP IgA (P < 
0.001). Anti-mCRP IgM was not found to be significantly different from the control (P < 
0.05). Within the male subgroup, anti-pCRP IgA and anti-mCRP IgA were observed to be 
significantly different from the control (P < 0.002, P < 0.003 respectively). Anti pCRP IgM, 
anti-pCRP IgG, anti-mCRP IgM and anti-mCRP IgG were not found to be significantly 
different from controls (P > 0.05). It is difficult to predict due to sample size whether these 
findings would be representative of a larger population size and no significance of these 
results can be assumed within the wider population.Table 6.3 illustrates the parameters of 
each group with data shown in terms of median (IQR)  split by male and female group.  
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Figure 6-19 Graph illustrating the variation of median auto-antibody serum levels separated 
by gender. a) anti-mCRP and b) anti-pCRP auto-antibodies, separated by gender (m or f) and 
health (RA – 1, control – 0). The median is illustrated by horizontal bars and all data is 
expressed as Absorbance per auto-antibody isotype.  
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Table 6.3 Laboratory parameters (median IQR), for RA and control samples split by male 
(shaded) and female groups. n = 8 males, 22 females (RA group), 7 males, 23 females 
(control group). 
Assay Group RA Control 
Anti-mCRP IgG 0.067 (0.000-0.067) 0.000 (0.000-0.064) 
Anti-mCRP IgM 0.070 (0.021-0.159) 0.044 (0.001-0.109) 
Anti mCRP IgA 0.113 (0.059-0.141) 0.000 (0.000-0.003) 
Anti-pCRP IgG 0.121 (0.058-0.235) 0.066 (0.000-0.133) 
Anti-pCRP IgM 0.061 (0.012-0.181) 0.011 (0.000-0.056) 
Anti-pCRP IgA 0.033 (0.014-0.046) 0.001 (0.000-0.048) 
Anti-mCRP IgG 0.023 (0.00-0.144) 0.000 (0.000-0.010) 
Anti-mCRP IgM 0.024 (0.017-0.072) 0.056 (0.000-0.090) 
Anti mCRP IgA 0.033 (0.024-0.151) 0.000 (0.000-0.001) 
Anti-pCRP IgG 0.080 (0.025-0.160) 0.055 (0.010-0.090) 
Anti-pCRP IgM 0.040 (0.022-0.122) 0.000 (0.000-0.050) 
Anti-pCRP IgA 0.056 (0.029-0.068) 0.000 (0.000-0.026) 
 
There was little correlation between antibody isotype found within groups, with no 
interaction found between anti-mCRP IgG and either IgM or IgA in both male and female 
groups p > 0.05. Within the anti-pCRP auto-antibody groups there was also no intergroup 
correlation found P > 0.05, however a positive interaction was observed within the male 
group between anti-pCRP IgG and anti- mCRP IgG, P < 0.022, and negative correlations 
between both anti-pCRP IgM and anti mCRP IgM, P < 0.027 and anti-pCRP IgA and anti-
mCRP IgA, P < 0.007. 
(a.) 
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No significant correlation was observed between either mCRP or pCRP and any auto-
antibody with the exception of pCRP with both anti-mCRP IgA, P < 0.021 and pCRP IgA, P 
< 0.021 within the male group and mCRP against anti-pCRP IgG, P < 0.02 within the female 
group. 
In order to address the question of whether age has an effect on health status and auto-
antibody profile, the cohort of 30 was analysed by Spearman’s Rank correlation as a 
combined gender group. An interesting correlation between age and auto-antibody 
concentration is evident within three of the 12 groups, those of anti-pCRP IgA and IgM 
within the RA group, both with negative correlations and also anti-pCRP IgM within the 
control group, a positive correlation (P < 0.035, P < 0.002 and P < 0.02 respectively). There 
were no other anti-pCRP vs age interactions within either RA or control group, nor were any 
anti-mCRP vs age groups considered to have a significant correlation. Although age and anti-
mCRP IgA were not found to be significantly correlated in either the RA or control groups (P 
> 0.05), binary logistic regression indicated that there was a significant association between 
anti-mCRP IgA levels and disease. Tables 6.4 and 6.5 show details of  Model 1, anti-mCRP 
IgA and health, and Model 2, anti-mCRP IgA, health and age (P < 0.0001), suggesting RA is 
significantly more likely when both age and anti-mCRP IgA levels increase.  
Table 6.4 Estimated logistic regression model parameters for discriminating RA (n=22) from 
healthy female patients (n=23) based on (a) serum derived IgA-mCRP (model 1) and (b) 
serum derived IgA-CRP and age (model 2). 
 Coefficienta Odds ratio (95% CI) 
a. Model 1 
Constant -2.0370  ±0.6140  
IGA  0.1641  ±0.0495 1.1784 (1.0695, 1.2983) 
   
b. Model 2 
Constant -9.5800  ±3.2700  
IGA CRP   0.2086  ±0.0706 1.2319 (1.0727, 1.4148) 
Age  0.1305  ±0.0500 1.1394 (1.0330, 1.2567) 
a Mean of coefficient ± one standard error; sign indicates direction of relationship. 
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 Table 6.5Assessment of the logistic regression model fit for health status (RA = 1, healthy = 
0) 
  Model 1 
(IGA) 
Model 2 
(IGA + Age) 
Significance of coefficientsa 
G  34.57 45.65 
df  1 2 
p-value  0.001 0.001 
    
Goodness of fit test 
Hosmer–Lemeshowb  4.66 3.47 
df  6 8 
p-value  0.588 0.902 
 
a Test that all slopes (coefficients) are zero, significance level of 0.05, null hypothesis: slopes 
are equal 
b Measure of how well health status is predicted by the model, significance level of 0.1, null 
hypothesis: model fits data. 
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6.4 Discussion 
6.4.1 Overview 
 
To our knowledge this study is the first that seeks to determine the presence of 
serum anti-mCRP and anti-pCRP IgA and IgM auto-antibodies in RA subjects, together 
with anti-pCRP IgG levels. The few studies that have considered anti-CRP auto-antibodies 
in RA have focussed on the detection of IgG antibodies directed towards mCRP and not 
pCRP (Minatani et al., 2001; Rosenau and Schur 2013). This chapter describes the 
presence of IgA, IgM and additionally IgG auto-antibodies directed against both mCRP 
and pCRP within RA serum. Our study successfully identified anti-mCRP and anti-pCRP 
auto-antibodies of all three isoforms within subjects of both the RA and control groups 
through development of a competitive ELISA. There were significantly higher levels of 
each auto-antibody present within RA patients compared to controls samples. It was 
established that anti-mCRP IgA auto-antibodies may play an important role in RA to the 
extent that anti-mCRP IgA was found to be a strong predictor of RA diseased state. Whilst 
the focus of the report considers the frequency of those samples found to be above the 
upper threshold for the normal control cohort, it is also interesting to consider the 
frequency of samples with a detectable level of auto-antibody present, as this also reveals 
some relevant findings between and within groups. Therefore, the discussion encompasses 
both levels of interpretation within its analysis. 
6.4.2 Distribution of Auto-antibody Isotype within RA Patients 
 
The first reported identification of auto-antibodies to CRP within serum detailed the 
finding within a single SLE patient (Robey et al., 1985). Ten years later a study on toxic 
oil syndrome, in which auto-antibodies directed towards CRP were again recorded, 
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highlighted the presence of auto-antibodies which only bound to CRP previously 
‘modified’ by urea treatment or plastic bound, allowing inter-subunit epitopes to be 
exposed, the antibodies identified were class IgG (Bell et al., 1995). The same authors 
again identified anti-CRP auto-antibodies of the IgG class in 1998 (Bell et al., 1998), and 
once more identified the target of these antibodies as ‘modified’ CRP. These antibodies 
were found in 75.7% of SLE patients and 35.4% of healthy controls. Since these earlier 
studies many have sought to characterise anti-CRP auto-antibodies, of which all considered 
the IgG class immunoglobulin (Jakuszko et al., 2017, Li et al., 2017; Minatani et al., 2001; 
Sjowell & Wettero 2008;  Sjowell et al., 2002,2003; Tan et al., 2008). 
Our pilot study focused on a cohort of 30 RA patients consisting of 22 females and 
eight males, each confirmed sera positive for RA. All were under various ongoing drug 
regimens and many had lived with RA symptoms for many years. Data was analysed in 
two ways, either including all samples with a detectable presence of an auto-antibody 
whatever level that may have been, or those designated elevated (≥ mean +2SD normal 
control population). All RA patients were found to have the presence of at least one auto-
antibody, with many showing the presence of all three, 23 of 30 patients within the anti-
pCRP auto-antibody assays and 15 of 30 patients within the anti-mCRP auto-antibody 
assays contained detectable levels of IgG, IgA and IgM auto-antibodies. Within the anti-
mCRP study 10 patients had elevated levels (≥ mean + 2SD normal controls) of IgG, 22 of 
IgA and eight of IgM. Within the anti-pCRP study nine patients were higher level for IgG, 
three for IgA and eight elevated for IgM. Analysis revealed significant differences between 
the frequency of patients with measurable presence of anti-mCRP and anti-pCRP auto-
antibodies vs control subjects, with anti-mCRP IgA , anti-pCRP IgA and anti-pCRP IgG all 
having 28 of 30 samples with detectable antibody amounts.  Perhaps surprisingly, in the 
anti-mCRP assay IgM and IgG isoforms were not the dominant class, with elevated 
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positive levels of IgA in 22 of 30 RA samples. This was found to be different within the 
anti-pCRP assays in which IgG had the greatest number of positive samples (nine), with 
IgM second with eight. Anti-pCRP IgA was the least likely auto-antibody to be positive 
within RA patient samples with just three samples elevated above the determined normal 
level. 
With respect to anti-CRP IgG auto-antibodies, these were found to be present 
within subjects of both the RA and the control groups. Following separation of the initial 
group into gender subsets, analysis of female levels of anti-mCRP IgG revealed a 
significantly higher level of auto-antibodies directed against mCRP in the RA group when 
compared to the control group, P < 0.018. However this was not reflected within the male 
RA group samples which remained similar in value to that of the controls P > 0.325. A 
similar picture emerged within anti-pCRP IgG results in which the female group once 
again showed significantly higher levels of anti-pCRP IgG than the control group (P < 
0.02), whilst the male group was again not significantly different (P > 0.524). This shows 
that significantly higher anti-mCRP and pCRP IgG auto-antibodies were found in RA 
rather than control subjects in the female group. When each auto-antibody class was 
directly compared between male and females, although female levels of auto-antibody 
were higher than their male counterpart in all auto-antibody groups within both RA and 
control subjects, with the exception of RA group anti-pCRP IgA, these differences were 
not significant. The trend apparent within these results supports the findings of Nagele et 
al., (2013) who also observed significantly higher levels of auto-antibodies within female 
subjects (P = 0.004), although these were only assessed within the control group, (n = 18 
female, n = 39 male). The low number of male subjects within this study however suggests 
these results can not be regarded as relevant within a larger population unless further 
explored with a larger sample group. 
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Studies have indicated that the prevalence of RA is higher within females than 
males and a 2006 study by Kvien et al was also able to determine the incidence by age 
group. RA was four to five times more likely to occur within females than males below the 
age of 50, but this fell to a ratio of only two to one as the population age rose to between 
ages 60-70. The determination of higher levels of auto-antibodies within the female 
population may in part be responsible for the observed increased prevalence of RA in 
women. Smoking is also determined to be a predictor of RA in males but not consistently 
in females, suggesting further genetic influences on disease (Nagele et al., 2013)  However 
disease severity was found to be significantly worse in female RA patients who had ever 
smoked than those who had not  (Mattey et al., 2002a, 2002b).  
Previous studies have focused detection methods on the ‘modified’ rather than 
native form of CRP as a target antigen, with identification of the CRP isoform determined 
by ELISA. Groups have bound CRP directly to a polystyrene plate, leading to 
conformational change and production of mCRP, or have used CRP that had previously 
been treated with urea in order to dissociate it (Jakuszko et al., 2017, Li et al., 2017; 
Minatani et al., 2001; Sjowall & Wettero 2007, Sjowall et al., 2002,2003; Tan et al., 
2008). Therefore the presence of specifically anti-pCRP auto-antibodies, rather than those 
with dual antigenicity, may have been missed due to assay design.  Auto-antibody studies 
within SLE patient groups (Jakuszko et al., 2017, Li et al., 2017; Minatani et al., 2001; 
Sjowall & Wettero 2007; Sjowall et al., 2002, 2003; Tan et al., 2008), have also focused 
upon IgG auto-antibodies directed towards monomeric and not pentameric CRP, as have 
those involving other diseases such as acute coronary syndrome (Wettero et al., 2009) and 
systemic autoimmune diseases including primary biliary cirrhosis, chronic graft-versus-
host disease, systemic scleroderma and even toxic oil syndrome (Bell et al., 1995,1998). 
These assays have included inhibition studies eliminating the effect of pCRP auto-
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antibodies, although they have only tested against immobilised mCRP rather than pCRP, 
suggesting any pCRP directed auto-antibodies would not have been identified. In these 
studies pentameric CRP was bound to the plate and left overnight to incubate and 
dissociate, serum was preincubated with urea treated mCRP and then incubated on half of 
the plate, with the other incubated with serum alone. The difference between the two 
values represented the inhibition by mCRP and therefore auto-antibodies present within the 
serum directed against it. However, as monomer only was used as a capture antibody, it 
was not possible to judge the presence or absence of anti-pCRP IgG. It was also not 
possible to tell how many of these IgG auto-antibodies may have contained dual 
recognition properties. 
Our study showed 66% of RA patient serum samples contained anti-mCRP IgG 
auto-antibodies as did 43% of control subjects, this was higher than the study conducted by 
Rosenau and Schur, (2006), in which they found 22.3% of RA and 23% of SLE patients 
were positive for anti-CRP IgG. However these samples were judged positive when levels 
were equal or above mean OD ± 2SD for their healthy individual cohort; when our data is 
compared on a similar basis (≥mean + 2SD normal control population), 10 of 30 (33.33%) 
of RA samples were determined to be elevated above normal levels and one of 30 (3.33%) 
of control samples showing a significant difference between groups (P < 0.003 Х2 
analysis). Further differences may be due to differences in methodology, a competitive 
ELISA was not used within their study and interactions between BSA and patient serum 
may have resulted in a lower frequency of positive patients. The differences within study 
designs may account for the differences found within the results of our study and those of 
previous. A second study by Minatani et al., (2000) showed 29% of RA patients were 
positive for anti-mCRP IgG, which is in closer alignment to results within our study. 
Levels of antibodies within healthy controls were unreported within Rosenau’s study but 
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two of 49 healthy control samples (4%) were elevated within the work of Minatani and 
colleagues.  
The number of RA high level samples for anti-pCRP IgG auto-antibodies is 
significantly higher than that of the control group (P < 0.01 Х2 analysis), illustrating a close 
association with disease. As existing studies have not sought to identify IgG auto-
antibodies directed against pCRP, it is not possible to judge equivalent levels to ours, 
although 30% of our RA samples were elevated for anti-pCRP (≥ mean + 2SD normal 
controls), which is in broad alignment with the frequency of positive anti-mCRP IgG 
samples in ours and previous mentioned studies. Antibodies directed against pCRP were 
similarly lower in the control group with only one sample elevated (3.33%). Whilst our 
results indicated a significantly higher levels of auto-antibodies within RA patients than 
controls, Nagele et al., (2013) reported a general decrease in IgG auto-antibodies against 
their age matched controls within certain diseases; Alzheimer’s disease, Parkinson’s 
disease and multiple sclerosis all reporting a statistically significant decrease in the number 
of auto-antibodies against control. It is clear that the indication of high levels of IgG auto-
antibodies may not always be considered detrimental to health. This is shown in the 
contrast between levels of anti-mCRP IgG within both RA and SLE, both are autoimmune 
diseases but SLE known for its high anti-CRP auto-antibodies and low CRP levels whereas 
RA is characterised by the opposite profile. 
The significantly higher frequency of elevated IgG auto-antibody samples was 
quite different from the number of samples with detectable levels, of which little difference 
was observed between RA group 93%, and control group 77%. When mean levels of anti-
mCRP IgG and anti-pCRP IgG auto-antibodies were compared there was no significant 
difference found (P > 0.159 female, P > 0.318 male). This suggests that although mean and 
median levels of anti-pCRP IgG were higher than anti-mCRP IgG in both male and female 
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groups, patients were not significantly more likely to have auto-antibodies directed towards 
one form of CRP at the expense of another.  This may suggest that should an individual 
lose self-tolerance to one form of CRP it is likely to be a matched reaction to the other. If 
antigen presentation of mCRP leads to dual antigenicity and additional self-recognition of 
pCRP, it may be due to recognition of an epitope on the surface of the mCRP subunit, 
rather than one normally buried between subunits. If the epitope recognised by the immune 
system is located within the inter-subunit site, normally hidden, then recognition of the 
monomeric form only will occur. Specific antibodies to pCRP alone are suggested to 
recognise antigenic areas that bridge two subunits, thus not present in mCRP. Therefore 
should self-recognition occur with an epitope shared by both isoforms of CRP, then both 
would be vulnerable to immune system eradication. This may result in differences within 
disease profile dependent on the levels of mCRP and pCRP present within serum or joint, 
and also whether one or both isoforms are found to present pro-inflammatory rather than 
anti-inflammatory roles. It is entirely possible that one is protective and the other not, thus 
the ratio of each within serum may be an important consideration within disease diagnosis 
and progression. If mCRP is determined to be pro-inflammatory and pCRP anti-
inflammatory as some studies suggest (Fujita,  2014; Khreiss, 2004; Molins, 2016; 
Thiele,  2015; Trial,  2016; Zouki,  2001), should mCRP be recognised and targeted by the 
immune system, pCRP could undergo the same fate. This would interrupt clearance of 
apoptotic cells and immune debris, possibly leading to the initiation of necrosis pathways 
and increased local and systemic autoreactivity. However our results showed no correlation 
between levels of mCPR and auto-antibody levels, nor between pCRP and either IgM or 
IgG, which suggests an alternative reason for similar levels between groups. Molecular 
mimicry may play a role, whereby a foreign antigen shares structural similarities or a 
sequence with a self-antigen (Cusick et al., 2012), therefore an as yet undetermined protein 
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may activate an immune response in which both mCRP and pCRP are caught up as 
innocent bystanders.  
Where mean levels of detected anti-mCRP IgG differed in statistical significance 
across male and female groups, this was not found to be the case within anti-mCRP IgA. 
Once again females had significantly higher % auto-antibodies within RA group samples 
when compared to control samples (P < 0.0001), however the male group also exhibited a 
similar difference (P < 0.002). Upon analysis of anti-pCRP IgA mean detected levels, once 
more the number of samples with detectable levels in both male (P < 0.033) and female (P 
< 0.02) were significantly higher within the RA patient group than the control samples. 
When RA detected mean levels of anti-mCRP and anti-pCRP IgA were considered and 
compared,  no significant difference between them was found (P = 0.385 female, P = 0.123 
male), however there were significantly more elevated samples within the anti-mCRP than 
anti-pCRP group (P > 0.001 Х2 analysis). This implies that whilst the overall amount of 
samples found to have anti-mCRP or pCRP IgA were the same (28 or 30), the control 
groups mean levels varied greatly leading to a low normal threshold within the mCRP 
group. It is likely that as with IgG auto-antibodies, a possible level of dual antigenicity 
occurs as a similar number of patients appear to have antigenicity towards both CRP forms. 
Within RA, anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are 
predominantly IgM or IgG isotype with little evidence to suggest IgA plays a diagnostic 
role. However studies have shown IgA auto-antibodies do seem to hold diagnostic value 
and our data agrees with this finding (Sieghart et al., 2016).Our data also suggests that IgA 
auto-antibodies may have a diagnostic value due not only to the significant difference 
between positive RA samples of anti-mCRP IgA when compared to controls, but also 
when associated with age, as a strong predictor of disease.  
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Analysis and comparison between RA and control group anti-mCRP IgM auto-
antibodies revealed no significant difference between detected levels in either the male P > 
0.524 or female P > 0.204 groups, although the male mean and median are actually higher 
within the control group than that of the RA. This was a surprise as IgM auto-antibodies 
are a feature of RA and therefore of the antibodies tested these were perhaps the class 
considered most likely to be present in RA serum. When anti-pCRP auto-antibodies are 
considered, the female RA group is significantly higher than the control (P < 0.03), 
whereas no significant difference was observed between male RA and control group levels 
of anti-pCRP IgM (P > 0.118). Again differences in gender are apparent; however the size 
of the male group prevents significant analysis of these findings. 
Upon comparison of RA group anti-mCRP and anti-pCRP IgM auto-antibody 
levels, no significant difference was found (P > 0.664 female, P > 0.270 male), indicating 
that as with the IgA and IgG auto-antibody investigations, there was no apparent likelihood 
of auto-antibodies being more prevalent against mCRP or pCRP, or for one to influence the 
levels of the other. When the frequency of RA samples with elevated levels of anti-mCRP 
IgM in the combined gender group were compared to those within the control group, a 
significant difference was found, with a greater number of elevated RA patients (eight), 
than elevated control subjects (zero), P < 0.01, Х2 analysis. No significant difference was 
found between elevated patient and control samples in the anti-pCRP IgM detection assays, 
RA patients (eight), and control (three), P > 0.05. 
IgM antibodies are not only the first class of antibody produced during a primary 
antibody response, but they predominantly produced by a subset of B cells, the long lived 
B1 cell, without necessary specific antigen stimulation. They also fulfil the role of ‘natural 
antibody’ present in the serum of healthy subjects prior to any infection (Boes, 2000). 
These natural antibodies are polyreactive to conserved structures such as heat shock 
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protein, carbohydrates, phospholipids and nucleic acids (Boes, 2000). It is possible that as 
a phylogenetically conserved protein, CRP may also be recognised by IgM natural 
antibodies. IgM  plays a role in the enhancement of IgG response to foreign antigens and 
has been implicated in development of IgG autoreactivity, (Cornall et al., 1995). The 
binding of IgM to a self-antigen, such as mCRP or pCRP, could result in the activation of 
complement and formation of an immune complex (antigen-IgM-C) which may then go on 
to stimulate an IgG antibody response; however in this case the antibodies would be 
primed against a self-antigen, CRP,  rather than a foreign one.   
Our study also examined the presence of IgA anti-CRP auto-antibodies and results 
demonstrate that levels directed against both mCRP and pCRP are also significantly higher 
in RA patients than in normal control subjects. IgA class auto-antibodies are prevalent 
within RA and although they are not used within diagnosis in the same manner as IgG and 
IgM auto-antibodies are, a recent study by Sieghart et al., (2017) showed anti-RF IgA were 
found within 44.7% of tested patients with 31% also positive for anti-ACPA IgA auto-
antibodies. Altogether 49% of 255 patients had at least one type of IgA auto-antibody 
(Sieghart et al., 2017). In their later study 50.68% of RA patients were identified as 
positive for IgA-RF (Sieghart et al., 2018). An early study showed elevated anti-
cytokeratine-18 IgA was found (± mean plus 2SD of healthy controls) in 39.6% of RA 
patient sera compared to 1.4% of healthy controls.  Levels of anti-epidermal keratin IgA 
were also raised in 20.75% of the RA patients and 4.5% of healthy controls (Borg et al., 
1993). These levels although directed against different self-proteins, are considerably lower 
than the 73.33% of  RA patients in our study who were found to have elevated levels of 
anti-mCRP IgA elevated above the normal upper limit (± mean plus 2SD of healthy 
controls), although in line with the frequency of  positive elevated  control samples 
(3.33%). 
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The results were quite different within the anti-pCRP IgA assay in which both RA 
and control groups had the same frequency of samples elevated above the normal range, 
three subjects (10%), considerably lower than both anti-mCRP IgA levels and the 
previously quoted studies. The reason this cohort contained a greater frequency of elevated 
anti-mCRP rather than pCRP IgA is not clear at present, it may be due to the very low 
levels observed within the anti-mCRP control group, resulting in a low upper threshold for 
samples to be considered high. The frequency of elevated samples differed between anti-
mCRP and anti-pCRP assays, however the number of samples with detectable levels of 
IgA was the same with mean levels not found to be significantly different (Male P > 0.128; 
Female P > 0.385). Whilst some differences between IgG and IgA auto-antibodies are 
apparent, what was clear  is that within the combined gender RA group anti-mCRP IgA 
levels show a significant positive correlation to mCRP levels (P < 0.035, Spearman’s Rank 
correlation), whereas no such correlation was observed between anti-pCRP IgA levels and 
pCRP (P > 0.087). The origin of these antibodies is also not known (i.e. mucosal or 
circulatory), although it is possible they may be produced in response to mucosal 
compartment stimulation. Antigenic stimulation of the mucosal immune system can result 
in the appearance of IgA auto-antibodies within peripheral blood (Olas et al., 2005). Where 
secretory IgA is generally considered to be a non-inflammatory antibody due to the fact it 
does not trigger inflammatory processes upon antigen binding, serum IgA and also serum 
IgG have been shown to downregulate the release of the anti-inflammatory cytokines IL-10 
and IL-12p40 from LPS-activated monocytes and peripheral blood monocytic cells 
(PBMC). This suggests that raised levels of serum IgA may lead to an enhanced 
inflammatory response (Olas et al., 2005).  However in a study using LPS activated 
monocytes and PBMC, it was shown that IgA also had the effect of down regulating 
chemokine MCP1, MIP1α and MIP1β release in LPS-activated monocytes as well as 
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peripheral blood monocytic cells (PBMC). These chemokines are essential within an acute 
inflammatory and effective innate immune response, by stimulating cell activation and  
migration of neutrophils and basophils, therefore leading to induction of pro-inflammatory 
IL-6, TNF-α and IL-1 synthesis (Olas et al., 2005).  This suggests that IgA auto-antibodies 
play a dual and possibly modulatory role within the normal immune response and therefore 
whilst elevated levels may provide key diagnostic information, the actual disease outcome 
of these auto-antibodies is unclear. 
This interplay between immunoglobin classes may be responsible for CRP 
autoantigenicity within RA rather than control samples. It is evident from our results that 
RA is associated with elevated IgG, IgA and IgM antibody production. When considered 
individually the frequency of isolated auto-antibodies within samples is interesting, 
however the profile of multiple auto-antibodies within each patient and control subject is 
especially relevant. Figures 6.14 to 6.18 illustrate the combination of immunoglobulin 
classes evident within control and patient samples, with a far higher proportion of RA 
patients experiencing a combination of auto-antibodies. Within the RA group anti-pCPR 
investigations 23 patients had the presence of all three antibody classes within their serum, 
compared to only 15 of the anti-mCRP patients. Anti-mCRP patients had significantly 
higher individuals with a combination of with both IgM and IgA auto-antibodies present 
(eight subjects), whilst the anti-pCRP assay revealed no individuals with this combination, 
which was found to be significantly different (P < 0.03). The frequency of individuals with 
all three classes of auto-antibodies in the control group were lower in both mCRP (four 
compared to 15 RA, P < 0.005) and pCRP assays (15 compared to 23 RA).   
 It is possible that the diseased state and microenvironment of inflamed joints is in 
part responsible for changes to proteins leading to auto-antibody production. However it 
cannot be discounted that the combination and presence of these immunoglobulins may 
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possibly be responsible for some of the pathology surrounding an RA diagnosis. The 
presence of anti-mCPR and pCRP IgG auto-antibodies in serum may not have all resulted 
from a breakdown in self-tolerance, despite the evidence that diseases such as SLE and RA 
provide to the contrary. Auto-antibodies have been found in many non-autoimmune 
diseases including cancer and neurological diseases (Avramcas et al., 2007; Linnoila 2016; 
Nolan and Lokshin 2010). In their 2013 study Nagele et al showed that several disease 
groups including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and breast 
cancer showed profiles of high auto-antibody frequency. Within this study a group of 57 
healthy controls were included and microarray analysis of 9,486 native human proteins 
revealed a mean of 1,996.9 different IgG auto-antibodies were present within each 
individual in all groups. Regardless of age, gender or health status 60% of samples 
contained a core of common and abundant auto-antibodies, with no individual having less 
than 301 auto-antibodies within their serum. This suggests that not only does the healthy 
population have a normal level of auto-antibodies, that they may each have core 
similarities and individual and identifiable profiles. These profiles may well correlate to 
specific diseases and provide future diagnostic help to distinguish between similar 
pathologies. Within our own study the profile of the three auto-antibodies is very clearly 
different between disease and non-disease and mCRP / pCRP assays. Within a larger 
population a clear blueprint may be ascertained allowing a predictive tool for disease. 
The body may respond to elevated levels of pCRP and mCRP by raising an 
autoimmune response, ultimately bringing balance back to CRP concentrations. If however 
CRP, which has been considered a protective protein capable of clearing apoptotic cells 
and therefore avoiding necrosis, is cleared by these antibodies, further inflammation may 
be triggered or sustained. The mechanism of mCRP interaction with the immune system 
must be fully understood in order to elucidate whether auto-antibodies against it play a 
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positive or negative role. The levels of anti-mCRP detected within SLE patients suggest 
mCRP may play a protective role, with its loss via antibody clearance possibly enhancing 
the disease state (Tan et al., 2008; .Minatani, 2001; Sjowall, 2009). 
Previous studies indicate that levels of auto-antibody may increase in correlation 
with advancing age (Nagele et al., 2013). Our study results show that age was found to 
correlate with levels of anti-pCRP auto-antibodies present in two of the RA and one of the 
control group assays. Within the RA group anti-pCRP IgA and IgM both showed a 
negative correlations with age (Spearman correlation -0.387, P < 0.035; -0.540, P < 0.002 
respectively). Of the control groups anti-pCRP IgM was positively correlated with age 
(Spearman correlation 0.431, P < 0.018), suggesting that as the RA population ages levels 
of anti-mCRP IgA and anti-pCRP IgM fall, whilst levels of anti-pCRP IgM  rise within the 
control population. This finding was in part supported by Griffin et al., (2001) who 
observed a gradual decrease in natural IgM levels with age, however in contrast to Nagele 
et al., (2013), who found a significant correlation between rising age and rising auto-
antibody concentrations. However Nagele et al. focused on IgG auto-antibodies alone.  
Our study showed a trend of higher levels of IgG auto-antibodies with increasing 
age in both anti-pCRP and anti-mCRP assays, although this was not found to be 
significant. Rising levels of auto-antibodies in the control population may in general 
provide an element of protection or moderation to the immune system which is not present 
in the diseased population. Findings within anti-pCRP assays were however not universally 
repeated within those of the mCRP investigations in which age bore no significant impact 
on the levels of anti-mCRP auto-antibodies in either RA or control groups, although the 
trend suggestes that as age increased in the RA group, so did levels of IgG and IgM auto-
antibodies whereas IgA auto-antibody levels appeared to fall.  
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It is interesting to note that the negative correlation between age and antibody level 
for anti-pCRP IgA is reflected in the albeit non-significant negative trend between age and 
anti-mCRP IgA. Anti-mCRP and anti-pCRP IgG both show positive associations with age, 
but this concordance between anti-mCRP and pCRP is not seen between IgM auto-
antibodies, where a positive anti-mCRP vs age trend is seen, but a significantly negative 
anti-pCRP vs age correlation is also apparent. Whilst incidence of RA is often associated 
with age due to a greater frequency of diagnosis with increasing age, it is interesting to see 
that whilst anti-mCRP IgA was not only found to be a strong positive indicator of RA (P < 
0.001, R2 51.54%), this indication was found to increase in significance when age was also 
taken into account (P < 0.0001, R2 69.74%).  It is unknown at this stage whether this 
indication of disease is due to cause or effect. As age increases within the anti-mCRP 
group, the level of anti-mCRP IgA does not appear to rise. These results appear to 
contradict the logistic regression showing age and anti-mCRP IgA levels correlate with 
disease, however the regression takes into account the much higher RA auto-antibody 
levels in older RA individuals (mean age 62.73 years), than those found within the 
youngest of an already low level control group (mean age 46 years). The reflected increase 
in the likelihood of RA occurring may possibly result from either a reduction in the level of 
mCRP due to increased likelihood of anti-mCPR IgA; or alternatively, the increase in RA 
risk in conjunction with ageing leads to an increase in anti-mCRP IgA levels due to the 
systemic inflammatory state created by the disease, therefore anti-mCRP IgA is not 
actually complicit RA development. The results of this study therefore have not been able 
to clarify fully whether the significant difference in IgA levels are implicated in 
pathogenesis of RA or are caused by it. 
When an antigen is detected within the body an immune response where necessary 
includes generation of antibodies, supporting the presumption that higher levels of either 
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mCRP or pCRP detected within serum would correlate with higher levels of auto-antibody 
present. This was the case within the combined male/female group, in which a significant 
positive correlation was found between levels of anti-mCRP IgA and mCRP (P < 0.035), 
illustrating that as mCRP levels rise so do associated IgA auto-antibodies. However when 
split by gender, RA mean levels of mCRP did not correlated against anti-mCRP IgG, IgA 
and IgM in either male or female groups P > 0.05, a finding reflected within the control 
cohort.  
As discussed previously there were strong gender differences between male and 
female groups, making some direct comparisons unreliable. A positive correlation was 
found in the male but not female group when pCRP and anti-pCRP IgA levels were 
investigated (P < 0.021), however it is difficult to draw conclusions from these results due 
to the small sample size. It is unknown as to whether this would be reflected within a larger 
population and no such indication was apparent within the larger female group. No 
significant correlation was observed between pCRP and either anti-pCRP IgG and IgM. 
Previous studies have also indicated that there was no correlation between CRP levels and 
those of auto-antibodies directed against it, but these have focused on IgG rather than IgM 
or IgA auto-antibodies (Jakuszko et al., 2017; Rosenau and Schur 2006; Sjowell et al., 
2003, Tan et al., 2003). 
The RA patients within this study whilst confirmed RA seropositive and all under 
clinical management at a routine hospital drug monitoring clinic, were not assessed for 
interaction with their drug regime as this was not an agreed aspect of the ethical review and 
permission. Therefore some results may have been impacted by unknown interactions, 
including certain classes of drug which modify immune pathways and influence the level 
of CRP within serum. Correlations between mCRP, pCRP and auto-antibodies directed 
against them may have been masked by the class of drug individuals were taking and the 
 
 
Chapter 6 - Detection of Anti-CRP Auto-antibodies Discussions 
313 
 
length of time it had been prescribed. The degree of disease activity and length of time 
from diagnosis, if the individual was experiencing an RA flare, together with comorbidity 
factors were also unknown and may have impacted upon analysis made within this study.  
6.4.3 Overall Conclusion 
 
To our knowledge this is the first study to address multiple auto-antibodies directed 
against both mCRP and pCRP within rheumatoid arthritis. The ELISA design was 
optimised to ensure interactions found within previous research studies, such as those 
between human serum and BSA, did not affect the results found within our study. RA 
patients were found to have significantly higher levels of auto-antibodies than those of 
normal control subjects, with the exception of the IgM isotype. This may be due to the 
level of natural antibodies present within both control and RA patient serum which exist as 
part of normal physiological and immunomodulatory roles, IgM may not be pro-actively 
produced but be the result of low level constant secretion. Gender differences were evident 
with significantly higher RA to control level auto-antibodies within the female group. 
Auto-antibodies were not found to differ significantly in detection between anti-mCRP or 
pCRP suggesting possible dual antigenicity with both CRP conformations. Auto-antibodies 
of each isotype were present within control samples, with only four subjects negative for 
IgM, IgG and IgA anti-mCRP auto-antibodies and just two negative for anti-pCRP 
antibodies. This indicates that not only is there a ‘normal level’ of serum pCRP and 
possibly mCRP, but also a retained level of self-directed antibodies against both. There 
was a strong correlation found between disease and anti-mCRP IgA, further enhanced 
when age was considered. It is possible that anti-mCRP IgA could prove to be an effective 
diagnostic tool which may aid diagnosis. Levels of auto-antibodies vary across the groups, 
however it is clear that although not all correlated, subtle interactions existed. The 
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diagnostic power of autoimmune diagnosis may be further enhanced by increasing the 
number of auto-antibodies detected within routine testing and analysis of the auto-antibody 
profile, rather than relying predominantly upon IgG and IgM auto-antibodies.  
 
Our research highlights the advantage of assessing whether additional tests focused upon 
both mCRP and pCRP auto-antibodies, which together with auto-antibody profiling, may 
further support physicians determining diagnosis. 
6.4.4 Future Work 
 
Future work should continue to determine whether auto-antibody levels detected 
within this pilot study are linked to RA development, prognosis or drug prescribed. A 
significant correlation between anti-mCRP IgA levels, age and RA has been established, 
this should be further investigated to determine how this relates to disease activity and if 
the predictive capabilities suggested in this study are a possible predictive tool of future 
disease, or severity of disease. This information may help determine the type of RA drug 
intervention chosen. Investigation between gender differences are a key area of research 
and a larger study population with greater proportion of male subjects would enable 
powerful statistical analysis of the trends suggested within this study. RA established risk 
factors include smoking, determined to be a predictor of RA in males but not consistently 
in females (Nagele et al., 2013). Disease severity is suggested to be significantly worse in 
female RA patients who had ever smoked than those who had not (Mattey et al., 2002a, 
2002b). Unfortunately our study did not collect smoking history and therefore we are 
unable to assess whether the levels of auto-antibodies determined in our study may have 
been affected by the influence of smoking history. Future work should also consider this 
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variable within experimental planning to ensure the influence of life style is also taken into 
account.  
Finally research should focus on establishing comparable methodologies in which 
simple and standardised assays reliably determine which form of CRP is the target of auto-
antibodies, including commercially available mAb with specificity against the monomeric 
form of CRP. Within both clinical and research settings variations in CRP and anti-CRP 
detection methods may be adding to an already confused and contradictory body of 
research, preventing clear determination of the role played by monomeric CRP and its 
auto-antibodies within inflammatory disease. 
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Chapter 7  – Discussion, Conclusion and Future Work 
7.1 Overview 
 
Since it was first observed by Oswald T. Avery in 1930 (Tillet & Francis, 1930), 
CRP has become a key biological marker for the presence of inflammation, infection or 
tissue damage within the body (Bell et al., 1998; Ford, 2003; Pepys & Hirschfield, 2003; 
Sowall & Wettero, 2007; Zhang et al., 2012). However previous research has reported 
conflicting roles, with CRP suggested to be both pro and anti-inflammatory (Hanriot et al., 
2008; Pasceri et al., 2000; Pepys & Hirschfield, 2003; Raaz-Schrauder et al., 2014; Thiele 
et al., 2015). The acute phase protein is widely accepted to be a strong independent risk 
factor for, and predictor of, future disease; for instance, cardiovascular disease (Chen et al., 
2018; Pepys & Hirschfield et al., 2003; Ridker et al., 1998; Shrivastava & Singh 2015); 
chronic obstructive pulmonary disease (Dahl et al., 2007) and type two diabetes (Pradhan 
et al., 2001) and is a component of the DAS28 testing and biomarker within RA. 
Alternative evidence has suggested that CRP may play a regulatory role within the immune 
system, moderating inflammation and other components within the immune system 
(Gershov et al., 2000). CRP is also correlated with SLE risk and severity due to a 
polymorphism associated with both development of SLE and decreased levels of CRP. 
This perhaps suggesting a protective role within SLE, possibly due to the clearance of 
nuclear antigen by CRP, a target of autoimmunity in SLE (Cunninghame et al., 2004). 
Whilst elevated concentrations of CRP are a feature of RA, it is unclear whether the raised 
levels found in RA patients result from their inflammatory state, or are directly implicated 
within pathology of this disease. 
The two main aims of this pilot research study were designed to clarify whether 
molecular variations of human CRP were present, detectable and quantifiable within RA 
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patient serum, and to determine the existence of auto-antibodies directed against both 
mCRP and pCRP within the same serum. Although the material within this study is limited 
to 30 rheumatoid arthritis patient and 30 control samples, many interesting and novel 
observations were made. The research shows experimental evidence contributing towards a 
greater understanding of CRP conformations and auto-antibodies within RA. Through 
optimised ELISA and western blot analysis our research identified a monomeric form of 
CRP within RA and control serum, together with the presence of IgG, IgA and IgM class 
antibodies directed against both monomeric and pentameric CRP.   
7.1.1 Production of monomeric CRP 
 
The native pentameric form of CRP has been studied and characterised extensively, 
however the physiological conformation of mCRP, its function and creation mechanism 
are still under consideration. The experimentation within Chapter 3 sought to produce and 
purify mCRP in vitro, evaluating methods of dissociation in order to determine optimum 
conditions for the creation of mCRP for further studies. Initial investigations considered 
the effect of pH on CRP. Whilst pH modification has previously been used to dissociate 
CRP in vitro, it was not considered an appropriate method of mCRP generation within this 
study, as the effects upon the dissociated protein could not be determined and the amount 
generated without heating the sample was limited. Localised physiological drops to pH are 
known to occur within certain diseases, however they are not found to fall as low as pH 
4.0. (Helmlinger et al., 1953; Kimmoun et al., 2015) It is therefore unlikely pH levels 
within the body would provide an environment supportive of the dissociation found within 
this in vitro testing system.  
Whilst an existing body of research indicates a potentially pro-inflammatory role 
for mCRP, the nature and origin of mCRP used within these studies has varied, for instance 
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8M urea was used within studies by Motie et al. (1988) and Slevin et al. (2015) whilst the 
groups of Chirco et al.( 2016) and Fujita et al. (2014) produced and used recombinant 
mCRP. However a greater proportion of previous studies generating mCRP in vitro used 
similar dissociation methods to the urea induced dissociation of subunits found within our 
study. However, many of these studies have used the harsher method of 8M urea rather 
than the 2M conditions developed within our research. Experimental evidence suggests 3M 
urea dissociated mCRP retains an ability to bind PC in a calcium dependent manner 
(Williams, 2016), however further functional clarity has not been determined within our 
research. Potential modifications to CRP by urea could not be confirmed, however it is 
postulated that urea may act either via its ability to interact with polar and non-polar 
components, allowing disruption of non-covalent bonds or weaken hydrophobic 
interactions between subunits (Caballero-Herrera et al., 2005; Hua et al., 2008; Rossky, 
2008; Zou et al 1998). It is also suggested it acts by directly interacting with the backbone 
of CRP (Caballero-Herrera et al., 2005; Hua et al., 2008; Stumpe & Grubmuller, 2007), or 
disrupts intersubunit salt bridges (Sun et al., 2014). The true structural effects may only be 
revealed following determination by crystallographic studies, however the functional 
phosphocholine binding properties of urea dissociated CRP are retained (Williams, 2017), 
suggesting minimal disruption of tertiary structure. Despite this it remains to be determined 
whether in vitro produced mCRP proves to be physiologically relevant. 
Dissociation investigations also revealed the importance of calcium to the stability 
of CRP. It was not possible to fully dissociate pCRP with either extremes of pH or urea 
alone, with dissociation achieved only after the addition of calcium chelator EDTA. 
Calcium is shown to maintain structural integrity of the subunits via interactions protecting 
key sites from proteolysis (Ramadan et al., 2002; Shrive et al., 1996) and this was evident 
within our study.  
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Perhaps surprisingly the reintroduction of calcium to mCRP in solution did not 
result in re-association of the protein, due possibly to the necessity of a final stage 
chaperone protein within physiological assembly of pCRP, or a required involvement of 
the 19 residue N-terminal signal peptide present pre cleavage. It is also possible that 
intersubunit salt bridges may become carbamylated by urea, preventing reassociation of 
subunits.  
Several theories have been previously suggested as to how mCRP may arise in vivo 
and what mechanisms may be involved, including mechanical dissociation initiated 
following membrane binding, or possible local expression of CRP as a monomer rather 
than a pentamer. It is also theoretically possible that within the inflammatory confines of 
an RA joint, reactive oxygen species and oxidative stress thought to be involved within the 
pathogenesis of RA (Biemond et al., 1984; Mateen et al., 2016; Ozturk et al., 1999), result 
in oxidation and damage to CRP. Key protein oxidation markers were found by Mateen et 
al. (2016) within RA patient plasma, alongside significantly low levels of non-enzymatic 
antioxidants (reduced glutathione and vitamin C). It is possible the oxidative environment 
found within RA joints may destabilise the pentameric structure of CRP, making it more 
vulnerable to previously mentioned dissociation factors. Physiological mCRP may 
however be a combination of several of these factors dependent on disease or inflammatory 
states within the body. Despite doubts as to the functional relevance of the monomer 
created within our study, it proved to be recognised not only by commercially available 
anti-mCRP antibody Clone 8, but by patient and control serum. This indicates that key 
structural recognition domains remain following urea treatment. 
The techniques used within this study provided a reliable method to reproducibly 
generate stable mCRP for further investigations within patient serum and antibody studies. 
Our results confirmed those previously reported, with the creation of a stable subunit 
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isoform of CRP. However our methods have been adapted to reduce the harsh techniques 
used within much existing research. The monomer created has been confirmed as 23kDa 
via calibrated size exclusion elutions and travels on native PAGE to a position estimated to 
be that of a monomeric subunit, in a distinctly different way to the pentamer. Western 
blotting further confirms the identity of the created subunit through the use of specific 
antibodies designed to recognise the intersubunit epitopes.  
7.1.2 Optimisation of Detection Assays 
 
CRP presents many challenges when attempting to carry out quite routine 
molecular biology or immunoassays involving it. It does not run ‘normally’ within a native 
gel in its monomeric form, due to a change in pI from that of its original pentamer 
formation. The pentamer itself does not all travel into the resolving section of a gel, with a 
quantity remaining within the stacking gel. It is not possible to run a standard direct or 
indirect ELISA to determine patient CRP isoform content as pCRP is unstable and 
dissociates on contact with the ELISA plate (Sjowell et al., 2002; 2003). In addition to this, 
components of both the RA and control serum interacted with BSA used within the 
blocking stages of both western blotting and ELISA and potentially any capture antibodies 
used. CRP within our study was also found to interact directly with both goat anti-human 
IgG and rabbit anti-mouse IgG, although not significantly at the dilutions used within this 
study. 
Our assay design carefully took into account the various factors required in order to 
avoid non-specific binding or high noise to signal ratio. Possible interaction with other 
pentraxins was countered by pre-testing antibodies with both SAP and PTX3 for 
specificity. A competitive ELISA was developed which minimised confounding variables 
at risk of creating false positive or negative results. Following ELISA, western blots were 
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carried out, and serum incubated with the milk blocking solution overnight in an attempt to 
reduce interaction with the blocking stage. Antibodies directed against mCRP are also 
known to bind Hsp60, with the epitope region of Hsp60 matching 26.6% amino acid 
sequence to residue region 77 to 90 of CRP (Udvarnok et al., 2007). This 58-65kDa 
protein was not pre tested within our assays, however the mouse anti-mCRP 3H12 used 
within our detection of mCRP was tested by Udvarnok et al. (2007) and found not to 
recognise Hsp60. Additionally it is known that 3H12 antibody recognises CRP residues 
199-206 rather than 77-90.  
Positive samples were also confirmed by western blotting, although only two 
initially determined positive for mCRP by ELISA were later identified as positive by 
western blot. Western blotting is less sensitive than ELISA and the concentration of mCRP 
found in both patient and control samples low, therefore only the highest samples provided 
visible bands. However it is important to ensure samples are positive within both western 
blot and ELISA, removing the risk of false positive results due to interference of system 
components. Within the study by Williams (2016), CRP was first isolated by affinity 
chromatography before size determination by both western blotting and size exclusion 
chromatography. It is possible that future studies could adopt this system to ensure mCRP 
antibody recognition and ELISA results are accurate. 
Possible interactions between assay components and serum antibodies were 
avoided by use of a competitive ELISA system and western blotting confirmed the ELISA 
results in all but anti-pCRP IgA detection assays. The absorbance of ELISA results ranged 
between 0-0.113 in the anti-pCRP IgA RA group and potential bands present may not be 
visualised over the background interaction between serum and blocking solution. Although 
all interactions may not have been fully eradicated, our study underlines the importance of 
thorough study design and optimisation before initiating assays. 
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7.1.3 Detection of CRP within Human Serum 
 
The serum of 30 RA patients and 30 control samples was tested for the presence of 
mCRP. Patients were recruited at a routine hospital drug monitoring clinic and were all 
confirmed seropositive for RA before informed consent was gained. Although a small 
sample size (study limitations discussed in section 7.7), our study did show that mCRP 
could be detected within patient serum samples. We identified both monomeric and 
pentameric CRP within ELISA assays. 
 Statistical analysis, prior to splitting the cohorts into gender subsets, found a 
significant difference between concentration levels of pCRP detected between the RA and 
control groups (P < 0.001), (RA group pCRP mean 22.85mg/l, control group pCRP mean 
0.742mg/l). Detectable levels of mCRP were found in 29 of the 30 RA samples and 24 of 
the 30 control samples, with significantly higher levels within the RA group (P < 0.01), 
(RA group mCRP mean 0.092mg/l, control group mean 0.069mg/l). However, once groups 
were split by gender no significant difference remained.  
To our knowledge this is one of the few studies to identify the presence of mCRP 
within patient serum samples. In 1987 Potempa et al. identified molecules expressing neo-
CRP antigenicity in the plasma of two RA patients (Potempa et al., 1987). A more recent 
study by Wang et al., (2015), also provided evidence suggesting the existence of soluble 
circulating mCRP (0.021 ± 0.002 mg/l). The study by Wang et al considered plasma of 
patients who recently had suffered acute myocardial infarction (AMI), however both of 
these studies considered plasma rather than serum. Plasma may contain microparticles, 
therefore presenting the possibility that mCRP found within the samples was microparticle 
bound, rather than soluble within serum. A recent study that did consider serum was that of 
Williams (2017), who isolated mCRP from serum, concentrating it before identifying and 
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quantifying it by ELISA and western blotting (Williams, 2017). The highest levels reported 
within Williams’ study were approximately 2.5 mg/l which is in the region of 100 times 
higher, although this study selected patients with in excess of 100mg/l serum CRP levels 
initially therefore potentially higher mCRP content than Wang et al., (2015). The results 
from our study are more comparable to Wang et al with 0.132mg/l in the highest patient 
sample.  
Concentration levels of pCRP were universally higher than mCRP across all 
samples within our study, with an increase observed within the RA group. There is less 
difference within the mean mCRP concentration between an RA state and non RA control 
state, with no samples elevated above normal threshold, suggesting that a low level of 
mCRP may be present in the serum of a normal healthy population. It is not possible to 
determine if a rise in the level of mCRP would be linked to inflammation or infection in 
the same way pCRP is, however, six of 30 (combined gender) control participants were 
negative for mCRP, whereas only one was negative within the RA group (P < 0.05). This 
suggests that like pCRP, mCRP may also be more prevalent within inflammatory or 
autoimmune disease and our research shows a small but significant increase within the RA 
cohort. It is also the case that once separated by gender there is no significant difference 
between RA and control serum levels, suggesting mCRP may circulate at a ‘normal’ albeit 
low level across the general population.  
 Elements of the mCRP identified within both patient and control samples may 
have originated from circulating pentameric CRP through local dissociation, which has 
been well described within recent literature (Ji et al ., 2009, Thiele et al., 2014, Eisenhardt 
et al., 2009). A recent study by Braig et al., (2017) provides evidence for a mechanism 
allowing pCRP to become ‘activated’ by binding to cell membranes resulting in a relaxed 
pentameric form, allowing C1q binding. The engagement of C1q within the central cavity 
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is suggested to further allow dissociation in mCRP (Braig et al., 2017). Autoimmune 
disorders such as RA can involve impairment to the clearance of apoptotic cells, linked to 
the development and progression of chronic inflammatory dieseases (Kruse et al., 2010; 
Mũoz et al., 2010; Szondy et al., 2014). When pCPR recognises and binds apoptotic cells, 
normal clearance procedures may not allow time for dissociation of the pentamer on the 
cell surface; however in situations of impaired clearance, dissociation may be enabled. This 
could ultimately lead to the clearance of apoptotic cells more rapidly, following secretion 
of pro-inflammatory cytokines by monocytes and macrophages induced by the newly 
formed mCRP. In this way mCRP may facilitate the recruitment of further immune cells to 
the locality, enhancing the clearance of cellular debris. The normal function of mCRP may 
therefore be the amplification of signal allowing a rapid recruitment of immune cells when 
apoptosis is inefficient. However within a diseased state this amplification may in part be 
responsible for perpetuating inflammation and auto-antibody generation, eventually 
resulting in auto-antibodies generated against mCRP itself as demostrated by the detection 
of IgG, IgA and IgM autoantibodies in patient serum within our study.  
Scenarios suggesting that mCRP originates purely from pCRP imply that its levels 
would correlate with reduced but corresponding concentrations of mCRP to those of pCRP. 
Such a correlation may have suggested the soluble mCRP detected within our serum 
samples was of pentameric origin, resulting from degradation or dissociation. However, no 
correlation was found between levels of pCRP and mCRP in either the RA or control 
group, RA (P > 0.708), control (P > 0.646), demonstrating perhaps that mCRP is not 
entirely resultant of physiological pCRP dissociation. Local pCRP expression at sites of 
inflammation or tissue damage have been identified  (Calabro et al., 2005; Gould et al., 
2001; Jabs et al., 2003; Thiele et al., 2014; Yasojima et al., 2001). It is possible that local 
expression of mCRP may also take place, although by an as yet to be determined pathway. 
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It has been demostrated within U937 macrophage studies that the form of CRP expressed 
by these cells is mCRP rather than pCRP (Ciubotaru et al., 2005), suggesting that a 
pathway exists allowing this event, perhaps during chronic disease state or during periods 
of high oxidation at the site of inflammation. It is possible that local disociation of pCRP 
upon a cellular surface would result in an activated intermediate form of bound CRP 
predisposed to complete dissociation. This dissociation may stimulate surrounding 
macrophage and other immune cells to secrete a combination of cytokines leading to 
cellular expression of mCRP in preference to pCRP and thus amplifying complement 
activation via C1q activation.   Further exploration of an mCRP mechanism independent of 
pCRP dissociation must be sought in order to fully explain the levels of mCRP/pCRP 
found within our study and the impact it has, if any, on disease states. 
When age and gender were considered as variables, interesting differences between 
the groups emerge. Within the pCRP detection assay, control group female levels were 
higher than males (mean 0.80mg/l, mean 0.54mg/l respectively, P > 0.05), however within 
the pCRP RA group, male levels were higher than females (male 24.70mg/l, female 
21.79mg/l, P > 0.05), this finding is supported by research by Siemons et al, (2014) who 
reported that in early RA men had 1.2 times higher CRP levels than women (Siemons et 
al., 2014). There was no significant difference between levels of male and female mCRP in 
either control or RA groups. Whilst both male and female mCRP levels within the RA 
group increase slightly as they grow older and both show declining pCRP values with age, 
these figures are based on a small sample size and are therefore affected by two particular 
male samples showing a greater decline in pCRP with age.  
It is evident that although standard clinical tests such as ELISA are able to quantify 
CRP levels, they may not be able to distinguish between the two isoforms, for instance the 
DuoSet used within our study is widely used within research and unable to detect mCRP. 
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Should further studies confirm additional forms of CRP within human serum or tissue, the 
question of accuracy and implied meaning of previous testing could be called into 
question, both within clinical and research settings (Crawford et al., 2006). Automated 
systems used within clinical settings rely upon the formation of an antigen-antibody 
complex and therefore results are subject to the choice of antibody. Findings generated 
over the last 20 years may have worked on the assumption of native pentameric CRP 
detection, when in fact samples could possibly have contained monomeric CRP or a 
combination of the two forms together. It is plausible to suggest the complex and 
contradictory results showing both the pro-inflammatory and protective effects assigned to 
CRP, may result from a of lack of determination of the isoform of CRP detected, with 
mCRP and pCRP playing potentially different roles within the inflammatory environment. 
 
7.5 Detection of Anti-CRP Auto-antibodies within Human Serum 
 
Anti-human IgG, IgM and IgA auto-antibodies directed against mCRP and pCRP were 
found in both control and RA serum. RA is a well categorised autoimmune disease, with 
serum auto-antibodies playing a key role not only within the development of RA but within 
its diagnosis. Where the presence of auto-antibodies within RA is well established, to our 
knowledge this is the first study to report the profile of IgG, IgA and IgM auto-antibodies 
directed against both mCRP and pCRP. 
Whilst anti-mCRP auto-antibodies are a feature of SLE (Meyer, 2010; Sjowell et 
al., 2002), they are less extensively studied within RA, with few studies considering anti-
pCRP auto-antibodies. Two previous studies have identified anti-mCRP antibodies in RA, 
with between 22-29% of patients positive for anti-mCRP IgG auto-antibodies within their 
serum (Minitani et al., 2001; Rosenau & Schur, 2006). Our study showed 66% of RA 
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samples contained detectable anti-mCRP IgG as did 43% of controls, although when 
adjusted for those above the normal threshold, levels dropped to 33% and 3.33% 
respectively, close to the top range of Minitani et al, 2001 study. Of interest was the profile 
of serum auto-antibody content within our study. All RA samples contained detectable 
levels of at least one auto-antibody class, with many determined to contain multiple 
isotypes. Table 7.1 provides a summary of all results including mCRP and pCRP levels 
with the equivalent auto-antibody level and western blot confirmation where available. 
Detectable levels of all three IgG, IgM and IgA auto-antibodies directed against pCRP 
were found within each of 23 of 30 RA patients and 15 of 30 control samples. This was in 
contrast to the lower frequency of samples with auto-antibodies directed against mCRP, of 
which 15 of 30 RA and 4 of 30 control samples possessed all three.  Whilst IgG, IgM and 
IgA auto-antibodies were found to be directed towards both mCRP and pCRP in RA 
patients, they are also shown to be present within non-RA control samples, indicating a 
background level present within the healthy population. The nature of these auto-
antibodies is unknown; however they may play a role in the clearance of cellular debris at 
low levels. However the higher number of RA samples with detectable levels present 
within serum suggests that within RA patients their role may be linked to disease. Cross 
reactivity between antibodies directed against Hsp60 may account for a proportion of these 
auto-antibodies. It is known that anti-Hsp60 auto-antibodies are prevalent within RA (van 
Halm et al., 2006; Watanabe et al., 2003) and it is possible antibodies directed against 
mCRP found within serum in our study originated against Hsp60.  
Once again the whole cohort was split into male and female groups, with the focus 
of attention on the female group due to its larger size. Data taken from the female cohort 
shows significantly higher levels of auto-antibodies in RA samples directed against both 
mCRP and pCRP of each antibody class than that of controls (P < 0.05), with the exception 
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of anti-mCRP IgM, which showed no significant difference. Binary logistic regression 
showed a significant association between anti-mCRP IgA levels and disease (P < 0.0001), 
showing increased anti-mCRP IgA associated with an increased likelihood of RA. When 
age is also taken into account this becomes a stronger indicator disease (P < 0.0001), 
suggesting RA is significantly more likely to occur with an increase in both age and anti-
mCRP IgA levels. However, the age profile of the female control group is lower than that 
of the RA group. The nature of control samples, with lower IgA auto-antibody levels and a 
younger age profile, suggests that this finding may not be repeated within an age matched 
control group.  
7.1.4 Interactions between CRP and Anti-IgG Antibodies 
 
Our study found interesting interactions between anti-IgG and CRP, which were 
stronger between the antibody and mCRP than pCRP. Existing research has suggested the 
risk of cross reactivity is elevated in proteins with a high level of homology amongst 
species (Delgado et al. 2003), which may also include CRP. It has also previously been 
reported that mCRP binds immunoglobulins non-specifically. Our research indicated an 
interaction with mCRP as low as 0.5µg/ml, that increased with protein concentration and 
resulted in considerable binding at both 2.5 and 5µg/ml.  It was thought possible that key 
similarities between Fcγ binding of both CRP and IgG may result in an area of homology 
leading to molecular mimicry; however no interaction was found when Fc specific anti-
IgG antibodies were used to test this theory. The exact nature of CRP and anti-IgG 
interaction therefore remains unknown, however the location of interaction on CRP may be 
an area close to the interface between subunits as there appears to be higher level of 
interaction between mCRP than pCRP. Steric hinderance between IgG and pCRP may 
reduce the capacity of interaction.  
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Table 7.1 Summary table containing pCRP, mCRP (mg/l) and auto-antibodies (absorbance) quantification as determined by ELISA (n=3), for 
each patient or control sample. Additionally western blot (n=3) results are indicated. Quantification of mCRP / pCRP - green highlighted boxes 
represent samples with mg/l below the calculated normal threshold (SEM ± 2SD), orange indicates those mg/l above the threshold. Western blot 
results are indicated by green for those samples tested but without a visable band and orange for those with a positive band, blue represents those 
samples which were not tested. 
ID 
mCRP (mg/l)  pCRP (mg/l)  WB 
result 
pCRP 
WB 
result 
mCRP 
AAB 
mCRP IgG 
AAb 
mCRP IgA 
AAb 
mCRP IgM 
AAb pCRP 
IgG 
AAb pCRP 
IgA 
AAb pCRP 
IgM 
Mean ± SEM Mean 
± 
SEM Mean WB Mean WB Mean WB Mean WB Mean WB Mean WB 
RA01 0.099 0.0010 1.985  0.0013 + - 0.080  0.147  0.311 + 0.188  0.010  0.303 + 
RA02 0.079 0.0023 55.905 0.2141 + - 0.000  0.074  0.157 - 0.232 + 0.013  0.140  
RA03 0.085 0.0012 43.742 0.0748 +  0.054  0.119  0.261 + 0.096  0.113  0.425 + 
RA04 0.077 0.0025 7.943 0.0262 +  0.092  0.046  0.008  0.211 + 0.014  0.078  
RA05 0.073 0.0022 18.701 0.0066 +  0.031  0.122  0.155 - 0.242 + 0.029  0.285 + 
RA06 0.101 0.0017 22.501 0.0515 + - 0.124 - 0.138  0.015  0.016  0.000 - 0.000  
RA07 0.101 0.0008 83.688 0.0101 + - 0.029  0.163 - 0.166 + 0.136  0.038 - 0.360 - 
RA08 0.118 0.0065 5.289 0.3151 + - 0.039  0.270 + 0.000  0.061  0.044 - 0.181 - 
RA09 0.083 0.0002 2.621 0.0181 +  0.097  0.102  0.000  0.077  0.005  0.183 - 
RA10 0.105 0.0005 4.464 0.0621 + - 0.031  0.106  0.100  0.252 + 0.036  0.157 - 
RA11 0.096 0.0004 11.495 0.0561 +  0.000  0.315 + 0.000  0.223 + 0.030 - 0.075  
RA12 0.099 0.0013 5.587 0.1052 +  0.000  0.089  0.168 - 0.297 + 0.020  0.000  
RA13 0.102 0.0011 9.528 0.0570 + - 0.110 - 0.138 - 0.085  0.000  0.020 - 0.000  
RA14 0.073 0.0002 1.079 0.0128 +  0.184 - 0.000  0.028  0.192  0.056 - 0.024  
RA15 0.105 0.0003 8.963 0.0952 + - 0.244 + 0.120  0.023  0.251 + 0.038  0.040  
RA16 0.131 0.0018 55.353 0.0161 + + 0.000  0.067  0.117 - 0.050  0.052  0.043  
RA17 0.119 0.0007 24.151 0.0913 + - 0.000  0.239 + 0.170 - 0.082  0.037 - 0.047  
RA18 0.054 0.0011 22.839 0.2109 +  0.214 + 0.139  0.025  0.295 + 0.041  0.039  
RA19 0.128 0.0022 29.258 0.2664 + + 0.185 - 0.053  0.119  0.000  0.015  0.000  
RA20 0.053 0.0010 21.542 0.2528 +  0.000  0.008  0.032  0.105  0.107  0.079  
RA21 0.083 0.0015 21.188 0.1281 +  0.092  0.000  0.025  0.094  0.066  0.000  
RA22 0.106 0.0007 29.968 0.7266 + - 0.202 + 0.061  0.055  0.051  0.005  0.017  
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RA23 0.133 0.0020 13.466 0.1931 + - 0.000  0.179  0.000  0.057  0.000 - 0.036  
RA24 0.102 0.0006 5.274 0.0750 + - 0.166 - 0.199  0.028  0.215 + 0.028  0.020  
RA25 0.098 0.0016 37.871 0.0515 +  0.000  0.023  0.031  0.079  0.081  0.027  
RA26 0.000 0.0000 28.321 0.1781 +  0.000  0.065  0.086  0.005  0.030  0.000  
RA27 0.089 0.0015 23.300 0.4198 +  0.054  0.030  0.019  0.014  0.065  0.084  
RA28 0.095 0.0002 24.632 0.5216 +  0.000  0.036  0.017  0.082  0.067  0.135  
RA29 0.055 0.0038 23.726 0.1204 +  0.148 - 0.027  0.018  0.089  0.047  0.044  
RA30 0.109 0.0035 41.014 0.2854 + - 0.130  0.008  0.281 + 0.184 - 0.068  0.215 - 
C01 0.092 0.0007 0.236 0.0078 -  0.079  0.017  0.113  0.083  0.020  0.062  
C02 0.086 0.0010 0.236 0.0089 -  0.000  0.019  0.001  0.000  0.000  0.000  
C03 0.087 0.0009 1.995 0.0666 +  0.000  0.000  0.000  0.007  0.000  0.011  
C04 0.084 0.0011 0.951 0.0230 +  0.040  0.000  0.088  0.133  0.048  0.000  
C05 0.062 0.0003 0.056 0.0012 -  0.147 - 0.000  0.122  0.000  0.000  0.029  
C06 0.077 0.0007 0.165 0.0010 -  0.011  0.003  0.048  0.099  0.000  0.012  
C07 0.098 0.0011 0.420 0.0041 -  0.000  0.000  0.000  0.089  0.000  0.000  
C08 0.087 0.0014 0.147 0.0018 -  0.000  0.003  0.000  0.257 + 0.080  0.183 - 
C09 0.078 0.0007 0.321 0.0028 -  0.000  0.000  0.000  0.139  0.065  0.056  
C10 0.096 0.0011 0.078 0.0009 -  0.064  0.000  0.059  0.159  0.000  0.000  
C11 0.075 0.0011 1.995 0.0057 +  0.000  0.000  0.044  0.040  0.002  0.000  
C12 0.104 0.0017 0.946 0.0010 + - 0.000  0.000  0.020  0.182  0.029  0.000  
C13 0.074 0.0009 0.946 0.0246 +  0.064  0.000  0.033  0.063  0.082  0.037  
C14 0.066 0.0007 5.406 0.0018 +  0.000  0.000  0.027  0.000  0.000  0.000  
C15 0.093 0.0020 2.470 0.0257 +  0.000  0.000  0.013  0.066  0.003  0.023  
C16 0.102 0.0003 0.190 0.0250 - - 0.000  0.000  0.112  0.000  0.014  0.000  
C17 0.000 0.0002 0.310 0.0015 +  0.000  0.084  0.000  0.118  0.000  0.000  
C18 0.115 0.0009 0.184 0.0097 - -- 0.000  0.000  0.109  0.118  0.000  0.000  
C19 0.086 0.0001 0.259 0.0026 -  0.101  0.000  0.133  0.182  0.001  0.000  
C20 0.075 0.0004 0.086 0.0002 -  0.016  0.000  0.127  0.006  0.000  0.041  
C21 0.000 0.0000 0.065 0.0012 -  0.056  0.000  0.026  0.000  0.062  0.173  
C22 0.090 0.0012 0.119 0.0008 -  0.000  0.032  0.106  0.044  0.080  0.169  
C23 0.085 0.0087 0.928 0.0286 +  0.072  0.011  0.056  0.000  0.001  0.066  
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C24 0.094 0.0010 0.081 0.0014 -  0.000  0.000  0.094  0.000  0.053  0.000  
C25 0.000 0.0000 0.117 0.0007 -  0.002  0.000  0.068  0.010  0.026  0.001  
C26 0.058 0.0001 1.297 0.0073 +  0.000  0.000  0.134  0.102  0.001  0.002  
C27 0.000 0.0012 0.000 0.0001 -  0.010  0.000  0.056  0.027  0.000  0.050  
C28 0.000 0.0000 0.724 0.0014 +  0.000  0.000  0.000  0.083  0.000  0.057  
C29 0.000 0.0011 0.592 0.0061 +  0.065  0.012  0.012  0.055  0.000  0.000  
C30 0.104 0.0007 0.951 0.0218 + - 0.000  0.001  0.000  0.090  0.000  0.003  
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7.1.5 Study Limitations 
 
The pilot study design did not incorporate ethical approval for the correlation of 
CRP to disease or drug treatment history, nor were lifestyle indicators such as smoking 
history collected. Future studies should address these limitations to study analysis as levels 
of CRP may have been impacted by either prescribed RA drugs, severity of disease or 
secondary conditions. Control samples were not age matched as they were collected from 
an existing bank of healthy volunteers within the NHS setting. Once again this proved to 
be a limitation as the age of the control volunteers was generally younger than those with 
RA. The result of this was a correlation between age and disease when perhaps one would 
not exist within an age and gender matched population. 
7.1.6 Conclusion and Future Work 
 
Our research provides evidence for a physiological monomeric form of CRP 
through the use of ELISA and western blotting analysis. Our ELISA and western blot 
protocols were carefully optimised with the presence of monomer confirmed by western 
blot in two patients who were among three showing highest level of mCRP within the 
ELISA. Monomeric CRP was generated with results confirmed by size exclusion 
chromatography. The study has shown detectable levels of mCRP within both RA patient 
and control samples, although once split for gender no significant difference was found. 
There is a suggestion that just as pCRP exists below a designated normal level within a 
healthy population, that mCRP may also be present at a normal baseline level. It is not 
known if, as is the case with pCRP, levels of mCRP increase in response to inflammation 
or infection, although results indicate higher levels of mCRP within the RA group than that 
of the control. There was no apparent correlation between mCRP and pCRP serum 
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concentrations indicating that dissociation of the pentameric form is not solely responsible 
for mCRP found within serum. 
 Serum auto-antibodies against both mCRP and pCRP were found, again in both 
RA and control populations. However the frequency of samples found with elevated levels 
was higher within the RA group than the control. The profile of auto-antibodies was 
different between the RA and control groups, and between assays investigating a different 
target antigen, mCRP or pCRP as visible within. This suggests that the profile of auto-
antibodies within RA serum may have value as a future diagnostic tool. It is possible that 
the auto-antibody profile may change as disease progresses, or could be apparent before 
symptoms manifest.  
The significance of anti-IgA auto-antibodies is interesting. Serum IgA interacts 
with FcαRI (CD89) expressed on the surface of immune cells. When complexed with an 
antigen, IgA binds to FcαRI promoting degranulation of eosinophils and basophils, 
phagocytosis and antibody-dependent cell-mediated cytotoxicity. It also results in 
respiratory burst, leading to localised oxidation conditions (Morton et al., 1996; Snoeck et 
al., 2006) creating an environmental with potential for pCRP dissociation. Should the local 
RA environment contain a protein such as Hsp60 with part homology to CRP, which is 
recognised and bound by the higher levels of IgA auto-antibodies present in RA, this may 
result in dissociation of pCRP to mCRP, leading to mCRP recognition by IgA originally 
directed against Hsp60. Excessive production of reactive oxygen species (ROS) can 
damage proteins (Hitchon and El-Gabalawy, 2004), it is therefore important to replicate 
these conditions in order to address the potential of oxidation within the generation of 
physiological mCRP. 
Further areas of future research include the requirement to repeat this pilot study 
within a larger sample group, with age and sex matched control groups. Key differences 
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between disease and drug treatment profile, together with lifestyle history may further 
enhance the value of our results. Auto-antibody studies may be further improved by the 
purification of antibodies from serum prior to testing, therefore avoiding problems with 
interactions between assay and serum components. The interesting interaction between 
anti-IgA and mCRP is an area requiring further investigation. RA is characterised as an 
autoimmune disease and many autoantigens have been profiled, however the interaction 
found within our studies may provide further useful information with regard to auto 
antigenicity.  
Lastly, the structural changes of in vitro dissociation methods upon CRP must be 
resolved through X-ray crystallographic studies. Although urea dissociated CRP appears to 
retain PC binding capabilities in a CaCl2 dependent manner, it is unknown whether this 
form of the protein retains the same structural fold as a subunit of pCRP. It is demonstrated 
from this research that consistent methodology for the detection of both mCRP and pCRP 
within clinical and research studies is required. Although the clinical significance of our 
research is yet to be revealed, it is clear from this study that there is a necessity for further 
research involving mCRP and auto-antibodies directed against it and against pCRP. Only 
then can we come to an understanding of the full role of mCRP and pCRP within the 
human immune system. 
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